MXPA99003877A - Multi-functional chimeric hematopoietic receptor agonists - Google Patents

Abstract

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proteins and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.

Description

AGENTS OF CHEMÉRICO, MULTIFUNCTIONAL HEMATOPOYETIC RECEPTOR The present application claims priority in accordance with title 35, United States Code, section 119, of the United States provisional application, serial No. 60 / 029,629, filed on October 25, 1996.

FIELD OF THE INVENTION The present invention relates to chimeric, multifunctional hematopoietic receptor agonists. These chimeric, multifunctional hematopoietic receptor agonists retain one or more activities of the individual components of the chimeric molecule, and may also exhibit improved hematopoietic cell stimulating activity and / or an enhanced activity profile which may include the reduction of undesirable biological activities. , associated with individual hematopoietic development factors and / or have improved physical properties which may include increased solubility, stability and refolding efficiency.

BACKGROUND OF THE INVENTION Colony stimulating factors (ECF) that stimulate the differentiation and / or proliferation of bone marrow cells have generated great interest due to their therapeutic potential to restore the depressed levels of cells derived from hematopoietic stem cells. FECs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte FEC (G-FEC) and macrophage FEC (M-FEC) stimulate in vitro formation of neutrophil granulocyte and macrophage colonies, respectively, while GM-FEC and interleukin-3 (IL-). 3) have broader activities and stimulate the formation of colonies of macrophages and neutrophil and eosinophil granulocytes. IL-3 also stimulates the formation of mastoidal, megakaryocytic and pure and mixed erythroid colonies. US 4,877,729 and US 4,959,455 describe a gibbon I L-3 cDNA and a deduced human IL-3 DNA sequence and the protein sequences that they encode. The hIL-3 described has serine in place of proline in position 8, in the protein sequence. International patent application (TCP) WO 88/00598 describes gibbon-like and human-like IL-3. The hlL-3 contains a Seri8-Pro8 replacement. It is suggested to replace Cys with Ser, thereby breaking the disulfide bridge, and replacing one or more amino acids at the glycosylation sites.

US 4,810,643 discloses a DNA sequence encoding G.FEC. human. WO 91/02754 describes a fusion protein consisting of GM-FEC and IL-3, which has increased biological activity, compared to GM-FEC or IL-3 alone. Analogous IL-3 proteins are also described and Non-glycosylated GM-FEC as components of the multifunctional chimeric hematopoietic receptor agonist. WO 92/04455 describes fusion proteins composed of I L-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-FEC. WO 95/21197 and WO 95/21254 describe fusion proteins capable of broad multi-functional hematopoietic properties. GB 2,285,446 refers to the c-mpl ligand (thrombopoietin) and various forms of thrombopoietin which have been shown to influence the reproduction, differentiation and maturation of megakaryocytes and megakaryocyte progenitors that can be used for the treatment of thrombocytopenia. EP 675,201 A1 refers to the c-mpl ligand (megakaryocyte growth and development factor (FCDM), allelic variations of c-mpl ligand and c-mpl ligand bound to water-soluble polymers, such as polyethylene glycol.) WO 95/21920 provides the murine and human c-mpl ligand and its polypeptide fragments The proteins are useful for in vivo and ex vivo therapy to stimulate platelet production.

U.S. Patent No. 4,703,008, to Lin, F-K, describes the cDNA sequence encoding erythropoietin, production methods and uses for erythropoietin. WO 91/05867 describes analogues of human erythropoietin having a number of sites for carbohydrate binding greater than human erythropoietin, such as EPO (Asn69), EPO (Asn125, Ser127), EPO (Thr125) and EPO (Pro124, Thr125). WO 94/24160 discloses erythropoietin muteins having increased activity, specifically amino acid substitutions at positions 29, 49, 73, 140, 143, 146, 147 and 154. WO 94/28391 describes the protein sequence of the natural ligand flt3 and a cDNA sequence encoding the ligand flt3, methods for expressing the ligand flt3 in a host cell transfected with the cDNA and methods for treating patients with a hematopoietic disorder, using the ligand flt3. U.S. Patent 5,554,512 is directed to human flt3 ligand as an isolated protein, DNA encoding flt3 ligand, host cells transfected with cDNAs encoding flt3 ligand and methods for treating patients with flt3 ligand. WO 94/26891 provides ligands of mammalian flt3, including an isolate having an insertion of 29 amino acids and their fragments.

REACOMODO OF PROTEIN SEQUENCES In evolution, the rearrangements of the DNA sequences serve the important role of generating a diversity of protein structure and function. Gene duplication and exon redistribution provide an important mechanism for rapidly generating diversity and, thus, providing a competitive advantage in organisms, especially since the rate of basal mutation is low (Doolittle, Protein Science, 1: 191 -200, 1992). The development of the recombinant DNA method has made it possible to study the effects of sequence transposition on the folding, structure and function of the protein. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins, which are related by the rearrangement of their amino acid sequences (Cunningham and coauthors, Proc. Natl. Acad. Sci. USA, 76: 3218-3222 , 1979, Teather and Erfle, J. Bacteriol 172: 3837-3841, 1990, Schimming and coauthors, Eur. J. Biochem., 204: 13-19, 1992, Yamiuchi and Minamikawa, FEBS LETT, 260: 127-130. , 1991; MacGregor and co-authors, FEBS Lett., 378: 263-266). The first in vitro application of this type of rearrangement to proteins was described by Goldenberg and Creighton (J. Mol. Biol., 165: 407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same amino acid order as the original of the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At that point, the new sequence is joined, either directly or through an additional portion of the sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues in the same sequence as the original , until it reaches a point that is at or near the amino acid that was N-terminal with respect to the site of the breakpoint of the original sequence; the new C-terminus of the chain forming that residue. This approach has been applied to proteins ranging in size from 58 to 462 amino acids (Goldenberg and Creighton, J. Mol. Biol. 165: 407-413, 1983, Li and Coffino, Mol. Cell. Biol., 13: 2377- 2383, 1993). The proteins examined have represented a wide range of structural classes, including proteins that predominantly contain an "a" helix (interleukin-4, Kreitman and co-authors, Cytokine, 7: 311-318, 1995); lamina "b" (interleukin-1; Horlick and co-authors, Protein Eng., 5: 427-431, 1992) or mixtures of these two (yeast phosphoribilanylanthranilate-isomerase; Luger and co-authors, Science 243: 206-210, 1989) . Broad categories of protein function are represented in these sequence organization studies.

Enzymes Chimeric protein interleukin-4, Kreitman and co-authors, Proc. Natl. Acad. Pseudomonas Sci. U.S.A., 91: 6889-6893, 1994). Exotoxin The results of these studies have been highly variable. In many cases lower activity, lower solubility or lower thermodynamic stability were observed (dihydrofolate reductase of E. coli, aspartate-transcarbamoiiase, phosphoribosyl anthranilate isomerase, glyceraldehyde 3-phosphate dehydrogenase, ornithine decarboxylase, omp A, dehydrogenase yeast phosphoglycerate). In other cases, the protein with rearranged sequence appeared to have many properties almost identical with its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, T1 ribonuclease, Bacillus b-glucanase, interleukin-1 b, SH3 domain of a-spectrin, pepsinogen, interleukin-4). In exceptional cases an unexpected improvement was observed with respect to some properties of the natural sequence, for example, the solubility and the refolding rate for the sequences of the SH3 domain of a-spectrin rearranged, and the receptor affinity and anti-tumor activity of the interleukin-4-exotoxin fusion molecule of Pseudomonas, transposed (Kreitman and coauthors, Proc. Natl. Acad. Sci. USA9V. 6889-6893, 1994; Kreitman and co-authors, Cancer Res., 55: 3357-3363, 1995). The primary motivation for these types of studies has been to study the role of small-scale and large-scale interactions in the folding and stability of the protein. The sequence rearrangements of this type convert a substring of interactions that are large scale in the original sequence, to short scale interactions in the new sequence, and vice versa. The fact that many of these sequence rearrangements are able to obtain a conformation with at least some activity is persuasive evidence that protein folding occurs by multiple folding trajectories (Viguera and co-authors J. Mol. Biol., 247: 670 681, 1995). In the case of the SH3 domain of a-spectrin, the selection of new ends in sites corresponding to b-hairpin spiers resulted in proteins with slightly less stability, but which nevertheless were able to fold. The positions of the internal breakpoints used in the studies cited here, are found exclusively on the surface of the proteins and are distributed throughout the linear sequence, without any obvious deviation towards the ends or towards the middle (the variation in the relative distance from the original N end to the breaking point is approximately 10 to 80% of the total length of the sequence). The linkers that connect the original N- and C ends in these studies have varied from 0 to 9 residues. In one case (Yang and Schachman, Proc. Natl. Acad. Sci. USA, 90: 11980-11984, 1993), a portion of the sequence of the original C-terminal segment has been omitted, and the connection was made from the end C truncated to the original N end. Flexible hydrophilic residues, such as Gly and Ser, are often used in linkers. Viguera and coauthors (J. Mol. Biol., 247: 670-681, 1995) compared the union of the original N and C ends with 3 or 4 residue linkers; the 3-residue linker was less thermodynamically stable. Protasova and coauthors (Protein Eng., 7: 1373-1377, 1994) used 3 or 5 residue linkers to connect the original ends of E. coli dihydrofolate reductases; only the 3-residue linker produced protein in good yield.

BRIEF DESCRIPTION OF THE INVENTION A hematopoietic protein comprising an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1 Wherein Ri and R2 are independently selected from the group consisting of: (I) A human EPO receptor agonist polypeptide, comprising an EPO amino acid sequence of the formula: AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys 10 20 GluAlaGluAsnlleT rThrGlyCysAlaGluHisCysSerLeiAsnGluAsnlleThr 30 40 ValProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValGlyGlnGlnAla 50 60 ValGluValTrpGlnGlyLe AlaLeuLeuSerGluAlaValLeuArgGlyGlpAlaLeu 70 80 euValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAspLysAlaValSer 90 100 GlyLeuArgSerLeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlalleSer 110 120 ProProAspAlaAlaSerAlaAlaProLeuArgThrlleThrAlaAspThrPheArgLys 130 140 LeuPheArgValTyrSerAsnPheLeuArgGlyLysLeuLysLeuTyrThrGlyGluAla 150 160 CysArgThrGlyAspArg SEQ ID NO: 464 166 wherein the N-terminus and 1-to-5 of the C-terminus of the EPO receptor agonist polypeptide can optionally be omitted; wherein the N-terminus is connected directly to the C-terminus or through a linker (L2) capable of connecting the N-terminus to the C-terminus, and having new C and N termini on the amino acids; 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 1 1 1-1 12 26-27 50-51 1 12-113 27-28 51-52 1 13-1 14 28-29 52-53 1 14-1 15 29-30 53-54 1 15-116 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 1 18-1 19 33-34 57-58 1 19-20 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44-45 88-89 130-131 108-109 108-109 131-132 46-47 respectively; and (II) a human trunk cell factor receptor agonist polypeptide, comprising a modified stem cell factor amino acid sequence of the formula: GluGlylleCysArgAsnArgValThrAsnAsnValLysAspValThrLysLeuValAla 10 20 AsnLeuProLysAspTyrMetlleThrLeuLysTyrValProGlyMetAspValLe Pro 30 40 SerHisCysTrpIleSerGluMetValValGlnLeuSerAspSerLeuThrAspLeuLeu 50 60 AspLysPheSerAsnlleSerGluGlyLeuSerAsnTyrSerllelleAspLys euVal 70 80 AsnlleValAspAspLeuValGluCysValLysGluAsnSerSerLysAspLeuLysLys 90 100 SerPheLysSerProGluProArgLeuPheThrProGluGluPhePheArglleP eAsn 110 120 ArgSerlleAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVal 130 140 SerSerThrLeuSerProGluLysAspSerArgValSerValThrLysProPheMetLeu 150 160 ProProValAlaAla SEQ ID NO: 465 165 wherein 1 to 23 amino acids may be omitted from the C-terminus of the trunk cell factor receptor agonist polypeptide; where the N-terminus is directly connected to the C-terminus or by means of a linker (L2) capable of connecting the N-terminus with the C-terminus and having new C and N termini at the amino acids: 23-24 39-40 96-97 24-25 40-41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68- 69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35 -36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 1 10-111 38-39 95-96 respectively, and (lll) A human flt-3 receptor agonist polypeptide, comprising a modified amino acid sequence of ligand flt-3 of the formula: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg 10 20 GluLeuSerAspTyr euLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp 30 40 GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu 50 60 LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis 70 80 P eValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnT rAsn 90 100 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr 110 120 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu 130 SEQ ID NO: 466 wherein optionally from 1 to 7 amino acids of the C-terminus of said flt-3 receptor agonist polypeptide are optionally omitted; wherein the N-terminus is connected to the C-terminus directly or by means of a linker (L2) capable of connecting the N-terminus to the C-terminus, and having new C and N termini on the amino acids; 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87- 88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40-41 92-93 respectively 41-42 (IV) a polypeptide comprising a modified human G-FEC amino acid sequence of the formula: 1 10 Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gln Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly 40 Ala Xaa Leu Gln Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 50 Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly He Pro Trp 60 70 Ala Pro Leu Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly 80 Xaa Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 90 100 Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu 110 Xaa Thr Leu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr He Trp 120 130 Gln Gln Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gln Pro Thr 140 Gln Gly Ala Met Pro Ala Phe Ala Be Ala Xaa Gln Xaa Xaa Ala 150 160 Gly Gly Val Leu Val Ala Ser Xaa Leu Gln Xaa Phe Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro SEQ ID NO: 85 wherein: Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa in position 2 is Pro or Leu; Xaa in position 3 is Leu, Arg, Tyr or Ser; Xaa in position 13 is Phe, Ser, His, Thr or Pro; Xaa in position 16 is Lys, Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Lie, Tyr or Arg; Xaa in position 18 is Leu, Thr, Pro, His, lie or Cys; Xaa in position 22 is Arg, Tyr, Ser, Thr or Ala; Xaa in position 24 is He, Pro, Tyr or Leu; Xaa in position 27 is Asp or Gly; Xaa in position 30 is Ala, He, Leu or Gly; Xaa in position 34 is Lys or Ser; Xaa in position 36 is Cys or Ser; Xaa in position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys or Leu; Xaa at position 44 is Pro, Gly, Arg Asp, Val, Ala, His, Trp, Gln or Thr, Xaa at position 46 is Glu, Arg, Phe, Arg, lie or Ala; Xaa in position 47 is Leu or Thr; Xaa in position 49 is Leu, Phe, Arg or Ser; Xaa in position 50 is Leu, He, His, Pro or Tyr; Xaa in position 54 is Leu or His; Xaa in position 64 is Cys or Ser; Xaa in position 67 is Gln, Lys, Leu or Cys; Xaa in position 70 is Gln, Pro, Leu, Arg or Ser; Xaa in position 74 is Cys or Ser; Xaa in position 104 is Asp, Gly or Val; Xaa in position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa in position 115 is Thr, His, Leu or Ala; Xaa in position 120 is Gln, Gly, Arg, Lys or His; X Xaaaa einn position 123 is Glu, Arg, Phe or Thr; Xaa in position 144 is Phe, His, Arg, Pro, Leu, GIn or Glu; Xaa in position 146 is Arg or Gln; Xaa in position 147 is Arg or Gln; Xaa in position 156 is His, Gly or Ser; X Xaaaa in position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa in position 162 is Glu, Leu, Gly or Trp; Xaa in lla < position 163 is Val, Gly, Arg or Ala; Xaa in lA. position 169 is Arg, Ser, Leu, Arg or Cys; Xaa in lla < position 170 is His, Arg or Ser; wherein optionally from 1 to 11 amino acids of the N-terminus and from 1 to 5 of the C-terminus, of said modified human G-FEC amino acid sequence can be omitted; Y wherein the N-terminus is connected to the C-terminus directly or by means of a linker (L2) capable of connecting the N-terminus with the C-terminus and having new C and N termini on the amino acids: 38-39 62-63 123 -124 39-40 63-64 124-125 40-41 64-65 125-126 41-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69 129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-133 53-54 91-92 133-134 54-55 92-93 134- 135 55-56 93-94 135-136 56-57 94-95 136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-140 60-61 98 -99 140-141 61-62 99-100 141-142 or 142-143, respectively; (V) A polypeptide comprising a modified human IL-amino acid sequence of the formula: Pro Wing Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120 Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130 wherein: Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa at position 19 is Met, Phe, Lie, Arg, Gly, Ala or Cys; Xaa in position 20 is lie, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa in position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or Lys; Xaa in position 31 is Pro, Asp, Gly, Ala, Arg, Leu or GIn; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa at position 36 is Asp, Leu or Val; Xaa at position 37 is Phe, Ser, Pro, Trp or He; Xaa at position 38 is Asn or Ala; Xaa at position 40 is Leu, Trp or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa in position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, GIn, Lys, His, Ala, Tyr, He, Val or Gly; Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro or His; Xaa in position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 55 is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or lie; Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; Xaa in position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa in position 65 is Val, Thr, Pro, His, Leu, Phe or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or His; Xaa in position 68 is Leu, Val, Trp, Ser, He, Phe, Thr or His; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is He, Ser, Arg, Thr or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa in position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Val or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser; Xaa in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, lie or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His; Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa at position 94 is Arg, lie, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He or Tyr; Xaa in position 96 is Pro, Lys, Tyr, Gly, He or Thr; Xaa in position 97 is lie, Val, Lys, Ala or Asn; Xaa in position 98 is His, He, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or His; Xaa in position 100 is Lys, Tyr, Leu, His, Arg, lie, Ser, GIn or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Tf, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, He, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gln, His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa in position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa in position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, lie, Tyr or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leu; where optionally from 1 to 14 amino acids of the N-terminus can be omitted and / or optionally from 1 to 15 amino acids of the C-terminus of said modified human IL-3 amino acid sequence; where from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin-3 (1-133); and where the N-terminus is connected to the C-terminus directly or through a linker (L2), capable of connecting the N-terminus to the C-terminus and having new C and N termini at the amino acids: 26-27 49-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-31 53-54 87-88 31-32 54-55 88-89 32-33 64- 65 89-90 33-34 65-66 90-91 34-35 66-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38 -39 70-71 99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83 102-103 0 103-104, respectively; (VI) A polypeptide comprising: a modified amino acid sequence of human c-mpl ligand, of the formula: SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer 1 5 10 15 HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro 20 25 30 35 ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu 40 45 50 55 ThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 60 65 70 75 AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly 80 85 90 95 GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa 100 105 110 XaaGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis 115 120 125 130 LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal 135 140 145 150 Arg SEQ ID NO: 860 153 where: Xaa in position 112 is omitted or is Leu, Ala, Val, He, Pro, Phe, Trp or Met; Xaa in position 113 is omitted or is Pro, Phe, Ala, Val, Leu, He, Trp or Met; Xaa at position 114 is omitted or is Pro, Phe, Ala, Val, Leu, He, Trp or Met; Xaa at position 115 is omitted or is Gln, Gly, Ser, Thr, Tyr or Asn; and where the N-terminus is connected to the C-terminus directly or by means of a linker (L2) capable of connecting the N-terminus to the C-terminus, and having new C and N termini at the amino acids: 26-27 51-52 108- 109 27-28 52.53 109-110 28-29 53-54 110-111 29-30 54-55 111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-115 34-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80 118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-122 43-44 83- 84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87 125-126 48-49 87-88 126-127 50-51 88-89 or 127-128 , respectively; (VII) A polypeptide comprising a modified amino acid sequence of human IL-3 of the formula: Pro Wing Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120 Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130 where: Xaa at position 17 is Ser, Lys, Gly, Asp, Met. Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala or Cys; Xaa in position 20 is He, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa in position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; Xaa in position 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; Xaa in position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa in position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, GIn, Ser, Leu or Lys; Xaa in position 31 is Pro, Asp, Gly, Ala, Arg, Leu or Gln; Xaa in position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa in position 33 is Pro, Leu, GIn, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, GIn, Thr; Arg, Ala, Phe, He or Met; Xaa in position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa in position 36 is Asp, Leu or Val; Xaa in position 37 is Phe, Ser, Pro, Trp or He; Xaa in position 38 is Asn, or Ala; Xaa in position 40 is Leu, Trp or Arg; Xaa in position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa in position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, _Ser, Thr, Cys, Glu, Asn, GIn, Lys, His, Ala, Tyr, lie, Val or Gly; Xaa in position 47 is lie, Gly, Val, Ser, Arg, Pro or His; Xaa in position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp; Xaa in position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 55 is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or lie; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val. Xaa in position 64 is Ala, Asn, Pro, Ser or Lys; Xaa in position 65 is Val, Thr, Pro, His, Leu, Phe or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or His; Xaa in position 68 is Leu, Val, Trp, Ser, He, Phe, Thr or His; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa in position 74 is He, Me. Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, GIn or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is He, Ser, Arg, Thr or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa in position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Val or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser; Xaa in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His; Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He or Tyr; Xaa in position 96 is Pro, Lys, Tyr, Gly, He or Thr; Xaa in position 97 is He, Val, Lys, Ala or Asn; Xaa in position 98 is His, He, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or His; Xaa in position 100 is Lys, Tyr, Leu, His, Arg, lie, Ser, Gln or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, He, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Lie, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gln His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, lie, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa in position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leu; where optionally from 1 to 14 amino acids of the N-terminus can be omitted and / or optionally from 1 to 15 amino acids of the C-terminus of the modified amino acid sequence of human IL-3; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin-3 (1-133); and (VIII) a factor selected from the group consisting of: colony stimulating factor, a cytokine, a lymphokine, an interleukin; and where Li is a linker capable of linking R-i to R2; provided that at least Ri or R2 is selected from the polypeptide of formula (I), (II) or (III); and said hematopoietic protein can be immediately preceded by (methionine "1), (alanine" 1) or (methionine "2, alanine" 1). The most preferred breakpoints in which the new C-terminus and N-terminus can be made in the polypeptide (I) above, are: 23-24, 24-25, 25-26, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36.37, 37.38, 38-39, 40-41, 41-42, 42-43, 52.53, 53-54, 54-55, 55.56, 77-78, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 109-110, 110- 11 1, 110-111, 111-112, 112-113, 113-114, 114-115-115-116-116-117, 117-118, 118-119, 119-120, 120-121, 121-122 , 122-123, 123-124, 124-125, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131 and 131-132. The most preferred breakpoints in which the new C-terminus and N-terminus can be made in the polypeptide (I) above are: 23-24, 24-25, 31-32, 32-33, 37-38, 38- 39, 82-83, 83-84, 85-86, 86-87, 87-88, 125-126, 126-127 and 131-132. The EPO receptor agonists of the present invention may contain amino acid substitutions such as those described in WO 94/24160 or one or more of the glycosylation sites in Asn24, Asn83 and Asn126 are changed to other amino acids such as, but not limited to. to them, Asp or Glu; omissions and / or insertions. It is also intended that the EPO receptor agonists of the present invention may also have amino acid omissions at either or both ends N and C of the original protein, and omissions of the novel N and / or C ends of the rearranged proteins in sequence, in the formulas shown above. The most preferred breakpoints in which the new C-terminus and N-terminus can be made in the above polypeptide (II) are: 23-24, 24-25, 25-26, 33-34, 34-35, 35- 36, 36.37, 38-39, 39-40, 40-41, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 89-90, 90-81, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102- 103, 103-104, 104-105, and 105-106, respectively.

The most preferred breakpoints in which the new C terminus and the new N terminus can be made in the above polypeptide (II) are: 64-65, 65-66, 92-93 and 93-94, respectively. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (III) are: 36-37, 37-38, 39-40, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100 and 100-101. The most preferred breakpoints, in which the new C-terminus and the new N-terminus can be made in the above polypeptide (III) are: 39-40, 65-66, 89-90, 99-100 and 100-101 . The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (IV) are: 39-39, 39-40, 40-41, 41-42, 48.49, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 60-61, 61-62, 62-63, 64-65, 65-66, 66- 67, 67-68, 68-69, 69-70, 96-97, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141 and 141-142. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (IV) are: 38-39, 48-49, 96-97, 125-126, 132-133 and 141-142. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (V) are: 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66- 67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 99-100, 100-101 and 101-102. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the polypeptide (V) above are: 34-35, 69-70 and 90-91. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (VI) are: 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 108-109, 109-110, 110-11 1, 111-112, 112-113, 113 -114, 114-115, 115-116, 116-1 17, 117-118, 118-119, 119-120, 121-121, 121-122, 122-123, 123-124, 124-125, 125-126 and 126-127. The most preferred breakpoints in which the new C-terminus and the new N-terminus can be made in the above polypeptide (VI) are: 81-82, 108-109, 115-116, 119-120, 122-123 and 125-126. The multifunctional receptor agonist of the present invention may also be represented by the following formula: (T1) a- (L1) b-X1- (L) c-X2- (L2) d- (T2) e X1- (L) C-X2- (L) -Y1- (L) C-Y2 in which: X1 is a peptide comprising an amino acid sequence corresponding to the sequence of residues n + 1 to J of the original protein having the amino acid residues numbered sequentially from 1 to J, with an amino terminus at residue 1; L is an optional linker; X2 is a peptide comprising an amino acid sequence residues 1 to n of the original protein; Y1 is a peptide comprising an amino acid sequence corresponding to the sequence of residues n = 1 to K of the original protein, which has amino acid residues numbered sequentially from 1 to K with an amino terminus at residue 1; Y2 is a peptide comprising an amino acid sequence of residues 1 to n of the original protein; L1 and L2 are optional peptide spacers; n is an integer ranging from 1 to J-1; each of b, c and d is independently 0 or 1; a and e are 0 or 1; provided that a and e can not be both zero; and T1 and T2 are proteins. The multifunctional chimeric hematopoietic receptor agonists of the present invention may contain substitutions, omissions and / or amino acid insertions in the individual protein components of the chimeric molecule. It is also intended that the multifunctional chimeric hematopoietic receptor agonists of the present invention they may have amino acid omissions at either or both N and C ends of the original protein, or omissions from the new N and / or C terminus of the rearranged sequence proteins of the formulas shown above. In a preferred embodiment of the present invention the linker (L), (L1) or (L2), of the above formulas, which connects the N-terminus to the C-terminus, is a polypeptide selected from the group consisting of: Ser; Asn; Gly Thr GlySer; AlaAla; GlySerGIy; GlyGlyGly; GlyAsnGly; GlyAlaGl; GlyThrGIy; AlaSerAla; AlaAlaAla; GlyGlyGlySer SEQ ID NO: 778; GlyGlyGlySerGIyGlyGlySer SEQ ID NO. 779; GlyGlyGlySerGIyGlyGlySerGIyGlyGlySer SEQ ID NO: 780; SerGIyGySerGIyGlySer SEQ ID NO. 781; GluPheGIyAsnMet SEQ ID NO. 782; GluPheGlyGIyAsnMet SEQ ID NO: 783; GluPheGlyGIyAsnGlyGIyAsnMet SEQ ID NO: 784; GlyGlySerAspMetAlaGly SEQ ID NO: 785; SerGIyGIyAsnGly SEQ ID NO: 786; SerGIyGIyAsnGlySerGI GIyAsnGly SEQ ID NO: 787; SerGIyGIyAsnGlySerGIyGIyAsnGlySerGIyGIyAsnGly, SEQ ID NO. 788; SerGIyGlySerGIySerGIyGlySerGIy SEQ ID NO. 789; SerGIyGlySerGIySerGIyGlySerGIySerGIyGiySerGIy SEQ ID NO. 790; GlyGlyGlySerGIyGly SEQ ID NO: 791; GlyGlyGlySerGIyGlyGly SEQ ID NO. 792; GlyGlyGlySerGIyGlyGlySerGIyGly SEQ ID NO: 793 GlyGlyGlySerGI GlyGlySerGIyGlyGlySerGIy SEQ ID NO: 794; GlyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIyGlyGly, SEQ ID NO: 795; GlyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIyGlyGly SERGIy SEQ ID NO: 796; ProProProTfSerProArgProLeuGIyAlaThrAlaProThrAlaGlyGInPro ProLeu SEQ ID NO 797; ProProProTfSerProArgProLeuGIyAlaThrAlaProThr SEQ ID NO: 798; and ValGIuThrValPheHisArgValSerGInAspGlyLeuLeuThrSer SEQ ID NO: 799.

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the chimeric, multifunctional hematopoietic receptor agonists, related microbial expression systems and methods for forming the chimeric multifunctional hematopoietic receptor agonists. The invention also relates to pharmaceutical compositions containing the multifunctional chimeric hematopoietic receptor agonists and methods for using the chimeric multifunctional hematopoietic receptor agonists. In addition to the use of the multifunctional chimeric hematopoietic receptor agonists of the present invention in vivo, it is contemplated that in vitro uses would include the ability to stimulate the bone marrow and the activation and growth of red blood cells before infusing them into patients. Another intended use is for the production of dendritic cells both in vivo and ex vivo. It is believed that the reduced affinity of fusion proteins should be, at least in part, to the inability of the individual portions to achieve their natural conformation when incorporated into the chimeric molecule, or to the steric hindrance between the active site of the individual portions of the fusion protein. This invention solves these limitations by providing chimeric, multifunctional, novel hematopoietic receptor agonists that have a binding affinity comparable to or greater than the individual components of the chimeric molecule.

BRIEF DESCRIPTION OF THE FIGURES Figure 1 schematically illustrates the rearrangement of a protein sequence. The N (N) end and the C (C) end of the native protein are connected by means of a linker, or are directly connected. The protein is open at a breaking point, which creates a new N (new N) and a new C (new C) end, which results in a protein with a new, linear amino acid sequence. A de novo rearranged molecule can be synthesized as a linear molecule and without going through the steps of connecting the original N and C ends, nor opening the protein at the point of rupture. Figure 2 shows a schematic view of method I for creating new proteins, in which the original N-terminus and C-terminus of the natural protein are connected with a linker, and a different N-terminus and C-terminus are created. the protein. In the example shown, the rearrangement of the sequence results in a new gene encoding a protein with a new N-terminus, created at amino acid 97 of the original protein; the original C-terminus (amino acid 174) connected to amino acid 11 (amino acids 1-10 are omitted) through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

Figure 3 schematically shows method II for creating new proteins, in which the original N and C ends of the native protein are connected without a linker, and a different N-terminus and C-terminus of the protein is created. In the example shown, the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein; the original C-terminus (amino acid 174) connected to the original N-terminus and a new C-terminus created at amino acid 96 of the original sequence. Figure 4 shows a scheme of method III to create new proteins, in which the original N and C ends of the natural protein are connected to a linker and different N and C ends of the protein are created. In the example shown, the rearrangement of the sequence results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein; the original C-terminus (amino acid 174) connected to amino acid 1 via a linker region, and a new C-terminus created at amino acid 96 of the original sequence. Figure 5 shows the bioactivity of the multifunctional receptor agonists comprising the fltd receptor agonists pMON32332, pMON32333, pMON32334, and Pmon32335, as compared to recombinant wild type ft3 (Genzyme) in the proliferation analysis of MUTZ-2 cells. MT = simulated transfection.

Figure 6 shows a DNA sequence encoding human mature EPO, based on the sequence of Lin and co-authors (PNAS, 82: 7580-7584, 1985). Figures 7a and 7b show a DNA sequence encoding natural trunk cell factor, based on the sequence of Martin and coauthors (Cell 63: 203-211, 1990). Figure 8 shows a DNA sequence encoding a soluble trunk cell factor, based on the sequence of Langley and co-authors (Archives of Biochemistry and Biophysics 311: 55-61, 1994). i o Figures 9a and 9b show the DNA sequence encoding the mature form of mature flt3 ligand, 209 amino acids, Lyman and co-authors (Oncogene, 11: 1165-1172, 1995). Figure 10 shows the DNA sequence encoding the soluble form, 134 amino acids, ligand flt3, Lyman and co-authors 15 (On8gene 11: 1165-1172, 1995).

DETAILED DESCRIPTION OF THE INVENTION The present invention comprises chimeric, multifunctional hematopoietic receptor agonists, formed from covalently linked polypeptides, each of which can act by means of a different and specific cell receptor, to initiate complementary biological activities. Hematopoiesis demands a series complex of cellular events, in which trunk cells continually generate large populations of cells that mature in all major lineages. There are currently at least 20 known regulators with hematopoietic proliferating activity. Most of these proliferating regulators can only stimulate one or another type of colony formation in vitro; The precise pattern of colony formation stimulated by each regulator is quite distinctive. No pair of regulators stimulates exactly the same pattern of colony formation, as assessed by colony numbers or, more importantly, by the lineage and maturation pattern of the cells that make up the developing colonies. The proliferating responses can be analyzed very easily in simplified in vitro culture systems. One can distinguish three quite different parameters: the alteration in the size of the colony, the alteration in the numbers of colonies, and the lineage of the cell. Two or more factors can act on the progenitor cell, inducing the formation of more progeny, thus increasing the size of the colony. Two or more factors may allow a greater number of progenitor cells to proliferate, either due to subsets other than existing progenitor cells, which respond exclusively to one factor, or because some parents need the stimulation of two or more factors before being able to respond. The activation of additional receptors in a cell, by the use of two or more factors, is likely to increase the mitotic signal, due to the coalescence of signal trajectories initially different, to a common final trajectory, that reaches the nucleus (Metcalf, Nature 339: 27, 1989). Other mechanisms could explain the synergy. For example, if a signaling path is limited by an intermediate activation of an additional signaling path that is caused by a second factor, then this may result in a super-additive response. In some cases, activation of a receptor thio can induce an increased expression of other receptors (Metcalf, Blood, 82: 3515-3523, 1993). Two or more factors may result in a different pattern of cell lines, than those of a single factor. The use of chimeric, multifunctional hematopoietic receptor agonists may have potential clinical advantages, which are the result of a proliferative response, which is not possible by any single factor. The hematopoietic factor receptors and other growth factors can be grouped into two distinct families of related proteins: (1) tyrosine kinase receptors, including those of the epidermal growth factor, M-FEC (Sherr, Blood 75: 1, 1990) and FEC (Yarden and co-authors, EMBO J. 6: 3341, 1987); and (2) hematopoietic receptors, which do not contain a tyrosine kinase domain, but which exhibit obvious homology in their extracellular domain (Bazan, PNAS USA 87: 6034-6038, 1990). Included in the latter group are: erythropoietin (EPO) (D'Andrea and co-authors, Cell 57: 277, 1989), GM-FEC (Gearing and co-authors, EMBO J. 8: 3667, 1989), IL-3 (Kitamura and coauthors, Cell 66: 1165, 1991), G-CEF (Fukunaga and co-authors, J. Bio, Chem., 265: 14008-15, 1990); I L-4 (Harada and co-authors, PNAS USA, 87: 857, 1990), IL5 (Takaki and co-authors, EMBO J., 9: 4367, 1990), IL-6 (Yamasaki and co-authors, Science 241: 825, 1988), IL-7 (Goodwin and co-authors , Cell 60: 941-51, 1990), LIF (Gearing and coauthors, EMBO J., 10: 2839, 1991) and IL-2 (Cosman and co-authors, Mol-lmmunol., 23: 935-94, 1986). Most of this last group of receptors exists in a high affinity form, as heterodimers. After ligand binding, the specific chains are associated with at least one other receptor chain (b chain, g chain). Many of these factors share a common receptor subunit. The a-chains for GM-FEC, IL-3 and IL-5 share the same b chain (Kitamura and co-authors, Cell 66; 1165, 1991), Takaki and co-authors, EMBO J. 10: 2833-8, 1991) and the receptor complexes for I L-6, LIF and IL-11 share a common b chain (gp130) (Taga. And co-authors, Cell 58: 573-81, 1989; Gearing and co-authors, Science 255: 1434-7, 1992). The IL-2, IL-4, IL-7, IL-9 and IL-15 receptor complexes share a common g chain (Kondo and co-authors, Science 262: 1874, 1993; Russeil and co-authors, Science 266: 1042-1045 , 1993, Noguchi and co-authors, Science 262: 1877, 1993, Giri and co-authors, EMBO J. 13: 2822-2830, 1994). The use of a hematopoietic factor of multiplier action can also have a potential advantage by reducing the demands imposed on the factor-producing cells and their induction systems. If there are limitations on a cell's ability to produce a factor, then, by lowering the necessary concentrations of each of the factors and using them in combination, one can usefully reduce the demands on the factor-producing cells. The use of a hematopoietic factor of multiplying action can diminish the quantity of the factors that would be necessary, probably reducing the probability of adverse side effects. The novel compounds of this invention are represented by a formula selected from the group consisting of: R1-L1-R2, R2-L1-R1, R? -R2 and R2-R1 where R1 and R2 are as defined above.

Preferably R2 is a colony stimulating factor with a different activity but complementary to R1. By "complementary activity" is meant the activity that increases or changes the response to another cell modulator. The R1 polypeptide is connected either directly or via a linker segment to the R2 polypeptide. The term "directly" defines chimeric, multifunctional hematopoietic receptor agonists, in which the polypeptides are connected without a peptide linker. Thus, L1 represents a chemical ligation or a segment of polypeptide to which both Ri and R2 are bound in the framework; most commonly, L1 is a linear peptide to which R1 and R2 are connected by amide linkages linking the carboxy terminus of R1 with the amino terminus of L1 and the carboxy terminus of L1 to the amino terminus of R2. By "connected in the frame" means that there is no termination or interruption of the translation between the reading frames of the DNA encoding Ri and R2.

A non-exclusive list of other growth factors, ie, colony stimulating factors (ECF) are: cytokines, lymphokines, interleukins, hematopoietic development factors, which may be connected to (I), (II) or (III) include GM-FEC, G-FEC, ligand m-mpl (also known as TPO or FCDM), M-FEC, erythropoietin (EPO), IL-1, I L-4, I L-2, I L-3, I L-5, I L-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, Ift3 ligand / flk2, hormone human growth, B cell development factor, B cell differentiation factor, eosinophil differentiation factor, and trunk cell factor (FCT), also known as steel factor or c-kit ligand. Additionally, this invention comprises the use of modified Ri or R2 molecules or of mutated or modified DNA sequences encoding those Ri or R2 molecules. The present invention also includes chimeric, multifunctional hematopoietic receptor agonists, in which Ri or R2 is a variant of hIL-3, a variant of c-mpl ligand or a variant of G-FEC. A "hlL-3 variant" is defined as a hlL-3 molecule having amino acid substitutions and / or portions of hlL-3 omitted, such as described in WO 94/12638, WO 94/12639 and WO 95 / 00646, as well as other variants known in the art. A "c-mpl ligand variant" is defined as a c-mpl ligand molecule having amino acid substitutions and / or portions of c-mpl ligand omitted, described in U.S. Patent Application Serial No. 08 / 383,035, as well as other variants known in the art. A "variant of G-FEC" is defined as a G-FEC molecule that has amino acid substitutions and / or portions of G-FEC omitted, as described herein, as well as other variants known in the art. In addition to the above list, the IL-3 variants taught in WO 94/12639 and WO 94/12638, G-FEC receptor agonists described in WO 97/12977; c-mpl receptor agonists, described in WO 97/12978; IL-3 receptor agonists, described in WO 97/12979, can be Ri or R2 of the present invention. As used herein, "variants of I L-3" refer to IL-3 variants taught in WO 94/12639 and WO 94/12638. As used herein, "fusion proteins" refers to the fusion protein taught in WO 95/21197 and WO 95/21254. As used herein, "G-CEF receptor agonists" refers to G-CSF receptor agonists described in WO97 / 12978. As used herein, "c-mpl receptor agonists" refers to c-mpl receptor agonists described in WO97 / 12978. As used here"IL-3 receptor agonists" refers to IL-3 receptor agonists described in WO 97/12979. As used herein, "multifunctional receptor agonists" refers to multifunctional receptor agonists taught in WO 97/12985 . The linker group (L-i) is generally a polypeptide between 1 to 500 amino acids long. The linkers that connect the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of one another; (2) have no tendency to develop an ordered secondary structure that could interfere with the functional domains of the two proteins; (3) have minimum hydrophobic characteristics that could interact with the domains of functional protein and (r) provide spherical separation of Ri and R2, in such a way that R-i and R2 could interact simultaneously with their corresponding receptors in a single cell. The surface amino acids, typically, in the flexible protein regions, include Gly, Asn and Ser. It would be expected that virtually any permutation of amino acid sequences containing Gly, Asn and Ser would satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, can also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence, to facilitate the construction of the multifunctional chimeric hematopoietic receptor agonists. Preferred L ^ linkers of the present invention include sequences selected from the group of formulas (Gly3Ser) p (SEQ ID NO: 861), (Gly4Ser) n (SEQ ID NO 862), (Gly5Ser) n (SEQ ID NO 863) ), (GlynSer) n (SEQ ID NO: 864) or (AlaGlySer) "(SEQ ID NO: 865) An example of a highly flexible linker is the glycine and serine rich separating region, present within the pll I protein of filamentous bacteriophages, for example, bacteriophages M13 or fd (Schaller and coauthors, PNAS USA 72: 737-741, 1975) This region provides a flexible, long spacer region between two domains of the surface protein plll. Separator consists of the amino acid sequence: GlyGlyGlySerGIyGlyGIySerGIyGiyGlySerGIuGlyGlyGlySerGIu GlyGlyGlySerGIuGlyGlyGlySerGIuGlyGlyGlySerGIyGlyGlySer (SEQ ID NO: 800). The present invention also includes linkers in which an endopeptidase recognition sequence is included. Said cleavage site can be valuable for separating the individual components of the chimeric hematopoietic receptor agonist, to determine if they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom protease, postproline dividing enzyme, V8 protease, thrombin. and factor Xa. The peptide linker segments of the hinge region of heavy chain immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship between the fixed polypeptides. Especially useful are those hinge regions in which the cysteines are replaced with serines. Preferred linkers of the present invention include sequences derived from the gamma 2b hinge region of murine IgG, where the cysteines have been changed to serines. These linkers may also include an endopeptidase cleavage site. Examples of such linkers include the following sequences: HeSerGIuProSerGIyProlleSerThrlIeAsnProSerProProSerLys GluSerHisLysSerPro (SEQ ID NO: 801); Y HeGIñuGIyArglIeSerGIuProSerGIyProlleSerThrlIeAsnProSer ProProSerLysGluSerHisLysSerPro (SEQ ID NO: 802).

However, the present invention is not limited by the shape, size or number of linker sequences employed, and the only requirement of the linker is that it does not interfere functionally with the folding or function of the individual molecules of the chimeric hematopoietic receptor agonist. , multifunctional.

DETERMINATION OF THE LINKER L? The length of the amino acid sequence of the linker L2 to be used in Ri and / or R2 can be selected empirically or with guidance from structural information, or using a combination of the two approaches. When structural information is not available, a small series of linkers can be prepared to test the use of a design whose length is varied to cover a scale of 0 to 50 A, and whose sequence is selected to be consistent with surface exposure (hydrophilicity, Hopp and Woods, Mol.Immunol., 20: 483-489, 1983), Kyte and Doolittle, J. Mol. Biol., 157: 105-132; surface area exposed to solvent, Lee and Richards, J. Mol. Biol, 55: 379-400, 1971), and the ability to adopt the necessary conformation without altering the conformation of R1 or R2 (conformationally flexible, Karplus and Schulz, Naturwissenschaften, 72: 212-213, 1985). Assuming a translation average of 2.0 to 3.8 Á per residue, this would mean that the length to be tested would be between 0 and 30 residues, with the preferred scale being from 0 to 15 residues. An example of this empirical series would be the construction of linkers that use a cassette sequence, such as "Gly-Gly-Gly-Ser", repeated n times, where n is 1, 2, 3 or 4. Those who are experts in the subject they will recognize that there are many sequences that vary in length or composition, which can serve as linkers, the primary consideration being not excessively long or short (see Sandhu, Critical Rev. Biotech., 12: 437-452, 1992); if they are too long, the effects of entropy will probably destabilize the three-dimensional folding; and they can also make the folding kinetically impractical; and if they are too short, they will probably destabilize the molecule due to torsional or steric stress. Experts in the analysis of protein structural information will recognize that by using the distance between the chain ends, defined as the distance between the C-alpha carbons, one can define the length of the sequence to be used, or at least limit the number of possibilities that must be proved in an empirical selection of the linkers. They will also recognize that it sometimes happens that the positions of the ends of the polypeptide chain are vainly defined in structural models derived from X-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when they are Certainly, this situation, therefore, needs to be taken into account in order to appropriately estimate the length of the necessary linker. From those residues whose positions are well defined are selected two residues that are close in sequence to the ends of the chain, and the distance between their carbons c-alpha is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, the linkers are then selected with a scale of number of residues (calculated using 2 to 3.8 A per residue). These linkers can be composed of the original, shortened or elongated sequence as needed, and when lengthened, additional residues can be selected to be flexible and hydrophilic, as described above, or optionally the original sequence can be replaced. using a series of linkers, the "Gly-Gly-Gly-Ser" cassette approach mentioned above being an example; or optionally, a combination of the original sequence may be used and the new sequence having the appropriate total length.

DETERMINATION OF THE AMINO AND CARBOXYL EXTREMES OF Ri AND R2 Sequences of Ri and R2 capable of folding into biologically active states, can be prepared by appropriate selection of the initial (amino end) and final (carboxyl end) positions from within the original polypeptide chain, at the same time as it is used. the linker sequence L2 that was described above. It is selected the amino and carboxyl ends of within a common stretch of sequence, termed the breakpoint region, using the guidelines described below. Thus, a novel amino acid sequence is generated by selecting the amino and carboxyl termini from within the same breakpoint region. In many cases, the selection of the new ends will be such that the original position of the carboxyl terminus immediately precedes that of the amino terminus. However, those skilled in the art will recognize that end selections at any point within the region may work, and that these will effectively lead to omissions or additions to the amino or carboxyl portions of the new sequence. It is a central principle of molecular biology that the sequence The primary amino acid of a protein governs the folding of the three-dimensional structure necessary for the expression of its biological function. There are methods known to those skilled in the art to obtain and interpret three-dimensional structural information using X-ray diffraction of protein monocrystals or nuclear magnetic resonance spectroscopy of protein solutions. Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of secondary protein structure (alpha sheets and 3-10 helices)., parallel and anti-parallel betas, investments and twists of chain and curls; Kabsch and Sander, Biopolymers, 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the degree and type of interactions of the residues with each other (Chothia, Ann.Rev. Biochem., 53: 537-572, 1984) and the static and dynamic distribution of conformations along the polypeptide chain (Alber and Mathews, Methods Eztinmol., 154: 511 -533, 1987). In some cases additional information is known about the solvent exposure of the waste; an example is a post-translational carbohydrate binding site that is necessarily on the surface of the protein. When experimental structural information is not available, or it is not feasible to obtain it, there are also methods to analyze the primary sequence of the amino acid, in order to make predictions of the tertiary and secondary protein structure, accessibility to the solvent and the occurrence of turns and curls. Biochemical methods are also sometimes applicable to empirically determine surface exposure, when direct structural methods are not feasible; for example, using the identification of chain cleavage sites, after limited proteolysis, in order to infer surface exposure (Gentile and Salvatore, Eur. J. Biochem., 218: 603-621, 1993). Using thus the experimentally derived structural information or the prediction methods (eg, Srinivisan and Rose, Proteins: Struct, Funct. &Genetics, 22: 81-99, 1995) the parental amino acid sequence is inspected to classify the regions of according to whether or not they are integral for the maintenance of the secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in the periodic secondary structure (alpha and 3-10 sheets) propellers; beta parallel and antiparallel) are regions that should be avoided. Similarly, regions of the amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so-called hydrophobic core of the protein, and should also be avoided for the selection of the amino and carboxyl ends. In contrast, those regions that are known or predicted to be in shallow turns or curls, and especially those regions that are known not to be necessary for biological activity, are the preferred sites for the location of the ends of the polypeptide chain. The continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as the breakpoint region. Additional peptide sequences may also be added to facilitate the purification or identification of hematopoietic, chimeric, multifunctional receptor agonist proteins (eg, poly-His). A strongly antigenic peptide allowing rapid analysis and easy purification of the chimeric, multifunctional, hematopoietic receptor agonist protein can also be added by a specific monoclonal antibody. "Mutant amino acid sequence", "mutant protein", "variant protein", "mutein" or "mutant polypeptide" refer to a polypeptide having an amino acid sequence that varies from a natural sequence due to omissions or amino acid substitutions, or both conditions, or is encoded by a nucleotide sequence that It was intentionally made variant of a natural sequence. "Natural sequence" refers to an amino acid or nucleic acid sequence that is identical to a wild type or natural form of a gene or a protein. Hematopoietic growth factors may be characterized by their ability to stimulate colony formation by hematopoietic progenitor cells. The colonies formed include: erythroids, granulocytes, megakaryocytes, granulocytic macrophages and their mixtures. Many of the hematopoietic growth factors have demonstrated the ability to restore bone marrow function and peripheral red blood cell populations to therapeutically beneficial levels in studies conducted initially in primates and subsequently in humans. Many of these biological activities, or all of them, of hematopoietic growth factors involve signal transduction and high affinity receptor binding. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may exhibit useful properties, such as having similar or greater biological activity when compared to an individual factor, or having an improved half-life or decreased adverse side effects, or a combination of those properties. Chimeric, multifunctional hematopoietic receptor agonists, which have little or no agonist activity, may be useful as antagonists or antigens for the production of antibodies to use in immunology or immunotherapy, as genetic probes or as intermediates used in the construction of other useful hIL-3 muteins. The biological activity of the chimeric, multifunctional, hematopoietic receptor agonist proteins of the present invention can be determined by DNA synthesis in factor-dependent cell lines or by counting the colony forming units in a bone marrow analysis in vitro. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may have an improved therapeutic profile, as compared to single-action hematopoietic agonists. For example, some chimeric, multifunctional hematopoietic receptor agonists of the present invention may have more potent growth factor activity relative to other hematopoietic agonists, without having a similar or corresponding increase in side effects. The present invention also includes the DNA sequences that encode the chimeric, multifunctional hematopoietic receptor agonist proteins, the DNA sequences that are substantially similar and perform substantially the same function, and the DNA sequences that differ from the DNAs encoding the agonists. of hematopoietic, chimeric, multifunctional receptor of the invention, solely due to the degeneracy of the genetic code. They are also included in this invention the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides encoded by these oligonucleotides. Genetic engineering techniques now standard in the art (U.S. Patent 4,935,233 and Sambrook and coauthors, "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) can be used in the construction of the sequences of the present invention. One such method is cassette mutagenesis (Wells and coauthors, Gene 34: 315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides encoding the desired amino acid substitutions in a portion. of the gene between two restriction sites. Synthetic complementary oligonucleotide pairs can be formed, which encode the desired gene, and can be fixed to one another. The DNA sequence of the oligonucleotide would encode the sequence for the amino acids of the desired gene, with the exception of those substituted and / or omitted from the sequence. The plasmid DNA can be treated with the selected restriction endonucleases, then ligated to the bound oligonucleotides. Blended mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Individual colonies can be collected and then the plasmid DNA is examined by restriction analysis and / or DNA sequence determination to identify the plasmids with the desired genes.

The cloning of the DNA sequences of the novel multifunctional hematopoietic agonists of at least one of them with the DNA sequence of the colony stimulating factor can be achieved by the use of intermediary vectors. Alternatively, a gene can be cloned directly into a vector that contains the other gene. The linkers and adapters can be used to connect the DNA sequences, as well as the replacement of the lost sequences, where a restriction site was internal with respect to the region of interest. Thus, the genetic material (DNA) encoding a polypeptide, peptide linker and the other polypeptides is inserted into a suitable expression vector, which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism was developed and the protein is isolated by normal techniques. Accordingly, the resulting product is a new protein having a colony stimulating factor linked by a linker region to a second colony stimulating factor. Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these hematopoietic receptor agonists., chimeric, multifunctional. These vectors contain the novel DNA sequences, described above, which encode the novel polypeptides of the invention. Suitable vectors that can transform the microorganisms capable of expressing the chimeric, multifunctional hematopoietic receptor agonists include expression vectors comprising nucleotide sequences encoding the agonists of Multipurpose chimeric hematopoietic receptor, connected to the transcriptional and translational regulatory sequences, which are selected according to the host cells used. Vectors that incorporate modified sequences as described above are included in the present invention and are useful in the production of hematopoietic, chimeric, multifunctional receptor agonist polypeptides. The vector employed in the method also contains regulatory sequences selected in operative association with the DNA coding sequences of the invention, and which are capable of directing their reproduction and expression in selected host cells. As another aspect of the present invention, a method is provided for producing the novel, multifunctional, chimeric hematopoietic receptor agonists. The method of the present invention comprises culturing suitable cells or suitable cell lines, which have been transformed with a vector containing a DNA sequence encoding the expression of a novel multifunctional chimeric hematopoietic receptor agonist. Suitable cells or cell lines can be bacterial cells. For example, the various E. coli cells are well known as host cells in the field of biotechnology. Examples of those strains include strains JM101 of E. coli (Yanish-Perro and co-authors, Gene 33: 103-119, 1985) and MON 105 (Obukowicz and co-authors, Applied Environmental Microbiology, 58: 1511-1523, 1992). The expression of the protein is also included in the present invention chimeric, multifunctional hematopoietic receptor agonist, which uses a chromosomal expression vector for E. coli, based on the bacteriophage Mu (Weinberg and co-authors, Gene 126: 25-33, 1993). Various strains of B. subtilis can also be used in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for the expression of the polypeptides of the present invention. When they are expressed in the cytoplasm of E. coli, the gene encoding the hematopoietic, chimeric, multifunctional receptor agonists of the present invention can also be constructed such that codons are added at the 5 'end of the gene to codify Met "2-Ala" 1 or Met "1 at the N-terminus of the protein.The N-termini of the proteins made in the cytoplasm of E. coli are affected by post-translational processing by methionine-aminopeptidase (Ben Bassat et al. coauthors, J. Bac, 169: 751-757, 1987) and possibly by other peptidases so that, by expression of methionine, the N-terminus is cleaved. The multifunctional chimeric hematopoietic receptor agonists of the present invention may include agonist polypeptides of multifunctional chimeric hematopoietic receptors that have Met "1, Ala" 1 or Met "2-Ala" 1 at the N-terminus. These mutant, multifunctional chimeric hematopoietic receptor agonists can also be to be expressed in E. coli by fusing a signal peptide of secretion to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. You can find more strategies to get high expression gene level of E. coli, in Savvas, C.M. (Microbiological Reviews, 60: 412-538, 1996). Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary (CHO) cells. General methods for the expression of foreign genes in mammalian cells are summarized in Kaufman, R. J., 1987), Genetic Engineering, Principles and Methods, volume 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter, capable of functioning in mammalian cells, drives the transcription of a coding region of eukaryotic secretion signal peptide, which is translationally connected to the coding region, for the chimeric, multifunctional hematopoietic receptor agonist. For example, plasmids can be used, such as pcDNA I / Neo, pRc / RSV and pRcA CM (obtained from Invitrogen Corp., San Diego, California). The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, ML Y co-authors, Proc. Natl. Acad. Sci, USA, 84: 2638-2642, 1987 ). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells. Said cells can be, for example, the lines COS7, HeLa, BHK, CHO or the mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted in the medium can be recovered by common biochemical approaches, after transient expression for 24 to 72 hours after transfection of the cells, or afthe establishment of stable cell lines, afselection for resistance to the antibiotic. The selection of mammalian host cells and methods for transformation, cultivation, amplification, selection and production of product, as well as purification, are known in the art. See, for example, Gething and Sambrook, Nature, 294: 620-625, 1981), or alatively, Kaufman and co-authors, Mol. Cell. Biol., 5 (7): 1750-1759, 1985) or Howley and co-inventors, U.S. Patent No. 4,419,446. Another suitable mammalian cell line is the COS-1 monkey cell line. A similarly useful mammalian cell line is the CV-1 cell line. When desired, insect cells can be used as host cells in the method of the present invention. See, for example, Miller and coauthors, Genetic Engineering, 8: 277-298 (Plenum Press 1986) and the references cited therein. Additionally, general methods for the expression of foreign genes in insect cells using Baculovirus vectors are described, for example, in Summers, MD, and Smith, GE, 1987) - A Manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricuitural Experiment Station Bulletin No. 1555. An expression vector is constructed consisting of a Baculovirus transfer vector in which a strong Baculovirus promo(such as the tetrahedral promo drives the transcription of a coding region of a signal peptide. eukaryotic secretion, which is translationally connected to the coding region for the hematopoietic receptor agonist polypeptide, chimeric, multifunctional. For example, plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, California, E.U.A.) can be used. Afthe construction of the vector carrying the gene coding for the chimeric, multifunctional hematopoietic receptor agonist polypeptide, two micrograms of this DNA are co-transfected with a microgram of Baculovirus DNA (see Summers and Smith, 1987), into insect cells. , strain SF9. Pure recombinant baculovirus carrying the chimeric, multifunctional, hematopoietic receptor agonist is used to infect cultured cells, for example, in serum-free Excell 401 medium (JRH Bioscience, Lenexa, Kansas, E.U.A.). The chimeric, multifunctional hematopoietic receptor agonist secreted into the medium can be recovered by normal biochemical approaches. The supernatants of mammalian or insect cells expressing the chimeric, multifunctional, hematopoietic receptor agonist protein can be concentrated first, using any of a number of commercial concentration units. The chimeric, multifunctional, hematopoietic receptor agonists of the present invention may be useful in the treatment of diseases characzed by decreased levels of myeloid, erythroid, lymphoid or megakaryocyte cells of the hematopoietic system, or combinations thereof. In addition, they can also be used to activate mature myeloid and / or lymphoid cells. Among the conditions amenable to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white blood cells) in the peripherally blood. Leukopenia can be induced by exposure to certain viruses or irradiation. It is often a side effect of various forms of therapy against cancer, for example, exposure to chemotherapeutic drugs, irradiation and infection or hemorrhage. The therapeutic treatment of leukopenia with these chimeric, multifunctional, hematopoietic receptor agonists of the present invention can avoid undesirable side effects, caused by treatment with currently available drugs. The chimeric, multifunctional, hematopoietic receptor agonists of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of conditions such as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may be useful in the treatment or prevention of thrombocytopenia. Currently, the only therapy for thrombocytopenia is platelet transfusion, which is expensive and carries significant risks of infection (HIV, HBV) and alloimmunization. The multifunctional chimeric hematopoietic receptor agonist can alleviate or decrease the need for platelet transfusion. Thrombocytopenia can be the result of genetic defects, such as the Fanconi, Wiscott-Aldrich or May Heggiin anemia syndromes. Acquired thrombocytopenia can be the result of auto-antibodies or allo-antibodies, such as immunological thrombocytopenia purpura, systemic lupus erythematosus, hemolytic anemia or fetal-maternal incompatibility. In addition, splenomegaly, disseminated intravascular coagulation, thrombotic trobocytopenic purpura, infection of prosthetic heart valves, may result in thrombocytopenia. Severe thrombocytopenia may also result from chemotherapy and / or irradiation therapy or cancer. Thrombocytopenia can also be the result of invasion of the marrow by carcinoma, lymphoma, leukemia or fibrosis. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may be useful in the mobilization of progenitor and hematopoietic stem cells in peripheral blood. Peripheral blood, derived from progenitors, has been shown to be effective in the reconstitution of patients in the establishment of autologous marrow transplants. Hematopoietic growth factors, including G-FEC and GM-FEC have also been shown to increase the number of circulating progenitor and trunk cells in the peripheral blood. This has simplified the procedure for the collection of peripheral trunk cells and dramatically decreased the cost of the procedure by decreasing the number of necessary pheresis. The chimeric, multifunctional hematopoietic receptor agonist may be useful in the mobilization of stem cells and further increases the efficiency of peripheral stem cell transplantation.

The chimeric, multifunctional, hematopoietic receptor agonists of the present invention may also be useful in the ex vivo expansion of hematopoietic progenitors and stem cells. Colony stimulating factors (ECF), such as hIL-3, have been administered alone, co-administered with other Eor in combination with bone marrow transplants, after high-dose chemotherapy to treat neutropenia and thrombocytopenia, which are frequently the result of said treatment. However, the period of severe neutropenia and severe thrombocytopenia may not be completely eliminated. The myeloid lineage, which consists of monocytes (macrophages), granulocytes (including neutrophils) and megakaryocytes, is critical to prevent infections and bleeding, which can be a threat to life. Neutropenia and thrombocytopenia can also be the result of diseases, genetic disorders, drugs, toxins, irradiation and many therapeutic treatments, such as conventional therapy in oncology. Bone marrow transplants have been used to treat this patient population. However, there are several problems associated with the use of bone marrow to reconstitute a threatened hematopoietic system, including: 1) the number of stem cells present in the bone marrow, spleen or peripheral blood is limited; 2) graft versus host disease; 3) rejection of graft and 4) possible contamination with tumor cells. Stem cells make up a very small percentage of the nucleated cells present in the bone marrow, spleen and blood peripheral. It is clear that there is a response to the dose in such a way that a larger number of stem cells would increase hematopoietic recovery. Therefore, in vitro expansion of stem cells should improve hematopoietic recovery and patient survival. Bone marrow from an allogeneic donor has been used to provide bone marrow for transplantation. However, graft status against host disease and graft rejection limits bone marrow transplantation even in recipients with consanguineous donors with equal HLA. An alternative for allogeneic bone marrow transplants is autologous bone marrow transplantation. In autologous bone marrow transplants, some of the patient's own bone marrow is harvested, before the myeloablasive therapy, for example, chemotherapy at high doses, and the patient is transplanted again later. Autologous transplants eliminate the risk of graft against host disease and graft rejection. However, autologous bone marrow transplants still present problems in terms of the limited number of stem cells in the marrow and possible contamination with tumor cells. The limited number of stem cells can be resolved by ex vivo expansion of the stem cells. In addition, stem cells can be isolated specifically, based on the presence of specific surface antigens, such as CD34 +, in order to decrease contamination with tumor cells, of the bone marrow graft. The following patents contain additional details on separating trunk cells, CD34 + cells, culturing the cells with factors hematopoietic, the use of cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy. 5,061, 620 refers to compositions comprising hematopoietic stem cells, human, provided by separating trunk cells from dedicated cells. 5,199,942 describes a method for autologous hematopoietic cell transplantation, comprising: (1) obtaining hematopoietic progenitor cells from a patient; (2) ex vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand, c-kit ligand, GM-FEC, IL-1, GM-FEC / IL-3 fusion protein and its combinations; (3) administer the cellular preparation to a patient. 5,240,856 refers to a cell separator that includes an apparatus for automatically controlling the process of cell separation. WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a mixture of cells. WO 91/18972 discloses methods for culturing a bone marrow in vitro, incubating a suspension of bone marrow cells using a hollow fiber bioreactor. WO 92/18615 relates to a method for maintaining and expanding bone marrow cells in a culture medium containing specific mixtures of cytokines, for use in transplants.

WO 93/08268 describes a method for selectively expanding trunk cells, comprising the steps of (a) separating CD34 + stem cells from other cells; and (b) incubating the separated cells in a selective medium, such that the stem cells are selectively expanded. WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood. WO 93/18648 refers to a composition comprising human neutrophil precursor cells, which have a high content of myeloblasts and promyelocytes, to treat acquired or genetic neutropenia. WO 94/08039 describes an enrichment method for human hematopoietic stem cells, by selection of cells expressing c-kit proteins. WO 94/11493 describes a population of trunk cells that are CD34 + and small in size, which are isolated using a counterflow method of elutriation. WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a heterogeneous, nucleated cell population from a heterogeneous cell mixture. WO 94/25848 describes an apparatus for cell separation for the collection and manipulation of target cells.

The long-term culture of strongly enriched CD34 + precursors, of hematopoietic progenitor cells, of human bone marrow in cultures containing IL-1 a, IL-3, IL-6 or GM-FEC is discussed in Brandt and co-authors, J. Clin. . Invest., 86: 932-941, 1990). One aspect of the present invention provides a method for the ex vivo selective expansion of stem cells. The term "trunk cell" refers to hematopoietic stem cells, totipotent, as well as to early precursors and progenitor cells that can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the differentiation and proliferation of cells The present invention provides a method for selective ex vivo expansion of stem cells, comprising the steps of: (a) separating throne cells from other cells; b) cultivating said separated stem cells with selective media containing one or more hematopoietic, chimeric, multifunctional receptor agonist proteins, and (c) harvesting said trunk cells, trunk cells, as well as the progenitor cells involved, destined to become neutrophils, erythrocytes, platelets, etc., can be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as CD34, which are present on the surface of those cells and / or by morphological characteristics. phenotype for a highly enriched human stem cell fraction is reported as CD34 +, Thy-1 + and lin-, p However, it should be understood that the present invention is not limited to the expansion of this population of stem cells. The human stem cell fraction, enriched in CD34 + can be separated by several reported methods, which include affinity columns or blood cell cytometry, magnetic beads or flow cytometry, using antibodies directed to surface antigens, such as CD34 +. Additionally, physical separation methods, such as counter-flow elutriation, can be used to enrich hematopoietic progenitors. The progenitors of CD34 + are heterogeneous and can be divided into several subpopulations characterized by the presence or absence of coexpression of different molecules associated with the cell surface, associated with different lineages. The majority of immature progenitor cells do not express any marker associated with lineage, known, such as HLA-DR or CD38; but they can express CD90 (thy-1). Other surface antigens, such as CD33, CD38, CD41, CD71, HLA-DR or c-kit, can also be used to selectively isolate hematopoietic progenitors. Separate cells can be incubated in selected medium in a culture flask, a sterile bag or in hollow fibers. Various colony stimulating factors can be used in order to selectively expand the cells. Representative factors that have been used for the ex vivo bone marrow expansion include: ligand c-kit, IL-3, G-FEC, GM-FEC, IL-1, IL-6, IL-11, ligand flt-3 or their combinations. The proliferation of trunk cells can be monitored by enumerating the number of stem cells and other cells, by common and current techniques (for example, hemacytometer, UFC, LTCIC) or by flow cytometry, before and after incubation. Various methods have been reported for ex vivo expansion of stem cells, using numerous methods of selection and expansion, using various colony stimulating factors, including c-kit ligand (Brandt and co-authors, Blood, 83: 1507-1514 (1994 ); McKenna and co-authors, Blood, 86: 3413-3420 (1995)), I L-3 (Brandt and co-authors, Blood 83: 1507-1514 (1994), Sato and co-authors, Blood 82: 3600-3609 (1993) , GM-FEC (Sato and coauthors, Blood 82: 3600-3609 (1993), IL-1 (Muench and co-authors, Blood 81: 3463-3473 (1993)), IL-6 (Sato and co-authors, Blood 82: 3600 -3609 (1993)), IL-11 (Lemoli and co-authors, Exp. Hem., 21: 1668-1672 (1993), Sato and co-authors, Blood 82: 3600-3609 (1993)), ligand Ift (McKenna and co-authors , Blood 86: 3413-3420 (1995)), and / or combinations thereof (Brandt and co-authors, Blood 83: 1507-1514 (1994), Haylock and co-authors, Blood, 80: 1405-1412 (1992), Koller and co-authors , Biotechnology, 11: 358-363 (1993), (Lemoli and co-authors, Exp. Hem., 21: 1668-1672 (1993)), McKenna and co-authors, Blood 86: 3413-3420 (1995), Muench and coauthors, Blood 81: 3463-3473 (1993), Patchen and coauthors, Biotherapy 7: 13-26 (1994), Sato and co-authors, Blood 82: 3600-3609 (1993 ), Smith and co-authors, Exp. Hem., 21: 870-877 (1993), Steen and co-authors, Stem Cells 12: 214-224 (1994), Tsujino and co-authors, Exp. Hem., 21: 1379-1386 ( 1993)). Among the individual colony stimulating factors, hIL-3 has been shown to be one of the most potent for expanding CD34 + cells in peripheral blood (Sato and co-authors, Blood, 82: 3600- 3609 (1993), Kobayashi and co-authors, Blood 73: 1836-1841 (1989)). However, no single factor has proven to be as effective as the combination of multiple factors. The present invention provides methods for ex vivo expansion using chimeric, multifunctional hematopoietic receptor agonists, which are more effective than an individual factor alone. Another aspect of the invention provides methods for supporting and / or expanding hematopoietic precursor cells, which includes inoculating the cells in a culture vessel containing a culture medium that has been conditioned by exposure to a stromal cell line, such as HS- 5 (WO 96/02662, Roecklein and Torok-Strob, Blood, 85: 997-1105, 1995), which has been supplemented with a chimeric receptor agonist., hematopoietic, multifunctional, of the present invention. It is also contemplated that the uses of the chimeric, hematopoietic, multifunctional receptor agonists of the present invention include blood banking applications, where EPO receptor agonists are given to a patient to increase the number of red blood cells and blood products. the blood that is removed from the patient, before some medical procedure. The blood products are stored and transfused back to the patient after the medical procedure. Additionally, it is contemplated that the uses of chimeric, hematopoietic, multifunctional receptor agonists include giving chimeric, hematopoietic, multifunctional receptor agonists to a donor of blood, before the blood donation, to increase the number of red blood cells, thus allowing the donor to give more blood, safely. Another projected clinical use of growth factors has been in in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the prolonged life span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the body, hematopoietic progenitor cells are good candidates for the transfection of ex vivo genes. In order to have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell, it is necessary to stimulate cell division and DNA replication. Hematopoietic stem cells perform their cycle at a very low frequency, which means that growth factors can be useful to promote gene transduction and thereby increase clinical prospects for gene therapy. Potential applications of gene therapy (see Crystal, Science 270: 404-410 (1995)) include: 1) the treatment of many congenital metabolic disorders and many immunodeficiencies (Kay and Woo, Trends Genet., 10: 253-257 ( 1994)); 2) neurological disorders (Friedmann, Trends Genet., 10: 210-214 (1994)); 3) cancer (Culver and -Blaese, Trends Genet., 10: 174-178 (1994)) and 4) infectious diseases (Gilboa and Smith, Trends Genet., 10: 139-144 (1994)).

There are a variety of methods, known to those skilled in the art, for introducing genetic material into a host cell. Numerous vectors, both viral and non-viral, have been developed to transfer therapeutic genes to primary cells. Viral basis vectors include: 1) recombinant, reproductively deficient retroviruses (Boris-Lawrie and Temin, Curr Opin, Genet, Dev., 3: 102-109 (1993), Boris-Lawrie et al., Temin, Annal. New York Acad. Sci., 716: 59-71 (1994), Miller, Current Top, Microbiol. Immunol., 158: 1-24 (1992)) and recombinant adenovirus deficient in reproduction (Berkner, BioTechniques, 6: 616- 629 (1988), Berkner, Current Top, Microbiol, Immunol., 158: 39-66 (1992), Brody and Crystal, Annal, New York Acad. Sci., 716: 90-103 (1994)). Non-viral base vectors include protein / DNA complexes (Christian and co-authors, PNAS USA, 90: 2122-2126 (1993) m, Curiel and co-authors, PNAS USA 88: 8850-8854 (1991), Curiel, Annal. New York Acad. Sci. 716: 36-58 (19949), electroporation and liposome-mediated delivery, such as cationic liposomes (Farhood et al., Annal, New York Acad. Sci., 716: 23-35 (1994)). present invention provides an improvement in existing methods for expanding hematopoietic cells, which has introduced new genetic material, as it provides methods using hematopoietic, chimeric, multifunctional agonist and receptor proteins, which have improved biological activity, which includes an activity that is not see in no colony stimulating factor, individually.

Many drugs can cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDl, alkylating agents and anti-metabolites used in chemotherapy, antibiotics, such as chloramphenicol, penicillin, ganciclovir, daunomycin and sulfas-based drugs; phenothiazones, tranquilizers such as meprobamate, analgesics, such as aminopyrine and dipyrone; anticonvulsants, such as phenytoin or carbamazepine; antithyroid drugs, such as propylthiouracil and methimazole; and diuretics. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may be useful for preventing or treating bone marrow suppression or hematopoietic deficiencies that frequently occur in patients treated with these drugs. Hematopoietic deficits may also occur as a result of viral, microbial or parasitic infections, burns and as a result of the treatment of kidney diseases or renal failure., for example, dialysis. The chimeric, multifunctional hematopoietic receptor agonists of the present invention may be useful in the treatment of such hematopoietic deficiencies. The treatment of hematopoietic deficiency may include the administration of a pharmaceutical composition containing the multifunctional chimeric hematopoietic receptor agonists to a patient. The chimeric, multifunctional, hematopoietic receptor agonists of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells, treating those cells in vitro with the hematopoietic, chimeric, multifunctional receptor agonist proteins of the present invention, before injecting the cells into a patient. A number of immunodeficiencies can also be beneficially affected, for example, in T and / or B lymphocytes, or immunological disorders, for example, rheumatoid arthritis, by treatment with the chimeric, multifunctional, hematopoietic receptor agonists of the present invention. Immunodeficiencies can be the result of viral infections, for example, HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy, or as a result of other medical treatments. The chimeric, multifunctional hematopoietic receptor agonists of the present invention can also be employed alone or in combination with other colony stimulating factors in the treatment of other red blood cell deficiencies, including thrombocytopenia (platelet deficiency) or anemia. Other uses for these novel polypeptides are in vivo or ex vivo treatment of patients recovering from bone marrow transplants, and in the development of monoclonal or polyclonal antibodies generated by common and current methods for use in diagnostic or therapeutic use. Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the receptor agonists. hematopoietic, chimeric, multifunctional, of the present invention, in a mixture with a pharmaceutically acceptable carrier. That composition can be administered parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention preferably has the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of said protein solution, parenterally acceptable, giving due consideration to pH, isotonicity, stability and the like, is within the knowledge of those skilled in the art. Another intended use of the chimeric, multifunctional, hematopoietic receptor agonists of the present invention is for the generation of larger numbers of dendritic cells, of precursors, to be used as adjuvants for immunization. Dendritic cells play a crucial role in the immune system. They are the cells that present professional antigen more efficient in the activation of T cells at rest and are the cells that present main antigen for the activation of innocent T cells in vivo and, in this way, for the initiation of primary immunological responses. Efficiently internalize, process and present tumor-specific (Ag) antigens, soluble. Dendritic cells have the unique ability to bind lucid T cells and respond to the Ag encounter by rapidly upregulating the expression of the major histocompatibility complex (PCH) and co-stimulatory molecules, the production of cytokines and the migration towards lymphatic organs Since dendritic cells are of central importance for sensitizing the host against a neo-antigen for CD4-dependent immunological responses, they also play a crucial role in the generation and regulation of tumor immunity. Dendritic cells originate from a precursor of CD34 + of bone marrow, common to granulocytes and macrophages, and the existence of a dendritic cell colony forming unit (CFU-CD) that gives rise to colonies of pure dendritic cells, has been established in humans. In addition, a CD14 + intermediate subsequent to CFU has been described, with the potential to differentiate the dendritic or macrophage cell path under different cytokine conditions. This bipotential precursor is present in the bone marrow, cord blood and peripheral blood. Dendritic cells have been isolated based on specific cell surface markers, such as CD1a +, CD3-, D4-, CD20- CD40 +, CD80 + and CD83 +, to delineate the maturation of cultured dendritic cells. Strategies based on dendritic cells provide a method to increase the immune response against tumors and infectious agents. AIDS is another disease for which dendritic cell therapies can be used, since dendritic cells play a major role in promoting the reproduction of HIV-1. An immunotherapy requires the generation of dendritic cells from cancer patients, their in vitro exposure to tumor Ag, derived from tumor masses surgically removed, and the reinjection of those cells in patients with tumor. The relatively crude membrane preparations of tumor cells are sufficient as sources of tumor antigen, avoiding the need for molecular identification of the tumor antigen. It can also be the tumor antigen synthetic peptides, carbohydrates or nucleic acid sequences. Additionally, concomitant administration of cytokines, such as chimeric, multifunctional hematopoietic receptor agonists of the present invention, may facilitate the induction of immunity to tumors. It is envisioned that immunotherapy can be performed in a live setting, where the hematopoietic, chimeric, multifunctional receptor agonists of the present invention are administered to a patient having a tumor, alone or with other hematopoietic growth factors, for increase the number of dendritic cells and the endogenous tumor antigen is present in the dendritic cells. It is also contemplated that in vivo immunotherapy can be done with the exogenous antigen. It is also contemplated that the immunotherapy treatment may include the mobilization of dendritic cell or mature dendritic precursors, administering the chimeric, multifunctional, hematopoietic receptor agonists of the present invention, alone or with other hematopoietic growth factors, to the patient; removing the dendritic cell precursors or mature dendritic cells from the patient, exposing the dendritic cells to antigen and returning the dendritic cells to the patient. Additionally, dendritic cells that have been removed may be cultured ex vivo with the hemopoietic, chimeric, multifunctional receptor agonists of the present invention, alone or with other hematopoietic growth factors, to increase the number of dendritic cells, before exposing the antigen. Dendritic cell-based strategies also provide a method to reduce the immunological response to autoimmune diseases. Studies on dendritic cells have been hampered greatly by difficulties in the preparation of cells, in sufficient numbers and in a reasonably pure form. In an ex vivo cell expansion scenario, the granulocyte-macrophage colony stimulating factor (FEC-GM) and tumor necrosis factor-alpha (TNF-alpha) cooperate in the ex vivo generation of dendritic cells of hematopoietic progenitors (cells CD34 +), recovered from bone marrow, cord blood or peripheral blood and ligand flk-2 / flt-3 and ligand c-kit (trunk cell factor (FCT)) synergize to increase the generation of dendritic cells, induced by FEC-GM plus FNT-alpha (Siena, S. Y co-authors, Experimental Hematology, 23: 1463-1471 (1995).) An ex vivo expansion method of dendritic cell or dendritic cell precursors is also provided. The use of the chimeric, multifunctional hematopoietic receptor agonists of the present invention to give sufficient quantities of dendritic cells for immunotherapy The dosage regimen involved in a method for treating congenital described above, will be determined by the attending physician, considering various factors that modify the action of drugs, for example, the condition, body weight, sex and diet of the patient, the severity of any infection, the time of administration and other clinical factors. In general, a daily regimen may be in the range of 0.2-150 μg of chimeric, multifunctional, hematopoietic receptor agonist protein, per kilogram of body weight. Dosages would be adjusted for the activity of a chimeric, multifunctional, hematopoietic receptor agonist protein, and it would not be unreasonable to note that dose regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of weight of the body, by day. Additionally, there may be specific circumstances in which the doses of hematopoietic, chimeric, multifunctional receptor agonist would be adjusted to more or less than the 0.2-150 microgram per kilogram of body weight scale. These include coadministering with other colony stimulating factors or IL-3 variants or growth factors; co-administration with chemotherapeutic drugs and / or irradiation; the use of chimeric, multifunctional, glycosylated hematopoietic receptor agonist protein; and various cases related to the patient, mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other colony stimulating factors (ECF), cytokines, lymphokines, hematopoietic and interleukin growth factors, appropriate, for simultaneous or serial co-administration with the polypeptides of the present invention include: FEC-GM, FEC-G, ligand c-mpl (also known as TPO or FCDM), M-FEC, erythropoietin (EPO), IL-1, I L-4, IL-2, IL -3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, ligand Ift3 / flk2, B cell growth factor, B cell differentiation factor and eosinophil differentiation factor, trunk cell factor (FCT), also known as steel factor or c-kit ligand, or combinations thereof. The doses mentioned above would be adjusted to compensate for those additional components in the therapeutic composition. The progress of the treated patient can be monitored by periodic determination of the hematological profile, for example, by differential cell count and the like.

MATERIALS AND METHODS Unless otherwise noted, all specialty chemicals were obtained from Sigma, Co. (St. Louis, MO, E.U.A.). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beveriy, MA, E.U.A.) or from Boehringer Mannheim (Indianapolis, IN, E.U.A.).

TRANSFORMATION OF E. COLI STRAINS E. coli strains, such as DH5aMR (Life Technologies, Gaithersburg, MD, USA) and TG1 (Amersham Corp., Arlington Heights, IL, USA), are used for transformation or ligation reactions and are the source of the plasmid DNA for transfect mammalian cells. Strains of E. coli, such as JM101 (Yanisch-Perro and co-authors, Gene, 33: 103-119, 1985) and MON105 (Obukowicz and co-authors, Appl. And Envir. Micr., 58: 1511-1523, 1992) can to be used to express the multifunctional chimeric hematopoietic receptor agonist of the present invention in the cytoplasm or in the periplasmic space. MON105 ATCC # 55204: F-, lambda-, IN (rrnD, rrE) 1, rpoD +, rpoH358. DH5aMR: F-, phi80dlacZdeltaM15, delta (lacZYA-argF) U169, deoR, recAl, endAl, hsdR17 (rk-, mk +), phoA, supE44lambda-, thi-1, gyrA96, relA1). TG1: delta (lac-pro), supE, thi-1, hsdD5 / F '(traD36, proA + B +, laclq, lacZdeltaM15). JM101 ATCC # 33876: delta (pro lac), supE, thi, F '(traD36, proA + B +, laclq, lacZdeltaM15). DH5aMR subcloning efficiency cells were purchased as competent cells and are ready for transformation using the manufacturer's protocol, at the same time as both strains of E. coli TG1 and MON105 they become competent to take DNA using a CaCl2 method. Typically 20 to 50 ml of cells are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto yeast extract, 150 mM NaCl) at an approximate density of 1.0 optical density unit at 600 nanometers (OD600) when it is measured by a Bausch & amp; spectrophotometer; Lomb Spectronic (Rochester, NY, E. U. A). The cells are harvested by centrifugation and resuspended in one fifth of the culture volume of CaCl2 solution (50 mM CaCl2, 10 mM Tris-CI, pH 7.4) and kept at 4 ° C for 30 minutes. minutes The cells are harvested by centrifugation and resuspended in a tenth of the culture volume of CaCl2 solution. The DNA bound to 0.2 ml of these cells is added and the samples are kept at 4 ° C for 30-60 minutes. The samples are moved at 42 ° C for 2 minutes and 1.0 ml of LB is added before shaking the samples at 37 ° C for one hour. Spread the cells of these samples on plates (LB medium plus 1.5% Bacto-agar) containing ampicillin (100 micrograms / ml), when selected for ampicillin-resistant transformants, or spectinomycin (75 ug / ml) when it is selected for spectinomycin-resistant transformants. The plates are incubated overnight at 37 ° C. Collect the colonies and inoculate in LB plus the appropriate antibiotic (100 ug / ml of ampicillin or 75 ug / ml of spectinomycin) and develop them at 37 ° C while shaking.

METHODS TO CREATE GENES WITH NEW EXTREME N / EXTREME METHOD I: - Creation of genes with new N-terminus / C-terminus, which contains a linker region (L2). Genes can be made with new N-terminus / C-terminus containing a linker region (L2) by separating the C-terminus and the N-terminus, following the method described in L. S. Mullins and coauthors (J. Am. Chem. Soc, 116, 5529-5533, 1994). Multiple steps of amplifications are used by polymerase chain reaction (PCR) to rearrange the DNA sequence encoding the primary amino acid sequence of the protein. The steps are illustrated in Figure 2. In the first step, the first sensitizer set ("new start" and "linker start") is used to create and amplify, from the original gene sequence, the DNA fragment. ("fragment start") containing the sequence encoding the new N-terminal portion of the new protein, followed by the linker (L2) connecting the C-terminal and N-terminal ends of the original protein. In the second step the second sensitizer set ("new high" and "linker high") is used to create and amplify, from the original gene sequence, the DNA fragment ("fragment height") encoding the same linker that was used before, followed by the new C-terminal portion of the new protein. The "new start" and "new high" sensitizers are designed to include the sites of appropriate restriction that allow the cloning of the new gene in the expression plasmids. Typical PCR conditions are a melting cycle at 95 ° C for two minutes; 25 cycles of denaturation at 94 ° C for one minute, fixation at 50 ° C for one minute and extension at 72 ° C for one minute; plus an extension cycle at 72 ° C for 7 minutes. A Perkin Elmer GeneAmp PCR core reagent kit is used. A reaction of 100 ul contains 100 pmol of each sensitizer and one ug of template DNA; and 1x PCR regulator, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. The PCR reactions are performed in a model 480 DNA cyclic thermal treater (Perkin Elmer Corporation, Norwalk, CT, E.U.A.). The "fragment start" and the "fragment height", which have complementary sequence in the linker region, and the coding sequence for the two amino acids on both sides of the linker, are connected to each other in a third step of PCR to form the full-length gene, which encodes the new protein. The "fragment start" and "fragment top" DNA fragments are resolved in a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex gel extraction kit (Qiagen). These fragments are combined in equimolar amounts, heated to 70 ° C for 10 minutes and allowed to cool to allow fixation by means of their shared sequence in "linker start" and "linker high". In the third step of CPR, sensitizers are added "new start "and" new high "to the fixed fragments to create and amplify the new full-length N-terminal / C-end gene.The typical RCP conditions are a melting cycle at 95 ° C for 2 minutes, 25 cycles of denaturation at 94 ° C for one minute, fixation at 60 ° C for one minute and extension at 72 ° C for one minute, plus an extension cycle at 72 ° C for 7 minutes, using a PCR core reagent kit Perkin Elmer GeneAmp A 100-ul reaction contains 100 pmol of each sensitizer and approximately 0.5 ug of DNA, and 1x of RCP buffer, 200 uM of dGTP, 200 uM of dATP, 200 uM of dTTP, 200 uM of dCTP, 2.5 units of AmpliTaq DNA polymerase and 2 mM MgCl2 PCR reactions are purified using a Wizard RCP Preps (Promega).

METHOD II.- CREATION OF GENES WITH NEW EXTREME N / EXTREME C WITHOUT LINKING REGION Genes can be made with a new N-terminus / C-terminus without a linker, by connecting the original N and C ends, using two amplification steps by PCR and a blunt-ended ligation. The steps in figure 3 are illustrated. In the first step, the first series ("new start" and "start of P-bl") is used to create and amplify, from the original gene sequence, the DNA fragment ( "fragment start") containing the sequence encoding the new N-terminal portion of the new protein. In the second step the first game ("new high" and "high of P-bl") is used to create and amplifying, from the gene sequence, the DNA fragment ("fragment high") containing the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new high" sensitizers are designed to include appropriate restriction sites that allow the cloning of the new gene into expression vectors. Typical CPR conditions with: a melting cycle at 95 ° C for two minutes; 25 cycles of denaturation at 94 ° C for one minute, fixation at 50 ° C for 45 seconds and extension at 72 ° C for 45 seconds. Deep vent polymerase (New England Biolabs) is used to reduce the occurrence of overpasses under the conditions recommended by the manufacturer. The "P-bl start" and "P-bl top" sensitizers are phosphorylated at the 5 'end to aid in the subsequent blunt end ligation of "fragment start" and "fragment height" with each other. A 100 ul reaction contained 150 pmol of each sensitizer and 1 ug of template DNA; and 1x Vent controller (New England Biolabs), 300 uM dGTP, 300 uM dATP, 300 uM dTTP, 300 uM dCTP and 1 unit Deep Vent polymerase. PCR reactions are carried out in a model 480 thermal cycle former (Perkin Elmer Corporation, Norwalk, CT, E.U.A.). The PCR reaction products are purified using the Wizard PCR Preps equipment (Promega). The sensitizers are designed to include appropriate restriction sites that allow the cloning of the new gene into expression vectors. The "snippet start" is typically designed to create the Ncol restriction site and the "fragment height" is designed to create the snippet site.

Hindlll restriction. Restriction digestion reactions are purified using a Magic DNA Clean-Up System (Promega). The initial and high fragments are resolved in a 1% TAE gel, stained with ethidium bromide and isolated using Qiaex equipment with gel extraction (Qiagen). These fragments are combined with and fixed to the ends of the Ncol / Hindlll vector fragment of about 800 base pairs of pMON3934, heating at 50 ° C for ten minutes and allowing to cool slowly. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim). The result is a plasmid containing the new end N gene / new end C, full length. A portion of the ligation reaction is used to transform the E. coli DHdalfa strain cells (Life Technologies, Gaithersburg, MD, E. U. A.). The plasmid DNA is purified and the sequence confirmed as discussed below.

METHOD lll.- CREATION OF GENES WITH NEW EXTREME N / NEW EXTREME C, BY MEANS OF DUPLICATION IN TANDEM Genes can be made with new N-terminus / new C-terminus based on the method described in R. A. Horlick and co-authors, Protein Eng., 5: 427-431, 1992). Amplification is carried out by polymerase chain reaction (PCR) of the genes with new N-terminus / C-terminus, using a Template duplicate DNA in tandem. The steps in figure 3 are illustrated.

The duplicate template DNA is created in tandem by cloning and contains two copies of the gene separated by the DNA sequence encoding a linker that connects the original C-terminal and N-terminal ends of the two copies of the gene. Specific sets of sensitizers are used to create and amplify a full-length N-terminus / C-terminus from the duplicate template DNA in tandem. These sensitizers are designed to include appropriate restriction sites that allow the cloning of the new gene into expression vectors. Typical CPR conditions are a melting cycle at 95 ° C for 2 minutes; 25 cycles of denaturation at 94 ° C for one minute, fixation at 50 ° C for one minute and extension at 72 ° C for one minute, plus an extension cycle at 72 ° C for 7 minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit (Perkin Elmer Corporation, Norwalk, CT, E.U.A.) is used. A reaction of 100 ul contains 100 pmol of each sensitizer and 1 ug of template DNA; and 1x PCR regulator, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are carried out in a model 480 thermal cycle former (Perkin Elmer Corporation, Norwalk, CT, E.U.A.). The PCR reactions are purified using a Wizard PCR Preps (Promega).

CLONING OF GENES WITH NEW EXTREME N / EXTREME C, IN EXPRESSION VECTORS OF RECEPTOR AGONIST MULTIFUNCTIONAL The gene is digested with a new N terminus / C terminus with restriction endonucleases to create ends that are compatible with insertion into the expression vector containing another colony stimulating factor gene. This expression vector is also digested with restriction endonucleases to form compatible ends. After purification, the gene and vector DNA are combined and ligated using T4 DNA ligase. A portion of the ligation reaction is used to transform E. coli. The plasmid DNA is purified and sequenced to confirm the correct insert. The correct clones are developed for protein expression.

ISOLATION AND CHARACTERIZATION OF DNA The DNA plasmid can be isolated by numerous different methods, using commercially available equipment, known to those skilled in the art. A few of these methods are shown here. Plasmid DNA is isolated using the Promega Wizard R Miniprep kit (Madison, Wl, E.U.A.), the Qiagen QIAwell plasmid isolation kits (Catsworth CA, E.U.A.) or the Qiagen Plasmid Midi kit. These The teams follow the same general procedure for the isolation of plasmid DNA. Briefly cell pellets are formed by centrifugation (5000 x g), the plasmid DNA is released with sequential treatment with NaOH / acid and the cellular waste is removed by centrifugation (10,000 x g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA binding resin, the column is washed and the plasmid DNA is eluted with TE. After selecting the colonies with the plasmid of interest, the E. coli cells are inoculated in 50-100 ml of LB plus appropriate antibiotic, to develop overnight at 37 ° C in an air incubator while shaking. The purified plasmid DNA is used for DNA sequence determination, another restriction enzyme digestion, additional subcloning of DNA fragments and transfection to mammalian cells, E. coli or other cells.

CONFIRMATION OF THE SEQUENCE The purified plasmid DNA is resuspended in dH2O and quantified by measuring absorbance at 260/280 nm on a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISMMR DyeDeoxyMR ABI Terminator chemistry sequencing equipment (Applied Biosystems Division from Perkin Elmer Corporation, Lincoln City, CA, USA) (No. of parts 401388 or 402078), in accordance with the protocol suggested by the manufacturers, usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are carried out in a thermal cycle former for model DNA 480 (Perkin Elmer Corporation, Norwalk, CT, E.U.A.), following the recommended amplification conditions. The samples are purified to remove the excess dye terminators with Centri-SepMR centrifuge columns (Princeton Separations, Adelphia, NJ) and lyophilized. The fluorescent dye-labeled sequencing reactions are resuspended in deionized formamide and sequenced in denaturing 4.75% -8M urea denaturing polyacrylamide gels using an ABI model 373A automatic DNA sequencer. The overlap of DNA sequence fragments is analyzed and assembled to contiguous master DNAs, using a Sequencher DNA Analysis application program (Gene Codes Corporation, Ann Harbor, Ml, E. U. A.).

EXPANSION OF MULTIFUNCTIONAL RECEPTOR AGONISTS IN MAMMALIAN CELLS TRANSFECTION / PRODUCTION IN MAMMALIAN CELL, MEDIUM-CONDITIONED The BCC-21 cell line from ATCC (Rockville, MD, E.U.A.) can be obtained. Cells are cultured in Dulbecco's modified Eagle's medium (DMEM / high glucose content), supplemented to 2 mM L-glutamine and 10% fetal bovine serum (SBF). This formulation means BHK development medium. The selective medium is BKH development medium supplemented with 453 units / ml of hibromycin B (Calbiochem, San Diego, CA, E. U. A.). The BHK-21 cell line was previously stably transfected with the HSV transactivator protein, VP16, which transactivates the IE110 promoter found in plasmid pMON3359 (see Hippenmeyer and co-authors, Bio / Technology, pages 1037-1041, 1993 ). The VP16 protein drives the expression of genes inserted behind the IE110 promoter. BHK cells expressing the transactivator protein VP16 are designated BHK-VP16. Plasmid pMON1118 (see Highkin et al., Poultry Sci., 70: 970-981, 1991), expresses the gene for hygromycin resistance of the SV40 promoter. A similar ATCC plasmid, pSV2-hph, is available. The BHK-VP16 cells are seeded in a 60 mm tissue culture dish at 3 x 10 5 cells per dish, 24 hours before transfection. Cells are transfected for 16 hours in 3 ml of "POTIMEM" MR (Gibco-BRL, Gaithersburg, MD, USA) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug of hygromycin resistance plasmid, pMON1118 and 80 ug of Gibco-BR "LIPOFECTAMINE" R per plate. The medium is subsequently aspirated and replaced with 3 ml of growth medium. At 48 hours after transfection, the medium of each dish is collected and analyzed for its activity (transient conditioned medium). Cells are removed from the dish by trypsin-EDTA, diluted 1: 10 and transferred to 100-mm tissue culture dishes, containing 10 ml of selective medium.

After about 7 days in selective medium, resistant cells grow to colonies several millimeters in diameter. These colonies are removed from the dish with a filter paper (cut to approximately the same size as the colonies and soaked in trypsin / EDTA) and transferred to individual concavities of a plate of 24 concavities containing 1 | ml of selective media. After the clones are developed to confluence, the conditioned medium is reanalyzed and the positive clones are expanded in development medium.

EXPRESSION OF MULTIFUNCTIONAL RECEPTOR AGONISTS IN E. COLI The E. coli strain MON 105 or JM 101, which harbors the plasmid of interest, is grown at 37 ° C in M9 medium plus casamino acids with shaking in a model G25 air incubator from New Brunswick Scientific (Edison, New Jersey, USA). ). The development is monitored at DO600, until it reaches a value of 1.0, at which time 10 mg / ml of nalidixic acid in 0.1 N NaOH is added, at a final concentration of 50 μg / ml. The cultures are then shaken at 37 ° C for three to four additional hours. A high degree of aeration is maintained throughout the cultivation period in order to obtain the maximum production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (Cl). 1 ml aliquots of the culture are taken out for analysis of the protein content, boiling the pelleted cells, treating them with reducing regulator and subjecting them to electrophoresis by SDS-PAGE (see Maniatis and co-authors, Molecular Cloning: A Laboratory Manual, 1982). The culture is centrifuged (5,000 x g) to pellet the cells.

PREPARATION OF INCLUSION BODY, EXTRACTION, REPLACEMENT, DIALYSIS, DEAE CHROMATOGRAPHY AND CARACT AERIZATION OF RECEIVER AGONISTS HEMATOPOYETIC, CHEMICAL, MULTIFUNCTIONAL. THAT ACCUMULATE AS INCLUSION BODIES IN E. COL! ISOLATION OF INCLUSION BODIES: The cell pellet of 330 ml of E coli culture is resuspended in 15 ml of sonic treatment buffer (10 mM 2-amino-2- (hydroxymethyl) -1,3-propanediol hydrochloride (Tris-HCl) , pH 8.0 + 1 mM ethylenediamine-tetraacetic acid (EDTA) .These re-suspended cells are sonically treated using the microtip probe of a Sonicator Cell Disruptor (model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, New York, USA) Three rounds of sonic treatment are used in the sonic treatment regulator, followed by centrifugation, to break the cells and wash the inclusion bodies (Cl) .The first round of sonic treatment is a 3 minute discharge, followed by a 1 minute discharge, and the final two rounds of sonic treatment are for 1 minute each.

EXTRACTION AND REPLACEMENT OF THE PROTEINS FROM THE INCLUSION BODY PELLETS: After the final centrifugation step, the Cl pellet is resuspended in 10 ml of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes, to allow the denaturation of the expressed protein. Transfer the extraction solution to a beaker containing 70 ml of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea, and stir gently while being exposed to air at 4 ° C for 18 to 48 hours, to allow the refolding of proteins. Refolding is monitored by analysis in a high pressure liquid chromatography column, reverse phase (RP-HPLC) of C18 Vydac (Hespoeria, CA, E. U. A.), 0.46 x 24 cm. A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is used to monitor refolding. This gradient is developed for 30 minutes at a flow rate of 1.5 ml per minute. The denatured proteins are usually eluted late in the gradient, with respect to the refolded proteins.

PURIFICATION After folding again, contaminating E. coli proteins are removed by acid precipitation. The pH of the refolding solution is titrated between pH 5.0 and pH 5.2, using acetic acid at 15% (volume / volume) HOAc). This solution is stirred at 4 ° C for 2 hours and then centrifuged for 20 minutes at 12,000 x g, to pellet with any insoluble protein. The supernatant of the precipitation step is dialyzed with acid using a Spectra / Por 3 membrane with a molecular meso cut (MWCO) of 3,500 daltons. Dialysis is performed against 2 changes of 4 liters (a 50-fold excess) of 10 mM Tris-HCl, pH 8.0, for a total of 18 hours. Dialysis lowers the conductivity of the sample and eliminates urea before chromatography with DEAE. The sample is then centrifuged (20 minutes at 12,000 x g) to pellet with any insoluble protein, after dialysis. A Bio-Rad Bio-Scaie DEAE2 column (7 x 52 mm) is used for ion exchange chromatography. The column is equilibrated in a regulator containing 10 mM Tris-HCl, pH 8.0 and a gradient from 0 to 500 mM sodium chloride (NaCl) in equilibrium buffer, over 45 column volumes, to elute the protein. A flow rate of 1.0 ml per minute is used throughout the operation. Collect the column fractions (2.0 ml per fraction) through the gradient and analyze by RP HPLC in a column C 8 Vydac (Hesperia, CA, E. U. A.) (0.46 x 25 cm). A linear gradient of 40% to 65% acetonitrile containing 0.1% trifluoroacetic acid (TFA) is used. This gradient is developed for 30 minutes at a flow rate of 1.5 ml per minute. The pooled fractions are then dialyzed against 2 changes of 4 liters (50 to 500 excess times) of 10 mM ammonium acetate (NH4Ac), pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra / Por 3 membrane with a MWCO of 3,500 daltons. Finally the sample is sterile filtered, using a 0.22 μm syringe filter (syringe filter μStar LB, Costar, Cambridge, MA, E.U.A.), and stored at 4 ° C. In some cases the folded proteins can be purified by affinity using affinity reagents, such as mAbs or receptor subunits fixed to a suitable matrix. Alternatively (or in addition to) purification can be achieved using any of a variety of chromatographic methods, such as: ion exchange, gel filtration or hydrophobic chromatography or reverse phase HPLC. These and other methods of protein purification are described in detail in Methods in Enzymology, volume 182, "Guide to Protein Purification", edited by Murray Deutscher, Academic Press, San Diego, CA, E. U. A. (1990).

CHARACTERIZATION OF THE PROTEIN: The purified protein is subjected to analysis by RP-HPLC, mass spectrometry by electroaspersion and SDS-PAGE. The protein quantification is performed by the amino acid composition, RP-HPLC and Bradford protein determination. In some cases, tryptic peptide mapping is carried out in conjunction with mass spectrometry by electroaspersion, to confirm the identity of the protein.

ANALYSIS OF AML PROLIFERATION FOR INTERLEUCINE-3 HUMAN BIOACTIVE The Factor-dependent AML 193 cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD, E. U. A.). This cell line, established from a patient with acute myelogenous leukemia is a cell line that depends on the growth factor, which exhibited increased development in medium supplemented with GM-FEC (Lange, B. And co-authors, Blood, 70: 192, 1987; Valtieri, M and coauthors, J. Immunol., 138: 4042, 1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D. and coauthors, J. Immunol., 139: 348, 1987). A cell line variant, AML 193 1.3, is used, which was adapted for long-term development in lL-3 by washing out the developmental factors and depleting the AML 193 cells. cytokine-dependent for the development factors, for 4 hours. The cells are then plated back into a plate of 24 concavities, at 1x10 5 cells / concavity, in media containing 10 U / ml of IL-3. It took approximately two months for the cells to develop rapidly in IL-3. Those cells are maintained as AML 193 1.3, subsequently, by supplementing the tissue culture medium (see below) with human IL-3. The AML 193 1.3 cells are washed six times in cold Hanks' balanced salt solution (HBSS, Gibco, Grand Island, NY, E.U.A.), centrifuging the cell suspensions at 250 x g for 10 minutes, followed by decanting the supernatant. The pelleted cells are resuspended in HBSS and the procedure is repeated until six wash cycles are completed. Cells washed six times by this procedure are resuspended in tissue culture medium at a density ranging from 2 x 10 5 to 5 x 10 5 viable cells / ml. This medium is prepared by supplementing Dulbecco's medium, modified from Iscove (IMDM, Hazelton, Lenexa, KS, E.U.A.) with albumin, transferin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, IN, E.U.A.) is added at 500 μg / ml; human transferrin (Boehringer-Mannheim, Indianapolis, IN, E.A.A.)) is added at 100 μg / ml, soybean lipid (Boehringer-Mannheim, Indianapolis, IN, E.U.A.) at 50 μg / ml; and 2-mercaptoethanol (Sigma, St. Louis, MO, E.U.A.) is added, at 5 x 10"5 M.

Serial dilutions of humanterleucin-3 or chimeric, multifunctional, hematopoietic receptor agonist proteins are made in triplicate series in tissue culture medium, supplemented as indicated above, in tissue culture plates of 96 concavities, Coastar 3596. Each concavity contained 50 μl of medium containing interleukin-3 or chimeric, multifunctional, hematopoietic receptor agonist proteins, once the serial dilutions are completed. The control concavities contained an ejido culture medium alone (negative control). Add suspensions of AML 193 1.3 cells, prepared as before, to each concavity, pipetting 50 μl (2.5 x 10 4 cells) into each concavity. Tissue culture plates are incubated at 37 ° C with 5% CO2 in humidified air for 3 days. On day 3, 05 μCi of 3 H-thymidine (2 Ci / mM, New England Nuclear, Boston, MA) is added in 50 μl of tissue culture medium. The cultures are incubated at 37 ° C with 5% CO2 in humidified air for 18-24 hours. Cellular DNA is harvested on glass filter mats (Pharmacia LKB, Gaithersburg, MD, USA) using a TOMTEC cell harvester (TOMTEC, Orange, CT, USA), which utilizes a wash cycle with water followed by a wash cycle with 70% ethanol. Align the filter mats to air dry and then place them in sample bags to which flash fluid is added (Scintiverse II, Fisher Scientific, St. Louis, MO, or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, MD, USA). The beta emissions of samples are counted from individual tissue culture concavities, in a counter of flash LKB BetaPlate model 1205 (Pharmacia LKB, Gaithersburg, MD, U. A.) and the data is expressed as counts per minute of 3H thymidine, incorporated into cells of each tissue culture concavity. The activity of each preparation of human interleukin 3 or chimeric, multifunctional hematopoietic receptor agonist protein preparation is quantified by measuring cell proliferation (3 H-thymidine incorporation) induced by graded concentrations of interleukin-3 or hematopoietic receptor agonist. , chimeric, multifunctional. Typically, scales of concentration of 0.05 pM - 105 pM are quantified in these analyzes. The activity is determined by measuring the dose of interleukin 3 or chimeric, multifunctional, hematopoietic receptor agonist protein, which provides 50% of the maximum proliferation (EC50 = 0.5 x (maximum average per-minute count of 3H-thymidine incorporated per concavity between the triplicate cultures of all tested interleukin-3 concentrations - background proliferation, measured by incorporation of 3H-thymidine observed in triplicate cultures lacking inteleucine-3.) This EC50 value is also equivalent to 1 unit of bioactivity.Each analysis is carried out with natural interleukin-3 as a reference standard, so that the levels of relative activity could be assigned Typically agonist proteins of hematopoietic, chimeric, multifunctional receptors were tested in a concentration scale of 2000 pM to 0.06 pM, titrated in double dilutions, serial.

The activity of each sample was determined by the concentration that gave 50% of the maximum response by adjusting a logistic model of four parameters, for the data. It was observed that the upper platform (maximum response) for the sample and the standard with which it was compared do not differ. Therefore, the relative power calculation for each sample was determined from EC50 estimates for the sample and the standard, as indicated above. AML 193.1.3 cells proliferate in response to hIL-3, hFEC-GM and hG-FEC. Accordingly, the following additional analyzes were performed for some samples, to demonstrate that the G-FEC receptor agonist portion of the chimeric, multifunctional, hematopoietic receptor agonist proteins were active. Proliferation analysis was performed with the chimeric, multifunctional hematopoietic receptor agonist, and the less neutralizing monoclonal antibodies, for the agonist portion of the hIL-3 receptor. In addition, a fusion molecule was divided with the factor Xa cleavage site, then the halves of the molecule were purified and analyzed for proliferation activity. These experiments demonstrated that both components of the chimeric, multifunctional, hematopoietic receptor agonist proteins were active.

DEPENDENT PROLIFERATION ANALYSIS OF THE LIGANDO TF1 c-mpl The proliferating activity of c-mpl ligand can be analyzed using a subclone of the pluripotent human TF1 cell line (Kitamura and co-authors, J. Cell Physiol, 140: 323-334 (1989)). The TF1 cells are maintained in h-IL3 (100 U / ml). To establish a subclone that responds to the c-mpl ligand, the cells are maintained in passage medium containing 10% supernatant of the BHK cells transfected with the gene expressing the 1-153 form of the c-mpl ligand (pMON26448). Most cells die, but a subset of cells survives. After cloning in dilution, a clone that responds to the c-mpl ligand is selected, and those cells are divided to the passage medium, at a density of 0.3 x 10 6 cells / ml the day before the start of the analysis. The means of passage for these cells is as follows: RPMI 1640 (Gibco), 10% FBS (Harían, lot # 91206), 10% supernatant of the c-mpl ligand of transfected BHK cells, 1 mM sodium pyruvate ( Gibco), 2 mM glutamine (Gibco) and 100 ug / ml penicillin-streptomycin (Gibco). The next day the cells were harvested and washed twice in RPMI or IMDM medium, with a final wash in the ATL, or analysis medium. The ATL medium consists of the following: IMDM (Gibco), 500 ug / ml bovine serum albumin, 100 ug / ml human transferin, 50 ug / ml soybean lipids, 4 x 10"8 M beta-mercaptoethanol and 2 ml of A9909 (Sigma, antibiotic solution) per 1000 ml of ATL.The cells are diluted in assay medium to a final density of 0.25 x 106 cells / ml in a plate of low evaporation, of 96 concavities (Costar) to a final volume of 50 ul. Transient supernatants (conditioned medium) of transfected clones are added to a volume of 50 ul as duplicate samples at a final concentration of 50% and diluted three times to a final dilection of 1.8%. It includes triplicate samples of a dose curve of pMON 13288, variant of IL-3, starting with 1 ng / ml and diluted using ai triple dilutions of 0.0014 ng / ml, including them as a positive control. The plates are incubated at 5% CO2 and 37 ° C. On day six of the culture, the plate is pressed with 0.5 Ci of 3H / concavity (NEN) in a volume of 20 ul / concavity and left to incubate at 5% CO2 and 37 ° C for four hours. The plate is harvested and counted in a Betaplate counter.

ANALYSIS OF CELL PROLIFERATION MUTZ-2 A cell line, such as MUTZ-2, which is a line of human myeloid leukemia cells (German Collection of Microorganisms and Cell Cultures, DSM ACC 271), can be used to determine the proliferating activity of flt3 receptor agonists. Cultures of MUTZ-2 are maintained with natural, recombinant flt3 ligand (20-100 ng / ml) in the development medium. Eighteen hours before starting the analysis, the MUTZ-2 cells are washed in IMDM medium (Gibco) three times and resuspended in the IMDM medium alone at a concentration of 0.5-0.7 x 10 E6 cells / ml and incubated at 37 ° C and 5% CO2 to deplete ligand cells flt3. The day of analysis the standards and the receptor agonist fit3 are diluted twice as much as the desired fine concentration in analysis media, in sterile tissue culture plates, of 96 concavities, treated. The flt3 receptor agonists and standards are tested in triplicate. 50 μl of analysis medium is loaded in all the concavities except row A. 75 μl of flt3 receptor agonists or standards are added to row A. 25 μl of the row is taken and serial dilutions are made (1 : 3) on the rest of the plate (rows B to G). Row H remains as media control only. The spent MUTZ-2 cells are washed twice in IMDM medium and resuspended in 50 μl of analysis medium. 50 μl of cells are added to each concavity, which results in a final concentration of 0.25 x 10 E6 cells / ml. Incubate assay plates containing cells at 37 ° C and 5% CO2 for 44 hours. Each concavity is then pressed with 1 μCi / concavity of tritiated thymidine in a volume of 20 μl for 4 hours. Then the plates are harvested and counted.

OTHER PROLIFERATION ANALYSIS BASED ON IN VITRO CELLS Other in vitro cell-based assays, known to those skilled in the art, may also be useful for determining the activity of hematopoietic, chimeric, multifunctional receptor-receptor agonists, depending on the factors comprising the molecule in a manner similar to that described in the cell proliferation analysis AML 193.1.3. The following are examples of other useful analyzes. TF1 proliferation analysis: TF1 is a line of pluripotent human cells (Kitamura and co-authors, J. Cell Physiol, 140: 323-334, 1989)), which responds to hIL-3. The 32D: 32D proliferation assay is a murine IL-3 dependent cell line, which does not respond to human IL-3, but which does respond to human G-FEC, which is not restricted to the species. The Baf / 3: Baf / 3 proliferation assay is a murine IL-3-dependent cell line, which does not respond to human IL-3 or the human c-mpl ligand, but which does respond to human G-FEC , which is not restricted to the species. T1165 Proliferation Analysis: T1164 cells are a murine cell line dependent on IL-6 (Nordan et al., 1986) that respond to IL-6 and IL-11. The meg-FEC analysis of human plasma clot: used to analyze the formation activity of megakaryocyte colony (Mazur and co-authors, 1981).

TRANSFECTED CELL LINES Cell lines can be transfected as the murine Baf / 3 cell line, with a colony stimulating factor receptor, such as the receptor Human G-FEC or the human c-mpl receptor, which does not have the cell line. These transfected cell lines can be used to determine the activity of the ligand for which the cell line has been transfected. One of said Gaf / 3 transfected cell lines was cloned into the cDNA encoding c-mpl from a bank made up of a cell line that responds to c-mpl and cloned into a multiple cloning site of the pcDNA3 plasmid (Invitrogen , San Diego, CA, USA). The Baf / 3 cells were transfected with the plasmid, by electroporation. The cells were developed under selection G418 in the presence of mouse IL-3 in Wehi conditioned medium. The clones were established by limited dilution. Similarly, the human G-FEC receptor can be transfected into the Baf / 3 cell line and used to determine the bioactivity of the hematopoietic, chimeric, multifunctional receptor agonists.

ANALYSIS OF THE PROLIFERING ACTIVITY OF THE LIGANDO c-mpl The methods 1. Analysis of bone marrow proliferation a) Purification of CD34 + cell. Aspiration (14-20 mol) of bone marrow from normal, allogeneic marrow donors was obtained after informed consent. The cells were diluted 1: 3 in phosphate buffered saline (PBS, Gibco-BRL), extended ml on 15 ml of Histopaque 1077 (Sima and centrifuged for 30 minutes minutes at 300 RCF The mononuclear interface layer was collected and washed in PBS. It was enriched in CD34 + cells from the preparation of mononuclear cells, using an affinity column according to the instructions of the manufacturers (CellPro, Inc., Bothell, WA, E. U. A.). After enrichment, it was determined that the purity of the CD34 + cells was 70% on average, using flow cytometric analysis, using anti-CD34 monoclonal antibody, conjugated with fluorescein, and anti-CD38, conjugated to phycoerythrin (Becton Dickinson, San José , CA). The cells were suspended at 40,000 cells / m in X-Vivo 10 medium (Bio-Whittaker, Waikersville, MD, E. U. A.) and extended 1 ml into tissue culture plates of 12 concavities (Costar). Growth factor rhlL-3 at 100 ng / ml (pMON5873) was added to some concavities. The hlL3 variants were used at 10 ng / ml up to 100 ng / ml. The conditioned media of the BHK cells, transfected with the plasmid encoding the c-mpl ligand or with chimeric, multifunctional hematopoietic receptor agonists, were tested by the addition of 100 μl of added supernatant to 1 ml cultures (approximately one dilution). from 10%). The cells were incubated at 37 ° C for 8-14 days at 5% CO2 in a humidified incubator at 37 ° C. b. Harvesting and analysis of cells At the end of the culture period, a total cell count was obtained for each condition. For fluorescence analysis and povid determination, the cells were washed in megakaryocyte buffer (MK regulator, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 μm PGE1, 1 1 mM glucose, 3% by weight / volume of BSA, in PBS, pH 7.4) (Tomer and co-authors, Blood 70: 1735-1742, 1987), was resuspended in 500 μl of MK regulator containing anti-CD41 antibody to FITC (1: 200, AMAC , Westbrook, ME) and washed in MK regulator. For DNA analysis, cells were permeabilized in MK regulator containing 0.5% Tween 20 (Fisher, Fair Lawn, NJ, USA) for 20 minutes on ice, followed by 0.5% fixation of Tween-20 and 1% paraformaldehyde (Fisher Chemial) for 30 minutes, followed by incubation in propidium iodide (Calbiochem, La Jolla, CA, USA) (50 μg / ml) with RNA-asa (400 U / ml) in 55% volume / volume of regulator MK (200 mOsm) for 1-2 hours, on ice. The cells were analyzed in a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, CA, E. U. A.). Green fluorescence (CD41 a-FITC) was collected along with the linear and logarithmic signals, for red fluorescence (Pl) to determine the DNA ploidez. All cells were collected to determine the percentage of cells that were CD41 +. Data analysis was performed using an application program, from LYSIS (Becton Dickinson, San Jose, CA, E. U. A.). The percentage of cells expressing the CD41 antigen of the flow cytometry analysis (percentage). The absolute number (Abs) of CD41 + cells / ml was calculated by: (Abs) = (cell count) * (%) / 100. 2. Analysis of megakaryocyte fibrin clot The population enriched in CD34 + was ated as described above. The cells were suspended at 25,000 cells / ml with or without cytokine (s) in a medium consisting of a basic Iscoves IMDM medium, supplemented with 0.3% BSA, 0.4 mg / ml apo-transferin, 667 μM FeCl2, 25 μg / ml of CaC-2, 25 μg / ml of L-asparagine, 500 μg / ml of e-amino-n-caproic acid and penicillin / streptomycin. Before spreading on 35 mm plates, thrombin (0.25 units / ml) was added to initiate clot formation. The cells were incubated at 37 ° C for 13 days, at 5% CO2 in a humidified incubator at 37 ° C. At the end of the culture period, the plates were fixed with methanokacetone (1: 3), dried in air and stored at -200 ° C until dyeing. A staining procedure was used by peroxidase immunocytochemistry (Zymed, Histostain-SP, San Francisco, CA, E.U.A.), using a combination of primary monoclonal antibodies consisting of anti-CD4a, CD42 and CD61. The colonies were counted after dyeing and classified as negative colonies UFC-MK (small colonies, 1-2 foci and less than about 25 cells), UFB-MK (large, multifocal colonies, with> 25 cells) or mixed colonies (mixture of positive and negative cells).

METHYLLELLULOSE ANALYSIS This analysis reflects the ability of colony stimulating factors to stimulate bone marrow cells to produce different types of hematopoietic colonies in vitro (Bradley and co-authors, Aust. Exp. Biol. Sci, 44: 287-300, (1966), Plznik and co-authors, J. Cell Comp. Physio. 66: 319-324, (1965)).

Methods Approximately 30 ml of fresh, normal, healthy bone marrow aspirate is obtained from individuals after obtaining informed consent. Under sterile conditions, the 1: 4 samples are diluted with a 1Z PBS solution (# 14040.059, Life Technologies, Gaithersburg, MD, USA), in a 50 ml conical tube (# 25339-50, Corning, Corning, MD, USA) ). Ficoll (Histopaque 1070, Sigma H-8889) is spread under the diluted sample and centrifuged at 300 x g for 30 minutes. The band of mononuclear cells is removed and washed twice in 1X PBS and once with 1% BSA in PBS (CellPro Co., Bothel, WA, E.U.A.). The mononuclear cells are counted and the CD34 + cells are selected using the Ceprate LC (CD34) equipment (CellPro Co., Bothel, WA, E. U. A.). This fractionation is carried out since all stem and progenitor cells, within the bone marrow, exhibit the CD34 surface antigen. The cultures are fixed in triplicate with a final volume of 1.0 ml in a petri dish of 35 x 10 mm (Nunc # 174926). Terry Fox Labs culture medium (medium HCC-4230 (Terry Fox Labs, Vancouver, BC Canada) is purchased and erythropoietin (Amgen, Thousand Oaks, CA, USA) is added to the culture medium, 3,000-10,000 cells are added CD34 + per dish Recombinant IL-3, purified from mammalian or E. coli cells, and chimeric, multifunctional, hematopoietic receptor agonist proteins are added in conditioned media from transfected or purified mammalian cells in conditioned media of mammalian cells transfected or from E. coli, to give final concentrations ranging from 0.001 nM to 10 nM.HlL-3 recombinant, Gm-FEC, c-mpl ligand and chimeric, multifunctional, hematopoietic receptor agonist are supplied at home. FEC (Neupogen) is from Amgen (Thousand Oaks, CA, USA), the cultures are resuspended using a 3 cc syringe and 1.0 ml is delivered per dish, and control cultures (baseline response) did not receive colony imulators. Positive control cultures received conditioned medium (human cells stimulated with PHA: Terry Fox Lab. H2400). The cultures are incubated at 37 ° C, 5% CO2 in humidified air. Hematopoietic colonies that are defined as more than 50 cells are counted on the day of the peak response (days 10-11) using a Nikon inverted phase microscope, with a combination of 40x lenses. Cell groups that contain less than 50 cells are called groupings. The colonies can be alternatively identified by spreading the colonies on a slide plate and staining, or they can be collected, resuspended and centrifuged on cytospin slide plates, for dyeing.

ANALYSIS OF THE HEMATOPOYETIC GROWTH FACTOR IN HUMAN CORD BLOOD Bone marrow cells are traditionally used for in vitro analyzes of hematopoietic colony stimulating factor (FEC) activity. However, human bone marrow is not always available, and there is considerable variability among donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer and co-authors, PNAS USA 89: 4109-113, 1992; Mayani and co-authors, Brool, 81: 3252-3258, 1993). ). In contrast to the bone marrow, cord blood is more easily available on a regular basis. There is also a potential to reduce the variability of analysis by pooling cells obtained from several recent donors, or to create a bank of cryopreserved cells for that purpose. By modifying the culture conditions and / or analyzing for lineage-specific markers, it is possible to specifically analyze the colonies of granulocytes / macrophages (UFC-GM), the activity of mega FEC: ariocytes, or the activity of colony-forming cells, with a high proliferating potential. (CFC-EPP) Methods The mononuclear cells (CMN) are isolated from cord blood, within 24 hours of collection, using a common density gradient (1.077 g / ml Histopaque). The cord blood CMNs were enriched, additionally, in trunk and progenitor cells, by various procedures, including the immunomagnetic selection of CD14-, CD34 +, performance cells for the SBA-, CD34 + fraction, using Applied Immune Science coated scales. (Santa Clara, CA, USA) and the selection of CD34 + using a CellPro avidin column (Bothell, WA, USA). Fractions enriched in freshly isolated or cryopreserved CD34 + cells are used for this analysis. Duplicate cultures are prepared for each serial dilution of sample (concentration scale from 1 pM to 1204 pM), with 1 x 104 cells in 1 ml of 0.9% methylcellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies , Vancouver, BC, Canada). In some experiments, Methocult H4330 containing erythropoietin (EPO) was used in place of Methocult H4230, or 50 ng / ml of stem cell factor (FCT) was added (Biosource International, Camarillo, CA, E. U. A.). After cultivating for 7-9 days, the colonies containing more than 30 cells were counted. In order to eliminate subjective deviations by scoring, the analyzes became blind. Other details about the recombinant DNA methods that can be used to create the variants, their expression in bacteria, mammalian cells or insect cells; the purification and refolding of the desired proteins, and the analyzes to determine the bioactivity of the proteins, can be found in the pending patent applications, of the same successor, WO 95/00646, WO 94/12639, WO 95/12638 , WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and US 08 / 383,035, which are thus incorporated herein by this reference, in their entirety. Other details known to those skilled in the art can be found in T. Maniatis and coauthors, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) and references cited therein, which is incorporated herein by reference; and in J.

Sambrook and coauthors, Molecular Cloning, A Laboratory Manual, 2a.

Edition, Cold Spring Harbor Laboratory, 1989), and references cited therein, which is incorporated herein by this reference.

TABLE 1 OLIGONUCLEOTIDES c-mplNcoI ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGCACTCCGAGTC SEQ ID NO: 317 N = A, C, G or T Ecompl ATGCACGAATTCCCTGACGCAGAGGGTGGA SEQ ID NO: 318 c-mplHindlII TGACAAGCTTACCTGACGCAGAGGGTGGACCCT SEQ ID NO: 319 4L-5 'AATTCGGCAA SEQ ID NO: 320 4L-3' CATGTTGCCG SEQ ID NO: 321 5L-5 'AATTCGGCGGCAA SEQ ID NO: 322 5L-3' CATGTTGCCGCCG SEQ ID NO: 323 8L-5 'AATTCGGCGGCAACGGCGGCAA SEQ ID NO: 324 8L-3 'CATGTTGCCGCCGTTGCCGCCG SEQ ID NO: 325 31-5' CGATCCATGGAGGTTCACCCTTTGCCT SEQ ID NO: 326 31-3 'GATCAAGCTTATGGGCACTGGCTCAGTCT SEQ ID NO: 327 35-5' CGATACATGTTGCCTACACCTGTCCTG SEQ ID NO: 328 35-3 'GATCAAGCTTAAGGGTGAACCTCTGGGCA SEQ ID NO: 329 39-5 'CGATCCATGGTCCTGCTGCCTGCTGTG SEQ ID NO: 330 39-3' GATCAAGCTTAAGGTGTAGGCAAAGGGTG SEQ ID NO: 331 43-5 'CGATCCATGGCTGTGGACTTTAGCTTGGGA SEQ ID NO: 332 43-3' GATCAAGCTTAAGGCAGCAGGACAGGTGT SEQ ID NO: 333 45-5 'CGATCCATGGACTTTAGCTTGGGAGAA SEQ ID NO: 334 45-3 'GATCAAGCTTACACAGCAGGCAGCAGGAC SEQ ID NO: 335 49-5' CGATCCATGGGAGAATGGAAAACCCAG SEQ ID NO: 336 49-3 'GATCAAGCTTACAAGCTAAAGTCCACAGC SEQ ID NO: 337 82-5' CGATCCATGGGACCCACTTGCCTCTCA SEQ ID NO: 338 82-3 'GATCAAGCTTACAGTTGTCCCCGTGCTGC SEQ ID NO: 339 109-5' CAGTCCATGGGAACCCAGCTTCCTCCA SEQ ID NO: 340 109-3 'GATCAAGCTTAAAGGAGGCTCTGCAGGGC SEQ ID NO: 341 116-5 'CGATCCATGGGCAGGACCACAGCTCAC SEQ ID NO: 342 116-3' GATCAAGCTTACTGTGGAGGAAGCTGGGTT SEQ ID NO: 343 120-5 'CGATCCATGGCTCACAAGGATCCCAATGCC SEQ ID NO: 344 120-3' GATCAAGCTTATGTGGTCCTGCCCTGTGG SEQ ID NO: 345 123-5 'CGATCCATGGATCCCAATGCCATCTTCCTG SEQ ID NO: 346 123-3 'GATCAAGCTTACTTGTGAGCTGTGGTCCT SEQ ID NO: 347 126-5' CGATCCATGGCCATCTTCCTGAGCTTCCAA SEQ ID NO: 348 126-3 'GATCAAGCTTAATTGGGATCCTTGTGAGCTGT SEQ ID NO: AATTCCGTCG TAAACTGACC TTCTATCTGA 349 SYNNOXA1.REQ AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC SEQ ID NO: 350 SYNNOXA2.REQ CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG SEQ ID NO: GTTACCCTTG AGCAAGCGCA GGAACAACAG 351 Llsyn.for GGTGGTGGCT CTAACTGCTC TATAATGAT SEQ ID NO: CGATCATTAT AGAGCAGTTA GAGCCACCAC 352 Llsyn.rev CCTGTTGTTC CTGCGCTTGC TCAAGG SEQ ID NO: 353 L3syn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT SEQ ID NO: 354 3syn. rev CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG SEQ ID NO: 355 35start. seq GATCGACCAT GGCTCTGGAC CCGAACAACC TC SEQ ID NO: 356 34rev. seq CTCGATTACG TACAAAGGTG CAGGTGGT SEQ ID NO: 357 70start. seq GATCGACCAT GGCTAATGCA TCAGGTATTG AG SEQ ID NO: 358 69rev.seq CTCGATTACG TATTCTAAGT TCTTGACA SEQ ID NO: 359 91start.seq GATCGACCAT GGCTGCACCC TCTCGACATC CA SEQ ID NO: 360 90rev.seq CTCGATTACG TAGGCCGTGG CAGAGGGC SEQ ID NO: 361 lOlstart.seq GATCGACCAT GGCTGCAGGT GACTGGCAAG AA SEQ ID NO: 362 lOOrev.seq CTCGATTACG TACTTGATGA TGATTGGA SEQ ID NO: 363 L-llstart.seq GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG SEQ ID NO: 364 L-llstop.seq CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG SEQ ID NO: 365 P -blstart seq GGGCTGCGCA AGGTGGCG SEQ ID NO: 366 P-blstop.seq ACACCATTGG GCCCTGCCAG C SEQ ID NO: 367 39start.seq GATCGACCAT GGCTTACAAG CTGTGCCACC CC SEQ ID NO: 368 38stop. Seq CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT SEQ ID NO: 369 97start.seq GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC SEQ ID NO.-370 96stop.Seq CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT SEQ ID NO: 371 126start.seq GATCGACCAT GGCTATGGCC CCTGCCCTGC AG SEQ ID NO: 372 125stop.Seq CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT SEQ ID NO: 373 133start. seq GATCGACCAT GGCTACCCAG GGTGCCATGC CG SEQ ID NO: 374 132stop.seq CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA SEQ ID N0: 375 142start.seq GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG SEQ ID NO: 376 141stop.Seq CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC SEQ ID NO: 3 July GLYXA1 GTAGAGGGCG GTGGAGGCTC C SEQ ID NO: 378 GLYXA2 CCGGGGAGCC TCCACCGCCC TCTAC SEQ ID NO: 379 lGGGSfor TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG SEQ ID NO: 380 lGGGSrev CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA SEQ ID NO: 381 NCOFLT CTGACCATGGCNACCCAGGACTGCTCCTTCCAA SEQ ID NO: 807 HIND160 ACTGAAGCTTAGGGCTGACACTGCAGCTCCAG SEQ ID NO: 808 HIND165 ACTGAAGCTTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 809 FL23For GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO: 810 FH3AFor GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO: 811 SCF. REV TGTCCAAACTCATCAATGTATC SEQ ID NO: 812 39FOR CATGGCCATGGCCGACGAGGAGCTCTGCGGGGGCCTCT SEQ ID NO: 813 39REV GCTAGAAGCTTACTGCAGGTTGGAGGCCACGGTGAC SEQ ID NO: 814 65FOR CATGGCCATGGCCTCCAAGATGCAAGGCTTGCTGGAGC SEQ ID NO: 815 65rev GCTAGAAGCTTACCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO: 816 89FOR CATGGCCATGGCCCCCCCCAGCTGTCTTCGCTTCGT SEQ ID NO: 817 89REV GCTAGAAGCTTAGGGCTGAAAGGCACATTTGGTGACA SEQ ID NO: 818 L5A CCCTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAAC SEQ ID N0: 819 L10A GCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 820 L15A ACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACT GCTCCTTCCAAC SEQ ID NO: 821 L5B GTGCCGTTGCCGCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 822 L10B ATTACCTCCACTGCCGTTACCGCCTGACAGGGTTGAGGAGTCGGG CTG SEQ ID N0: 823 L15B GCTCCCATTGCCACCACTGCCGTTACCTCCAGACAGGGTTGAGGA GTCGGGCTG SEQ ID NO: 824 L15C GATGAGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGG ACTGCTCCTTCCACC SEQ ID NO: 825 L15D GATGACGGATCCGTTACCTCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID N0: 826 L15E GATGACGGATCCGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 827 339F0R2 GACTGCCATGGCCGACGAGGAGCTCTGCG SEQ ID NO: 828 339REV2 GACTCAAGCTTACTGCAGGTTGGAGGCC SEQ ID NO: 829 339-10FOR3 GACTCGGGATCCGGAGGTTCTGGCACCCAGGACTGCTCC SEQ ID NO: 830 339-15FOR2 GACTGGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACC SEQ ID NO: 831 339REV3 GACTTGGGATCCACTACCTCCAGACAGGGTTGAGGA GTC SEQ ID NO: 832 FLN3 ACTGACGGATCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 833 FLN7 ACTGACGGATCCACCTCCTGACCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 834 FLN11 ACTGACGGATCCACCTCCTGACCCACCTCCTGACCCACCGCCCAG GGTTGAGGAGTCGGGCTG SEQ ID NO: 835 C-term ACGTAAAGCTTACAGGGTTGAGGAGTCG SEQ ID NO: 836 FLC3 GTCAGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAA C SEQ ID NO: 837 FLC4 GTCAGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 838 FLC10 TCAGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAAC SEQ ID NO: 839 N-term TAGTCCATGGCCACCCAGGACTGCTCC SEQ ID NO: 840 134.rev GCATTACGTAGGGCTGACACTGCAGCTCCAG SEQ ID NO: 841 139. rev GCATTACGTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 842 F129for GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO: 843; FL29rev TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 844; FL35for GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA SEQ ID NO: 845; FL35rev TCTGACAAGCTTACACGGTGACTGGGTAACTTGAAGC SEQ ID NO: 846; FL63 for GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC SEQ ID NO: 847; FL63rev TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 848; FL95 for GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 849; FL95rev TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 850; FL99for GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO: 851; FL99rev CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG SEQ ID NO: 852; FLTAFLS1 GATCACATGTCTACAAATCAAGATCTGCCTGTG SEQ ID NO: 853 FLTR1N GATCGAATTCGTTGTCTTGGATGAAAGGGA SEQ ID NO: 854 HGCFOR ACTTGAATTCATCATCCTGGGCCTGTTCGGGC SEQ ID NO: 855 HGCREV ACTCAAGCTTAGAAGCTCCCCAGCGCCTCC SEQ ID NO: 856 FL29FOR GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO: 382 FL35FOR GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA SEQ ID NO: 383 FL63FOR GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC SEQ ID NO: 384 FL95FOR GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 385 FL99FOR GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO: 386 FL29REV TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 387 FL35REV TCTGACAAGCTTACACGGTGACTGGGTAATCTTGAAGC SEQ ID NO: 388 FL63REV TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 389 89 REVSTOP GTCAAGAAGCTTACGGCTGAAAGGCACATTTG SEQ ID NO: 390 FL95REV TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 391 FL99REV CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG SEQ ID NO: 392 Flt36 GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGT GCGGGGGCCTCTGGCGGCTG SEQ ID NO: 393 Fl 37 GTTGCCATGGCNAAYCTGCARGAYGARGARCTGTGYG GGGGCCTCTGGCGGCTGGTC SEQ ID NO: 394 Fl138 GTTGCCATGGCNCTGCARGAYGARGARCTGTGYGGYG GCCTCTGGCGGCTGGTCCTG SEQ ID NO: 395 Fl 39 GTTGCCATGGCNCARGAYGARGARCTGTGYGGYGGYC TCTGGCGGCTGGTCCTGGCA SEQ ID NO: 396 Fl 40 GTTGCCATGGCNGAYGARGARCTGTGYGGYGGYCTCT GGCGGCTGGTCCTGGCACAG SEQ ID NO: 397 FLT41 GTTGCCATGGCNGARGARCTGTGYGGYGGYCTCTGGC GGCTGGTCCTGGCACAGCGC SEQ ID NO: 398 Flt42 GTTGCCATGGCNGARCTGTGYGGYGGYCTGTGGCGYC TGGTCCTGGCACAGCGCTGG SEQ ID NO: 399 Flt43 GTTGCCATGGCNCTGTGYGGYGGYCTGTGGCGYCTGG TCCTGGCACAGCGCTGGATG SEQ ID NO: 400 40 COLI GTTGCCATGGC SEQ GATGAAGAACTGTGTGGNGGNCTGTGGCGG ID NO: 401 36REV TATGCAAGCTTAGGCCACGGTGACTGGGTA SEQ ID NO: 402 37REV TATGCAAGCTTAGGAGGCCACGGTGACTGG SEQ ID NO: 403 38REV TATGCAAGCTTAGTTGGAGGCCACGGTGAC SEQ ID NO: 404 39REV TATGCAAGCTTACAGGTTGGAGGCCACGGT SEQ ID NO: 405 41REV TATGCAAGCTTAGTCCAGGTTGGAGGCCAC SEQ ID NO: 406 42REV TATGCAAGCTTACTCGTCCAGGTTGGAGGC SEQ ID NO: 407 43REV TATGCAAGCTTACTCCTCGTCCAGGTTGGA SEQ ID NO: 408 39N TERM-2 GACTAGCCATGGCNGAYGARGARCTGTGYGGTGGCCTCTGGCGG SEQ ID NO: 409 SNA B1CTERM GACTAGTACGTACTGCAGGTTGGAGGCCACGG SEQ ID NO: 410 29SMB1 GCAGGTTACGTATTGAAGCAGGTAGTCAGACAGCTC SEQ ID NO: 411 34SNAB1 GCAGGTTACGTACACGGTGACTGGGTAATCTTGAAG SEQ ID NO: 412 63SNAB1 GCAGGTTACGTAAGTCTTGAGCCGCTCCATCCAGC SEQ ID NO: 413 66SNAB1 GCAGGTTACGTAGCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO: 414 89N-TERMCSLI GTCAAGCCATGGCNCCRCCRAGCTGTCTRCGCT TCGTTCAGACCAACTC SEQ ID NO: 415 89SNAB1 GCAGGTTACGTACGGCTGAAAGGCACATTTGGTGACAA SEQ ID NO: 416 945 SMB1 GCAGGTTACGTAAAGACAGCTGGGGGGGGG SEQ ID NO: 417 98SUAB1 GCAGGTTACGTACTGGACGAAGCGAAGACAGCTG SEQ ID NO: 418 BAM FOR 1 TCAGTTGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTA SEQ ID NO: 426 BAM REV 1 TCAGTTGGATCCTCCGCCAGAACCACCGCCTGACCCACCTCCTGACCC SEQ ID NO: 427 NAVREV L GTCTGAGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCC AGGACTGCTCCTTC SEQ ID NO: 428 NAVREV S GTCTGAGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 429 NAVFOR GTCTGAGGCGCCGAGTGGACGCGGGCTCCACGGTGGCGGCAGGGT TGAGGAGTCGGGCTG SEQ ID NO: 43o XBAFOR1 GCTACGTCTAGATCTCCTGACCTCGACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 447 XBAREV1 GCTAGTTCTAGACCATCCTGGCTGACACGGTGAAACACCGTCTCTACG GGCTGACACTGCAGCTCCAG SEQ ID NO: 448 LNK1FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGCTCCTGCAGG TTGGAGGCCACGG SEQ ID NO: 449 LNK1REV GTCAGTACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGC SEQ ID NO: 450 LNK2FOR GTCAGTTCCGGAGATTTCGGTTCTGCAGAGGGCTGCGCAAGG TGGCGTA SEQ ID NO: 451 LNK2REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTTCTA ATCTGCAAGATGAAGAGCTG SEQ ID NO : 452 LNK7FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGAAAGGCACATTT GGTGACAAAGTGTATC SEQ ID NO: 453 LNK7REV GTCAGTACTAGTCCGCCATCTCCGGGTACACCATTAGGCCCTG CCAGC SEQ ID NO: 454 LNK8REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTAAGGCC TTTCAGCCCCCCCCCAG SEQ ID NO: 455 C1FOR GTCAGACCATGGCCACTCAGGACTCCTCTTTTC SEQ ID NO: 456 C3FOR CACTTTGTCACCAAATCTGCCTTTCAG SEQ ID NO: 457 C3REV CTGAAAGGCAGATTTGGTGACAAAGTG SEQ ID NO: 458 C5FOR GCCCCCCCCCAGCTCTCTTCG SEQ ID NO: 459 C5REV CGAAGAGAGCTGGGGGGGGGC SEQ ID NO: 460 C6REV GTCAGTTACGTACAGGGTTGAAGGAGTCGGGCTGAGACTGC SEQ ID NO: 461 GPFOR1 GTCAGTCCATGGCTACTCAAGGTGCTATGC SEQ ID NO: 462 GPREV2 GTAGCATACGTAGGGCTGCAGGGCAGGGGCC SEQ ID NO: 463 TABLE 2 GENE SEQUENCES pMON30304 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT SEQ ID NO: l pMON26458 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTC SEQ ID NO: 2 pMON28548 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGG ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: 3 pMON28500 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA GAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGG AAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAG GGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCA CAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: 4 pMON28501 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: 5 pMON28502 TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACC CTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCCCCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCACACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC AGG SEQ ID NO: 6 Syntanl 1 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA 51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC 101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT 151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC 201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT 251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT 351 CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA 401 CCTGCACCTT TGCTGGACCC GAACAACCTC AATGACGAAG ACGTCTCTAT 451 CCTGATGGAC CGAAACCTTC GACTTCCAAA CCTGGAGAGC TTCGTAAGGG 501 CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TCTTCGTAAT 551 CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT 601 CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT 651 ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTAC SEQ ID NO: 7 Syntan3 1 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA 51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC 101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT 151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC 201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT 251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT 351 CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA 401 ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA 451 CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC 501 CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 551 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC 601 GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 651 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG 701 GAACAACAGT AC SEQ ID NO: 8 pMON31104 1 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT 51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT 301 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT 351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 9 pMON31105 1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACT GCTCTATAAT 201 GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG 251 ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 301 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA 351 ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 10 pMON31106 1 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA 51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC 101 AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT 151 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT 201 CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA 251 ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 301 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC 351 CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 11 pMON31107 1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT 51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT 101 CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 151 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA 201 CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 251 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 301 CGACATCCAA TCATCATCAA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT 351 GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA 401 ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT 451 TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 501 CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 12 pMON31108 1 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT 51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC 301 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA 351 CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO: 13 pMON31109 1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG 201 CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA 251 AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC 301 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT 351 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGCGCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO: 14 pMON31110 1 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA 51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC 101 AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC 151 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 201 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA 251 TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC 301 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA 351 ACCATGTCTG CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO: 15 pMON31111 1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT 51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG 101 GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT 151 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA 201 CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG 251 AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG 301 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC 351 CTCTCGACAT CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO: 16 pMON13182 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC 501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC 801 GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT 851 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 901 CTGTGTGCCA CCTAATAA SEQ ID NO: 17 pMON13183 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG 901 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 951 TGCCACCTAA TAA SEQ ID NO: 18 pMON13184 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG 651 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG 701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC 751 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA 851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 901 GAAGGGATAT CCTAATAA SEQ ID NO: 19 pMON13185 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 701 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT 751 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC 801 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC 851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG 951 GATATCCTAA TAA SEQ ID NO: 20 pMON13186 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT 451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG 501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG 551 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 601 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC 651 CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG 701 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG 751 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT 801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA 851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 901 GAAGAACTGG GATAATAA SEQ ID NO: 21 pMON13187 1 ATGGCTAACT- GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 601 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA 651 GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA 701 AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATCCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG 801 CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC 851 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 901 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA 951 ACTGGGATAA TAA SEQ ID NO: 22 PMON13188 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA 551 GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 601 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA 651 GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA 701 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 751 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT 801 ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG 851 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 901 GCCCTGCAGC CCTAATAA SEQ ID NO: 23 pMON13189 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG_801_CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951 GCAGCCCTAA TAA SEQ ID NO: 24 pMON13190 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC 501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG 551 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 601 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT 651 GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 701 TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 751 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA 801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA 851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 901 CCGGCCTTCG CCTAATAA SEQ ID NO: 25 pMON13191 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG 551 GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 601 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA 651 CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA 701 TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 751 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT 801 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC 851 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA 901 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC 951 CTTCGCCTAA TAA SEQ ID NO: 26 pMON13192 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC 501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC 801 GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC 851 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC 901 CAGGAGAAGC TGTGTGCCAC CTAATAA SEQ ID NO: 27 pMON13193 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 901 TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA 951 GAAGCTGTGT GCCACCTAAT AA SEQ ID NO: 28 pMON25190 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC 651 CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA 701 AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 751 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT 801 CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 851 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 901 CAGGCCCTGG AAGGGATATC CTAATAA SEQ ID NO: 29 pMON25191 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT 701 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC 751 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT 801 GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 851 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC 901 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC 951 CCTGGAAGGG ATATCCTAAT AA SEQ ID NO: 30 pMON13194 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT 451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG 501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCACAC 551 CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 601 GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT 651 GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC 701 ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 751 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA 801 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA 851 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 901 CAGCAGATGG AAGAACTGGG ATAATAA SEQ ID NO: 31 pMON13195 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG 601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 651 AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA 801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG 851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA 951 GATGGAAGAA CTGGGATAAT AA SEQ ID NO: 32 pMON13196 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT GCCAGCTCCC 551 TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG 601 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG 651 CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG 701 CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 751 AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT 801 GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG 851 ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 901 ATGGCCCCTG CCCTGCAGCC CTAATAA SEQ ID NO: 33 pMON13197 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 34 pMON13198 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC 501 ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT 551 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 601 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG 651 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG 701 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 751 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC 801 CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT 851 GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG 901 GGTGCCATGC CGGCCTTCGC CTAATAA SEQ ID NO: 35 pMON13199 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT 551 TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAGGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 651 TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 701 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 751 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA 801 GGGGCTCTGTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT 851 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 901 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC 951 CATGCCGGCC TTCGCCTAAT AA SEQ ID NO: 36 pMON31112 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG_801_CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951 GCAGCCCTAA TAA SEQ ID NO: 37 PMON31113 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 38 PMON31114 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 301 ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT 351 ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT 401 GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG 451 CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 501 TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG_801_CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951 GCAGCCCTAA TAA SEQ ID NO: 39 pMON31115 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 40 pMON28505 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAG GTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAA ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCT GGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG 5 GGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGC AACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGAC TCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA SEQ ID NO: 41 pMON28506 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAG GAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGT TTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCT CCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTT CACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT SEQ ID NO: 42 pMON28507 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTC CTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCA CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT SEQ ID NO: 43 pMON28508 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT GTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTG GGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGC CTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA GAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT SEQ ID NO: 44 pMON28509 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCT CATAAATCTCCAAACATGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT GGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT CACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG SEQ ID NO: 45 PMON28510 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCGGTTACCCTTG AGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCC AATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGG AGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCT TTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGGCCTCCTTGGAACCCAGCTTCCTCCA CAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTTCCTGAGCTTCCAACACCTGCTCC GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCTGCGTCAGGGAATTCGGCGG CAACATGGCGTCTCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGAC TCCCATGTCCTTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCC TGCTGCCTGCTGTGGACTTTAGTTG SEQ ID NO: 46 pMON28511 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA CCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCC AATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTA GGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCT TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTT CTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG SEQ ID NO: 47 pMON28512 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC CCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAG ATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT SEQ ID NO: 48 PMON28513 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGC AGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAAC ATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCC CATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAG GACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGA CCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG GTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG SEQ ID NO: 49 pMON28514 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT CACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTC CTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCC GCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG GACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTC TCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTC CTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA SEQ ID NO: 50 pMON28515 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACC CTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG SEQ ID NO: 51 pMON28516 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT SEQ ID NO: 52 pMON28519 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAG GTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAA ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCT GGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG GGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAAC ATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCC CATGTCCTTCACAGCAGACTGAGCCAGTGCCCA SEQ ID NO: 53 pMON28520 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAG GAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGT TTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCC GCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT SEQ ID NO: 54 pMON28521 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTC CTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCA CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCT TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC CAGTGCCCAGAGGTTCACCCTTTGCCTACACCT SEQ ID NO: 55 pMON28522 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT GTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTG GGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGC CTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGA GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAG GTTCACCCTTTGCCTACACCTGTCCTGCTGCCT SEQ ID NO: 56 pMON28523 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT GGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC CCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG SEQ ID NO: 57 pMON28524 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA GAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACAC CTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA TTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA CCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG SEQ ID NO: 58 pMON28525 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA CCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCC AATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTA GGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGT GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAG TGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGA GAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTG SEQ ID NO: 59 PMON28526 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGT AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATG GAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA GCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT SEQ ID NO: 60 pMON28527 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGC AGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATG GCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT GTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGAC ATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCC ACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTG CAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG SEQ ID NO: 61 pMON28528 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGeA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT CACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTC CTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCT CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGC AGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT GGAACCCAGCTTCCTCCACAGGGCAGGACCACA SEQ ID NO: 62 pMON28529 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCT TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTT CTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTG GGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAG CTTCCTCCACAGGGCAGGACCACAGCTCACAAG SEQ ID NO: 63 pMON28530 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA GAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGG AAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAG GGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCA CAGGGCAGGACCACAGCTCACAAGGATCCCAAT SEQ ID NO: 64 pMON28533 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTC CAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAAT TCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATTGGTTACCCTTGAGC AAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCAATC TCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCAC CCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAG ATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGC GGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGT GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA SEQ ID NO: 65 pMON28534 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAG GAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGT TTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAAC ATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCC CATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT SEQ ID NO: 66 PMON28535 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTC CTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCA CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCA GCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT SEQ ID NO: 67 pMON28536 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT GTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTG GGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGC CTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCT TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT SEQ ID NO: 68 pMON28537 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT GGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG SEQ ID NO: 69 pMON28538 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA GAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACAC CTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA TTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC CCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG SEQ ID NO: 70 pMON28539 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA CCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCC AATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTA GGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCG CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGC AGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG SEQ ID NO: 71 pMON28540 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGA ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA GAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGG AAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAG GGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT SEQ ID NO: 72 pMON28541 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGC AGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAAC GGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA CCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACC AAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGA CAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG SEQ ID NO: 73 pMON28542 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCT CACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTC CTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATG GCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT GTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGAC ATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCC ACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTG CAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA SEQ ID NO: 74 pMON28543 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCA GCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG GACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTC TCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTC CTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG SEQ ID NO: 75 pMON28544 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACC CTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT SEQ ID NO: 76 pMON28545 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTT CCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCA ATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATC ATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACC CTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGGGCAGGACCACAGCTCACAAG SEQ ID NO: 77 pMON15981 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG 451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG 901 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG 951 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA; SEQ ID NO: 78 pMON15982 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA 701 CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT 751 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA 801 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG 851 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 901 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT 951 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA; SEQ ID NO: 79 pMON15965 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGGCGGCG 551 GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 601 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC 651 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG 701 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC 751 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA 801 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT 851 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 901 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC 951 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA SEQ ID NO: 80 pMON15966 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC 601 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT 651 CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG 701 CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 751 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC 801 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA 851 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 901 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT 951 TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA S? Q ID NO: 81 pMON15967 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA 601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 651 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC 751 AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 801 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG 851 TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA 901 TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 951 TAA SEQ ID NO: 82 pMON15960 1 ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT 51 CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC 101 AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG 151 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC 201 CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 251 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG 301 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 351 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA 401 GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG 451 AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT 501 GACATGGCTA 551 CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT 601 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA 651 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG 701 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 751 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT 801 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC 851 CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC 901 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA 1001 TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT 1051 CTACGCCACC TTGCGCAGCC CTGATAA SEQ ID NO: 83 PMON32132 TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGG SEQ ID NO: 84 PMON32133 TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGG SEQ ID NO: 85 pMON32134 TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGG TCCACCCTCTGCGTCAGG SEQ ID NO: 86 Pmonl3181 1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG 51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT 101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA 251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA 401 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA 451 CCGCATGCAA GCTT SEQ ID NO: 87 Pmonl3180.Seg 1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG 51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT 101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA 251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA 401 AGGTACCGCA TGCAAGCTT SEQ ID NO: 88 pMON30237.seq GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC SEQ ID NO: 89 pMON30238.seq GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 90 pMON30239.seq TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC CCAAATGTGCCTTTCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 91 pMON32329.seq GGAACTCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC SEQ ID NO: 92 pMON32330.seq TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA GGTACCCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 93 pMON32341.seq GCCACTCAGGACTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC SEQ ID NO: 94 TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC pMON32342.seq GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 95 pMON32320.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO: 96 pMON32321-seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 97 pMON32322-seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 98 pMON32323.seq TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA ATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT GCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGG SEQ ID NO: 99 pMON32324.seq TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 100 pMON32325-seq TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 101 pMON32326.seq GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA TGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCC SEQ ID NO: 102 pMON32327.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 103 pMON32328.seq GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT CTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 104 pMON32348.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAGTGGATCCGGAGGTTCTGGCAACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 105 pMON32350-seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG S Q ID NO: 106 FLT3N.seq CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCC SEQ ID NO: 107 FLT3C-seq GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC TGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT SEQ ID NO: 108 FLT7N.seq CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC SEQ ID NO: 109 FLT4C.seq GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT SEQ ID NO: 110 FLTllN.seq CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCAC.CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAG GAGGTGGATCC SEQ ID NO: 111 FLTIOC-seq GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCA GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA ACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG TAAGCTT SEQ ID NO: 112 pMON32365.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 113 pMON32366.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACC TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 114 pMON32367.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 115 pMON32368.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC AACCTGCAG SEQ ID NO: 116 pMON32369.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO: 117 pMON32370.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CCCCCCCCCAGCTGCCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTC AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 118 pMON30247 -seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAÁCTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO: 119 pMON30248. I know that GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTG SEQ ID NO: 120 pMON32332.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 121 pMON32333.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 5 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA O ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT 5 AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG OR SEQ ID NO: 122 pMON32334.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG 5 TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA O CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA 5 GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 123 pMON32335.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA O TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 5 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 5 CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC O CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 124 pMON32336.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 5 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG O CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG 5 TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO: 125 pMON32337.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 126 pM0N32338.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 127 pMON32339.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC SEQ ID NO: 128 pMON32364.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCGACTCAGGAC TGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO: 129 pMON32377.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGAC TGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTG SEQ ID NO: 13O pMON32392.seq GCCACTCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAA AGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTC TTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGA CATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACT GACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 131 pMON32352-seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 132 pMON32353.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC SEQ ID NO: 133 pMON32354-seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 2. 3 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 134 pMON32355.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAA? TCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG 2 CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 135 pMON32356.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG 2 GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 136 pMON32357.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 137 pMON32358.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 138 pMON32359.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG AACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG SEQ ID NO: 139 pMON32360.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA 5 ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AGTGGATCCGGAGGTTCTGGCACCCAGGACTGCTCCTTCCAACACAGCCC OR CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC. TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 140 pMON32362.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 5 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG O CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 5 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG AGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACCCAGGACTGCTC SEQ ID NO: 141 pMON32393.seq GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGT GAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGA ATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAA TTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAAC CTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCC AAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAG GTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACG GCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGA ATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGG at AACAACAG SEQ ID NO: 142 pMON32371.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 143 pMON32372.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 144 pMON32373-seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC SEQ ID NO: 145 pMON32374.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 146 pMON32375.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG SEQ ID NO: 147 pM0N32376.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAG SEQ ID NO: 148 pMON32378.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCC AACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 149 pMON32379.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG 5 ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA O CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT GGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 150 pMON32380.seq 5 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC O TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG 5 CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC 'CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 151 pMON32381.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCGTGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 152 pMON32382.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC GGG SEQ ID NO: 153 pMON32383.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 5 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT O CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG 5 GAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG O AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG CGGCTCAAGACTGTCGCTGGG SEQ ID NO: 154 pMON32384.seq * GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGGCTGGTGGCGCTGACTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGGCAGTGTCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACCTGGATGGGCTCAAGACTGTCGCGTGGTCCAAGATGCAAGGCTTGCTGGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCC SEQ ID NO: 155 pMON32385.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGGCTGGTGGCGCTGACTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGGCAGTGTCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAGGATGAGGCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACCTGGATGGGCTCAAGACTGT CGCTGGGTCCAAGATGCAAGGCTTGCTGGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCC SEQ ID NO: 156 pMON32386.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGGCTGGTGGCGCTGACTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGGCAGTGTCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACCTGGATGGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCC SEQ ID NO: 157 pMON32387.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGGCTGGTGGCGCTGACTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGGCAGTGTCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA ACACCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC GAGGCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACCTGGAT GGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCC SEQ ID NO: 158 pMON32388.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG SEQ ID NO: 159 pMON32389.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCC SEQ ID NO: 160 flt3-28291inkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGG AGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 161 hflt3-28291i ---. kl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCA TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAA SEQ ID NO: 162 hflt3-3435linkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 163 hflt3-34351inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAAGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTG SEQ ID NO: 164 hflt3-62631inkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 165 hflt3-62631inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 2 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCG GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACT SEQ ID NO: 166 hflt3-94951inkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC GGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 167 hflt3-94951inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTT SEQ ID NO: 168 hflt3-98991inkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 169 hflt3-98991inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAG SEQ ID NO: 170 hflt3-28291ink6-seq ? GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 171 hflt3-28291ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 172 hflt3-28291inkl3.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGG GGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO.-173 hflt3-28291ink21.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCT 5 CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAA SEQ ID NO: 174 hflt3 -3435link6. I know that GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 10 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC 20 GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTG SEQ ID NO: 175 hflt3-34351ink7.seq ? GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGA ACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTGGCACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTG SEQ ID NO: 176 hflt3-34351inkl3.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACTGC TCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 177 hflt3-34351ink21.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC 5 GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA O ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CTCAGGGGGAGGTAGTGGTAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTG SEQ ID NO: 178 hflt3-62631ink6.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACT 5 GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 179 hflt3-62631ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 20 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 180 hflt3-6263linkl3.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGG GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 181 hflt3 -6263link21. I know that GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACT SEQ ID NO: 182 hflt3-94951ink6.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG CCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 183 hflt3-9495link7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT GTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 184 hflt3-94951inkl3-seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 185 hflt3-94951ink21.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 186 hflt3-98991ink6.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTC TGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGG ACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCC CCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 187 hflt3-98991ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG 5 TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC O TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC 5 CCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 188 hflt3-98991inkl3 -seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA O TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 5 TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 189 hflt3-9899link21.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGCCCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 190 pMON32390 GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGT CCGCCCCGCCATGTCTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTT TAATCAATCATAAGAACAATGATTCATCAGTGGGGAAGTCATCATCATAT CCCATGGTATCAGAATCCCCGGAAGACCTCGGGTGTGCGTTGAGACCCCA GAGCTCAGGGACAGTGTACGAAGCTGCCGCTGTGGAAGTGGATGTATCTG CTTCCATCACACTGCAAGTGCTGGTCGATGCCCCAGGGAACATTTCCTGT CTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTT ACAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCC AAGCTGGAGAATACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACA ATATTGTTTACAGTGAGTATAAGAAATACCCTGCTTTACACATTAAGAAG ACCTTACTTTAGAAAAATGGAAAACCAGGACGCCCTGGTCTGCATATCTG AGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGATTCACAGGGG GAAAGCTGTAAAGAAGAAAGTCCAGCTGTTGTTAAAAAGGAGGAAAAAGT GCTTCATGAATTATTTGGGATGGACATAAGGTGCTGTGCCAGAAATGAAC TGGGCAGGGAATGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCT CAGACCACATTGCCACAATTATTTCTTAAAGTAGGGGAACCCTTATGGAT AAGGTGCAAAGCTGTTCATGTGAACCATGGATTCGGGCTCACCTGGGAAT TAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATGAGTACCTAT TCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGT GGCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCA GTCAATCAGCTTTGGTTACCATCGTAGAAAAGGGATTTATAAATGCTACC 5 AATTCAAGTGAAGATTATGAAATTGACCAATATGAAGAGTTTTGTTTTTC TGTCAGGTTTAAAGCCTACCCACAAATCAGATGTACGTGGACCTTCTCTC GAAAATCATTTCCTTGTGAGCAAAAGGGTCTTGATAACGGATACAGCATA TCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGC AGAAAATGATGATGCCCAATTTACCAAAATGTTCACGCTGAATATAAGAA O GGAAACCTCAAGTGCTCGCAGAAGCATCGGCAAGTCAGGCGTCCTGTTTC TCGGATGGATACCCATTACCATCTTGGACCTGGAAGAAGTGTTCAGACAA GTCTCCCAACTGCACAGAAGAGATCACAGAAGGAGTCTGGAATAGAAAGG CTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACTCTAAACATG AGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAATTCCCT 5 TGGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTT TCATCCAAGACAACGAATTCATCATCCTGGGCCTGTTCGGCCTCCTGCTG TTGCTCACCTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAG GAAGAATCCCCTCTGGCCAAGTGTCCCAGACCCAGCTCACAGCAGCCTGG GCTCCTGGGTGCCCACAATCATGGAGGAGGATGCCTTCCAGCTGCCCGGC O CTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAGGAGGATGAAAA GAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTCC CCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCC ACCCAGCCCCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCA GCTGCTGGGCAGCCCCACAAGCCCAGGGCCAGGGCACTATCTCCGCTGTG 5 ACTCCACTCAGCCCCTCTTGGCG GGCCTCACCCCCAGCCCCAAGTCCTAT GAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTGGTAACCCCAGC CCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCCC TCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTC SEQ ID NO: 191 pMON30329.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCC TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGC TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC CCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 192 pMON32173.seq GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCT CATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 193 pMON32175.seq GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCATGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCT CATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAG CTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGC TCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTG CTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGC CCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGG GGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACT GGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTG CTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTG GAGGTGTCGTACCGCGTTTTACGCCACCTTGCGCAGCCC SEQ ID NO: 194 pMON32204.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCC TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGC TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC CCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGG AGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT G SEQ ID NO: 195 pMON32205.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGC ACCTTTGCTGGCCCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACC GAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT 5 CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGG ACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGC GGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACG O GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG CCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTC TGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTC 5 CAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT GGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCC O CCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCT CCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 196 pMON32208.seq 5 GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG 5 CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCT O CATAAATCTCCAAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAG CTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGC TCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTG CTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGC CCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGG 5 GGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACT GGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTG CTTTCCAGCGCCGGGCAGGAGGGGT CCTGGTTGCTAGCCATCTGCAGAGCTTCCTG GAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGG O AGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT G SEQ ID NO: 197 pMON35767.seq / pMON32191.seq GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC AACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCA GCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC TGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCG GGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTC CCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCG ATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAG GAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTG CCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTT TCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCC ACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCA GATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGG CCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTG CAGAGCTTCCTGGAGGTGTCGTACCGCGTTC TACGCCACCTTGCGCAGCCG SEQ ID NO: 198 pMON32397.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGT CAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 199 pMON32398.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGT CAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT GCTTCAA SEQ ID NO: 200 pMON32399.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID No.201 pMON35700.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACA? CCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAAGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTG SEQ ID NO: 202 pMON35701.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCA? ACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG GGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC SEQ ID AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT NO: 203 pMON35702.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG GGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACT SEQ ID NO: 204 pMON35703. I know that GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCG TCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 205 pMON35704.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCG TCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAG GTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGC GCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAG CGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAG CTGTCTT SEQ ID NO: 206 pMON35705.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGG GGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCG CTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 207 pMON35706.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGC GGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACG GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAG SEQ ID NO: 208 pMON35733.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATC TGCAAGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTG GATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCC SEQ ID NO: 209 pMON35734.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCAACCTGC AAGATGAAGAGCTGTGTGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTC GCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGAT CCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTGGCCTCC SEQ ID NO: 210 pMON35735.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGCAGG ATGAGGAACTGTGCGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG CGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCTTTTCAGCCCCCCCCCAGCTGTCTTCGCT TCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA GCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGA TTACCCAGTCACCGTGGCCTCCAAC SEQ ID NO: 211 pMON35736.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATG AAGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGA GATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCG TCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAG GTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO: 212 pMON35738.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAAGAAC TGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG O ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCT 5 CAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGAC SEQ ID NO: 213 pMON35739.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAGCTGT GTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT 5 TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAAAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTC AACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAG GGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC O TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAG SEQ ID NO: 214 pMON35740.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT O TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCG GTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT 5 CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGG GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT GGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO: 215 pMON35741.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATC TGCAAGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTG GATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCC SEQ ID NO: 216 pMON35742.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATG AAGAACTGTGCGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGA GATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCG TCCAGACCAACATCTCCCGCCTCCTGCGGGAGACCTCCGAGCAGCCGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAG GTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO: 217 pMON35743. I know that GCT7? ACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAA CCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAC GAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCG GTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGG GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT GGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO: 218 pMON32179.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCG TCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATC TCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGA GACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATC CTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAA GCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTC TGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGAC TGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCA GGAACAACAG SEQ ID NO: 219 pMON35707.seq GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTG CTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGC TGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTT CGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATC AGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAA AAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 220 pMON35708.seq GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACT-GACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 221 pMON35709.seq GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 222 pMON35710.seq GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCCTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCCTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 223 pMON35711.seq GCGGATGAGGAGCTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGGGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 224 pMON35719.seq GGCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAATACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTC TGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTC CAAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGA CCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCT GATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGC ACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTG CCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTG GCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGG AACAACAG SEQ ID NO: 225 pMON35720.seq GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCT GGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC'C CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGAC CTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGT GCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 226 pMON35721.seq GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCA CCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAGGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 227 pMON35722. I know that GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 228 pMON35723.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGA GACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 229 pMON35725.seq GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTYGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 230 pMON35726.seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA 5 CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAACGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTTTTTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT O GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTAATCTCC AAAGCTAACTGCTCTATAATGATCGATGAAATTATAACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCGTAAGGGCTGTCAAGCA CTTAGAAAATGAGGTATTGAGGCAATTCTTCGTAATCTCCAACTCTGC 5 CCTCTGCCACGGCCGCACCCTCTCGACAATATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 231 pMON35744. I know that GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGC ACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCC TGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG S Q ID NO: 232 pMON35745. I know that GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGA GCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 233 pMON35746.seq GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTTGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCA GCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC TGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACC TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 234 pMON35747.seq GCGCAAGATGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCCCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 235 pMON35748.seq GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG 5 ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT O CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 236 pMON35749.seq GCTCTGTGCGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC O CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC 5 CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGT ^ ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 237 pMON35750.seq GCACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 238 pMON35769. I know that GCTCTGTGTGGCGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 239 pMON35771.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 240 pMON35774.seq GCTCAAGATGATGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGT GGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGG TACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTAC TATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACT GCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCT TCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCAT CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCC GCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGA AAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 241 pMON35775.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGC GCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAG SEQ ID NO: 242 pMON35776.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGC GCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTA TACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTA ATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATC ATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTAC CCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 243 pMON32169. seq / pMON40000 I know that GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG 5 CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT O GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCA 5 CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT O CAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 244 pMON32188.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCAAATCTGCAAGACGAGGAGCTGTGCGGGGGCCTCTGGCGGCTG GTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTC AGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGATCAACATCTCCCGCCTCCTGCAG GAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC CCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAG GAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC SEQ ID NO: 245 pMON32273.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCA GAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCG GTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCC SEQ ID NO: 246 pMON35795. I know that GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTCTGCAGGATGAGGAACTGTGCGGCGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCG GTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAG GTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC SEQ ID NO: 247 pMON35796.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC 5 GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTCAAGATGAAGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTT GCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCC CCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC O TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTG CCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTG GGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGC TCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTC TGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG SEQ ID 5 NO: 248 pMON35797.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT O AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC 5 GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAG 5 CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCA GCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGA GCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAG O GAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC SEQ ID NO: 249 pMON35798.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC O ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG 5 GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGAGCTGTGTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT GCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG SEQ ID NO: 250 pMON35799.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTG GATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO: 251 pMON39914. I know that GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTC CACTCGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 252 pMON39915. I know that GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAG SEQ ID NO: 253 pMON39916. I know that GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTC CACTCGGCGCCACCGCACCGACCGCTGGACA ACCGCCTCTGACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 254 pMON35712. I know that GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGG CCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG GGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAA SEQ ID NO: 255 pMON35713. I know that GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCT GGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGAC CTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGT GCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTG SEQ ID NO: 256 pMON35714.seq GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA 5 CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCA CCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT O GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACT SEQ ID NO: 257 pMON35715.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT 0 GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGG SEQ ID NO: 258 pMON35716-seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGA GACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCC SEQ ID NO: 259 pMON35717.seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTCTT SEQ ID NO: 260 pMON35718.seq GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAG SEQ ID NO: 261 pMON32170.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 262 pMON32187.seq GCAGATGAAGAACTGTGTGGGGGACTGTGGCGTCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCC CACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 263 pMON32271-seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT O CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCC ACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC 5 AAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCC CCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAG CTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGGAAGATCCAGG GCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCC GAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTC O CTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCC TTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCA GCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGC CGGCCTTCGCCTCTGCTTTCCAGCG CCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT 5 CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 264 pMON32272.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA 5 ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGT TCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTAC O CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAA CATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGT CTTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTG 5 TGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCT GGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAG GCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCC CTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGT CGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTG O CCCTGCAGCCCACCCAGGGTGCC ATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGG GCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCG CGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 265 pMON32274.seq 5 GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCC ACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTT CCTGCTCAAGTCTTTAGAGCAAGTGAGRAAGATCCAGGGCGATGGCGCAGCGCTCC AGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTC GGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCT GCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGC TCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTG CAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGG AATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTT TCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 266 pMON35751.seq GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC 5 AGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACC ATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAG TGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTG O GGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATA TCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGC CACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCA CCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTC 5 CTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA CCTTGCGCAGCCC SEQ ID NO: 267 pMON35752.seq O GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT 5 GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 268 pMON35753.seq GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTGTACGCCACCTTGCGCAGCCC SEQ ID NO: 269 pMON35754.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGA GACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCGTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO: 270 pMON35755.seq GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGC ACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCC TGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCATCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 271 pMON35756.seq GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGA GCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO: 272 pMON35757.seq GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTTGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCA GCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC TGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACC TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCC CACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 273 pMON35758.seq GCACTGTGCGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTACAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCC CACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 274 pMON35759.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT 5 CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA O GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG 5 CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC O CTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 275 pMON35760.seq 5 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCC GGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC S? Q ID NO: 276 pMON35761.seq GCGCTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCAACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATTTTTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 277 pMON35762.seq GCTGAACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCT GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGC CCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 278 pMON35763. I know that GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 279 pMON35764.seq GCTCAGGACGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT 5 GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCÁGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC O GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 280 pMON35765.seq 5 GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTTGCTGTCAA O AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 5 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 281 pMON35766. seq / pMON32190. seq / pMON40001 I know that GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGC CAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCC AGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAG CTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCG GCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTG GGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTG GCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCA TGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCC G SEQ ID NO: 282 pMON35768. I know that GCTCAAGATGAAGAACTGTGCGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGC GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 283 pMON35770-seq GCGCTGTGTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATATGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAA CCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAA ATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCC TGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAG GAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGG ACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGC AGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTC CTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCA GCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAA TGGCCCCTGCCCTGCAGCCCACCCAGGGTGC CATGCCGGCCTTCGCCTCTGCTTTC CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGT GTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 284 pMON35772. I know that GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTTCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCT GGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCC GGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 285 pMON35773.seq GCTCAAGACGAAGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG 5 TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGT GGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGG O TACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTAC TATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACAC CATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAA 5 GTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTA CAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCT GGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGC CAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGAT ATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG O CCACCACCATCTGGCAGCAGATG GAAGAACTGGGAATGGCCCCTGCCCTGCAGCCC ACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGT CCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCC ACCTTGCGCAGCCC SEQ ID NO: 286 pMON35777.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGC GCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCA AGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCC CTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTA CCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 287 pMON35778.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGC GCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 288 pMON35779.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGT TCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG 5 CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTAC TATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACAC CATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAA GTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTA CAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCT O GGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGC CAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGAT ATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCC ACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGT 5 CCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCC ACCTTGCGCAGCCC SEQ ID NO: 289 pMON35780.seq O GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCCCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT 5 GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGT TCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTAC TATCAACCCGTCTCCTCCGTCTAA GAATCTCATAAATCTCCAAACATGGCTACAC CATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAA GTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTA CAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCT GGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGC CAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGAT ATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCC ACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGT CCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCC ACCTTGCGCAGCCC SEQ ID NO: 290 pMON35782.seq GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCC ACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC ACCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGC CCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCT GGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCA GCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTT GGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGG AAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 291 pMON39908. I know that GCTGATGAGGAGCTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGTAGAGACGGTGTTTCACCGTGTCAGCCAGGATGGTCTAGATCTCCTG ACCTCGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGT CAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCT GCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGG AGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGA CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCA GCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCC TGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAG CTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAAT GGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCC AGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTG TCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 292 pMON32275.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAA CCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAA ATCTCCAAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCC TGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAG GAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGG ACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGC AGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTC CTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCA GCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAA TGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGT GTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCT CCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCAACCCAGGACTGCTCTTTTCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 293 pMON35781.seq GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGAGCCGAAGAGCCCGGACACCCATACTAGTCCGCCATCTCCGACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGT GAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACA AGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGG GCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCA ACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATAT CCCCCGAGTTGGGCCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCC ACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCC TGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCCTCTGCAGAACCGAAATCTCCGGATACTCATACCAGCCCGCCATC CCCGGGTTCTAATCTGCAAGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCC TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGC TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC CCCCCCCAGCTGCCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 294 pMON35783.seq GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTGGCAGGGGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCCGAAGAGCCCGGACA CCCATACTAGTCCGCCATCTCCGGGTACACCATTGGGCCCTGCCAGCTCCCTGCCC CAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGC AGCGCTCCAGGAGAAGCTGTGTGCCACTACAAGCTGTGCCACCCCGAGGAGCTGGT GCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCC AGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTAC CAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGA CACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAG AACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCC TCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTT CCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCTGCAGAACCGA AATCTCCGGATACTCATACCAGCCCGCCATCCCCGGGTAAGGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCC TGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 295 pMON32276.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTCCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGC CAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCC AGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAG CTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCG GCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTG GGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTG GCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCA TGCCGGCCTTCGCCTCTGCTTTCCAGCGCCG GGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCC G SEQ ID NO: 296 pMON32277.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTCCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGCGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 297 pMON32278.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTAGAGCTGCAGT CTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGC CAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCC AGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAG CTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCG GCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTG GGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTG GCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCA TGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCC G SEQ ID NO: 298 pMON32279.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCAGATGAAGAACTGTGTGGGGGCCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTCTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTCTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACTCAGGACTGTTCT TTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 299 pMON35790.seq GCCACTCAGGACTCCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGA TGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGG AGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTT CCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCA CCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAG ATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGC AGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 300 pMON35791-seq GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT CTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGA TGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGG AGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTT CCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCA CCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAG ATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGC AGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 301 pMON35792.seq GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCA ACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCT GTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTC TGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGC CCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACG TCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCG GGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACC SEQ GCGTTCTACGCCACCTTGCGCAGCCG ID NO: 302 pM0N39905 I know that GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA 5 ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT O GCAGTCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGA TGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGG AGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC 5 CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTT CCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCA CCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAG ATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGC O AGAGCTTCCTGGAGGTGTCGTAC CGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 303 pMON39906. I know that GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGCGCCTGGAGCT GCAGTCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGG GTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGA TGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGG AGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTT CCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCA CCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAG ATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGC AGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 304 pMON39909-seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACTCAAGGTGCTATGCC AGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGTGGTGTTCTGGTTGCTAGCCATC TGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCT GGCGGCTCTGGCGGCTCTCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAA GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGT GCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCA TAGCGGCCTTTTCCTCTACCÁGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCG AGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACC ATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCC SEQ ID NO: 305 pMON39910.seq GCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGTGG TGTTCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTAC GCCACCTTGCGCAGCCCTCTGGCGGCTCTGGCGGCTCTCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCT GTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTC TGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGC CCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACG TCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCC AATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACA TGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTG GATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 306 pMON35727.seq GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGC GCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAG CGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAG CTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGC AGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 307 pMON32168.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAA AGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCC CCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA AATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCT CTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 308 pMON32195.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCT-T CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGC CAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCC AGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAG CTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCG GCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTG GGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTG GCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCA TGCCGGCCTTCGCCTCTGCTTTCCAGCGCC GGGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCC CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAA GAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 309 pMON32196'.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGG GCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTG SEQ ID NO: 310 pMON32197.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTT AGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTG CCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGC ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTG CTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGG AAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAG GAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACC 5 GTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAAT CTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCC CCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC O GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGG 5 GCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGG TGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCG CTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT O CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCA CTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGG AGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG 5 GCCTCCAACCTGCAG SEQ ID NO: 311 pMON32206.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGC • CCTTTOCT8-1CCCG C CCTC? AXG? CGa G CGTCTCTMCCIGAIGG CC GAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAA AATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAAT TCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT 10 CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAG AACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGAT ACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAG 15 CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTG fc GCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTG 20 AACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCT GGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGAC 25 CTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGT GCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 312 pMON32207.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTGATGAAGAACTGTGTGG TGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCG CTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCA CTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGG AGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCT GCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGG TCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCT GTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTC 5 TGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGC CCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACG TCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCG O GGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACC GCGTTCTACGCCACCTTGCGCAGCCCTGATAAGGATCCGAATTCGGCAGC SEQ ID NO: 313 pMON35728.seq 5 GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT O GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG TGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 5 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGAC CACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTG ATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCA CTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGC CCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGA ACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCT CTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCC GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAG SEQ ID NO: 314 pMON32183.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGT GTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAATTCAAGCTTGAGCCCAGA GGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGG TGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCC TGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTC CAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCA TAGAGAGGATTACAACAGTACTCTCCGGGCGGTCAGTGCCCTCCCCATCCAGCACC AGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCA GCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGT ATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCT GCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGG AAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTA CTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCT ACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTC TCCCGGACTCCGGGTAAA SEQ ID NO: 315 pMON32184.seq GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCT GTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGAATTCAAGCTTGAGCCCAGAGGGCCCA CAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCA TCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCC CATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCA GCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAG GATTACAACAGTACTCTCCGGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGACTG GATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCA TCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTC TTGCCTCCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGT CACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAG AGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATG TACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTG TTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGA CTCCGGGTAAA SEQ ID NO: 316 TABLE 3 PROTEIN SEQUENCES pMON26458pep SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAspAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe SEQ ID NO: 467 pMON28548pep SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla LeuProAlaValAspPheSerLe GlyGluTrpLysThrGlnMetGluGluThrLysAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis Val LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln euHisSerArg euSerGlnCysProGluValHisPro euProThrProValLeu LeuGlyProThrCysLeuSerSer euLeuGlyGln euSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArg SEQ ID NO: 468 pMON28500 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro euProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrp LysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCys LeuSerSerLeuLeuGlyGln euSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr AlaHisLysAspProAsr-AlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgVal LeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGln CysProGluValHisProLeuProThrProValLeuLeuProAlaValAsp PheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSer euLeuGlyThrGlnLeuPro ProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSer PheGlhHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGly SerThrLeuCysValArg SEQ ID NO: 469 pMON28501 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 70 pMON28502 SerProAlaProProAlaCysAsp euArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSer euGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspIleLeuGlyAlaValThrLe LeuLeuGluGlyValMetAlaAla ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGly LysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 471 13182. Pept Asn Cys Ser lie Met lie Asp Glu lie lie His Leu Lei Lys Arg Pro Pro Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly lie Glu Wing lie Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro lie lie lie Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Wing Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly lie Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly lie Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr lie Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys lie Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Thr wing SEQ ID NO: 472 13183. Pept Asn Cys Ser lie Met lie Asp Glu lie lie His Leu Lei Lys Arg Pro Pro Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly lie Glu Wing lie Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro lie lie lie Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro lie Ser Thr lie Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Leu Leu Leu Le Gly His Ser Leu Gly lie Pro Pro Pro Leu Le Ser Ser Cys Pro Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Lie Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr lie Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys lie Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr SEQ ID NO: 473 13184. ept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Gl Le Pro Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser SEQ ID NO: 474 13185. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe Val Arg Wing Val Lys Asn Leu Glu Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Pro His Lys Pro Pro Asn Met Pro Wing Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Be Gln Be Phe Leu Leu Lys Be Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser SEQ ID NO: 475 13186. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Gly As As Met Met Wing Met Wing Pro Wing Gl Le Pro Gln Gly Wing Pro Met Gl Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Being Phe Leu Glu Val Being Tyr Arg Val Leu Arg His Leu Wing Gln Pro Being Gly Gly Being Gly Gly Being Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln M et Glu Glu Leu Gly SEQ ID NO: 476 13187. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Met Wing Pro Wing Pro Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly SEQ ID NO: 477 13188. Pept Asn Cys Being He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Thr Gln Gly Wing Met Pro Wing Ala Phe Wing Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 478 13189. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 479 13190. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Being Wing Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys' Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala S? Q ID NO: 480 13191. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Ser Wing Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Leu Val Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Glu Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing SEQ ID NO: 481 13192. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Gly As As Met Wing Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr SEQ ID NO: 482 13193. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Leu Val Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr SEQ ID NO: 483 25190. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Gl Le Pro Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser SEQ ID NO: 484 pMON25191.Pep Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Al to Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser SEQ ID NO: 485 13194. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Ser Asn Met Wing Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Phe Wing Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly SEQ ID NO: 486 13195. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Wing Ala Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Al Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 'Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly SEQ ID NO: 487 13196. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Ser Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Glu Leu Leu Gln Wing Leu Glu Gly Glu Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 488 13197. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Se r Gln Ala Leu Gln Leu Gly Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 489 13198. Pept Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Ser Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Glu Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Ala SEQ ID NO: 490 13199. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe Val Arg Wing Val Lys Asn Leu Glu Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Ser Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing SEQ ID NO: 491 31104. Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Asn Cys Ser He Met He As As Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Be Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Be Gly Gly Be Gln Be Phe Leu Leu Lys Be Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 492 31105. Pep Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Pro Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Pro Wing Phe Wing Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 493 31106. Pep Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Be Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Be Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 494 31107. Pep Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 495 31108. Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Wing Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys He He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 96 31109. Pep Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Being Asn Cys Being He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 497 31110. Pep Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 498 31111. Pep Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Being Gly Gly Gly Being Asn Cys Being He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro SEQ ID NO: 499 pMON15981 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThr SEQ ID NO: 500 pMON15982 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSe lleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisPro11e11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSer SEQ ID NO: 501 pMON15965 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyr ysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPhe Wing SEQ ID NO: 502 pMON15966 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr HeTrpGlnGlnMetGluGluLeuG ly SEQ ID NO: 503 pMON15967 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 504 pMON31112.pep MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 505 pMON31113.pep MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer ThrArgHisProI1eIIeIIeArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlixAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro SEQ ID NO: 506 pMON31114.pep MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAspAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerTh lleAsnProSerProProSerLysGlu TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 507 pMON31115.pep MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro SEQ ID NO: 508 pMON28505 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIle11eIIeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaPro ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSer ArgLeuSerGlnCysPro SEQ ID NO: 509 pMON28506 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProIIeIIe11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAsp LeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGln CysProGluValHisPro SEQ ID NO: 510 pMON28507 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProHellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProPrsGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrPro SEQ ID NO: 511 pMON28508 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg ThrProValLeuLeuPro SEQ ID NO: 512 pMON28509 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn Me AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAsp SerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro ValLeuLeuProAlaVal SEQ ID NO: 513 pMON28510 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro AlaValAspPheSerLeu SEQ ID NO: 514 pMON28511 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMet GluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMet AlaAlaArgGlyGlnLeu SEQ ID NO: 515 pMON28512 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIIe11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro AlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeu SEQ ID NO: 516 pMON28513 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly GluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeu LeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeu LeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGly ThrGlnLeuProProGln SEQ ID NO: 517 pMON28514 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGlnGlyArgThrThr SEQ ID NO: 518 pMON28515 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisPro11e11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla ArgThrThrAlaHisLys SEQ ID NO: 519 pMON28516 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIIe11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr AlaHisLysAspProAsn SEQ ID NO: 520 pMON28519 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysPro SEQ ID NO: 521 pMON28520 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIIeIIe11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisPro SEQ ID NO: 522 pMON28521 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaliePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrPro SEQ ID NO: 523 pMON28522 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuPro SEQ ID NO: 524 pMON28523 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMet LeuLeuProAlaVal SEQ ID NO: 525 pMON28524 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSerLeu SEQ ID NO: 526 pMON28525 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIIeIIe11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeu SEQ ID NO: 527 pMON28526 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIIeIIe11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHe LeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro ThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAla LeuGlnSerLeuLeu SEQ ID NO: 528 pMON28527 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProllellelleLysAl GlyAspTrpGlnGluPheArgGluLysLeuThr I TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAsp erHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGln SEQ ID NO: 529 pMON28528 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProHellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLys LeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro LeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln MetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyVal MetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSer GlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProPro GlnGlyArgThrThr SEQ ID NO: 530 pMON28529 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLys SEQ ID NO: 531 pMON28530 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAla LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln HisLysAspProAsn SEQ ID NO: 532 pMON28533 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSer ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVal LeuHisSerArgLeuSerGlnCysPro SEQ ID NO: 533 pMON28534 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProHellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaliePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysProGluValHisPro SEQ ID NO: 534 pMON28535 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl1eIIeIIeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrPro SEQ ID NO: 535 pMON28536 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProHellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuPro SEQ ID NO: 536 pMON28537 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaVal SEQ ID NO: 537 pMON28538 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet LeuLeuProAlaValAspPheSerLeu SEQ ID NO: 538 pMON28539 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProl1eIIe11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeu SEQ ID NO: 539 pMON28540 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeu SEQ ID NO: 540 pMON28541 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAla CysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeu SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPhe SerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAla ValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeu SerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSer LeuLeuGlyThrGlnLeuProProGln SEQ ID NO: 541 pMON28542 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGlnGlyArgThrThr SEQ ID NO: 542 pMON28543 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGlnGlyArgThrThrAlaHisLys SEQ ID NO: 543 pMON28544 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer ArgHisProIlellel1eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGly AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla ArgThrThrAlaHisLysAspProAsn SEQ ID NO: 544 pMON28545 AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHi s Proll and II and II ELYS Al aGlyAspTrpGlnGluPheArgGluLysLeuThr Phe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLys SEQ ID NO: 545 pMON32132 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 546 PMON32133 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArg SEQ ID NO: 547PMON32134 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln * LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 548 pMON30237.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyAlaLeuTrpArgLeu ValLeuAlaGlriArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 549 pMON30238.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeu SEQ ID NO: 550 pMON30239.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeu SEQ ID NO: 551 pMON32329.pep GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 552 pMON32330.pep GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeu SEQ ID NO: 553 pM0N32341.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 554 pMON32342.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeu SEQ ID NO: 555 pMON32320.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGln SEQ ID NO: 556 pMON32321.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 557 pMON32322.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGln SEQ ID NO: 558 pMON32323.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGly SEQ ID NO: 559 pMON32324.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 560 pMON32325.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGly SEQ ID NO: 561 pM0N32326.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnPro SEQ ID NO: 562 pMON32327.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 563 pMON32328-pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnPro SEQ ID NO: 564 pMON32348.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlySerGlySerGlyGlySerGlySerGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGln SEQ ID NO: 565 pMON32350.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlySerGlySerGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 566 FLT3N.pep MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro Trp11eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySer SEQ ID NO: 567 FLT3C.pep GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpI1eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeu SEQ ID NO: 568 FLT7N.pep MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 569 FLT4C.pep GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeu SEQ ID NO: 570 FLTHN.pep MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 571 FLTIOC.pep GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 572 pMON32365.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrp11eThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 573 pMON32366.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 574 pMON32367.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 575 pMON32368.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuVa1AlaLeuLysProTrp11eThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 576 pMON32369.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGln SEQ ID NO: 577 pMON32370.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGln SEQ ID NO: 578 pMON30247.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSe lle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluI1eHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 579 pMON30248.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 580 pMON32332.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrp11eThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 581 pMON32333.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 582 pMON32334.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGly SEQ ID NO: 583 pMON32335.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle 11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGly SEQ ID NO: 584 pMON32336.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 585 pMON32337.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnPro S Q ID NO: 586 pMON32338.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGIylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGly GlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnPro SEQ ID NO: 587 pMON32339.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle LeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAla ValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGly GlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 588 pMON32364-pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 589 pM0N32377.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu S Q ID NO: 590 pMON32352.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHi? LeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 591 pMON32353.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrp11eThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 592 pMON32354.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGly SEQ ID NO: 593 pMON32355.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGly SEQ ID NO: 594 pMON32356.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 595 pMON32357.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnPro SEQ ID NO: 596 pM0N32358.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGly GlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnPro SEQ ID NO: 597 pMON32359.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGly GlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 598 pMON32360.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlySerGlySerGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 599 pMON32362.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLe-LAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuSerGlyGlySerGlySerGlyGly SerGlySerGlyGlySerGlyThrGl-aAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 600 pMON32392.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr HeAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProPro AsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeu MetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGln ProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuVal ThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 601 pMON32393.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLys SerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHis LeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAla PheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalle LeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArg HisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeu ThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 602 pMON32396.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerProHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 603 pMON32371.pep AlaAsnCysSerlleMetlleA? PGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsr-AsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGln SEQ ID NO: 604 pMON32372.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGln SEQ ID NO: 605 pMON32373.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuVa1LeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 606 pM0N32374.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO.-607 pMON32375.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 608 pMON32376.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerglyGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gln SEQ ID NO: 609 pMON32378.pep AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuT - - pArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGly SEQ ID NO: 610 pMON32379.pep AlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGly SEQ ID NO: 611 pMON32380.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGly SEQ ID NO: 612 pMON32381.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Glr-AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 613 pMON32382.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGln-HisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 614 pMON32383.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla Gly SEQ ID NO: 615 pMON32384.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnPro SEQ ID NO: 616 pMON32385.pep ? AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProA nAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnPro SEQ ID NO: 617 pMON32386.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnPro SEQ ID NO: 618 pMON32387.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln 5 AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 619 pMON32388.pep • AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGl AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 620 pMON32389.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln Pro SEQ ID NO: 621 hflt3-28291inkl0.pep ? AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLy ArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGln SEQ ID NO: 622 hflt3-28291inkl5.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 623 hfIt3-3435linkl0.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrVal SEQ ID NO: 624 hflt3-34351inkl5.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGIylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg VálAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 625 hflt3-62631inkl0.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThr SEQ ID NO: 626 hflt3-62631inkl5.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 627 hflt3-94951inkl0.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeu SEQ ID NO: 628 hflt3-94951inkl5.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 629 hflt3-98991inkl0.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySer SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlyGlyGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGln SEQ ID NO: 630 hflt3-98991inkl5.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 631 hflt3-28291ink6.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGln SEQ ID NO: 632 hflt3-28291ink7.pep AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuPrsSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGln SEQ ID NO: 633 hflt3-2829linkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 634 hflt3-28291ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys Thr SEQ ID NO: 635 hflt3-34351ink6.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProArSerThrLeuGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrVal SEQ ID NO: 636 hflt3-34351ink7.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle 11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrVal SEQ ID NO: 637 hflt3-3435linkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg t ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAla euLysProTrp11eThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 638 hflt3-34351ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr Val SEQ ID NO: 639 hflt3-62631ink6.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThr SEQ ID NO: 640 hflt3 -6263link7.pep To AsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThr SEQ ID NO: 641 hflt3-62631inkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 642 hflt3-62631ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys Thr SEQ ID NO: 643 hflt3-94951ink6.pep AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeu SEQ ID NO: 644 hflt3-94951ink7.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeu SEQ ID NO: 645 hflt3-9495linkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle IIeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlr-AspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeu SEQ ID NO: 646 hflt3-94951ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys Leu SEQ ID NO.-647 hfIt3-98991ink6.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySer SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGln SEQ ID NO: 648 hflt3-98991ink7.pep ? AlaAsnCysSerlleMetlleA pGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySer SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu ArgPheValGln SEQ ID NO: 649 hflt3-9899linkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySer SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGln SEQ ID NO: 650 hflt3-98991ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPro ProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHe LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeu ValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal Gln SEQ ID NO: 651 GlySerThrMetSerArgLeuProValLeuLeuLeuLeuGlnLeuLeuValArgProAlaMet SerThrAsnGlnAspLeuProValIleLysCysValLeuIleAsnHisLysAsnAsnAspSer SerValGlyLysSerSerSerTyrProMetValSerGluSerProGluAspLeuGlyCysAla LeuArgProGlnSerSerGlyThrValTyrGluAlaAlaAlaValGluValAspValSerAla SerlleThrLeuGlnValLeuValAspAlaProGlyAsnlleSerCysLeuTrpValPheLys HisSerSerLeuAsnCysGlnProHisPheAspLeuGlnAsnArgGlyValValSerMetVal HeLeuLysMetThrGluThrGlnAlaGlyGluTyrLeuLeuPhelleGlnSerGluAlaThr AsnTyrThrlleLeuPheThrValSerlleArgAsnThrLeuLeuTyrThrLeuArgArgPro TyrPheArgLysMetGluAsnGlnAspAlaLeuValCysIleSerGluSerValProGluPro HeValGluTrpValLeuCysAspSerGlnGlyGluSerCysLysGluGluSerProAlaVal ValLysLysGluGluLysValLeuHisGluLeuPheGlyMetAspHeArgCysCysAlaArg AsnGluLeuGlyArgGluCysThrArgLeuPheThrlleAspLeuAsnGlnThrProGlnThr ThrLeuProGlnLeuPheLeuLysValGlyGluProLeuTrpHeArgCysLysAlaValHis ValAsnHisGlyPheGlyLeuThrTrpGluLeuGluAsnLysAlaLeuGluGluGlyAsnTyr PheGluMetSerThrTyrSerThrAsnArgThrMetlleArglleLeuPheAlaPheValSer SerValAlaArgAsnAspThrGlyTyrTyrThrCysSerSerSe rLysHisProSerGlnSer AlaLeuValThrlleValGluLysGlyPhelleAsnAlaThrAsnSerSerGluAspTyrGlu HeAspGlnTyrGluGluPheCysPheSerValArgPheLysAlaTyrProGlnlleArgCys ThrTrpThrPheSerArgLysSerPheProCysGluGlnLysGlyLeuAspAsnGlyTyrSer HeSerLysPheCysAsnHisLysHisGlnProGlyGluTyrllePheHisAlaGluAsnAsp AspAlaGlnPheThrLysMetPheThrLeuAsnlleArgArgLysProGlnValLeuAlaGlu AlaSerAlaSerGlnAlaSerCysPheSerAspGlyTyrProLeuProSerTrpThrTrpLys LysCysSerAspLysSerProAsnCysThrGluGluIleThrGluGlyValTrpAsnArgLys AlaAsnArgLysValPheGlyGlnTrpValSerSerSerThrLeuAsnMetSerGluAlalle LysGlyPheLeuValLysCysCysAlaTyrAsnSerLeuGlyThrSerCysGluThrlleLeu LeuAsnSerProGlyProPheProPhelleGlnAspAsnGluPhellelleLeuGlyLeuPhe GlyLeuLeuLeuLeuLeuThrCysLeuCysGlyThrAlaTrpLeuCysCysSerProAsnArg LysAsnProLeuTrpProSerValProAspProAlaHisSerSerLeuGlySerTrpValPro ThrlleMetGluGluAspAlaPheGlnLeuProGlyLeuGlyThrProProIleThrLysLeu ThrValLeuGluGluAspGluLysLysProValProTrpGluSerHisAsnSerSerGluThr CysGlyLeuProThrLeuValGlnThrTyrValLeuGlnGlyAspProArgAlaValSerThr GlnProGlnSerGlnSerGlyThrSerAspGlnValLeuTyr GlyGlnLeuLeuGlySerPro ThrSerProGlyProGlyHisTyrLeuArgCysAspSerThrGlnProLeuLeuAlaGlyLeu ThrProSerProLysSerTyrGluAsnLeuTrpPheGlnAlaSerProLeuGlyThrLeuVal ThrProAlaProSerGlnGluAspAspCysValPheGlyProLeuLeuAsnPheProLeuLeu GlnGlylleArgValHisGlyMetGluAlaLeuGlySerPhe SEQ ID NO: 652 pMON30329.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuVa1LeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 653 pMON32173.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 654 pMON32175.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 655 pMON32204.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpH eThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 656 pMON32205.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeu LeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeu ProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisS erProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 657 pMON32208.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAl aSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu 5 HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 658 pMON35767.pep / pMON32191.pep • AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGl AspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 659 pMON32397.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGln SEQ ID NO: 660 pMON32398.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerproGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly euLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGl nThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla eu ysProTrpIleThrArgGlnAsnP heSerArgCysLeuGluLeuGlnCysGlnProAspSerSerT rLeuGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlyT rGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGln SEQ ID NO: 661 pMON32399.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle 11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrVal SEQ ID NO: 662 pMON35700.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrVal SEQ ID NO: 663 pMON35701.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThr SEQ ID NO: 664 pMON35702.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThr SEQ ID NO: 665 pMON35703.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeu SEQ ID NO: 666 pMON35704.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeu SEQ ID NO: 667 pMON35705.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGln SEQ ID NO: 668 pMON35706.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle IlelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrAsnl1eSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHis heValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGln SEQ ID NO: 669 pMON35733.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla IleLeu-ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAla SEQ ID NO: 670 pM0N35734.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAsp11eLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSer SEQ ID NO: 671 pM0N35735.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle IlelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsn SEQ ID NO: 672 pMON35736.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeu SEQ ID NO: 673 pMON35738.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAsp11eLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAsp SEQ ID NO: 674 pMON35739.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAsp11eLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGlu SEQ ID NO: 675 pMON35740.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAsp11eLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle IlelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGlu SEQ ID NO: 676 pMON35741.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspSerAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAla SEQ ID NO: 677 pMON35742.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuArgGluThrSerGluGlnProValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeu SEQ ID NO: 678 pMON35743.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGlu SEQ ID NO: 679 pMON32179.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValTyrValGluGlyGlyGlyGlySerProGlyGluPro SerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsn MetAlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArg ThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGlu AlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisPro HellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 680 pMON35707.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuArgProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr HeAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsn LeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAla PheValArgAlaValLy HisLeuGluAsnAlaSerGIylleGluAlalleLeuArgAsnLeu GlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGly AspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGlu GlnGln SEQ ID NO: 681 pM0N35708.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla IleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 682 pMON35709.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 683 pMON35710.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgLeuValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla IleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 684 pMON35711.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlyArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProlleíleíleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr • PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 685 pMON35719.pep MetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluPro SerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsn MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArg ThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGlu AlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisPro IIeIIeIIeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 686 pMON35720.pep AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 687 pMON35721.pep AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 688 pMON35722.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle IIeIIeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 689 pMON35723.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle IlelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 690 pMON35725.pep AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 691 pMON35726.pep AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysPheTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 692 pMON35744.pep AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGIylleGluAlalleLeuArgAsnLeuGInProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 693 pMON35745.pep AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluA pMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 694 pMON35746.pep AlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 695 pMON35747.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 696 pMON35748.pep AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 697 pMON35749.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProA? NMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 698 pM0N35750.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 699 pMON35769.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProI1eSerSerAspPheAlaVa1LysIIeArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 700 pMON35771-pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSer ? GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleA pGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 701 pMON35774.pep AlaGlnAspAspGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlle AspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsn SerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheVal ArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnPro CysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 702 pMON35775.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProPro TrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 703 pMON35776.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProPro TrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLys ArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAla ProSerArgHisProllelle11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 704 pMON32169.pep / pMON40000.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 705 pMON32188.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnlle AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyGlySerglyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSer SEQ ID NO: 706 pM0N32273.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuT rpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 707 pMON35795.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg Glr-AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsn SEQ ID NO: 708 pM0N35796.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeu SEQ ID NO: 709 pM0N35797.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAsp SEQ ID NO: 710 pMON35798.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGlu SEQ ID NO: 711 pM0N35799.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyT hrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGlu SEQ ID NO: 712 pMON39914.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSer ProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 713 pMON39915.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 714 pMON39916.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSer ProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 715 pMON35712.pep AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGln SEQ ID NO: 716 pMON35713.pep AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrVal SEQ ID NO: 717 pMON35714.pep AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThr SEQ ID NO: 718 pMON35715.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGly SEQ ID NO: 719 pMON35716.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnPro SEQ ID NO: 720 pMON35717.pep AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeu SEQ ID NO: 721 pM0N35718.pep AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerglyGlyGlySerGlyGlyGlyGlyGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGln SEQ ID NO: 722 pMON32170.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspVa1AlaAspPheAlaThrThrIIeTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAl aSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 723 pMON32187.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTh rGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 724 pMON32271.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrp SerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySer ProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly HisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAla ThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHis LeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 725 pMON32272-pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAla ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCys HisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeu TyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMet AlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArg AlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnPro SEQ ID NO: 726 pMON32274.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis P eValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrp SerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePro TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeu HisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGln MetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla SerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGlu ValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 727 pMON35751.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuArgProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr HeAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGln GlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeu LeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAsp ValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAla GlnPro SEQ ID NO: 728 pMON35752.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAla PheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 729 pMON35753.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValValArgHisLeuAlaGlnPro SEQ ID NO: 730 pMON35754.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerValProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePrsTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal HeArgHisLeuAlaGlnPro SEQ ID NO: 731 pMON35755.pep AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerHisProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 732 pMON35756.pep AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTh rGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValHeArgHisLeuAlaGlnPro SEQ ID NO: 733 pMON35757.pep AlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThr GlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 734 pMON35758.pep AlaLeuCysGlyGlyLeuTrpArgLeuVa1LeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 735 pMON35759.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 736 pMON35760.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrp11eThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlr-AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 737 pMON35761.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAsnPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIlePheThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 738 pMON35762.pep AlaGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTh rGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 739 pMON35763.pep AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 740 pMON35764.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 11eSerArgLeuLeuGlnGluThrSerGluGlnLeuVa1AlaLeuLysProTrp11eThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 741 pMON35765.pep AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerlyGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 742 pMON35766.pep / pMON32190.pep / pMON40001.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAl aGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 743 pMON35768.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspSerAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThr GlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 744 pMON35770.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysTyrAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGlu ProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerPro AsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeu GluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyr LysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGly LeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThr LeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 745 pMON35772.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhePheArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLjeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspVa1AlaAspPheAlaThrThr11eTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 746 pMON35773.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAla SerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVal LeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 747 pM0N35777.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProPro TrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAla PheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnPro SEQ ID NO: 748 pMON35778.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProPro TrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 749 pMON35779.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAla SerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVal LeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGl yMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 750 pMON35780.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg ProLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp11eThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAla SerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVal LeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 751 pMON35782.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrp SerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly ThrProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 752 pMON39908.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProValGluThrValPheHisArgValSer GlnAspGlyLeuAspLeuLeuThrSerThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAla ThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrp AlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSer AlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVal SerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 753 pMON32275-pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGly GlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylle SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr HeTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGln SerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProTyrValGluGlyGly GlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGln SEQ ID NO: 754 pMON35781.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnGluPro LysSerProAspThrHisThrSerProProSerProThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly HisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAla ThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHis LeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerAlaGlu ProLysSerProAspThrHisThrSerProProSerProGlySerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpH eThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 755 pMON35783.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyTrpGlnGlyArgValAsnThrGluIleHisPheValThr LysCysAlaPheProLysSerProAspThrHisThrSerProProSerProGlyThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeu LeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAsp ValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAla GlnProSerAlaGluProLysSerProAspThrHisThrSerProProSerProGlyLysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 756 pMON32276.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspSer SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 757 pMON32277.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyGlySerglyThrGlnAspSerSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 758 pMON32278.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAl aGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 759 pMON32279.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 760 pMON35790.pep AlaThrGlnAspSerSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 761 pMON35791.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 762 pMON35792.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAla ThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrp AlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSer SEQ ID AlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVal SerTyrArgValLeuArgHisLeuAlaGlnPro NO: 763 pMON39905.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuAr gHisLeuAlaGlnPro SEQ ID NO: 764 pMON39906.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgArgLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPr SEQ ID NO: 765 pMON39909.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylle SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr HeTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 766 pMON39910.pep AlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeu ValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProSerGlyGlySerG? YGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGln GlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGln LeuAspValAlaAspPheAlaThrThr11eTrpGlnGlnMetGluGluLeuGlyMe Alapro AlaLeuGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSer ThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 767 pMON35727.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspT yrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGln SEQ ID NO: 768 pMON32168.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsnTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeu SEQ ID NO: 769 pMON32195.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGln GlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProTyrVal GluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerPro ProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgL euLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGln SEQ ID NO: 770 pMON32196.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTy rValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 771 pMON32197.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGl ySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyGlyGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 772 pMON32206.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeu LeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeu ProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle 11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSer ProProSerLysGluSerHis LysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 773 pMON32207.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGln AsnPheSerA gCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGly SerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLe uGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIle SerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrPro LeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLys HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGln GlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGln LeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProSTPSTPGlySerGluPheGlySer SEQ ID NO: 774 pMON35728.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlyGlyGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeu LeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThr ProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAla HeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIle HelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 775 pMON32183.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnGluPheLysLeuGluProArg GlyProThrlleLysProCysProProCysLysCysProAlaProAsnLeuLeuGlyGlyPro SerValPhellePheProProLysIleLysAspValLeuMetlleSerLeuSerProIleVal ThrCysValValValAspValSerGluAspAspProAspValGlnlleSerTrpPheValAsn AsnValGluValHisThrAlaGlnThrGlnThrHisArgGluAspTyrAsnSerThrLeuArg AlaValSerAlaLeuProIleGlnHisGlnAspTrpMetSerGlyLysGluPheLysCysLys ValAsnAsnLysAspLeuProAlaProIleGluArgThrlleSerLysProLysGlySerVal ArgAlaProGlnValTyrValLeuProProProGluGluGluMetThrLysLysGlnValThr LeuThrCysMetValThrAspPheMetProGluAspHeTyrValGluTrpThrAsnAsnGly LysThrGluLeuAsnTyrLysAsnThrGluProValLeuAspSerAspGlySerTyrPheMet TyrSerLysLeuArgValGluLysLysAsnTrpValGluArgAsnSerTyrSerCysSerVal ValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrProGlyLys SEQ ID NO: 776 pMON32184.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGluPheLysLeuGluProArg GlyProThrlleLysProCysProProCysLysCysProAlaProAsnLeuLeuGlyGlyPro SerValPhellePheProProLysIleLysAspValLeuMetlleSerLeuSerProIleVal ThrCysValValValAspValSerGluAspAspProAspValGlnlleSerTrpPheValAsn AsnValGluValHisThrAlaGlnThrGlnThrHisArgGluAspTyrAsnSerThrLeuArg AlaValSerAlaLeuProIleGlnHisGlnAspTrpMetSerGlyLysGluPheLysCysLys ValAsnAsnLysAspLeuProAlaProIleGluArgThrlleSerLysProLysGlySerVal ArgAlaProGlnValTyrValLeuProProProGluGluGluMetThrLysLysGlnValThr LeuThrCysMetValThrAspPheMetProGluAspHeTyrValGluTrpThrAsnAsnGly LysThrGluLeuAsnTyrLysAsnThrGluProValLeuAspSerAspGlySerTyrPheMet TyrSerLysLeuArgValGluLysLysAsnTrpValGluArgAsnSerTyrSerCysSerVal ValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrProGlyLys SEQ ID NO: 777 The following examples will illustrate the invention in greater detail, although it should be understood that the invention is not limited to those specific examples.

EXAMPLE 1 CONSTRUCTION OF THE BHK PARENTAL EXPRESSION VECTOR A.- Removal of the Afllll site from the mammalian expression plasmid.

A new mammalian expression vector was constructed to accept fragments of the Ncol-Hindlll or Afllll-Hindlll gene in frame and the pMON13146 gene of the hlL-3 receptor agonist (WO 94/12638) and a mouse lgG2b linker fragment. . First, the only Afllll site of pMON3934 which is a derivative of pMON3359 was deleted. pMON3359 is a vector based on pUC18 which contains a mammalian expression cassette. The cassette includes a herpes simplex viral promoter IE10 (-800 to +120), followed by a modified human IL-3 signal peptide sequence, and by a late SV40 polyadenylation (poly-A) signal, which had been subcloned into the pUC18 linker (see Hippenmeyer and co-authors, Bio / Technology, 1993, pages 1037-1041). The modified human IL-3 signal sequence, which facilitates the secretion of gene products out of the cell, is flanked by a BamH1 site at the 5 'end and a unique Ncol site at the 3' end. A single Hindlll site is 3 'with respect to the Ncol site and 5' with with respect to the poly-A sequence. The DNA sequence encoding the signal peptide is shown below (the restriction enzyme sites are indicated above). The codon ATG (methionine) within the Ncol site is in frame with the ATG primer of the signal peptide (underlined): BamHl l or 5'GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTG GTCCGCCCCGCA Ncol TGG (SEQ ID NO 857) The unique Afllll site was removed from pMON934 by digestion with Afllll, followed by filling in the residues by the addition of a DNA polymerase and nucleotides. The digested DNA fragment was purified by agic PCR Cleanup (Promega) and ligated with T4 DNA ligase. The ligation reaction was transformed to DH5alphaMR and the cells were applied on 0 LB-agar plus ampicillin. The individual colonies were discriminated in terms of Afllll site loss by restriction analysis with Afllll and Hindlll, which results in a single fragment, if the Afllll site was deleted. The resulting plasmid pMON30275 was designated.

B.- TRANSFER OF THE CASETTE Pmon13416 / lqG2b OF RECEPTOR AGONIST hlL-3 IN PMON30275 The Ncol-Hindlll fragment (about 425 base pairs of pMON30245 to the Ncol-Hindlll fragment (about 3800 base pairs) was ligated to pMON30275. pMON30245 (WO 94/12638) contains the gene encoding the receptor agonist pMON13416. hlL-3 connected to a fragment of mouse lgG2b hinge Immediately 3 'to hinge lgG2b and 5' with respect to the Hindlll site there is an Afllll site, clones can be cloned in Afllll-Hindlll sites such as fragments Ncol-HindIII or Afllll -Hindlll in the frame with the hinge pMON13416 / lgG2b of the hlL-3 variant to create novel chimeras The Ncol site and the Afllll site have compatible residues and will bind but both recognition sites are lost The plasmid pMON30304 containing the sequence DNA (SEQ ID NO: 1), which encodes the hIL-3 variant pMON13416, linked to the mouse lgG2b hinge region, was the result of this cloning.

EXAMPLE 2 CONSTRUCTION OF AN INTERMEDIARY PLASMIDE CONTAINING A COPY OF THE LIGATING GENE c-mpl (1-153) OF THE DIMERIC TEMPLATE In order to generate a plasmid DNA with the coding sequence of the c-mpl ligand (1-153), followed by a single EcoRI restriction site, the gene is isolated by reverse transcriptase / polymerase chain reaction (TI / RCP). Human A + RNA (batch # 38130) and adult liver (batch # 416018) are obtained from Clontech (Palo Alto, CA, E. U. A.) for messenger RNA source (mRNA) of c-mpl ligand. The cDNA reactions are carried out in the first filament, using a cDNA Cycle MR kit from Invitrogen (San Diego, CA, E. U. A.). In the TI reaction, random sensitizers and oligo-dT sensitizer are used to generate cDNA from a combination of human and fetal liver mRNA. For amplification of the c-mpl ligand gene fragment encoding amino acids 1-153, the IT product serves as a template for PCR, with a combination of the sensitizers, positive sensitizer: c-mp1 Ncol (SEQ ID NO: 317) and reverse sensitizer: Ecompl. The c-mp1 Ncol sensitizer binds to the c-mpl ligand gene (bases # 279-311, based on the c-mpl ligand sequence of access library Gene, # L33410 or de Sauvage and co-authors, Nature 369: 533- 538 (1994)) and encodes a restriction enzyme Ncol site, immediately 5 'with respect to the first codon (Ser + 1) of the ligand c-mpl. The Ncol restriction enzyme site encodes the methionine and alanine codons before Ser + 1 and includes the codon degeneracy for the Ala codon and the first four codons (Ser, Pro, Ala and Pro) of the c-mpl ligand. The Ecompl sensitizer binds bases # 720-737 of the c-mpl ligand and encodes an EcoRI site (GAATTC) in frame with the c-mpl ligand gene (immediately after Arg-153.) The EcoRI site creates the Glu and Phe codons after Arg-153, the PCR product was purified from about 480 base pairs, digested with Ncol and EcoRI and ligated to the Ncol-EcoRI vector fragment of pMON3993 (about 4550 base pairs). a derivative of pMON3359 (described in example 1). The human IL-3 signal peptide sequence, which had been subcloned as a BamHI fragment at the unique BamHI site between the IE110 promoter and the poly-A signal, contains a Ncol site at its 3 'end and is followed by a unique EcoRI site: The plasmid, pMON26458 containing the DNA sequence of (SEQ ID NO: 2), encoding amino acids 1-153 of the c-mpl ligand (SEQ ID NO: 2) No. 467) was the result of that cloning.

EXAMPLE 3 CONSTRUCTION OF THE PARENTAL PLASMIDS CONTAINING THE SECOND GENES OF THE DIMERIC TEMPLATES For the amplification of the c-mpl ligand gene fragments, which start at amino acid 1 (Ser), with a stop codon after of amino acid 153 (Arg), the TI reaction of example 2 serves as a template for PCR, with a combination of the following sensitizers: c-mpI Ncol (SEQ ID NO: 317) (positive sensitizer) and c-mp1 Hindlll ( SEQ ID NO: 319) (reverse sensitizer). The c-mp1 Ncol sensitizer (SEQ ID NO: 317) is described in example 2. The c-mp1 Nindlll sensitizer (SEQ ID NO: 319), which binds to bases No. 716-737 of the c-mpl ligand , increases both a stop codon and a Hind III restriction enzyme site immediately after the final codon, Arg153. Two types of PCR products are generated from the TI cDNA samples: one with an omission of the codons for amino acids 112-115 and one without the omission of those codons. The PCR products of the c-mpl ligand (approximately 480 base pairs) are digested with the restriction enzymes Ncol and Hindlll for transfer to a mammalian expression vector, pMON3934. PMON3934 is digested with Ncol and Hindlll (approximately 3800 base pairs) and will accept the PCR products. Plasmid p ON32132 (SEQ ID NO: 84), which codes for amino acids 1-153 (SEQ ID NO: 546) of the c-mp1 ligand, was a result of that cloning. The pásmido pMON32134 (SEQ ID NO: 86), which encodes amino acids 1-53 (SEQ ID NO: 548) of the c-mpl ligand, was a result of that cloning. Plasmid pMON32133 (SEQ ID NO: 85), which encodes amino acids 1-153 of the c-mpl ligand, with omission of codons 112-114 (? 112-115) (SEQ ID NO: 547), was also a result of that cloning.

EXAMPLE 4 GENERATION OF THE TEMPLATE 5L DIMERICA OF CPR WITH OMISSION OF 112-115 IN THE SECOND GENE OF THE LIGANDO c-mpl A PCR template is constructed to generate novel forms of c-mpl ligand by ligating the 3.7 Kpb BstXI / EcoRI fragment (pb = base pairs) of p-MON26458, to the 1 Kpb Ncol / BstXI fragment of pMON32133 (containing the omission of amino acids 112-115) together with the linker 5L-5 * (SEQ ID NO: 322) and 5L-3 '(SEQ ID NO: 323) of the synthetic oligonucleotide 5L of EcoRI / Afllll. The EcoRI end of the linker will be ligated to the EcoRI end of pMON26458. The Afllll end of the linker will be ligated to the Ncol site of pMON32133, and no restriction site will be retained when ligating. The BstXI sites of pMON26458 and pMON32133 will also be linked. Plasmid pMON48548 is the result of cloning and contains the DNA sequence (SEQ ID NO: 3) encoding amino acids 1-153 of the fused c-mpl ligand via the linker GluPheGlyGIyAsnMet (SEQ ID NO: 783) to amino acids 1 -153 of the c-mpl ligand containing the omission of amino acids 112-115 (SEQ ID NO: 468).

EXAMPLE 5 GENERATION OF THE TEMPLATE 4L DIMERICA OF RCP A PCR template is constructed to generate novel forms of c-mpl ligand, binding the 37 Kpb BstXI / EcoRI fragment of PMON26458 to the 1 Kpb Ncol / BstXI fragment of pMON32132, together with linker 4L-5 '(SEQ ID NO: 320) and 4L-3' (SEQ ID NO: 321) of the synthetic EcoRI / AflIll oligonucleotide. The EcoRI end of the linker will be ligated to the EcoRI end of pMON26458. The Afllll end of the linker will be ligated to the Ncol site of pMON32132, and no restriction site will be retained when ligating. The BstXI sites of pMON26458 and pMON32132 will also be linked. Plasmid pMON28500 is the result of cloning and contains the DNA sequence of (SEQ ID NO: 4) encoding amino acids 1-153 of the c-mpl ligand, fused by the linker (4L) GlyPheGIyAsnMetAla (SEQ ID NO: 223 ) to amino acids 1-153 of the c-mpl ligand (SEQ ID NO: 469).

EXAMPLE 6 GENERATION OF THE TEMPLATE 5L DIMERICA OF RCP A PCR template is constructed to generate novel forms of the c-mpl ligand, ligating the BstXI / EcoRI fragment of 3.7 Kpb. pMON 26458, to the 1 Kpb Ncol / BstXI fragment of pMON32132, together with linker 5L-5 '(SEQ ID NO: 322) and 5L-3' (SEQ ID NO: 323). The EcoRI end of the linker will be ligated to the EcoRI end of pMON26458. The Afllll end of the linker will be ligated to the Ncol site of pMON32132, and no restriction site will be retained when ligating. The BstXI sites of pMON26458 and pMON32132 will also be linked. The plasmid pMON28501 is the result of the cloning and contains the DNA sequence of (SEQ ID NO: 4) encoding amino acids 1-153 of the c-mpl ligand, fused by the linker (5L) GluPheGlyGIyAsnMet (SEQ ID NO: 783 ) to amino acids 1-53 of the c-mpl ligand (SEQ ID NO: 470).

EXAMPLE 7 GENERATION OF 8L DIMERIC TEMPLATES OF CPR A PCR template is constructed to generate novel forms of c-mpl ligand, by attaching the 3.7 Kpb BstXI / EcoRI fragment of pMON26458 to the 1 Kpb Ncol / BstXI fragment of pMON32134, together with the 8L-5 'linker (SEQ ID NO. : 324) and 8L-3 '(SEQ ID NO: 325) of the synthetic oligonucleotide EcoRI / AflIll. The EcoRI end of the linker will be ligated to the EcoRI end of pMON26458. The Afllll end of the linker will be ligated to the Ncol site of pMON32134 and no restriction site will be retained when ligating. The BstXI sites of pMON26458 and pMON32134 will also be linked. The plasmid pMON28502 is the result of the cloning containing the sequence of (SEQ ID NO: 6) and encodes amino acids 1-153 of the fused c-mpl ligand by the enylator (8L) GluPheGlyGIyAsnGlyGIyAsnMetAla (SEQ ID NO: 224) to amino acids 1 -153 of the ligand c-mpl (SEQ ID NO: 471).

EXAMPLES 8-44 GENERATION OF NOVEDOS GENES OF LIGANDO c-mpl WITH NEW EXTREME N AND NEW EXTREME C A. Generation by PCR of genes that encode novel agonists of c-mpl ligand receptor.

Genes encoding c-mpl ligand receptor agonists are generated using the lll method (Horlic and co-authors, Prot. Eng., 5: 427-433, 1992). Restrictions were performed on CPR using dimeric templates, pMON 28500, 28501, 28502 or 28548, and one of the sets of synthetic sensitizers cited below. (The first number refers to the position of the first amino acid in the original sequence, for example, 31-5 'and 31-3' refers to the 5 * and 3 'oligosensitizers, respectively, for the sequence that starts at the codon corresponding to residue 31 of the original sequence). 31-5 '(SEQ ID NO: 326 and 31-3' (SEQ ID NO: 327), 35-5 '(SEQ ID No. 328) and 35-3' (SEQ ID No. 329), 39-5 '(SEQ ID NO: 330) and 39-3' (SEQ ID NO: 331), 43-5 '(SEQ ID NO: 332) and 43-3' (SEQ ID NO: 333), 45-5 '(SEQ ID No. 334) and 45-3' (SEQ ID NO: 335), 49- 5 '(SEQ ID NO: 336) and 49-3' (SEQ ID NO: 337), 82-5 '(SEQ ID NO: 338) and 82-3' (SEQ ID NO. 339), 109-5 ' (SEQ ID NO 340) and 109-3 '(SEQ ID No. 341), 115-5 * (SEQ ID NO: 342) and 115-3' (SEQ ID NO: 343), 120-5 '(SEQ ID NO: 344) and 120-3 '(SEQ ID NO: 345), 123-5' (SEQ ID NO: 346) and 123-3 '(SEQ ID NO: 347), 126-5' (SEQ ID NO: 348) and 126-3 '(SEQ ID NO 349). The templates and sets of oligonucleotides used in the PCR reactions are shown in Table 4. The products that were generated were approximately 480 base pairs and were purified by Magic PCR Clean up equipment (Promega).

B. Subcloning of novel gene agonist products of the c-mpl receptor in mammalian expression vector, for the generation of chimeras.

The agonist gene PCR products of the c-mpl receptor were digested with restriction enzymes Ncol and Hindlll or Afllll and Hindlll (about 470 base pairs) to be transferred to a mammalian expression vector. The expression vector pMON30304 was digested with Ncol and Hindlll (about 4200 base pairs and accepts the PCR products as the Ncol-Hindlll or Afllll-Hindlll fragments.) Table 4 shows the restriction digest of the PCR product and the resulting plasmids.

TABLE 4 EXAMPLE 45 CONSTRUCTION OF pMON15960 Construction of pMON15960, an intermediate piásmido used to construct plasmids containing DNA sequences encoding Ser17 G-FEC with a new N-terminus and a new C-terminus. DNA was digested from plasmid pACYC177 (Chang, ACY and Cohen, SN, J. Bacteriol., 134: 1141-1156, 1978), with restriction enzymes Hindlll and BamHl, which resulted in a Hindill-BamHI fragment of 3092 base pairs. Plasmid DNA pMON13037 (WO 95/21254) was digested with Bgl ll and Fspl, resulting in a Bgl ll, Fspl fragment of 616 base pairs. DNA was digested from a second sample of plasmid pMON13037 with Ncol and Hindlll, which resulted in a Ncol, Hindlll fragment of 556 base pairs. The oligonucleotides IGGGSfor (SEQ ID NO: 380) and IGGGSrev (SEQ ID NO: 381) were fixed to each other, and then digested with Afl lll and Pspl, which resulted in an Afl III fragment, Fspl of 21 pairs of bases. The restriction fragments were ligated and the ligation reaction mixture was used to transform strain JM101 of E coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and analyzed by restriction analysis to confirm the correct insert.

EXAMPLE 46 CONSTRUCTION OF pMON15981 Construction of pMON15981, a plasmid containing DNA sequences encoding a multifunctional hematopoietic receptor agonist. The plasmid DNA pMON 15960 was digested with Smal restriction enzyme and used as a template in a PCR reaction using sensitizers synthetic high DNA oligonucleotides 38 (SEQ ID NO: 369) and 39 initiation (SEQ ID NO 368) , which resulted in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, which resulted in a Hindlll, Ncol fragment of 558 base pairs. DNA from plasmid pMON13181 was digested with Hindlll and Afllll, which resulted in a HindIII.AflIll fragment of 4068 base pairs. Restriction fragments were ligated and the ligation reaction mixture was used to transform strain JM101 of E. coli K-12. The transforming bacteria was selected in plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. Plasmid pMON15981 contains the DNA sequence of (SEQ ID NO: 78) encoding the following amino acid sequence: MetAlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsr-AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeiJ-ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO: 500) EXAMPLE 47 CONSTRUCTION OF pMON15982 Construction of pMON15982, a plasmid containing DNA sequences encoding a multifunctional hematopoietic receptor agonist. Plasmid DNA pMON15960 was digested with Smal restriction enzyme and used as a template in a PCR reaction using as sensitizers oligonucleotides 96 high (SEQ ID NO: 371) and start 97 (SEQ ID NO: 370), synthetic DNA, which resulted in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, which resulted in a Hindill, Ncol fragment of 558 base pairs. Plasmid DNA pMON13181 was digested with Hindlll and Afllll, which resulted in a Hindlll, Afllll fragment of 4068 base pairs. Restriction fragments were ligated and the ligation reaction mixture was used to transform strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. Plasmid pMON15982 contains the DNA sequence of (SEQ ID NO: 79) encoding the following amino acid sequence: MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuJY-etAspArgAsn LeuArgLeuProAsnLeuGluS e r Phe Val Val ARGAL LysAsnLeuGluAsnAl aS er GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrlleTrpGlnGln etGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnProGlyGlyGlySerAsp etAlaThrProLeuGlyProAlaSer SerLeuProGlnSerPheLeuLe LysSerLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGl Leu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSer (SEQ ID NO: 501) EXAMPLE 48 CONSTRUCTION OF pMON15965 Construction of pMON 15965, a plasmid containing DNA sequences encoding a multifunctional hematopoietic receptor agonist. DNA from plasmid pMON15960 was digested with the restriction enzyme SmaI and used as a template in a PCR reaction using oligonucleotides 142 high (SEQ ID NO: 337) and initiation (SEQ ID NO: 376) of the synthetic DNA, as sensitizers; which results in the amplification of a DNA fragment that has 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, which resulted in a HindlIl.Ncol fragment of 558 base pairs. DNA from plasmid pMON13181 was digested with Hindlll and Afllll, which resulted in a Hindlll, Afllll fragment of 4068 base pairs. Restriction fragments were ligated and the ligation reaction mixture was used to transform strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. Plasmid pMON15965 contains the DNA sequence of (SEQ ID NO: 80) which encodes the following amino acid sequence: MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLe - AsnAspGluAspValSerIleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGl AlalleLeuArgAsnLe GlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProGlyGlyGlySerAsp etAlaThrProLeuGlyProAlaSerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlriLeuAspValAlaAsp PheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO: 502) EXAMPLE 49 CONSTRUCTION OF pMON15966 Construction of pMON 15966, a plasmid containing DNA sequences encoding a multifunctional hematopoietic receptor agonist. DNA of the plasmid pMON15960 was digested with the restriction enzyme Smal and used as a template in a PCR reaction using the oligonucleotides 126 high (SEQ ID NO: 372) and 125 start (SEQ ID NO: 373) of the synthetic DNA, as sensitizers , which resulted in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, which resulted in a Hindlll, Ncol fragment of 558 base pairs. DNA from plasmid pMON13181 was digested with Hindlll and Afllll, which resulted in a Hindll fragment, Afllll of 4068 base pairs. Restriction fragments were ligated and the ligation reaction mixture was used to transform strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. Plasmid pMON15966 contains the DNA sequence of (SEQ ID NO: 81) encoding the following amino acid sequence: MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn Le - ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAla etAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGl LeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO: 503)? EXAMPLE 50 CONSTRUCTION OF pMON15967 Construction of pMON 15967, a plasmid containing DNA sequences encoding a multifunctional hematopoietic receptor agonist. DNA from pMON15960 was digested with the restriction enzyme Smal and used as a template in a PCR reaction using oligonucleotides 132 high (SEQ ID NO: 375) and initiation (SEQ ID NO: 374) of synthetic DNA as sensitizers, which resulted in amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with the restriction enzymes Hindlll and Ncol, which resulted in a Hindlll, Ncol fragment of 558 base pairs. DNA from plasmid pMON13181 was digested with Hindlll and Afllll, which resulted in a Hindlll, Afllll fragment of 4068 base pairs. The restriction fragments were ligated and the reaction mixture and ligation was used to transform strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. Plasmid pMON15967 contains the DNA sequence of (SEQ ID NO: 82), which encodes the following amino acid sequence: MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeu etAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIle11e11eLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlpAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAsp etAlaThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys 11eGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 504 EXAMPLE 51 CONSTRUCTION OF pMON13180. AN INTERMEDIARY PLASMID USED TO BUILD PLASMIDS CONTAINING THE DNA SEQUENCE THAT CODIFIES RECEPTOR AGONISTS HEMATOPOYETIC, MULTIFUNCTIONAL DNA of plasmid pMON13046 (WO 95/21254) was digested with Xmal and SnaBI restriction endonucleases, resulting in a vector fragment of 4018 base pairs. The Xmal-SnaBI fragment of 4018 base pairs was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.) where the 25-base pair Xmal-SnaBI fragment is not retained. The complementary pair of synthetic oligonucleotides glyxal (SEQ ID NO: 378) and glyxa2 (SEQ ID NO: 379) was designed to eliminate the sequence encoding a factor Xa cleavage site. When these oligonucleotides are properly assembled, they also result in Xmal and SnaBI ends. The Glyxal and gluxa2 sensitizers were fixed in fixation buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgC-2, 50 mM NaCl), heating at 70 ° C for 10 minutes and allowing to cool slowly.

The Xmal-SnaBI fragment of 4018 base pairs, from pMON13046, was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA and transformants were isolated and analyzed using PCR-based analysis. The plasmid DNA of the selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid pMON13180 was designated (SEQ ID NO: 88).

EXAMPLE 52 CONSTRUCTION OF pMON13181, AN INTERMEDIARY PLASMIDE USED TO BUILD PLASMIDS CONTAINING DNA SEQUENCES THAT CODE RECEIVER AGONISTS HEMATOPOYETIC, MULTIFUNCTIONAL DNA from plasmid pMON13047 (WO 95/21254) was digested with Xmal and SnaBI restriction endonucleases, which resulted in a vector fragment of 4063 base pairs. The Xmal-SnaBI fragment of 4063 base pairs was purified using the Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.), in which the 25-base pair Xmal-SnaBI insert fragment is not retained. The complementary pair was designed of synthetic oligonucleotides glyxal (SEQ ID NO: 378) and glyxa2 (SEQ ID NO: 379) to eliminate the sequence encoding the factor Xa cleavage site. When properly assembled, these oligonucleotides also result in Xmal and SnaBI ends. Glyxal and glyxa2 were fixed in fixation buffer by heating at 70 ° C for 10 minutes and allowed to cool slowly. The 4063 bp Xmal-SnaBI fragment from pMON 13047 was ligated with the assembled oligonucleotides, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated from the transformants and analyzed using a PCR-based analysis. The plasmid DNA of the selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid pMON13181 (SEQ ID NO: 87) was designated.

EXAMPLE 53 CONSTRUCTION OF PMON13182 The new end N gene / new C terminus was created in pMON13182, using method I that was described in Materials and Methods. The Start fragment was created and amplified in the G-FEC Ser17 sequence in pMON13037, using the sensitizer 39 starter kit (SEQ ID NO: 368) and L- 11 start (SEQ ID NO: 364). The high fragment was created and amplified in the G-FEC Ser17 sequence in pMON 13037, using the sensitizer 38 high (SEQ ID NO: 369) and high L-11 (SEQ ID NO: 365). The full-length Ser17 G-FEC gene was created, with new N-terminus / new C-terminus, and amplified from the fixed and high fragments, using the 39 start and 38 high sensitizers. The resulting DNA fragment containing the new gene was digested with Ncol and Hindlll restriction endonuclease and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13182 was designated. E. coli strain JM101 was transformed with pMON13182 for protein expression and protein isolation from inclusion bodies.

Plasmid pMON13182 contains the DNA sequence of (SEQ ID NO: 17) which encodes the following amino acid sequence: Asn Cys Ser lie Met lie Asp Glu lie lie His Leu Lei Lys Arg Pro Pro Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly lie Glu Wing lie Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro lie He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Gly As As Met Wing Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln S er Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr (SEQ ID NO: 472) EXAMPLE 54 CONSTRUCTION OF pMON13183 The new end N gene / new C terminus was created in pMON13183 using method I described in Materials and Methods. The "start fragment" was treated and amplified in the G-FEC Ser17 sequence in pMON13037, using the sensitizer 39 starter kit (SEQ ID NO: 368) and starter L-11 (SEQ ID NO: 364). The high fragment was created and amplified in the G-FEC Ser17 sequence in pMON 13037, using the sensitizer 38 high (SEQ ID NO 369) and high L-11 (SEQ ID NO: 365). The full-length G-FEC Ser17 gene was created, with new N-terminus / new C-terminus and amplified in the fixed start and stop fragments, using 39 start and 38 stop. The resulting DNA fragment containing the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transforming bacteria were selected in plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13183 was designated. E coli strain JM101 was transformed with pMON13183 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13183 contains the DNA sequence of (SEQ ID NO: 18), which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Leu Val Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Wing Phe Wing Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Be Gly Gly Ser Gln Be Phe Leu Leu Lys Be Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr (SEQ ID NO: 473) EXAMPLE 55 CONSTRUCTION OF pMON1384 The new N-terminus / C-terminus gene was created in pMON13184 using method I that was described in Materials and Methods. The start fragment was created and amplified in the G-FEC Ser17 sequence in pMON 13037, using the primer 97 sensing kit (SEQ ID NO: 370) and L-11 initiation (SEQ ID NO: 364). The high fragment was created and amplified in the G-FEC Ser17 sequence in pMON13037, using the high 96 sensitizer kit (SEQ ID NO: 371) and high L-11 (SEQ ID NO: 365). The full-length Ser17 G-FEC gene was created, with new N-terminus / new C-terminus and amplified from the start and stop fixed fragments, using 97 start and 96 stop. The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The purified restriction fragments were combined and ligated using T4 Adn-ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13184 was designated. E.coli strain JM101 was transformed with pMON13184 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13184 contains the DNA sequence of (SEQ ID NO: 19) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Wing Val His Ser Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser (SEQ ID NO: 474) EXAMPLE 56 CONSTRUCTION OF pMON13185 The new N-terminal / C-terminus gene was created in pMON1318d, using method I that was described in Materials and Methods. The start fragment was created and amplified in the G-FEC Ser17 sequence in pMON 13037, using the primer 97 sensing kit (SEQ ID NO: 370) and L-11 initiation (SEQ ID NO: 364). The high fragment was created and amplified in G-FEC Ser17 in pMON13037, using the high 96 sensitizer kit (SEQ ID NO: 371) and high L-11 (SEQ ID NO: 36d). The new gene G-FEC Ser17 was created with a new end N / new end C, full length, and amplified from the fixed fragments start and stop, using 97 start and 96 stop. The DNA fragment containing the new gene with restriction endonucleases Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 pairs of bases, and it was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringen, Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.) Transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON1318d was designated. E.coli strain JM101 was transformed with pMON1318d for protein expression and protein isolation from the inclusion bodies. Plasmid pMON1318d contains the DNA sequence of (SEQ ID NO: 20) that encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Gl Le Pro Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Be (S? Q ID NO: 475) EXAMPLE 57 CONSTRUCTION OF pMON13186 The new N-end / C-terminus gene was created in pMON13186 using method I that was described in Materials and Methods. The start fragment was created and amplified in the Ser17 G-FEC sequence of pMON 13037, using the 126 primer starter kit (SEQ ID NO: 372) and L-11 starter (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON 13037, using the sensitizer 125 high (SEQ ID NO: 373) and high L-11 (SEQ ID NO: 365). The G-FEC Ser17 gene was created from new N-terminus / new C-terminus, full-length, and amplified from the fixed start and stop fragments, using 126 start and 12d stop.

The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) ). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13186 was designated. E. coli strain JM101 was transformed with pMON13186 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13186 contains the DNA sequence of (SEQ ID NO: 21) which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Met Wing Pro Wing Wing Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly (SEQ ID NO: 76) EXAMPLE 58 CONSTRUCTION OF PMON13187 The new N-end / C-terminal gene was created in pMON13187 using method I that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence Se17 in pMON13037 using the primer 126 sensing kit (SEQ ID NO: 372) and L-11 initiation (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the sensitizing equipment 12dalto (SEQ ID NO: 373) and L-11 high (SEQ ID NO: 365). The G-FEC Ser17 gene was created from new N-terminus / new C-terminus, full-length, and amplified from the fixed start and stop fragments, using 126 start and 125 stop. The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA). ). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13187 was designated. E. coli strain JM101 was transformed with pMON13187 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13187 contains the DNA sequence of (SEQ ID NO: 22) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Wing Ala Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Se r Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly (SEQ ID NO: 477) EXAMPLE 59 CONSTRUCTION OF pMON13188 The new N-end / C-terminal gene was created in pMON13188 using method I which was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence Se17 in pMON13037 using the 133 primer starter kit (SEQ ID NO: 374) and L-11 starter (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the sensitizer 132 high (SEQ ID NO: 375) and high L-11 (SEQ ID NO: 365). The G-FEC gene Ser17 was created from the new N-terminus / new C-terminus, full-length, and amplified from the fixed start and stop fragments, using 13 start and 132 stop. The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) ). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13188 was designated. E. coli strain JM101 was transformed with pMON13188 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13188 contains the DNA sequence of (SEQ ID NO: 23) which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Ser Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 478) EXAMPLE 60 CONSTRUCTION OF PMON13189 The new N-terminus / C-terminus gene was created in pMON13189 using method I that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence Se17 in pMON13037 using the 133 primer starter kit (SEQ ID NO: 374) and L-11 starter (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the sensitizer 132 high (SEQ ID NO: 37d) and high L-11 (SEQ ID NO: 365). The G-FEC Ser17 gene was created from new N-terminus / new C-terminus, full-length, and amplified from the fixed start and stop fragments, using 133 start and 132 stop. The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E.U.A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up kit. up System (Promega, Madison, Wl, E. U. A.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid PMON13189 was designated. E.coli strain JM101 was transformed with pMON13189 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13189 contains the DNA sequence of (SEQ ID NO: 24) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 479) EXAMPLE 61 CONSTRUCTION OF pMON13190 The new N-end / C-terminal gene was created in pMON13190 using method I that was described in materials and methods. The start fragment was created and amplified from the Se17 G-FEC sequence in pMON 13037 using the priming sensing kit 142 (SEQ ID NO: 376) and L-11 initiation (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON 13037, using the sensitizer kit 141 high (SEQ ID NO: 377) and L-11 high (SEQ ID NO: 365). The G-FEC Ser17 gene was created from the new N-terminus / new C-terminus, of full length, and amplified from the fixed start and stop fragments, using 142 start and 141 stop.

The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) ). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13190 was designated. E.coli strain JM101 was transformed with pMON13190 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13190 contains the DNA sequence of (SEQ ID NO: 2d) which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Being Asn Met Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Being Phe Leu Glu Val Being Tyr Arg Val Leu Arg His Leu Wing Gln Pro Being Gly Gly Being Gly Gly Being Gln Being Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing (SEQ ID NO: 480) EXAMPLE 62 CONSTRUCTION OF PMON13191 The new N-terminal / C-terminus gene was created in pMON13191 using method I that was described in materials and methods. The start fragment was created and amplified from the Se17 G-FEC sequence in pMON13037 using the priming sensing kit 142 (SEQ ID NO: 372) and L-11 initiation (SEQ ID NO: 364). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the sensitizing equipment 141 high (SEQ ID NO: 373) and L-11 high (SEQ ID NO: 365). The G-FEC Ser17 gene was created from the new N-terminus / new C-terminus, of full length, and amplified from the fixed start and stop fragments, using 142 start and 141 stop. The resulting DNA fragment containing the new restriction endonuclease gene Ncol and Hindlll was digested and purified using a Magic DNA Clean-up System (Promega, Madison, Wl, E. U. A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up System (Promega, Madison, Wl, USA) ). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). Transformant bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid pMON13191 was designated. E.coli strain JM101 was transformed with pMON13191 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13191 contains the DNA sequence of (SEQ ID NO: 26) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Ser Wing Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Le u His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala (SEQ ID NO: 481) EXAMPLE 63 CONSTRUCTION OF PMON13192 The new N-terminal / C-terminal gene was created in pMON13192 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the sensitizer 39 starter kit (SEQ ID NO: 368) and P-b1 starter (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the high sensitizer 38 (SEQ ID NO: 369) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). It was combined The purified restriction fragments were ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13192. E. coli strain JM101 was transformed with pMON13192 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13192 contains the DNA sequence of (SEQ.

ID NO: 27) that encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Ser Asn Met Wing Tyr Lys Leu Cys Hie Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Being Ser Cys Pro Being Gln Wing Leu Gln Leu Wing Gly Cys Leu Being Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Wing Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Gln Glu Lys Wing Cys Wing Thr (SEQ ID NO: 482) EXA 64 CONSTRUCTION OF pMON13193 The new N-end / C-terminal gene was created in pMON13193 using method II that was described in materials and methods. The start fragment was created and afied from the G-FEC Ser17 sequence in pMON13037 using the sensitizer 39 starter kit (SEQ ID NO: 368) and home P-b1 (SEQ ID NO: 366). The high fragment was created and afied from the G-FEC Ser17 sequence in pMON13037, using the high sensitizer 38 (SEQ ID NO: 369) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of PMON3934. The above described intermediate plasmid contained the total length of the G-FEC Ser17 gene of new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length G-FEC Ser17 gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13193. E. coli strain JM101 was transformed with pMON13193 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13193 contains the DNA sequence of (SEQ ID NO: 28) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Pro Pro Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Wing Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Gln Glu Lys Wing Cys Wing Thr (SEQ ID NO: 83) EXA 65 CONSTRUCTION OF pMON25190 The new N-end / C-terminal gene was created in pMON25190 using method II that was described in materials and methods. The start fragment was created and afied from the G-FEC sequence in pMON 13037 using the starter sensitizer kit 97 (SEQ ID NO: 370) and start P-b1 (SEQ ID NO: 366). The high fragment was created and amplified from the sequence G-FEC Ser17 in pMON13037, using the sensitizer 96 high (SEQ ID NO: 371) and high P-b1 (SEQ ID NO 367). The starting fragment was digested with restriction endonuclease Ncol and the high fragment was digested with restriction endonuclease Hindill. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON2d190.

E. coli strain JM101 was transformed with pMON2d190 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON26190 contains the DNA sequence of (SEQ ID NO: 29) encoding the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Gl Le Pro Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly I Ser (SEQ ID NO: 484) EXAMPLE 66 CONSTRUCTION OF pMON25191 The new N-end / C-terminal gene was created in pMON25191 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the starter sensitizer kit 97 (SEQ ID NO: 370) and home P-b1 (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the high 96 sensitizer kit (SEQ ID NO: 371) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene of new N-terminus / new C-terminus, and it was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). It was combined The purified restriction fragments were ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON26191. E. coli strain JM101 was transformed with pMON2d191 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON2d191 contains the DNA sequence of (SEQ.

ID NO: 30) that encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Oly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser (SEQ ID NO: 485) EXAMPLE 67 CONSTRUCTION OF pMON13194 The new N-end / C-terminal gene was created in pMON13194 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the 126 primer starter kit (SEQ ID NO: 372) and P-b1 primer (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the high 12d sensitizing kit (SEQ ID NO: 371) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above described intermediate plasmid contained the total length of the G-FEC Ser17 gene of new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length G-FEC Ser17 gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13194. E. coli strain JM101 was transformed with pMON13194 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13194 contains the DNA sequence of (SEQ ID NO: 31) which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Wing Thr Ala Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Met Wing Pro Wing Wing Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu sly (SEQ ID NO: 486) EXAMPLE 68 CONSTRUCTION OF pMON13195 The new N-end / C-terminal gene was created in pMON13195 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the 126 primer starter kit (SEQ ID NO: 372) and P-b1 primer (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the sensitizing kit 12d high (SEQ ID NO: 373) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON1319d. E. coli strain JM101 was transformed with pMON1319d for protein expression and protein isolation from the inclusion bodies.

Plasmid pMON13195 contains the DNA sequence of (SEQ ID NO: 32) encoding the following amino acid sequence: Asn Cys Ser He Met He Asp slu He He His His Leu Lys Arg Pro Pro Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp slu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu slu Asn Wing Being sly He slu Wing He Leu Arg Asn Leu Oln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing sly Asp Trp sln slu Phe Arg Olu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Oln Tyr Val Olu sly Oly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Pro Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Met Wing Pro Pro Wing Leu sln Pro Thr Oln Oly Wing Met Pro Wing Phe Wing Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Olu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Olu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Oln Leu Ala sly Cys Leu Ser Oln Leu His Ser Oly Leu Phe Leu Tyr sln Oly Leu Leu Oln Wing Leu Glu Oly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp sln Gln Met Glu Glu Leu Gly (SEQ ID N0: 487) EXAMPLE 69 CONSTRUCTION OF PMON13196 The new N-end / C-terminal gene was created in pMON13196 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON13037 using the 133 primer starter kit (SEQ ID NO: 374) and P-b1 start (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the high sensitizer 132 (SEQ ID NO: 37d) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). It was combined The purified restriction fragments were ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13196. E. coli strain JM101 was transformed with pMON13196 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13196 contains the DNA sequence of (SEQ.

ID NO: 33) that encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Olu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Gly Gly Ser Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro sln Ser Phe Leu Leu Lys Ser Leu Glu Oln Val Arg Lys He Gln Gly Asp Oly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 488) EXAMPLE 70 CONSTRUCTION OF PMON13197 The new N-terminal / C-terminal gene was created in pMON13197 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the 133 primer starter kit (SEQ ID NO: 374) and P-b1 start (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON 13037, using the high sensitizer 132 (SEQ ID NO: 37d) and high P-b1 (SEQ ID NO 367). The Ncol restriction endonuclease start fragment was digested and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated to the fragment of the Nco-I-Hindlil vector of approximately 3800 base pairs, from pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, it was stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, E.U.A.). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13197. E. coli strain JM101 was transformed with pMON13197 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13197 contains the DNA sequence of (SEQ ID NO: 34) encoding the following amino acid sequence: Asn Cys Ser He Met As As Asp Glu He He As His As Leu As Aru Pro Asu Leu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Asu As Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu sln Leu Wing Oly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Oln Gly Leu Leu Gln Wing Leu Olu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Oln Gly Wing Met Pro Wing Phe Wing Wing Being Wing Phe Gln Arg Arg Wing Oly Gly Val Leu Val Wing His Ser Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr (SEQ ID NO: 489) EXAMPLE 71 CONSTRUCTION OF pMON13198 The new N-end / C-terminal gene was created in pMON13198 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the 142 primer starter kit (SEQ ID NO: 376) and P-b1 start (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON 13037, using the high sensitizer kit 141 (SEQ ID NO: 377) and high P-b1 (SEQ ID NO 367). The fragment was digested start with restriction endonuclease Ncol and the high fragment was digested with restriction endonuclease HindIII. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13180 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4023 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13198. E. coli strain JM101 was transformed with pMON13198 for protein expression and protein isolation from the inclusion bodies.

Plasmid pMON13198 contains the DNA sequence of (SEQ ID NO: 3d) which encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Sly Ser aly Gly Gly Ser Asn Met Wing Being Wing Phe Gln Arg Arg Wing Oly Gly Val Leu Val Wing His Ser Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Oln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Olu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Ala (SEQ ID NO: 490) EXAMPLE 72 CONSTRUCTION OF PMON13199 The new N-end / C-terminal gene was created in pMON13199 using method II that was described in materials and methods. The start fragment was created and amplified from the G-FEC sequence in pMON 13037 using the 142 primer starter kit (SEQ ID NO: 376) and P-b1 start (SEQ ID NO: 366). The high fragment was created and amplified from the G-FEC Ser17 sequence in pMON13037, using the high sensitizer 141 (SEQ ID NO: 377) and high P-b1 (SEQ ID NO 367). The starting fragment was digested with restriction endonuclease Ncol and the high fragment was digested with Hindlll restriction endonuciease. After purification, the digested start and top fragments were combined with, and ligated into, the approximately 3800 base pair Nco-I-Hindlll vector fragment of pMON3934. The above-described intermediate plasmid contained the total length of the G-FEC Ser17 gene from the new N-terminus / new C-terminus, and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved in a 1% TAE gel, stained with ethidium bromide and the full-length Ser17 G-FEC gene was isolated, with new N-terminus / C-terminus using Geneclean (Bio101, Vista, CA, USA) ). The intermediate plasmid pMON13181 was digested with restriction endonucleases Hindlll and Afllll, which resulted in a vector fragment of 4068 base pairs, and was purified using a Magic DNA Clean-up kit (Promega, Madison, Wl). It was combined The purified restriction fragments were ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN, E. U. A.). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD). Transformant bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13199. E. coli strain JM101 was transformed with pMON13199 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON13199 contains the DNA sequence of (SEQ.

ID NO: 36) that encodes the following amino acid sequence: Asn Cys Being As Met Asp Asp Glu He He As His Leu Lys As Pro Asu Leu As Asn Leu As As Asp As As Val As As As As As As As As As As As As As As As As As As As Val As As As Val As Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln Tyr Val Olu Gly Gly Gly Sly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Ser Wing Phe Gln Arg Arg Ala Gly Gly Val Leu Val Wing His Ser Leu Oln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala (SEQ ID NO: 491) EXAMPLE 73 CONSTRUCTION OF DUPLICATED PLASMIDE TEMPLATE IN TANDEM Svntanl To create the Syntanl template of the pMON13416 agonist of the tandem duplicated hlL-3 receptor, three DNAs were ligated by ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046 containing the pMON13416 agonist of hIL-3 receptor, digested with BstEII and SnaBI; 2) the fixed complementary pair of synthetic oligonucleotides Llsyn.for (SEQ ID NO: 352) and Llsyn.rev (SEQ ID NO: 353), which contain the sequence encoding the linker that connects the C terminal and N terminal ends of the original protein and a small amount of the surrounding pMON13416 sequence, which, when assembled appropriately, results in BstEII and Clal ends; and 3) a portion of the pMON13416 agonist of hIL-3 receptor, digested from pMON13046 with Clal (DNA that had been developed in dam cells, DM1 (Life Technologies)) and SnaBI. The DNA digested in 0.9% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). DNA was isolated from minipreparations of the transformants, and the transformants were selected using an analysis based on PCR. The plasmid DNA of the selected transformants was sequenced to obtain the correct template. The resulting plasmid syntanl was designated and contains the DNA sequence of (SEQ ID NO: 7).

EXAMPLE 74 CONSTRUCTION OF DUPLICATED PLASMIDE TEMPLATE IN TANDEM Svntan3 To create the Syntan3 template of the pMON13416 agonist of the tandem duplicated hIL-3 receptor, three DNAs were ligated by ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046 containing the pMON13416 agonist of hIL-3 receptor, digested with BstEII and SnaBI; 2) the fixed complementary pair of synthetic oligonucleotides L3syn.for (SEQ ID NO: 354) and L3syn.rev (SEQ ID NO: 35d), which contain the sequence encoding the linker connecting the C terminal and N terminal ends of the original protein and a small amount of the surrounding pMON13416 sequence, which, when assembled appropriately, it results in BstEII and SnaBI extremes; and 3) a portion of the pMON13416 agonist of hIL-3 receptor, digested from pMON13046 with Clal (DNA that had been developed in dam cells, DM1 (Life Technologies)) and SnaBi. The DNA digested in 0.9% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101). A portion of the ligation reaction was used to transform cells from the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). DNA was isolated from minipreparations of the transformants, and the transformants were selected using an analysis based on PCR. The plasmid DNA of the selected transformants was sequenced to obtain the correct template. The resulting plasmid syntan3 was designated and contains the DNA sequence of (SEQ ID NO: 8).

EXAMPLE 75 CONSTRUCTION OF PMON31104 The gene with new end N / new end C was created in pMON31104 using the method lll that was described in Materials and Methods. The new full-length N / new C-terminus gene of the pLON13416 agonist of hIL-3 receptor was created and amplified from the Syntanl intermediary plasmid using the 3D start sensitizer kit (SEQ ID NO: 3d6) and 34 rev (SEQ ID NO: 357).

The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (B¡o101, Vista, CA, E. U. A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the hLL3 receptor agonist pMON13416, and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, CA, USA), then of resolution in a gel ai 0.8% of TAE, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The piásmido DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31104. E. coli strain JM101 was transformed with pMON31104 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31104 contains the DNA sequence of (SEQ ID NO: 9) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Be Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro I've been Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Glu Leu Gig Leu Glu Le Le Gly Le Gly He Pro Trp Wing Pro Leu Ser Cys Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly H e Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 492) EXAMPLE 76 CONSTRUCTION OF pMON31105 The gene with new end N / new end C was created in pMON31105 using the method lll that was described in Materials and Methods. The new full-length C-terminus N gene was created, full-length, of the pLON13416 agonist of hIL-3 receptor and amplified from the intermediate plasmid Syntanl, using the initialization sensitizer kit 70 (SEQ ID NO: 3d8) and 69 rev (SEQ ID NO: 359). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBI. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the hLL3 receptor agonist pMON13416, and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, CA, USA), then of resolution in a 0.8% TAE gel, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. DNA was isolated of plasmid and it was sequenced to form the correct insert. The resulting plasmid was designated pMON3110d. E.coli strain JM101 was transformed with pMON3110d for protein expression and protein isolation from the inclusion bodies. Plasmid pMON3110d contains the DNA sequence of (SEQ.

ID NO: 10) that encodes the following amino acid sequence: Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Be Phe Leu Leu Lys Be Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Being Ser Cys Pr o Be Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 493) EXAMPLE 77 CONSTRUCTION OF pMON31106 The gene with a new end N / new end C was created in pMON31106 using the method lll that was described in Materials and Methods. The new full-length N-terminus N gene, full-length, of the pLON13416 agonist of hIL-3 receptor was created and amplified from the Syntanl intermediate plasmid, using the starter sensitizer kit 91 (SEQ ID NO: 360) and 90 rev (SEQ ID NO: 361). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBI. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the pLON13416 agonist from hlL3 receptor, and the vector fragment of 4264 base pairs was isolated using Geneclean (Bio101, Vista, CA, USA), after of resolution in a gel at 0.8% TAE, and staining with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31106. E.coli strain JM101 was transformed with pMON31106 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31106 contains the DNA sequence of (SEQ ID NO: 11) encoding the following amino acid sequence: Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO; 494) EXAMPLE 78 CONSTRUCTION OF PMON31107 The gene with a new end N / new end C was created in pMON31107 using the method lll that was described in Materials and Methods. The new full-length N-terminus N gene, full-length, of the pLON13416 agonist of hIL-3 receptor was created and amplified from the intermediate plasmid Syntanl, using the starter sensitizer 101 (SEQ ID NO: 362) and 100 rev (SEQ ID NO: 363). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBI. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E. U. A.). The pMON13189 DNA was previously digested with Ncol and SnaBI to remove the coding sequence of the hIL3 receptor agonist pMON13416, and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, CA, USA), then of resolution in a 0.8% TAE gel, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31107. E. coli strain JM101 was transformed with pMON31107 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31107 contains the DNA sequence of (SEQ ID NO: 12) which encodes the following amino acid sequence: Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Wing Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID NO: 495) EXAMPLE 79 CONSTRUCTION OF PMON31108 The gene with new end N / new end C was created in pMON31108 using the method lll that was described in Materials and Methods. The new full-length N / new C-terminus gene of the hLL-3 receptor agonist pMON13416 was created and amplified from the Syntan3 intermediate plasmid, using the 3D start sensitizer kit (SEQ ID NO: 3d6) and 34 rev (SEQ ID NO: 357). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBl. It was solved the DNA fragment digested in a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E. U. A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the pLON13416 agonist from hlL3 receptor, and the vector fragment of 4264 base pairs was isolated using Geneclean (Bio101, Vista, CA, USA), after of resolution in a 0.8% TAE gel, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31108. E. coli strain JM101 was transformed with pMON31108 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31108 contains the DNA sequence of (SEQ ID NO: 13) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Being Asn Cys Being He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr G n Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr lie Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID N0: 496) EXAMPLE 80 CONSTRUCTION OF PMON31109 The gene with new end N / new end C was created in pMON31109 using the method lll that was described in Materials and Methods The new full-length C-terminus N gene was created, full length, of the pLON13416 agonist of hIL-3 receptor and amplified to starting from the Syntan3 intermediate plasmid, using the starter sensitizer kit 70 (SEQ ID NO: 3d8) and 69 rev (SEQ ID NO: 359). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBl. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the hLL3 receptor agonist pMON13416, and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, CA, USA), then of resolution in a 0.8% TAE gel, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31109. E. coli strain JM101 was transformed with pMON31109 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31109 contains the DNA sequence of (SEQ ID NO: 14) which encodes the following amino acid sequence: Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Being Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Being Asn Cys Being He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pr or Trp Wing Pro Leu Being Ser Cys Pro Being Gln Wing Leu Gln Leu Wing Gly Cys Leu Being Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID N0: 497) EXAMPLE 81 CONSTRUCTION OF pMON31110 The gene with a new end N / new end C was created in pMON31110 using the method lll that was described in Materials and Methods. The new full-length, N-terminus N gene was created, full-length, of the pLON13416 agonist of hIL-3 receptor and amplified from the Syntan3 intermediate plasmid, using the starter sensitizer kit 91 (SEQ ID NO: 360) and 90 rev (SEQ ID NO: 361). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBl. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the pLON13416 agonist from hlL3 receptor, and the vector fragment of 42d4 base pairs was isolated using Geneclean (Bio101, Vista, CA, USA), after of resolution in a 0.8% TAE gel, and of dyeing with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. DNA was isolated of plasmid and it was sequenced to form the correct insert. The resulting plasmid was designated pMON31110. E. coli strain JM101 was transformed with pMON31110 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31110 contains the DNA sequence of (SEQ ID NO: 15) that encodes the following amino acid sequence: Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pr or Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro (SEQ ID N0: 498) EXAMPLE 82 CONSTRUCTION OF pMON31111 The gene with a new end N / new end C was created in pMON31111 using the method lll that was described in Materials and Methods. The new full-length N / new end C gene of the pLON13416 agonist of hIL-3 receptor was created and amplified from the intermediate plasmid Syntan3, using the starter sensitizer 101 (SEQ ID NO: 362) and 100 rev (SEQ ID NO: 363). The resulting DNA fragment, containing the new gene, was digested with restriction endonucleases Ncol and SnaBl. The DNA fragment digested in a 1% TAE gel was resolved, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, CA, E.U.A.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer, Mannheim, Indianapolis, IN, E.U.A.). The DNA of pMON13189 was previously digested with Ncol and SnaBI to remove the coding sequence of the pLON13416 agonist from hlL3 receptor, and the vector fragment of 4254 base pairs was isolated. using Geneclean (Bio101, Vista, CA, E.U.A.), after resolution in a 0.8% TAE gel, and staining with ethidium bromide. A portion of the ligation reaction was used to transform the cells of the E. coli DHdalfa strain (Life Technologies, Gaithersburg, MD, E. U. A.). The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to form the correct insert. The resulting plasmid was designated pMON31111. E. coli strain JM101 was transformed with pMON31111 for protein expression and protein isolation from the inclusion bodies. Plasmid pMON31111 contains the DNA sequence of (SEQ.

ID NO: 16) that encodes the following amino acid sequence: Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Wing Val Lys Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Glu Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro ( SEQ ID NO: 499) EXAMPLE 83 CONSTRUCTION OF PMON31112 Construction of pMON31112, a plasmid containing a DNA sequence encoding a multifunctional hematopoietic receptor agonist, which activates the hIL-3 receptor and the G-FEC receptor. The plasmid DNA pMON13189 was digested with Ncol and Xmal restriction enzymes, which resulted in a Ncol, Xmal fragment that was isolated and purified on a 0.8% agarose gel. DNA from a second plasmid, pMON13222 (WO 94/12639, US application Serial No. 08/411, 796), was digested with Ncol and EcoRl, resulting in a Nol-EcoRI fragment of 281 base pairs. The fragment was isolated and purified in a gel of agarose at 1.0%. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO: 3d0) and SYNNOXA2.REQ (SEQ ID NO: 351) were ligated and ligated with the DNA fragment of 281 pairs of gases of pMON 13222, to the DNA vector fragment of pMON13189 . A portion of the ligation mixture was then transformed to strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment and sequenced to confirm the correct inserts. Plasmid pMON31112 contains the DNA sequence of (SEQ ID NO: 37), which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuP roLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLe uArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAla HeGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrA rgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTy rLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisL ysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgAr gAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysS erLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAl aThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePro TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnL euHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGl uLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 505) EXAMPLE 84 CONSTRUCTION OF PMON31113 Construction of pMON31113, a plasmid containing a DNA sequence encoding a multifunctional hematopoietic receptor agonist, which activates the hIL-3 receptor and the G-FEC receptor. Plasmid pMON13197 DNA was digested with restriction enzymes Ncol and Xmal, which resulted in a Ncol, Xmal fragment that was isolated and purified on a 0.8% agarose gel. The DNA of a second plasmid, pMON13239 (WO 94/12639, US application Serial No. 08/411, 796), was digested with Ncol and EcoRI, which resulted in an Ncol-EcoRI fragment of 281 base pairs. The fragment was isolated and purified on a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO: 350) and SYNNOXA2.REQ (SEQ ID NO: 351) were ligated and ligated with the DNA fragment of 281 pairs of gases from pMON13239, to the DNA vector fragment of pMON13197. A portion of the ligation mixture was then transformed to strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment and sequenced to confirm the correct inserts.

Plasmid pMON31113 contains the DNA sequence of (SEQ ID NO: 38), which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuPr oLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetGluAsnAsnLeuA rgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalle GluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHi sProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuL ysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGlu ProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerPr oAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyG lyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSe rLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaT hrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrp AlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHi sSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuG lyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGln MetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 506) EXAMPLE 85 CONSTRUCTION OF pMON31114 Construction of pMON31114, a plasmid containing DNA sequence encoding a hematopoietic receptor agonist, multifunctional, which activates the hlL-3 receptor and the G-FEC receptor. The plasmid DNA pMON13189 was digested with Ncol and Xmal restriction enzymes, which resulted in a Ncol, Xmal fragment that was isolated and purified on a 0.8% agarose gel. DNA from a second plasmid, pMON 13239 (WO 94/12639, US application Serial No. 08/411, 796), was digested with Ncol and EcoRI, resulting in a Nol-EcoRI fragment of 281 base pairs . The fragment was isolated and purified on a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO: 350) and SYNNOXA2.REQ (SEQ ID NO: 351) were ligated and ligated with the DNA fragment of 281 pairs of gases from pMON 13239, to the DNA vector fragment of pMON13189 . A portion of the ligation mixture was then transformed to strain JM101 of E. coli K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment and sequenced to confirm the correct inserts. Plasmid pMON31114 contains the DNA sequence of (SEQ ID NO: 39), which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuP roLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLe uArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAla HeGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrA rgHisProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTy rLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisL ysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGl Argar gAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysS erLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAl aThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePro TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnL euHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGl uLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 507) EXAMPLE 86 CONSTRUCTION OF pMON31115 Construction of pMON31115, a plasmid containing a DNA sequence encoding a multifunctional hematopoietic receptor agonist, which activates the hIL-3 receptor and the G-FEC receptor. Plasmid pMON13197 DNA was digested with restriction enzymes Ncol and Xmal, which resulted in a Ncol, Xmal fragment that was isolated and purified on a 0.8% agarose gel. The DNA of a second plasmid, pMON13222, was digested with Ncol and EcoRI, resulting in an Ncol-EcoRI fragment of 281 base pairs. The fragment was isolated and purified on a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO: 3d0) and SYNNOXA2.REQ (SEQ ID NO: 3d1) were fixed and ligated with the DNA fragment. of 281 base pairs of pMON13222, to the DNA vector fragment of pMON13197. A portion of the ligation mixture was then transformed to strain JM101 of E. coii K-12. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment and sequenced to confirm the correct inserts. Plasmid pMON31115 contains the DNA sequence of (SEQ ID NO: 40), which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuP roLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLe uArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAla HeGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrA rgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTy rLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisL ysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgAr gAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal LeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheL euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLy sLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysL euSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyll eSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGln-MetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 508) EXAMPLE 87 DETERMINATION OF IN VITRO ACTIVITY OF HEMATOPOYETIC, MULTIFUNCTIONAL AGE RECEIVING PROTEINS The protein concentration of the multifunctional hematopoietic receptor agonist protein can be determined using a sandwich ELISA, based on an affinity purified polyclonal antibody. Alternatively, the protein concentration can be determined by analysis of the amino acid composition. The bioactivity of the multifunctional hematopoietic receptor agonist can be determined by means of several in vitro analyzes. For example, a multifunctional hematopoietic receptor agonist, which binds the hIL-3 receptor to the G-FEC receptor, can be analyzed in a cell proliferation assay, using cell lines that express hIL-3 receptors. and / or G-FEC. One such analysis is the proliferation analysis of AML-193 cells. AML-193 cells respond to IL-3 and G-FEC, which allows the combined bioactivity of the multifunctional hematopoietic receptor agonist, IL-3 / G-FEC, to be determined. Another such analysis is the proliferation analysis of TF1 cells.

In addition, other factor-dependent cell lines may be used, such as M-NFS-60 (ATCC, CRL 1838) or 32D, which are murine IL-3-dependent cell lines. The activity of IL-3 is specific for the species, whereas G-FEC is not; therefore, the bioactivity of the G-FEC component of the multifunctional hematopoietic receptor agonist IL-3 / G-FEC can be determined independently. Another such analysis is the analysis of TF1 cell proliferation. In addition, other lines that depend on the factor can be used, such as M-NFS-60 (ATCC, Rl 1838) or 32D which are cell lines that depend on murine IL-3. The activity of IL-3 is specific for the species, whereas G-FEC is not; therefore, the bioactivity of the G-FEC component of the multifunctional hematopoietic receptor agonist of IL-3 / G-FEC can be determined independently. Cell lines, such as BHK or murine Baf / 3, which do not express the receptor for a given ligand, can be transfected with a plasmid containing a gene encoding the desired receptor. An example of said cell line is BaF3 transfected with the hG-FEC receptor (BaF3 / hG-FEC). The activity of the multifunctional hematopoietic receptor agonist in these cell lines can be compared with hIL-3 or G-FEC alone or together. The bioactivity of the examples of multifunctional hematopoietic receptor agonists of the present invention, analyzed in the proliferation analyzes of BaF3 / hG-FEC cells and of proliferation of TF1 cells, is shown in Table 5 and Table 6. The bioactivity of the hematopoietic receptor agonist Multifunctional is expressed as relative activity, as compared to a protein of norm pMON130d6 (WO 9d / 212d4) having IL-3 and G-FEC receptor binding activity. The bioactivity of the examples of hematopoietic receptor agonists, multifunctional, of the present invention, analyzed in the proliferation analysis of BaF3 / c-mpl cells and proliferation of TF1 cells is shown in table 7 and table 8.

TABLE 5 PROLIFERATIVE ACTIVITY OF CELLS OF AGONISTS OF DOUBLE RECEIVER IL-3 / G-FEC n.d. = not determined * The bioactivity of the multifunctional hematopoietic receptor agonist is expressed as the relative activity compared to a standard protein, pMON13056. N = 3 or greater.

TABLE 6 PROLIFERATIVE ACTIVITY OF CELLS OF THE DOUBLE RECEPTOR AGONISTS IL-3 / G-FEC n.d. = not determined The bioactivity (n = 1 or 2) of the multifunctional hematopoietic receptor agonist is expressed as a relative activity, compared to a norm protein, pMON130d6. "+" indicates that the molecule was comparable with pMON130d6.

TABLE 7 PROLIFERATION ACTIVITY OF CELLS * Activity measured in the Baf3 cell line, transfected with the c-mpl receptor, in relation to the c-mpl ligand (1-163). Activity measured in relation to pMON130d6. Similarly, other factor-dependent cell lines, known to those skilled in the art, can be used to measure the bioactivity of the desired multifunctional hematopoietic receptor agonist. Methylcellulose analysis can be used to determine the effect of multifunctional hematopoietic receptor agonists on the expansion of hematopoietic progenitor cells and the pattern of different types of hematopoietic colonies in vitro. Methylcellulose analysis can give an estimate of the precursor frequency, since it measures the frequency of the parents per 100,000 input cells. Long-term, stromal-dependent cultures have been used to delineate primitive hematopoietic progenitors and stem cells. This analysis can be used to determine if the multifunctional hematopoietic receptor agonist stimulates the expansion of very primitive progenitors and / or very primitive stem cells. In addition, cultures in limiting dilution can be performed which will indicate the frequency of the primitive progenitors, stimulated by the multifunctional hematopoietic receptor agonist.

TABLE 8 EXAMPLE 88 G-FEC variants containing single or multiple amino acid substitutions were made, using PCR mutagenesis techniques, as described in 20 94/12639 and in WO 94/12638. These and other variants (ie, substitutions, insertions or omissions of amino acids and N-terminal or C-terminal extensions) could also be made by one skilled in the art, using a variety of other methods, including the assembly of synthetic genes or site-directed mutagenesis (see Taylor and co-authors, Nucí Acids Res., 13: 7864-8785 (1985); Kunkel and co-authors, Proc. Natl. Acad. Sci. USA 82: 488-492 (1985); Sambrook et al. coauthors, Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989), (WO 94/12639) and (WO 94/12638)). These substitutions may be made one at a time or in combination with other substitutions and / or omissions and / or insertions and / or amino acid extensions. After verification in the sequence of the changes, the plasmid DNA can be transfected into a mammalian cell, insect cell or appropriate bacterial strain, such as E. coli, for production. Known variants of G-FEC, which are active, include substitutions at positions 1 (Thr to Ser, Arg or Gly, 2 (Pro to Leu), 3 (Leu to Arg or Ser) and 17 (Cys to Ser) and omissions of amino acids 1-11 (Kuga and co-authors, Biochemical and Biophysical Research Comm., 159: 103-111 (1989)). These variants by amino acid substitution in G-FEC can be used as a template to create receptor agonists of G-FEC in which a new N-terminus and a new C-terminus are created. Examples of amino acid substitution variants in G-FEC are shown in Table 9.

EXAMPLE 89 DETERMINATION OF THE BIOACTIVITY OF VARIANTS BY AMINO ACID SUBSTITUTION IN G-FEC The variants can be analyzed by amino acid substitution in G-FEC for cell proliferation activity, using the Gaf / 3 cell line, transfected with the human G-FEC receptor. The bioactivity of the examples of amino acid substitution variants in G-FEC are shown in table 9, in relation to natural human G-FEC. A "+" indicates an activity comparable to the natural one, and "-" indicates significantly reduced or non-measurable activity.

TABLE 9 CELL PROLIFERATION ACTIVITY OF THE VARIANTS OF G-FEC IN THE LINE OF CELLS BAF3, TRANSFECTED WITH THE HUMAN G-FEC RECEPTOR * activity in relation to natural hG-FEC n.d. = not determined.

EXAMPLE 90 ISOLATION OF cDNA THAT CODIFIES THE LIGANDO flt3 Three clones of flt3 ligand were amplified from poly A + RNA of human bone marrow (Clontech) using sensitizers of RCP NCOLFT, HIND160 and HIND165 (according to the conditions suggested by the manufacturers). These amplified PCR products were gel purified and cloned into the BHK expression vector pMON5723, which generates pMON30237 (NCOLFT + HIND160), pMON30238 (NCOFLT + HIND165) and a default clone pMON30239 (NCOFLT + HIND 165). The omission in pMON30239 is from amino acid residues 89 to 106.

EXAMPLE 91 Flt3 receptor agonists of rearranged sequence were constructed, using various methods and various types of linker. The first series of constructs containing the linker peptide (SerGlyGlyAsnGly) X (where X = 1, 2 or 3) with breakpoints 39/40, 65/66 and 89/90 was formed, using a two-step PCR procedure described by Mullins and coauthors, in which the front half and the back half of each molecule of rearranged sequence is formed separately in the first step of PCR, and then the product pairs of the first reaction step are combined in a second step of CPR and extend in the absence of exogenous sensitizers. For example, to form the three precursor molecules with 89/90 breakpoint, with the amino acid linkers SerGIyGIyAsnGly SEQ ID NO: 786, SerGIyGIyAsnGlySerGIyGIyAsnGly SEQ ID NO: 787 and SerGIyGiyAsnGlySerGIyGIyAsnGIySerGIyGIyAsnGiy SEQ ID NO: 788, (pMON32326, pMON32327 and pMON32328, respectively), six initial CPR products were generated. The follg pairs of sensitizers were used in the PCR reaction of the first step: a) 89For / L5B; b) 89For / L10B; c) 89For / L1dB; d) 89Rev / L5a; e) 89Rev / L10A and f) 89Rev / L1 dA. The identical approach was used to form the precursors pMON32321 (breaking point 39/40, sensitizing pairs 39For / L10B and 39Rev / L10A) and pMON32325 (cleavage point 65/66, sensitizing pairs 65For / L5B and 65Rev / LdA). Except for what is noted below, all subsequent PCR reactions used the components of the PCR Optimizer (Invitrogen) and the amplification conditions according to the protocol suggested by the manufacturers. Reactions were established as follows: 50 pmol of each sensitizer, 10 ul of B 5X buffer (300 mM Tris-HCl (pH 8.6), 10 mM MgCl2, 75 mM (NH4) 2S04) were combined in template. , 5 U of Taq polymerase and 100 ng of heat denatured DNA (in this example, pMON30238), and carried to 45 ul of final volume with dH20. The reactions were pre-incubated for 1-5 minutes at 80 ° C, then 5 ul of 10 mM dNTP was added to each reaction, and heat denatured for 2 minutes at 94 ° C before amplification in a thermal cycle former DNA Perkin Elmer model 480. Seven cycles of DNA amplification under the follg conditions: denaturation with heat for one minute at 94 ° C, fixation, 2 minutes at 65 ° C, followed by extension, 3 minutes at 72 ° C. 23 additional cycles consisting of one minute of denaturation with heat at 94 ° C were performed, followed by four minutes of fixation / extension at 72 ° C; and then a final extension cycle for 7 minutes at 72 ° C. With the exception of pMON32328, the PCR amplification products were extracted on a 1.2% TAE agarose gel and the appropriate size bands were excised (the main amplification product and purified using Geneclean II (Bio 101). suspend the samples in 10 ul of dH20.The amplification products were purified for pMON32328 directly using a Wizard PCR Clean-up kit (Promega) and the DNA was eluted in 60 ul of dH20.The method was modified to construct the precursors of pMON32322 (breaking point, 39/40, sensitizing pairs 39For / L5B and 39Rev / LdA), increasing the amount of template to 1 ug and changing the amplification conditions by PCR as follows: six cycles of 94 ° C, 1 minute 65 ° C for 2 minutes and 72 ° C for 2.6 minutes, followed by 15 cycles of 94 ° C for 1 minute, 70CC for 2 minutes and 72 ° C for 2 minutes, followed by a single extension cycle at 72 ° C for 7 minutes, the second step of RC P used purified gel precursors from the first PCR step as a sensitizer / template combination, as follows: 5 ul of each of the precursor molecules (ie, for pMON32328, the PCR products of the sensitizing pairs 89For / LdB and 89Rev / LdA), 10 ul of regulator B 5X, 5 U of Taq poiimerase and 24 ul of dH20. The reactions were heated for d minutes at 80 ° C, 10 mM dNTP was added and the reactions were heat denatured for two minutes at 94 ° C. The DNA amplification conditions were as follows: 1d cycles of 94 ° C for 1 minute, 69 ° C for 2 minutes, followed by an extension of 3 minutes at 72 ° C. To allow the extension to be completed, this last cycle was followed by a single extension step at 72 ° C for 7 minutes. The incubation time was reduced to 80 ° C at two minutes and the number of cycles was reduced to ten cycles for pMON32325 (products of RCP 65For / LdB and 65Rev / LdA). The PCR products of the appropriate size were gel purified on a 1.2% TAE agarose gel using Geneclean II. For pMON32322 (39For / LdB and 39Rev / LdA), the fixation temperature was reduced to 68 ° C and the extension time was reduced to 2 minutes. In addition, the PCR product was purified using a Wizard PCR Clean-up kit (Promega) according to the protocol suggested by the suppliers. The second step of PCR for pMON32326 (CPR products of 89For / L15B and 89Rev / L1dA) was modified in the following manner. Three series of PCR reactions were performed identically as above, except for the type of sample regulator (regulator dX B, D or J - PCR Optimizer equipment). The composition of regulators D and J differs from regulator B only at pH or (MgCi2). The (MgCl2) for the regulator D is 3.d mM, while the pH of the regulator J is 9.6. The protocol was modified increasing the number of PCR cycles to 20 and aliquots of 15 ul were extracted at the end of cycles 10, 15 and 20. 5 ul of each aliquot time point was analyzed for the presence of the amplified material on an agarose gel at 1.2% of TBE. The rest of the PCR reaction mixtures were combined with regulator B, D and J and subsequently purified using the Wizard PCR Clean-up kit protocol. The DNA was eluted in 60 ul of dH20. The purified samples of the PCR reaction of the second step were digested with Ncol / Hindlll using one of two normalized digestion conditions. For purified samples in Geneclean II, 10 ul of DNA was digested in a 20 ul reaction with 7.6 U of each of Ncol / Hindlll for two hours at 37 ° C, and gel purified again on an agarose gel at 1.1% of APR, with Geneclean II. Samples ready for ligation were resuspended in 10 ul of dH20. For pMON32322, 20 ul of sample was digested in a reaction volume of 50 ul with 20 U of each of Ncol and Hindlll for 3 hours at 37 ° C. 0.1 volume of 3M NaOAc (pH 5.d) and 2.6 volumes of EtOH was added, mixed and stored at -20 ° C overnight. The DNA was recovered by pelletizing for 20 minutes at 13,000 r.p.m. at 4 ° C in a Sigma Mk 202 microfuge. The DNA pellet was rinsed with cold 70% EtOH, lyophilized and resuspended in 10 ul of dH20.

EXAMPLE 92 An alternative approach was used to construct pMON32320 (39/40 breakpoint, 15 amino acid linker), pMON32323 (breakpoint 65/66, 15 amino acid linker) and pMON32324 (breakpoint 65/66, ten amino acid linker) ). New sensitizers (L15C, L15D, L15E) were designated to incorporate the BamH1 restriction site into the sensitizer, which was in frame to allow cloning into the MabHI site and maintain the appropriate reading frame. The conditions of the PCR reaction were performed during the first step in an identical manner to that described for pMON32322, except that the following series of sensitizing pairs were used: 65For / L1dD and 6d Rev / L1dE (pMON32324); 39For / L1dD and 39Rev / L1dC (pMON32320); and 65For / L1dD and 65Rev / L1dC (pMON32323). The PCR reaction products were purified using a Wizard PCR Clean-Up kit as described and eluted in 609 ul of dH20. Samples were digested with Ncol / BamHI (39For / L15D and 65For / L1dD) or BamHI / HindIII (39Rev / L1dC, 65Rev / L1dC and 65Rev / L1dE). Restriction digestions were carried out as follows: 10 ul of purified PCR reaction products, 3 ul of universal 10X restriction buffer, 16 U of Ncol or Hindlll, 1 d U of BanHI, in a final volume of 30 ul reaction The reactions were incubated for 90 minutes at 37 ° C, and the PCR products were gel purified on a 1.1% TAE agarose gel, using Geneciean II. The DNA ready for ligation was resuspended in 10 ul of dH20.

Inserts were ligated to pMON3977 digested with Ncol / HindIII (mammalian expression vector BHK) which had been treated with shrimp alkaline phosphatase (FAC) either in a three-way ligation reaction (pMON32320, pMON32323 or pMON32324) or two lanes (pMON32321, pMON32322, pMON3232d, pMON32326, pMON32327 and pMON32328) as follows: 2.5 ul of the insert (2 ul of each amplicon of sensory pair for pMON32320, pMON32323 and pMON32324) was added to 50 ng of vector in one reaction of 10 ul using common and common ligation conditions. 2 ul of each reaction was transformed with 100 ul of chemically competent DHdalfa cells (Gibco / BRL), following the protocol suggested by the manufacturers. Aliquots of 26 ul and 200 ul were spread on LB plates containing 60 ug / ml of ampicillin and incubated overnight. The isolated colonies were collected and the DNA was prepared from 60 ml of night cultures, using Qiagen DNA midiprep kits. The DNA was quantified by absorbance at A260 / A280, and verified for the correct insert size by agarose gel electrophoresis, after digestion of 1 ug of template with restriction endonucleases Ncol / HindIII. Sequences containing inserts of the predicted size in both orientations were sequenced using sensitizers specific for the vector, using an automated, fluorescent DNA sequencer, model 373A (Perkin Elmer ABI). Sequence reactions were carried out in 20 ul reaction volumes, using the Perkin Elmer model 480 thermal cycle former, as follows: 1 ug of template, 3.2 pmol of sensitizer, 1 ul of DMSO, 9.6 ul of dideoxy premixture of the Taq terminator (Perkin Elmer ABI) and subjected to 2d cycles of sequence-determining amplification, as follows: 30 seconds at 94 ° C, 15 fixing seconds at 50 ° C, followed by an extension cycle of 4 minutes at 60 ° C. The samples were purified using Centri-Sep spin columns (Princenton Separations) following the protocol suggested by the manufacturers; it was lyophilized and subjected to sequence analysis. Samples containing the predicted amino acid sequence were selected for analysis and assigned pMON numbers.

EXAMPLE 93 A similar approach was used to construct pMON32320, pMON323 and pMON324, to introduce the second type of linker (SerGlyGlySerGly) X, where X = 2 or 3), into two sequences with sequence rearrangement, containing the breakpoint 39/40 (pMON32348 and 32360). Sensitizing pairs were the following: for pMON32348 the combinations of 339For2 / 339Rev3 and 339Rev2 / 339-10For3 were used and for pMON32350 the combinations of 339For2 / 339Rev3 and 339Rev2 / 339-1dFor3 to create three PCR amplification products. Each PCR amplification was established as follows: 100 pg of heat sensitized pMON32320, 60 pmol of each sensitizer pair, 10 ul of buffer B dX, dU of Taq polymerase and dH20 to a final volume were added. of 45 ul. The reactions were preincubated as described previously. 15 cycles of amplification were carried out under the following conditions: thermal denaturation at 94 ° C, 1 minute, followed by 2 minutes of fixing step at 70 ° C and 3 minutes of extension at 72 ° C. After the last cycle, a single extension step was made at 72 ° for 7 minutes. PCR amplification products were purified from sensitizing pairs 339For2 / 339Rev3, 339Rev2 / 339-10For3 and 339Rev2 / 339-1dFor2, using the Wizard PCR Clean-up kit (Promega) and eluted in 60 ul of dH20. The Ncol / BamHI digests for the sensitizing pair 339For2 / 339Rev3 were: 8ul of DNA template was mixed with 2ul of universal restriction buffer and 10 U of each of Ncol and BamHl in a reaction volume of 20 ul, and it was incubated for 90 minutes at 37 ° C. The digestion products were purified using the Geneclean II direct purification protocol and the DNA ready for ligation was resuspended in 10 ul of dH20. Restriction digestion and subsequent purification were performed for 339Rev2 / 33910For3 and 339Rev2 / 3390-1dFor2, in a manner identical to that described for the 339For2 / 339Rev3 amplicon, except that Ncol was replaced by 10 U of HindIII. Normal ligations were performed by adding 50 ng of pMON3977 treated with Ncol / Hindlll / SAP, gel purified, 0.5 ul of the 339For2 / Rev3 amplicon, 1 ul of the amplicon 339Rev2 / 339-10For3 (pMON32348) or of the amplicon 339Rev2 / 339 -15For3 (pMON32350), 5U of T4 DNA ligase, and 1ul of 10X ligase buffer in a 10 ul reaction volume, for 60 minutes at room temperature. The steps were made Subsequent tests that lead to final DNA sequence confirmation as described above.

EXAMPLE 94 A third type of linker was incorporated, with a repeating variable motif (GlyGlyGlySer) x, in another set of receptor agonists flt3, with sequence rearrangement, from templates constructed in a modular manner. These linker stretches were: amino acid residues of the six amino acid linker (GlyGlyGlyGlySerGIyGly, SEQ ID NO: 792), seven amino acid linker (GlyGlyGlyGlyGyGlyGly, SEQ ID NO: 793), ten amino acid linker (GlyGlyGlyGerGyGlyGlySerGIyGly, SEQ ID NO: 794 ); thirteen amino acid linker (GlyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIy, SEQ ID NO: 795) fifteen amino acid linker (GlyGlyGlyGyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly, SEQ ID No. 796), and twenty one amino acid linker (GlyGlyGlySerGIyGly GlySerGIyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIy, SEQ ID NO: 797). These modular templates, each of which comprises an hflt3 ligand dimer, separated by a single length BamHl-containing linker, were constructed as follows: Six intermediate plasmid templates, FL3N; FL7N, FL11 N, FL3C, FL4C and FL10C, using PCR, using pairs of sensitizers and pMON30238 as a template, using cycle formation conditions similar to used for pMON32322. Fifty pmol of each sensitizer was added per reaction to 100 ng of thermally denatured template, and the reactions were assembled as described for pMON32322. The cycle conditions were as follows: seven cycles at 94 ° C, one minute; two minutes at 65 ° C and 2.5 minutes at 72 ° C, followed by 10 cycles of 1 minute at 94 ° C, 2 minutes at 70 ° C and 2.6 minutes at 72 ° C. A single 7 minute extension at 72 ° C completed the cycle reactions. The sensitizing pairs used to construct each intermediary were: N-term / FLN3 (FL3N); N-term / FLN7 (FL7N), N-term / FLN11 (FL11 N); Cterm / FLC3 (FL3C); C-term / FLC4 (FL4C) and C-term / FLC10 (FL10C). The amplification products were purified by PCR, with Wizard PCR Clean-up (Promega) and eluted in 50 ul of dH20. The purified DNA from the first subseries, FL3N, FL7N and FL11 N, was digested with Ncoi / BamHI, gel purified as previously described and ligated to the vector DNA pSE420 treated with Ncoi / BamHI / Sap (Invitrogen). Intermediary templates of the second subseries, FL3C, FL4C and FL10C, were constructed in an identical manner, except that Hindlll was used instead of Ncol. The following steps were carried out leading to the confirmation of the final DNA sequence, as described above.

EXAMPLE 95 To make the final six templates, the two subseries of intermediaries were digested in pSE420 with Ncol / BanHI (FL3N, FL7N, FL11N, subseries 1) or with BamHI / Hindill (FL3C, FL4C, FL10C, subseries 2), and gel purified using Geneciean II, as previously described. An intermediate amplicon from each subseries was ligated to pMON3977 treated with Ncol / Hindlll / SAP, by reaction, and transformed into DHdalfa cells as previously described, using the following combinations to generate specific linker stretches: six amino acid linker (FL3N and FL3C), seven amino acid linker (FL3N and FL4C), ten amino acid linker (FL7N and FL3C), thirteen amino acid linker (FL3N and FL10C), fifteen amino acid linker (FL11 n and FL4C) and 21 amino acid linker (FL11 N) and FL10C). DNA was prepared, in 60 ml nocturnal cultures of individual colonies of each of the six combinations described above, analyzed for the correct size of the insert, by means of restriction analysis with Ncol / HindIII, and used as a template. Sensitizing pairs 39For / 39Rev (breakpoint 39/40), 65For / 65Rev (breakpoint 65/66) and 89For / 89Rev (breakpoint 89/90) were used to amplify each template by PCR, as described for pMON32322, except that 75 pmol of each sensitizer was used. The amplification conditions were modified as follows: six cycles of 94 ° C for 1 minute; 2 minutes at 70 ° C, 2.5 minutes at 72 ° C, followed by 9 cycles of 94 ° C for 1 minute and three minutes at 72 ° C. After the last cycle, a final extension of six minutes at 72 ° C allowed sufficient time for the full extension of the products.

Samples were purified using the Wizard PCR Clean-up kit, as described, and digested twice with Ncol / Hindlll. These amplification products were purified again using a Wizard PCR Clean-up kit. In addition, the six different linker length molecules were cloned for the 39/40 breakpoint, in pMON3977 treated with Ncol / Hindlll / SAP, as individual proteins (pMON32365, pMON32366, pMON32367, pMON32368, pMON32369 and 32370). The subsequent steps leading to the confirmation of the final DNA sequence as described above were carried out.

EXAMPLE 96 We constructed genes encoding chimeric, multifunctional receptor agonist molecules, consisting of the IL-3 receptor agonist, pMON13416 (WO 94/12638) linked by a linker lgG2b to wild-type ligand flt3 or to flt3 receptor agonists, of rearranged sequence , examples 91-93. Inserts containing the desired receptor rearrangement flt3 agonist molecule were isolated from the parent plasmid as an Ncol / Hindill restriction fragment and ligated to pMON30304 digested with Afllll / Hindlll / SAP. The following steps were carried out leading to the confirmation of the final DNA sequence as described above. -? 47 The resulting plasmids, which contain the DNA sequences encoding multifunctional chimeric molecules, comprising an IL-3 receptor agonist (from pMON13416) and a flt3 receptor agonist of rearranged sequence, are indicated in Table 9.

TABLE 9 EXAMPLE 97 We constructed genes that encode the chimeric, multifunctional receptor agonist molecules, which consist of an agonist of IL-3 receptor, from pMON13288 (WO 94/12638), linked by a linker lgG2b to natural flt3 ligand flt3 receptor agonists, or with rearranged sequence, examples 91-93. Inserts containing the flt3 receptor agonist molecule of desired, rearranged sequence of the parent plasmid were isolated as an Ncol / HindIII restriction fragment and ligated to pMON30311, digested with Afllll / HindIII / SAP. The subsequent steps were carried out, which lead to the confirmation of the final DNA sequence, as described above. The resulting plasmids, which contain the DNA sequences encoding multifunctional chimeric molecules, comprising the IL-3 receptor agonist (from pMON13288) and a flt3 receptor agonist of rearranged sequence, are indicated in Table 10.

TABLE 10 EXAMPLE 98 Two chimeric molecules were constructed with the hflt3 receptor agonist component with rearranged sequence, at the N-terminus of the chimeric molecule, by PCR, using plasmid DNA pMON32360 and pMON32362, as a template, and N-term / 134rev and N-term sensitizer pairs. term / 139rev to replace the high codon at the C-terminus of the natural fit3 ligand molecules, with a SnaBI restriction site within the frame. The reaction mixtures were established as previously described for pMON32322. The cycle conditions were the following: seven cycles of 94 ° C, one minute; 65 ° C, two minutes and 72 ° C 2.d minutes, and another 10 cycles of amplification were carried out additionally, in which the fixing temperature rose from 6d ° C to 70 ° C. The samples were purified using the Wizard PCR purification kit and its protocol, and eluted in 60 ul of dH2O, 20 ul of each of the samples, digested with Ncol and SnaBl. The plasmid DNA pMON26431 was digested with Ncol and SnaBI and ligated with the PCR reactions digested with Ncol / SnaBI. The Transformation of the competent DHdalfa cells and the subsequent steps leading to the final confirmation of the DNA sequence were carried out as before.

EXAMPLE 99 Five additional hflt3 ligand breakpoints were made using the indicated sensitizers 28/29 (28For / 28Rev), 34/35 (34For / 34Rev), 62/63 (62For / 62Rev), 94/94 (94For / 94Rev) and 98/99 (98For / 98Rev), to amplify the linker of ten and fifteen amino acids (GlyGlyGlySer) x, as described above. The resulting PCR products were digested with Ncol / HindIII and ligated into pMON30311, digested with 11 L Afl / 11 L Hind / SAP as previously described. The transformation of the competent DHdalfa cells and the subsequent steps leading to the confirmation of the final DNA sequence were carried out as described above.

EXAMPLE 100 For increased expression of hf! T3 receptor agonists of rearranged sequence in E. coli, specific sensitizers for N-terminal, encoding degenerate codons were used to redesign both the 1-134 and 1-139 forms of the native hflt3 ligand in the vector expression pMON5723 from E coli. Sensitizer pairs FH3AFor / FCT.rev (Ala2) and Flt23For / FCT (Gly2) were used to amplify in PCR a degenerate N-terminal mixture of sequences encoding the natural ligand flt3 using reaction conditions described for pMON23222, except that the number of amplification cycles was reduced to fifteen cycles of 1 minute at 9d ° C, 2 minutes at 5d ° C and 2.5 minutes at 72 ° C. Amplicons were purified using the Wizard PCR Clean-up kit (Promega) and eluted in 50 ul of dH2o. Restriction digestion was carried out with Ncol / HindIII and subsequent gel purification using Geneclean II, as previously described. The inserts were ligated to Ncol / Hindlll / pMON5723 plasmid DNA treated with SAP, gel purified, and transformed into competent DHdalfa cells, as previously described. Aliquots of transformed cells were spread on plates of Lb agarose medium containing 75 ug / ml spectinomycin, incubated for 14-16 hours at 37 ° C and the colonies counted. After confirmation of the colonies, the remainder of each transformation mixture was incubated overnight (14-16 hours) at 37 ° C in 2 x 5 ml of LB medium containing 7dug / ml spectinomycin. Miniprep DNA was prepared using a Wizard DNA 373A Miniprep kit (Promega), following the recommended protocol. The purified Miniprep DNA was eluted in 50 ul of dH20 and 1-2 ul was used to transform chemically competent MON207 cells. Aliquots of 25 and 200 ul were spread on plates of LB medium containing 75 ug / ml of spectinomycin, and incubated for 12-15 hours at 37 ° C. The isolated colonies of 40-60 concavities, representing each The original sensitizer pair was selected and scored on LB / spectinomycin master plates and incubated for another 4-6 hours at 37 ° C. The hflt3 receptor agonist clones were selected, with individual rearranged sequence, for expression in E. coli in a 96-well microtiter format, to select for improved expression levels. 100 ul of minimal M9 medium was inoculated by concavity (which included 1% casamino acids) by a single colony (40-dO isolates) for each PCR sensitizer pair hlft3) and incubated at 37 ° C at 200 r.p.m. for 3-4 hours (I = 0) and was induced by addition of d ul / concavity, of 1 mg / ml freshly prepared nalidixic acid (in 0.1 N NaOH). After another four hours of incubation at 37 ° C (I = 4), aliquots of approximately d-10 ul were extracted from each concavity and analyzed by light microscopy when in the presence of retractable bodies, and the results were marked as an appropriate percentage of cells containing the shrinking bodies, with respect to the total number of cells. The clones having the maximum expression levels were selected for the following 10 ml bank-scale expression studies. Night dml cultures were grown in LB medium in the presence of 7d ug / ml spectinomycin at 37 ° C. At 10 ml minimum M9 freshly prepared (with 1% casamino acids) in 125 ml shake flasks, inoculation with enough nocturnal cells was performed to obtain an initial reading of 20 Klett units, and then incubated for about 3-4 hours at 37 ° C with shaking until it reached a density of about 110-150 Klett units (I = 0) and was induced with 50 ul of freshly prepared nalidixic acid (10 mg / ml 0.1 N NaOH). Aliquots of 1 ml were removed and pellets were formed with the cells for one minute in a microfuge. The supernatants were removed by aspiration and the pellets were stored at -20 ° C until they were ready for SDS-PAGE analysis. The rest of the induced cells was incubated for another four hours at 37 ° C with shaking, after this time point (I = 4) the density of the cells was measured (in Klett units). An aliquot of 1 ml of each sample was removed, pellet formed and stored as described above. Another aliquot of d-10 ul was taken from each flask and analyzed by luminous microscopy for the presence of shrinking bodies. The pellet samples were resuspended in a volume (in ul) of 2X the charge regulator (including 1% of B-mercaptoethanol) equal to the l = 4 value of Klett, boiled for 5 minutes and loaded with 6-7 ul. in a gel of 12 or 14% Tris-Glycine, SDS-polyacrylamine, and subjected to electrophoresis for 90 minutes at 90 volts. The gels were fixed, stained and prepared for drying according to the suggested protocol (Novex). Clones were selected at this point to scale the fermentation, based on the increased expression levels, of a single induced protein band (I = 4) corresponding to the predicted size, when compared to the I = 0 samples. prepared Midiprep DNA from selected actions that express a high level of induced protein, as previously described, and steps that lead to confirmation of Final DNA sequence, were performed exactly as described above. Those clones were designated pMON32329, pMON32330, pMON32341 and pMON32342.

EXAMPLE 101 A set of multifunctional receptor agonist chimeric molecules comprising an IL-3 receptor agonist (from pMON13288) and natural ligand flt3 was also constructed for expression in E. coli. The genes encoding the multifunctional receptor agonist chimeric molecules, pMON32364 and pMON32377, were released from the parental vector, by digestion with Ncol / HindIII and ligated to pMON5677 vector, transformed into MON207 cells and the individual isolates were collected, as described above. These constructs were designated pMON32394 (insert of pMON32364) and pMON32395 (insert of pMON32377).

EXAMPLE 102 A truncated flt3 receptor was isolated as a 1.4 Kb PCR product, using 50 pmol of the sensitizers FLTAFLS1 and FLTR1 N, with about 10 ng of the plasmid pMON27184, as template. The sensitizers were designed to produce an Afllll restriction site just d 'respect to the first codon Asn in the mature coding sequence, as well as an EcoR restriction site! just 5 'with respect to the putative transmembrane region. The reaction was digested with Afllll and EcoRI using common reaction conditions and ligated to plasmid pMON26458 digested with Ncol / EcoRI. This plasmid contains the following DNA sequence: '- GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACT CCTGGTCCGCCCCGCCATGGCTAAAGCTT - 3' SEQ ID NO: 857 which encodes the signal sequence I L-3. This sequence contains a BamH1 restriction site at the 5 'end and includes the methionine of ATG as the first amino acid of the 3' signal sequence with respect to the BamH1 site. This sequence signal is divided by the cell, leaving a d 'Met / Ala, generated by melting the Ncol site of the fused signal sequence to the Afllll site of the receptor produced in the PCR reaction. All the truncated form of the receptor, together with the IL-3 signal sequence, could be cut back from the vector, as a BamHI / EcoRI digest (hLL3L / hFflt3R). The catalytic domain of pMON30298 (hG-CSFR) was redesigned to create an EcoRI frame restriction site, in transmembrane / cytoplasmic junction, by means of PCR, in the following manner. To O.d ug of pMON30298 heat denatured, 100 pM of each of the sensitizers HGCFfor and HGCFrev, 10 ul of buffer J dX, dU of Taq polymerase and dH20, to a final volume of 4d ul, as described, was added. HE performed the PCR amplification in the following manner: six cycles (1 minute at 94 ° C, 2 minutes at 64 ° C and three minutes at 70 ° C), followed by nine cycles (one minute at 94 ° C, four minutes at 70 ° C). A final extension of one minute was performed, for seven minutes at 70 ° C. 10 ul of each PCR reaction was purified in gel using Geneclean II as previously described, and eluted in 10 ul of dH20. Samples were digested with 10 U of each of EcoRI and Hindlll in 20 ul of reactions for 90 minutes at 37 ° C. Gel samples were again purified (Geneclean .II) as previously described and eluted in 10 ui of dH20. 2 ul of insert was ligated to 50 ng of NcOI / HindIII / pSE420 vector phosphatased in a 10 ul reaction, as previously described. Exactly as described above, the transformation of competent cells of DHdalfa was carried out and the subsequent steps leading to the final DNA sequence confirmation were carried out, as described above. The selected clones were then sequenced to verify the presence of the EcoRI site in the frame, as well as the confirmation of the correct GFECR catalytic domain DNA sequence. Clones containing the predicted sequence were digested with EcoRI / HindIII as previously described and gel purified. Purified inserts of the fragments hG-FCTR (EcoRI / HindIII) and hLL3L / hFlt3R (BamHI / EcoRI) were ligated to BamHI / HindlIl / factor pcDNA 3.1 (-) phosphatased (Invitrogen). The transformation of the competent DHdalfa cells and the subsequent steps leading to the confirmation of the final DNA sequence were carried out as described above.

EXAMPLE 103 Additional genes encoding flt3 ligands of rearranged sequence were constructed using the dimeric template intermediates previously described. For sequence rearrangement, flt3 receptor agonists of rearranged sequence were used having the linker of 15 amino acids (GlyGlyGlySer) 3GiyGlyGly, SEQ ID NO: 795, and the dimeric intermediates Flt4C.seq and FltU N.seq were used as template. Breakpoints were constructed corresponding to residues 28/29, 34/36, 62/63, 94/95 and 98/99 amino acid of ligand flt3 3, using the PCR-based approach, using a PCR Optimizer kit (Invitrogen ) and the following pairs of sensitizers: FL29For / FI29Rev, FI35For / FL3dRev, FL563For / FI63Rev, FL95For / FI9dRev, FL999For / FL99Rev, as described in example 94. The amplification conditions were as follows: 7 cycles of 94 ° C for 1 minute, 62 ° C for 2 minutes and 2.5 minutes at 70 ° C; 12 cycles of 94 ° C for 1 minute, 68 ° C for 2 minutes and 70 ° C for 2.5 minutes; followed by a final cycle of 7 minutes at 72 ° C. CPR products corresponding to the insert size predicted with Ncol and Hindlll were digested and gel purified as previously described, using Gene Clean II (Bio 101) following the protocol suggested by the manufacturer. The samples were resuspended in 10 ul of final volume with dH20. Inserts were cloned as individual genes into the mammalian expression vector pMON3934 (Ncol / HindIII / treated with SAP) and designated pMON3d712, pMON36713, pMON35714, pMON3671d, pMON3d716, pMON35717 and pMON36718, respectively. Chimeric protein encoding genes were prepared in the L-3 receptor agonist, encoded by pMON13288 (WO 94/12638), here designated "I receptor agonist I L-3", and the rearranged sequence ligand FIt3 was prepared, cloning restriction-digested, purified, break-point RCP products 28/29, 34/36, 62/63, 94/96 and 98/99, and the sensitizing pairs in pMON30311 treated with Afllll / Hindlll / SAP. The resulting plasmids were designated pMON32398, pMON36700, pMON3d702, pMON36704 and pMON35706, respectively. In addition, the same sensitizing pairs were used, in conjunction with the dimeric template intermediates Flt7N.seq and Flt3C.seq to construct the linker of 10 amino acids (GlyGlyGlySer) 2GlyGly, SEQ ID NO: 793, the forms of these chimeric proteins l / Flt3L IL-3 receptor agonists, pMON32397, pMON32399, pMON35701, pMON35703 and pMON3670d, respectively.

EXAMPLE 104 Chimeric i / Flt3L receptor agonist genes encoding iL-3 receptor were constructed, which contained the 21 amino acid residue linker (GlyGlyGlySer) 5Gly, SEQ ID NO: 796, using a similar PCR approach, which used template intermediates dimer FltU N.seq and FltlOC.seq and the following sensitizing pairs: Flt36 / 36Rev, Flt42 / 42Rev, and Flt43 / 43Rev. These sensitizing pairs correspond to the following ligand breakpoints Flt3: 35/36, 36/37, 37/38, 38/39, 40/41, 41/42 and 42/43 (the breakpoint 39/40 was previously constructed as pMON32376) and used for PCR amplification using the following cycle conditions: 7 cycles at 94 ° C for one minute, 66 ° C for 2 minutes and 2.5 minutes at 70 ° C; 15 cycles of 94 ° C for 1 minute and 70 ° C for 4 minutes, followed by a final cycle of 7 minutes at 72 ° C, using the Invitrogen PCR Optimizer equipment (regulator B). After confirmation of the DNA sequence, these constructs were designated pMON35733, pMON35734, pMON35735, pMON35736, pMON35738, pMON36739, pMON35740, pMON3d741, pMON35742 and pMON3d743, respectively. PCR incorporation errors resulted in two substitutions of a single amino acid, the chimeric flt3 rearranged sequence partner (pMON3d741, break point 36/36, and pMONd743, breakpoint42 / 43) and a construct (pMON35742, breakpoint) 38/39) containing 2 amino acid substitutions Q133 to R133 and Q100 to R100 and L112 to P112 in the Flt3L portion, constructed and tested as part of this series. Other chimeric Flt3L / IL-3 receptor agonist I proteins were also constructed, in which the alternative Flt3L cleavage sites corresponding to the amino acid residues of the ligand Flt3 28/29, 34 / 3d, 62/63 were also constructed. , 65/66, 89/90, 94/95 and 98/99, previously described, with the linker of 15 amino acids (GlyGlyGlySer) 3 GlyGlyGly, templates Flt4C and Flt11 N. The PCR reaction mixtures were similar to those described in Example 103, except that the reverse sensitizers encoding the C-terminus of the Flt3 portions of rearranged sequence were modified by replacing the Hindlll restriction site with a SnaBi recognition sequence. The parameters of the PCR amplification cycle were the following: 7 cycles of 94 ° C for 1 minute, 66 ° C for 2 minutes and 2.5 minutes at 70 ° C; 14 cycles of 94 ° C for 1 minute and 70 ° C for 1 minute, followed by a final cycle of 7 minutes at 72 ° C. Cleaning was performed by PCR, restriction digestion and purification as previously described. Inserts were ligated to pMON26431 treated with Ncol / SnaBI / SAP (a BKH expression vector containing an I agonist portion of the lgG2b / IL-3 linker receptor, as follows: 50 ng treated vector, insert (10: 1 of insert: vector), 1 unit of T4 DNA-ligase (Gibco BRL), and 1 ul of 10X ligase regulator in a 10 ul reaction volume. The ligations were incubated for one hour at room temperature, then separated from the cells. ul of each ligation and used to transform 100 ul of chemically competent DH10B cells (alternatively, DHdalfa) (Gibco BRL), following the protocol suggested by the manufacturer, one fifth and 1/26 of the volume of each transformation mixture was extended , on LB agar plates supplemented with the appropriate antibiotic markers and incubated overnight (14-16 hours) at 37 ° C.

The isolated colonies were collected and the DNA was prepared using the Quagen midiprep protocol as previously described. Sequence analysis of selected clones for break point 28/29 (pMON35719), breakpoint 34/36 (pMON35720), breakpoint 62/63 (pMON35721), breakpoint 65/66 was confirmed (pMON35722), break point 89/90 (pMON35723) and break point 98/99 (pMON3672d). PMON36726 contains a single amino acid substitution (Leu94 for Phe94) for the breakpoint 94/95. Chimeric Flt3L / IL-3 receptor agonist I constructs, with a flt3L breakpoint of 39/40 and variable lengths of amino acid linker 10, 15 and 21, are represented by pMON35707, pMON3d708, pMON3d709, pMON3d710 and pMON35711. These constructions are generated by PCR amplification of one of the following templates: pMON32373, pMON3237d or pMON32376, and the sensitizing pair specific for Flt3L, 39N TERM-1 / SNAB1C TERM. Normal PCR reaction mixtures were established, as previously described, and the DNA product was amplified using the following parameters: 7 cycles of 94 ° C for 1 minute; 62 ° C for 2 minutes and 2.d minutes at 70 ° C; 12 cycles of 94 ° C for 1 minute, 68 ° C for 2 minutes and 70 ° C for 2.5 minutes; followed by a final cycle of 7 minutes at 72 ° C. PCR products corresponding to the predicted insert size were digested, until complete with Ncol and SnaBI, gel purified and cloned as previously described in the mammalian expression vector pMON26431 (treated with Ncol / SnaBI / SAP) as the chimeric agonist proteins I of Flt3L / lgG2b / IL-3 receptor. Two of these constructs contained PCR incorporation errors in the flt3 chimeric partner of rearranged sequence, which resulted in substitutions of a single amino acid F96 to L96 and E58 to G58 (pMON35710 and pMON35711).

EXAMPLE 105 Another series of chimeric proteins, agonists I of Flt3L / IL-3 receptor of rearranged sequence, was also constructed, with the breakpoints corresponding to the amino acid residues of ligand Flt3: 35/36, 36/37, 38/39, 40/41, 41/42, 42/43 and 66/66, previously described, and also a linker of 21 amino acids, using the Flt3L agonists I constructs of IL-3 / Flt3L receptor of rearranged sequence, selected, as a template (see Table 11 below). An exception was that the 15 amino acid linker template (pMON3571d) was used to construct the 66/66 breakpoint, pMON3d771.

TABLE 11 AGONISTA I OF RECEIVER FU3L / IL-3 / AGONISTA I OF RECEIVER IL-3 Sensitizing pairs encoding the same restriction sites as those used to construct pMON35719-36725 were used. The reverse sensitizers 36Rev \ 37Rev ', 38Rev', 39Rev \ 41 Rev ', 42Rev' and 43Rev 'were used to create the Snabi framework site. The same positive sensitizers Flt36, Flt37, Flt38, Flt39, Flt41, Flr42 and Flr43 were used. The PCR reaction mixtures were identical to those previously described; however, with the exception of pMON35771, the amplification conditions were modified in the following manner: 18 cycles of 94 ° C for 1 minute; 68 ° C for 2 minutes and 70 ° C for 2.5 minutes; followed by a single extension cycle at 70 ° C for 7 minutes. For pMON35771, the amplification conditions were as follows: six cycles of 94 ° C for 1 minute; 66 ° C for 2 minutes, and 2.5 minutes at 70 ° C; 15 cycles of 94 ° C for 1 minute and 70 ° C for 4 minutes, followed by a final cycle of 7 minutes at 72 ° C. PCR amplification products were digested by restriction specific for Flt3, were purified and cloned in pMON26431 | (a BHK expression vector containing a linker portion lgG2b / IL-3 receptor agonist I, as described in example 104. A variant, pMON32179, was constructed as a 34/40 breakpoint using the sensitizing pair RCP Flt40 / 34Rev and dimeric template intermediaries FltU N.seq and FltlOC.seq PCR amplification conditions and subsequent cloning were identical to those used to clone pMON36771. Three additional Flt3L / agonist I chimeras were designed and constructed of receptor lL-3 (breakpoint 38/39) to test the effects of alternative lengths and composition of the linker Using template pMON36709, the length of the GlySer linker was expanded to encompass 29 amino acid residues, with the motif (GlyGlyGlySer) 7Gly, using the sensitizing pairs BamFor1 / 38Rev (the reaction product called PCR A) and Flt38 / BamRev1 (the reaction product called PCR B) .The amplification conditions were the Next: 6 cycles of 94 ° C for 1 minute, 66 ° C for 2 minutes and 2.5 minutes at 70 ° C; 15 cycles of 94 ° C for 1 minute and 70 ° C for 4 minutes, followed by a final cycle of 7 minutes at 72 ° C. The resulting PCR products were cleaned using a Promega PCR Clean-up kit, and digested with Ncol / BamHI (PCRA) or with BamHI / SnaBI (PCR B), gel purified and ligated to pMON26431 (an expression vector BHK containing a portion of lgG2b / agonist linker of IL-3 receptor, as previously described, the resulting construct was sequenced, confirmed and designated pMON35774. comparison, pMON35775 and 35776, different because the amino acids 140-154 of natural Flt3L (pMON3577d) or 140-160 (pMON35776) containing a single amino acid substitution were replaced with the GlySer linker, the PCR reaction conditions were identical to those described for pMON36774, except that the following sensitizing pairs were used: 38For / Navfor and 38Rev / NavRevS (pMON3d77d) and 38For / Navfor and 38Rev / NavRevL (pMON3d776). BamHl was replaced by Kasl; otherwise, the steps and cloning of these PCR amplification products were identical to those used for pMON36774. Sequence analyzes revealed PCR-induced errors in multiple isolates for both pMON3d77d and 36776. In order to obtain the final correct sequences, it was necessary to redigest selected subclones with Narl / SnaBI and Ncol / Nari, and use these purified fragments in gel to reclonar the desired constructions. . Several FIt3L dimeric chimeric molecules were also constructed to test them as transient BHK. PMON32173 was assembled, which consisted of two natural Flt3L molecules, linked by a linker lgG2b, from two pre-existing molecules, as follows: The insert containing Ncol / SnaBI Flt3L, from pMON32393, was ligated to pMON32377, cut Ncol / SnaBI, gel purified, in which the chimeric agonist I receptor I I-3 had been released. Similarly, pMON35727 (39/40 breakpoint, 15 amino acid linker) was assembled using the Flt3L insert of pMON35708 (as an Ncol / SnaBI insert) to the gel purified pMON3237d, in which the chimeric agonist partner had been excised. I of IL-3 receptor. The third dimer, Flt3L, pMON32168 (breaking point 39/40, linker of 21 amino acids) was assembled as follows: The Ncol / SnaBI insert of pMON32165 (equivalent in E. coii of pMON36709, assembled by subcloning the Ncol fragment) was subcloned / BamHI from pMON32163 and the BamHI / HindIII fragment from pMON3d709 in pMON6723 digested with Ncol / HindIII), the Ncoi / Snal insert from pMON32165 (1-139 from Flt3L (39/40) L21) and the SnaBI / HindIII insert (lgG2b / Flt3L, 1-139 (39-40) L21) of pMON32376, in the E. coli production vector pMON6723, which creates pMON32167. The Ncoi / Hindlll insert of pMON32167 was then subcloned into pMON30304 and designated pMON32168.

EXAMPLE 106 A series of trimeric molecules was also constructed, each of which consisted of two portions Flt3L and a single copy of the IL-3 receptor agonist I or the IL-3 receptor agonist II (an IL-3 receptor agonist encoded by pMON13416 (WO 94/12638), referred to herein as "IL-3 receptor agonist II"), from pre-existing molecules, using restriction-digested, gel-purified fragments. PMON36728 was assembled using the Ncol / EcoRI insert (Flt3L / lgG2b / IL-3 receptor agonist I) from pMON3237d and the EcoRI / HindIII insert (IL-3 / lgG2b / FIt3L receptor agonist I) from pMON36708. The two fragments were then religated to the mammalian expression vector pMON3934, treated with Ncol / Hind MI / SAP, and subcloned as previously described. PMON32205 (IL-3 / lgG2B / Flt3 1-139 / lgG2B / Flt3 1-139 receptor agonist II) was ligated by ligating the Ncol / HindIII fragment from pMON32173 at the Afllli / HindIII site of pMON30304. A similar approach was used to construct pMON32206 (IL-3 receptor agonist II / lgG2b / Flt3L (39/40) L21 / lgG2b / Flt3L (39/40) L21). The Ncoi / HindIII fragment from pMON32167 was gelled and subcloned into pMON30304 digested with Afllll / HindIII (containing the II receptor agonist portion IL-3 / IgG2b). Plasmid pMON32207 (Flt3L (39/40) L21 / lgG2b / Flt3L (39/40) L21) / G-FEC was assembled by subcloning the gel-purified Ncol / Hindlll insert from pMON32170, into the intermediate pMON32198 (Afllll / Hindlll) . PMON32208 (Flt3l 1-139 / lgG2b / G-FEC / lgG2b / Flt3L1-139) was joined by subcloning the gel-purified SnaBI insert, from pMON30320 (as lgG2b / G-FEC) into pMON32173 digested with SnaBI / treated with SAP. PMON32204 was joined by subcloning the Ncol / Hindlll insert of pMON32173 into pMON30309 digested with Afllll / Hindlll (containing G-FEC / Flt3L 1-139 (39/40) L21), subcloning the Ncol / Sacl insert of pMON32190 and the Sacl / fragment. Hindlll from pMON32171, in pMON30304 digested with Ncol / HindIII. PMON32196 (G-FEC / lgG2b / Fit3L 1-139 (39/40) L21 / lgG2b / Flt3L 1-139) was assembled by subcloning the Ncol / Afllll fragment, from pMON30309 (as G-FEC / lgG2b) into pMON32168 treated with Ncol / SAP (Flt3L 1-139 (39/40) L21 / lgG2b / flt3L 1-139) and confirming the orientation by DNA sequence and restriction analysis. It was built pMON32197 (G- FEC (lgG2b / Flt3L 1-139 (39/40) L21 / lgG2b / Flt3L 1-139 (39/40) L21), subcloning the Ncol / Hindlll insert of pMON32167 (Flt3L 1-139 (39/40) L21 / lgG2b / Flt3L 1-139 (39/40) L21) in the Afllll / Hindlll site of PMON30309 (G-FEC / lgG2b).

EXAMPLE 108 A series of molecules containing Flt3L were constructed as transients of BHK, replacing the receptor I agonist I L-3 or the IL-3 receptor agonist II, with G-FEC as a chimeric partner. For chimeric proteins transiently expressed and formed using the pMON3934 vector of GHK, the G-FEC portion could encode Ser or Cys at position 17. For molecules used for expression in E. coli or expressed non-transiently in expression systems of mammals, position 17 of the G-FEC participant exclusively encoded Ser. Natural Flt3L and G-FEC chimeras were prepared as BHK expression constructs in both orientations: G-FEC / lgG2b / FIt3L (pMON30329) and Flt3L / lgG2b / G-FEC (pMON32175). PMON30329 was assembled by subcloning the insert Flt3L 1-139 of pMON30238 (as a Ncol / Hindlll digest) into pMON30309 (containing G-FEC / IgG2b), digested with Afllll / Hindlil, while pMON3217d was constructed using the Ncol / SnaBI insert gel purified, from pMON32393 to pMON26420 digested with Ncol / SnaBI (containing the IgG2b / G-FEC gene). A third natural chimeric molecule G-FEC / FIÍ3L, pMON32191, differs from pMON3217d in that it has a GlySer linker in place of the chimeric linker lgG2b and was designed for expression in E. coli. PMON32191 was assembled using the same gel-purified Ncol / SnaBI insert from pMON32393 in pMON31123 digested with Ncol / SnaBI (containing the GlySer / G-FEC gene). The BHK equivalent, pMON3d757, was assembled by subcloning the gel-purified chimeric Ncol / Hindlll gene from pMON32191 into the vector pMON3934 from BHK.

EXAMPLE 109 Two series of Flt3L chimeras of rearranged sequence were constructed, replacing the agonist component I of receptor I L-3 with G-FEC. The first series, with the G-FEC / lgG2B / Flt3L orientation of rearranged sequence, was assembled essentially as follows: pMON30329 (G-FEC / lgG2B (Flt3L 1-139) was digested with SnaBI / HindIII, and purified in The vector containing the G-FEC portion, as described above, was then subcloned into the inserts digested by SnaBI / HindIII from the appropriate IL-3 receptor / Ft3L agonist constructions, shown below in Table 12, pMON30329 (SnaBI / HindIII).

TABLE 12 CONSTRUCTIONS G-FED / lgG2b / Flt3L AND SUA ANALOGUE AGONISTS I RECEIVER IL-3 It was assembled pMON32169 (G-FEC / lgG2b / Flt3L 1-1390 (39/40) L21) using the Ncol / BamHI insert of pMON32163 and the BamHI / HindIII insert of pMON32370 was subcloned into pMON30309 digested with Afllll / Hindlli. Three molecules in this series do not have direct counterparts of IL-3 receptor agonist I. The first, pMON39914 was assembled using the expression vector pMON30309 of BHK (containing G-FEC (lgG2b) digested with Afllll / Hindlll, and the insert Flt3 1-139 (39/40) L29 of pMON32243 (as Ncoi / Hindill) For pMON39915m, the gene Flt3L1-154 (39/40) was subcloned into the parental vector pMON30309. pMON39916 was assembled exactly as for pMON3991d, except that the insert Flt3L 1-160 (39/40) of pMON32252 was used. 32242, 32243 and 32262 are constructions of expression in E. coli, containing the non-chimeric Flt3L gene, of rearranged sequence (as Ncol / Hindlll). Finally, the pMON35799 insert was subcloned into pMONd723 (as the Ncol / Hindlll fragment) for expression in E. coii. This production plasmid in E. coli was designated pMON39904.

EXAMPLE 110 Many of the second series of G-FEC chimeras with the orientation Flt3L / igG2b / G-FEC were also constructed from their IL-3 receptor agonist I analogues, as indicated in Table 13 below.

TABLE 13 CONSTRUCTIONS OF Flt3L / lqG2b / G-FEC and its analogs I of receptor I L-3 These constructs were assembled using pMON36113, digested with Ncol / SnaBl (a BHK vector containing the gene lgG2b / G-FEC) and FIt3L inserts of rearranged sequence, digested with Ncol / SnaBI, specific, of the chimeric proteins Flt3L receptor agonists I / IL-3, shown in the previous table. was designated the resulting plasmids pMON32170, pMON32871, pMON32271, pMON32172, pMON32174, pMON357d1, pMON357d2, pMON35763, pMON35764, pMON3d7dd, pMON3d7d6, pMON3d7d7, pMON3d7d8, pMON367d9, pMON36760, pMON3d761, pMON3d762, pMON3d763, pMON36764, pMON35765, pMON3d766, pMON35767, pMON35768, pMON36770, pMON3d772, pMON35773, pMON36777, pMON35778 pMON35779, pMON35780, pMON3d782 and pMON35908. PMON3d777 and pMON35778 were constructed by PCR and assembled from the same Ncol / Narl and Narl / SnaBI inserts that were described for pMON3677d and pMON3d776, except that pMON3d7d1 digested with Ncol / SnaBI was used as a parental vector containing the IgG2b gene / G-FEC. To construct the 39/40 equivalent break point of pMON3d778, used the C-tip Flt40 / SnaBI sensing pair, and the pMON3d778 template was re-amplified. The amplification conditions were used as previously described for pMON3d771, except that the Tf¡jaCión was decreased from 66 to 5d ° C. The resulting construct pMON3d782 (Flt3 1-160 (39/40) / lgG2b / G-FEC) was designated. PMON32170 () Flt3L 1-139 (39/40) L21 / lgG2B / G-FEC) was assembled using the Ncol / SnaBI insert of pMON32165 linked to pMON26430 digested with Ncol / SnaBI (containing lgG2B / G-FEC). PMON3d764 (Flt3L (38/39) L21 / lgG2b / G-FEC) was cloned), as follows: The Flt3L insert of the rearranged sequence was amplified by PCR, using as template pMON35736 and the sensitizing pair Flt39 / 39Rev. The amplification conditions were identical to those used for pMON35771, except that the initial Tf¡jaClon was decreased from 66 to 66 ° C. The PCR amplification digested with Ncol / SnaBI containing the IgG2b / G-FEC gene was subcloned. PMON35768 (Flt3L (38/39) L21 / igG2b / G-FEC) has a mutation at residue 15 (Ser a Phe) of the chimeric partner Flt3. PMON35762 (Flt3 template pMON35739), pMON35763 (Flt3 template 35738), pMON35758 (Flt3 template 35740), pMON35770 (pMON35743 was constructed as template Flt3L exactly as described for pMON35764.) PMON35772, a mutant S125 to F125 of the gene Flt3, was cloned. of sequence rearranged in pMON35760, by PCR using pMON3571d as the template Flt3, and the sensitizing pairs 6dFor / 6dSnaBI.The conditions of the PCR cycle were identical to those used to amplify the Fit3 genes of pMON3d733, pMON36734, pMON3573d and pMON3d736 previously described. PMON3d761 is a mutant Q133 to R133 of the gene Flt3L of sequence rearranged in pMON3d7d8. PMON35773 (Flt3L 1-139 (38/39) L29 / lgG2B / G-FEC was cloned as previously described for pMON35774, except that pMON26430 (treated with Ncol / SnaBl / SAP), which contained the IgG2b / G- gene, was used. FEC as a parental vector To construct the 39/40 rupture point equivalent, pMON35773 was used as a template in a PCR amplification reaction with the Flt40 / SnaBI sensitizing pair, C-terminal. The amplification was performed exactly as described above for pMON3d771 The amplification product digested with Ncol / SnaBI was subcloned into pMON26430 (treated with Ncol / SnaBl / SAP), which resulted in pMON35779 (Flt3L 1-139 (39/40) L29 / lgG2B (G-FEC). PMON3d780 is a variant of pMON35779 and encodes a single amino acid mutation (L60 to P60) in the chimeric flt3 fragment of rearranged sequence pMON32190 (Flt3L 1-139 (39/40) L21 / GS / G-FEC) contains an alternative GlySer chimeric linker that replaces the lgG2b linker of pMON32170. The Flt3L gene of the Ncol / SnaBI fragment from pMON32165 (agonist I of the receptor Flt3L 1-139 (39/40) L21 / igG2b / IL-3 in the expression vector pMONd723 of E. coli) was subcloned in pMON31123 digested with Ncol / SnaBl . PMON35766 equivalent to the BHK expression was constructed by subcloning the entire Flt3L / GIySer / G-FEC chimeric insert as an Ncol / HindIII fragment into pMON3934.

PMON39908 is similar to pMON3d779, except that residues 133-160 of amino acid Flt3L were replaced by the amino acid sequence VETVFGRVSQDGLDLLTS, SEQ ID NO: 798, which is homologous with an alternative splicing variant of Flt3L (access no. Genbank HSU29874). PMON32190 was used as a PCR template with the following series of sensitizing pairs: Flt40 / XbaRev and SnaBiCterm / XbaFor. The amplification conditions previously described for pMON35771 were carried out, except that the initial Tfijation of 66 to 64 ° C was decreased. Both amplification products were digested by PCR, purified in gei, with Ncol / Xbal (PCR product with Flt40 / XbaRev) or Xbal / SnaBI (PCR product with SnaBICterm / XbaFor) and subcloned in pMON26430 (treated with NcoISnaBI / SAP ). It was built pMON32273 (Flt3L 1-139 (39/40) L21 / lgG2b / G-FEC) by PCR from pMON3d777 with the FltConNco / Grev sensitizing pairs to reamplify the 38/39 Flt3L portion as 39/40. The purified amplicon was digested with Ncol / SnaBI and subcloned into pMON32191 digested with Ncol / SnaBI, and designated pMON32259 (for production in E. coli). For BHK expression, the Ncol / Hindlll insert of pMON32259 was subcloned into pMON3934 (Ncol / Hindlll).

EXAMPLE 103 Another series of chimeric proteins was constructed in which the Flt3L participant contained one or two Cys mutations (XIA and XIB boxes). HE constructed pMON3d790 (Flt3L 1-139 (C4 -> S4, C85 ^ S85) / GS / G-FEC (Ser17)), by PCR using pMON32191 as a template and the sensitizing pairs C1 For / C3Rev and C3For / 139Rev in two reactions . PMON36791 (Flt3L 1-139 (C93? -S93, C132? -S132) / GS / G-FEC (Ser17)) was also constructed by PCR using the template pMON32191 and the sensitizing pairs C5For / C6Rev and C5Rev / N-term as template. The amplification conditions previously described for pMON36771 were carried out, except that the initial Tf¡jac-ón was decreased from 66 to 64 ° C. A second round of PCR was performed using the amplicons (10 ul of each) from the first round, and then the PCR products were purified, digested with Ncol / SnaBI and subcloned into pMON32191 digested with Ncol / SnaBl. The amplification conditions were modified for the second round, as follows: The initial rate was increased to 68 ° C and the number of cycles increased from 6 to 16. No further amplification was necessary. These constructs, pMON36787 (C4 -> S4, C85 -> S85) and pMON36788 (C93 ^ S93, 132 _ ^ gi32 ^ were used for expression in E. coli. BHK, pMON3d790 and 36791 expression equivalents were constructed. , subcloning the correctly mutated Flt3L / GlySer / G-FEC chimeric inserts, as Ncol / HindIII fragments in pMON3934. pMON35792 (Flt3L 1-132 (C132-S132) / GlySer / G-FEC (Ser17)) was constructed by PCR using template pMON32191 and the FLDI Rev / FItNterm sensitizer pair pMON3990d (Flt3L 1-139 (C132 ^ S132) / GlySer / G-FEC (Ser17)) was constructed by PCR using pMON32191 as template and pair FLMI Rev / FItNTerm sensitizer. For its part, pMON39906 (Flt3L 1-139 (C127 -> S127 / C32 - S132) / GlySer / G-FEC (Ser17)) contains a single amino acid substitution at residue 127 of the Flt3L partner of rearranged sequence, a result of an error induced by PCR during the PCR amplification of pMON39905. PMON32276 (Flt3L 1-139 (39/40) L21 (C4 -> S4 / C85 - S85) / GlySer / G-FEC (Ser17)) was constructed by two rounds of PCR. Three initial amplicons were generated: RCP1 (template pMON32190 and sensitizing pairs G10L / 85N); RCP7 (template pMON32190 and sensitizing pairs 4N (7dS); and RCP4 (template pMON32198 and sensitizing pairs 4S / 3605Rev) For the second round, RCP1, 4 and 7 were re-amplified in a combined mixture, resulting in CPR A. PCR A was purified, digested with Ncol / SnaBI and subcloned into pMON30277 (GlySer / G-FEC) The following three constructions were generated in a similar manner: pMON32277 (G-FEC (Ser17) / lgG2B / Flt3L 1 -139 (39/40) L21 (C4 - »S4 / C85 -» S85)) generated by PCR in the first round three initial amplicons: RCP1 (template pMON32190 and sensitizing pairs 4N / 85N); RCP7 (template pMON32190 and sensitizing pairs 4N (85S); and RCP6 (template pMON32169 and sensitizing pairs 4S / 360dRev.) For the second round, RCP1, 6 and 7 were re-amplified in a pooled mixture, resulting in RCP B. RCP B was purified, digested with Ncol / Hindlll and subcloned in pMON30309 digested with Ncol / HindIII (G-FEC (Ser17) / lgG2B) .PMON32278 (Flt3L 1-139 (39/40) L21 (C93 - > S93 / C132? - S132) / GlySer / G-FEC (Ser 17)) generated by CPR at first round three initial amplicons: RCP2 (template pMON32190, and sensitizing pairs G10L / 93N); RCP8 (template pMON32190 and sensitizing pairs 132N / 93S); and RCP3 (template (pMON32198 and sensitizing pairs 132S / 36045Rev) .For the second round, RCP2, 3 and 8 were re-amplified in a pooled mixture, resulting in CPR C. CPR was purified, digested with Ncol / SnaBI and was subcloned into pMON30277 (GlySer / G-FEC). PMON32279 G-FEC (Ser17) / lgG2B / Flt3L 1-139 (39/40) L21 (C93-S93 / C132-S132)) generated by PCR in first round three initial amplicons: RCP2 (template pMON32190 and sensitizing pairs G10L / 93N); RCP8 (template pMON32190 and sensitizing pairs 132N / 93S); and RCPd (template pMON2169 and sensitizing pairs 132S / 3605Rev). For the second round, RCP2, 5 and 8 were re-amplified in a pooled mixture that resulted in RCP D. CPR D was purified, digested with Ncol / Hindlll and subcloned in pMON30309 digested with Ncol / HindIII, (G- FEC (Ser17) / lgG2B).

EXAMPLE 112 PMON39909 (Flt3L 1-139 (39/40) L21 / GS / G-FEC (Ser17) (133/132)) is one of two Flt3 / G-FEC chimeric proteins, in which both proteins have rearrangement of the sequence. The Ncol / Afllll fragment from pMON32198, comprising the gene Flt3L 1-139 (39/40) L21 / GlySer was subcloned in pMON2d187 treated with Ncol / SAP (production plasmid in E. coli containing a single copy of G- FEC (Ser17) (133/132)). After confirming the DNA sequence, the chimeric insert was subcloned into pMON3934 as the Ncol / HindIII fragment and designated pMON39909. PMON39910 (G-FEC (Se) (133/132 / lgG2B / Flt3L 1-139 (39/40) L21) was constructed by PCR using as template pMON25187 and the sensitizing pair GPFor1 / GPRev2.The amplification conditions were identical to the used for pMON39908. G-FEC (Ser17) (133/132) digested with Ncol / SnaBI was subcloned into the Ncol / SnaBI site of pMON32376 containing the gene lgG2B / Flt3L 1-139 (39/40) L21.

EXAMPLE 113 PMON40000 is the production plasmid modified from pCIneo (Promega) containing G-FEC (Ser17) / GlySer / Fit3L 1-139 (39/40) L21 for expression in NSO cells (pMON32169 is the BHK equivalent). PMON40000 contains the promoter / enhancer element CMV IE and the leader sequence IL-3 immediately upstream of FEC (Ser17) / GlySer / Flt3L 1-139 (39/40) L21, the truncated thymidine kinase promoter, the sequence of late SV40 poly A signal and several regions hypersensitive to DNase (part of lgH3 min RCL).

EXAMPLE 114 BIOACTIVITY OF HEMATOPOYETIC RECEPTOR AGONISTS. CHEMICALS MULTIFUNCTIONAL TABLE 14 IN VITRO BiOANALYSIS OF HEMATOPOYETIC, CHEMICAL RECEPTOR AGONISTS. MULTIFUNCTIONAL Legend:: Decreased power (displaced to the right) compared to the control. : Power equivalent to the control (inside the double): Increased power (displaced to the left), compared to the control. 1 Compared to the pMON30247 control 2 Compared to the pMON323d2 control 3 Compared to the appropriate coarse control. 4 Analyzed as a set of clones pMON40000 and pMON40002.

EXAMPLE 115 DETERMINATION OF BIOACTIVITY TABLE 15 EX VIVO BIOANALYSIS OF HEMATOPOYETIC, CHEMICAL RECEPTOR AGONISTS. MULTIFUNCTIONAL 1 Legend: +: Activity decreased, compared to IL-3, IL-6, FCT, G-FEC (control of literature) ++: Activity equivalent to IL-3, IL-6, FCT, G-FEC (control of the literature) (within 20%)). +++: Increased activity compared to IL-3, IL-6, FCT, G-FEC (control of the literature). Culture condition: X-live, medium 10, 37 ° C, 5% CO2. incubation for 11 days. 2 Legend: +: Activity decreased compared to GM-FEC, FNTa, FCT (control of literature) ++: Activity equivalent to GM-FEC, FNTa, FCT (control of literature) (within 20%)).

+++: Increased activity compared to GM-FEC, FNTa, FCT (control of the literature).

Culture condition: IMDM-20 medium, supplemented with 100 ng / ml of GM-FEC. 100 ng / ml TNF, 20 ng / ml FCT, at 37 ° C / 5% CO? for 18-22 days.

MFR agonist I = pMON31140 (WO 95/21197) MFR agonist II = pMON28571 (WO 97/12985).

EX VIVO HEMATOPOYETIC EXPANSION ANALYSIS Human bone marrow-CD34 + enriched progenitor cells were isolated and cultured at 5x104 cells / ml in X-vivo 10 + 1% and HSA, with test cytokines and controls to determine the cytokine expansion potential. The cells were expanded and re-extended to 5 x 10 4 cells / ml with new media and cytokines, around day d, depending on the growth of the cells. The cells were harvested on day 10 and characterized. The cells were harvested from the plates and diluted to a concentration of 1x106 cells / ml. The total cell expansion was determined and the cells were characterized for hematopoietic progenitor cells, by pre- and post-expansion in CFU, in methylcellulose (Stem Cell Technologies, MethocultHCC3534). The expanded cells were also characterized by flow cytometry for determination of lineage-specific phenotype: CD11b (PE) / CD15 (FITC), CD34 (FITC), CD41a (FITC).

EX VIVO EXPANSION ANALYSIS OF DENDRITIC CELLS Progenitor cells enriched in CD34 + from human bone marrow were isolated and cultured at 2 x 10 5 cells / ml in IMDM / 20% FCS with test cytokines and controls to determine the expansion potential. The cells were expanded and re-tended at 5 x 10 4 cells / ml with new media and cytokines around day d, depending on the growth of the cells. On day 18-22 the cells were harvested and characterized. The total expansion of the cells was determined, the expanded cells were characterized by flow cytometry for determination of the lineage-specific phenotype: HLA-DR + (PE) / CD1a + (FITC), CD86 + (PE) / CD1a + (FITC), CD19- (FITC). The dendritic cell expansion times were determined as the total cellular expansion x% of HLA-DR + / CD1a +. The functional activity of the cells was determined using a mixed lymphocyte reaction in one direction. Washed, irradiated, dendritic cells cultured in graded doses were added to the allogeneic responder peripheral blood mononuclear cells in 96 concavity microtiter plates. The ability of the dendritic cells to serve as antigen-presenting cells was determined by the degree of stimulated proliferation in the preparations of responding cells, as measured by 3 H-thyimidine incorporation.

EXAMPLE 116 JOINING A RECEIVER TABLE 16 ANALYSIS OF UNION TO RECEIVER The data are expressed as the mean "SEM of at least three experiments determined by triplicate, except pMON32360, where only two (2) experiments were completed. The affinity of the Flt-3 agonist containing chimeric molecules was evaluated in the analysis of receptor binding.

BIACORE directly immobilizing Flt3-Fc and the Kd value was computed from the determination of the association and dissociation rate constants. Competitive binding assays were used to evaluate the interactions of the chimeric molecules, with the G-FEC receptor transfected in BaF3 cells or the "IL-3 receptor subunit expressed in BHK cells." Competition analysis using these cells employed a radioligand specific for the agonist and Cl50 values were generated for the competing chimeras, using logit-log analysis and dose-response curves.

EXAMPLE 117 IN VIVO BIOACTIVITY TABLE 17 ANALYSIS DATA FOR RECEIVER AGONISTS C47BL / 6 mice were injected subcutaneously with pMON30247, pMON32342 or pMON32360 (150 ug / day) or pMON32191 (200 ug / day) or mouse serum albumin (MSA, acronym by its English name: Mouse Serum Albumin, 200 ug / day) for 10 days. On day 11, bleeding was performed by cardiac puncture. White blood cell counts were obtained. The leukocytes were obtained in peripheral blood, by gradient centrifugation (Histopaque), followed by lysis with ammonium chloride for eliminate the erythrocytes further. The blood cells were stained for flow cytometry, using direct fluorescein or monoclonal antibodies conjugated with phycoerythrin (Pharmingen). Before staining, binding to a non-specific Fc receptor was blocked using FcBIock (Pharmingen). The cells were analyzed in a FacScan flow cytometer (Becton / Dickinson). The percentage of positive cells was determined by integration and the number of phenotypes was calculated based on the white blood cell count. The spleens were removed from the treated animals, aseptically, they were left aside in RPMI medium with needles. A cell suspension was obtained using the flat end of a 5 cc syringe plunger, followed by filtration through a cotton plug to remove lumps. The erythrocytes were removed by lysis with ammonium chloride, the cells were washed, resuspended and counted using a Coulter counter (Coulter Electronics). The cells were prepared for flow cytometry as described above. The phenotype was expressed as the number of cells / spleen, based on the percentage of cells with a positive phenotype and the total white blood cell count of the spleen. Cultures of CFU were obtained by spreading 1.5 x 105 spleen cells / 1 ml in triplicate concavities of methylcellulose, with murine cytokines with / without erythropoietin (Stem Cell Technologies). The cultures were incubated for 10 days at 37 ° C and counted in an inverted microscope. A CFU was defined as a colony of cells with > 50 cells. The increase in CFU / spleen times (total number of CFU / test compound spleen / total number of CFU / MSA control spleen) was determined. MSA control values for blood peripheral were 15 and 347 cells / ul for l-Ab + / CD11c + and l-Ab + / CD8 +, respectively. The MSA control values for the splenic leukocytes were 2 and 1 x 106 cells / spleen for l-Ab + / CD11c + and l-Ab + / CD8 +, respectively. Without further complication, it is believed that whoever is skilled in the art, by using the preceding description, can use the present invention to its fullest extent. Accordingly, it should be considered that the following specific preferred embodiments are merely illustrative and do not limit the remainder of the description absolutely in any way. More details can be found in relation to molecular biology techniques, protein purification and bioanalysis in WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 9d / 212d4 and WO 96/23888, which are incorporated herein by reference , In its whole. All references, patents or applications cited herein are incorporated herein by reference, in their entirety, as if they were written therein. Other various examples will be apparent to the person skilled in the art, after reading the present description, without departing from the spirit and scope of the invention. It is intended that all these other examples be included within the scope of the claims that come at the end.

LIST OF SEQUENCES (1) GENERAL INFORMATION: (i) APPLICANT: G. D. Searle (ii) TITLE OF THE INVENTION: Hematopoietic, chimeric, multifunctional receptor agonists. (iii) NUMBER OF SEQUENCES: 865 (V) ADDRESS FOR CORRESPONDENCE (TO) RECIPIENT: G. D. Searle & Co. (B) STREET: P. O. Box 5110 (C) CITY: Chicago (D) STATE: IL (E) COUNTRY: E. U. A. (F) POSTAL CODE: 60680 (v) FORM THAT CAN BE READ IN COMPUTER: (A) TYPE OF MEDIUM: Flexible disk (B) COMPUTER: Compatible with IBM (C) OPERATING SYSTEM: TWO. (D) Program: FastSEQ for Windows, version 2.0 (vi) DATA OF THIS APPLICATION: (A) APPLICATION NUMBER: (B) DATE OF SUBMISSION: October 22, 1997 (C) CLASSIFICATION: (vii) PREVIOUS APPLICATION DATA: (A) APPLICATION NUMBER: 60 / 029,629 (B) SUBMISSION DATE October 25, 1996 (viii) APPORTER / AGENT INFORMATION: (A) NAME: Bennett , Dennis A. (B) REGISTRATION NUMBER: 34,547 (C) REFERENCE / NO. CASE: C-2994 (ix) TELECOMMUNICATIONS INFORMATION (A) TELEPHONE: 314-737-6986 (B) TELEFAX: 314-737-6972 (C) TELEX: (2) INFORMATION FOR SEQ ID NO: 1: (i) ) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 439 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (x) DESCRIPTION OF THE SEQUENCE SEQ ID NO: 1: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGT 439 (2) INFORMATION FOR SEQ ID NO: 2: fl) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear. (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 2: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG 180 TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 240 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC 300 CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC 360 TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTC 465 (2) INFORMATION FOR SEQ ID NO: 3: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (D) NUMBER OF FILAMENTS: one only (E) TOPOLOGY: linear . (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 3: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360 CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGCG 480 TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 540 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC 600 AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG 660 TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 720 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA 780 CCACAGCTCA CAAGGATCCC 840 AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGG 900 927 (2) INFORMATION FOR SEQ ID NO: 4: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 936 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xii) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 4: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360 CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CATGGCGTCT 480 CCCGCTCCGC CTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CTCCCATGTC 540 CTTCACAGCA GACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TGTCCTGCTG 600 CCTGCTGTGG ACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CAAGGCACAG 660 GACATTCTGG GAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GGGACAACTG 720 GGACCCACTT GCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TCTCCTCCTT 780 GGGGCCCTGC AGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CACAGCTCAC 840 AAGGATCCCA ATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC 900 CTGATGCTTG TAGGAGGGTC CACCCTCTGC GTCAGG 936 (2) INFORMATION FOR SEQ ID NO: 5: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 939 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 5: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360 CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGCG 480 TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC 540 CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC 600 AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG 660 TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 720 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC 780 CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC 840 TGCTCCGAGG AAAGGTGCGT 900 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 939 (2) INFORMATION FOR SEQ ID NO: 6: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 948 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS:, only one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 6: TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC 60 CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC 120 AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG 180 TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 240 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC 300 CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC 360 TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACGGCGGC 480 AACATGGCGT CCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 540 GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 600 CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG 660 ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA 720 CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC 780 CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG 840 ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GCTCCGAGGA 900 AAGGTGCGTT TCCTGATGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG 948 (2) INFORMATION FOR SEQ ID NO: 7: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 688 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 7: CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA 120 CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC 180 AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC 240 CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 300 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC 360 TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TGCTGGACCC 420 GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GACTTCCAAA CTTAGAAAAT 480 GCATCAGGTA CTGTCAAGAA CCTGGAGAGC TTCGTAAGGG 540 TTGAGGCAAT TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT 600 CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CCTTGAGCAA GCGCAGGAAC CTGACGTTCT ATCTGGTTAC 660 688 AACAGTAC (2) INFORMATION FOR SEQ ID NO: 8: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 712 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 8: CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA 120 CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC 180 AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC 240 CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 300 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG 360 CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 420 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 480 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 540 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT 600 GACTGGCAAG AATTCCGGGA 660 AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT AC 712 (2) INFORMATION FOR SEQ ID NO: 9: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 975 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 9: ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 60 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 120 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 180 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG 240 GTGGTGGCTC TAACTGCTCT ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC 300 CTGCACCTTT GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 360 CTACTATCAA CCCGTCTCCT 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840 CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960 CTGCAGCCCT AATAA 975 (2) INFORMATION FOR SEQ ID NO: 10: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 976 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 10: ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT 60 GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC 120 CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT 180 GGCTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 240 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 300 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA ATACGTAGAG 360 GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840 CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960 CTGCAGCCCT AATAA 975 (2) INFORMATION FOR SEQ ID NO: 11: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 975 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 11: ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC 60 AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT 120 TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA 180 TCCTGATGGA CCGAAACCTT 240 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 300 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CTACGTAGAG 360 GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT 720 CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT 780 TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT 840 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG 900 AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA 960 975 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 975 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 12: ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 60 GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT 120 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA 180 GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 240 GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 300 TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GTACGTAGAG 360 GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 660 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT 720 CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT 780 TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT 840 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG 900 AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA 960 975 (2) INFORMATION FOR SEQ ID NO: 13: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 13: ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 120 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 180 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 240 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC 300 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA 360 CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC 540 GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC 600 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 660 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG 720 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT 780 TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA 840 TATCCCCCGA GTTGGGTCCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 (2) INFORMATION FOR SEQ ID NO: 14: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 14: ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 60 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG 120 CGCAGGAACA ACAGGGTGGT 180 AACTGCTCTA TAATGATCGA GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT TGAAATTATA CATCACTTAA AGAGACCACC 240 CTGGACCCGA ACAACCTCAA TGCACCTTTG TGACGAAGAC 300 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CGTAAGGGCT 360 GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 600 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 (2) INFORMATION FOR SEQ ID NO: 15: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 15: ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT 60 GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC 120 CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT 180 GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA 240 CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC 300 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CGTAAGGGCT 360 GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC 480 GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC 540 GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC 600 TCAAGTCTTT AGAGCAAGTG 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960 999 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (2) INFORMATION FOR SEQ ID NO: 16: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 16: ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 60 GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC 120 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC ACCTTTGCTG 180 GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT 240 CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG 300 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT 360 CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC 600 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 660 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG 720 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT 780 TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA 840 TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA 900 CCACCATCTG GCAGCAGATG 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 (2) INFORMATION FOR SEQ ID NO: 17: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 17: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 360 ACAAGCTGTG CCACCCCGAG 420 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 480 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 540 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 600 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 660 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 720 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 780 CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG 840 CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 900 CTGTGTGCCA CCTAATAA 918 (2) INFORMATION FOR SEQ ID NO: 18: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 18: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT 480 GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC 540 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG 600 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 660 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT 720 TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 780 CGTACCGCGT TCTACGCCAC 840 CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG 900 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA 960 TAA 963 (2) INFORMATION FOR SEQ ID NO: 19: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 19: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG 420 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 480 CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT 540 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 600 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC 660 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AGCGCTCCAG 720 GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC 780 TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 840 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 900 GAAGGGATAT CCTAATAA 918 (2) INFORMATION FOR SEQ ID NO: 20: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 20: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG 480 AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT 540 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG 600 AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 660 AGAGCTTCCT GCTCAAGTCT 720 TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 780 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 840 TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 900 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA 960 963 TAA (2) INFORMATION FOR SEQ ID NO: 21: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 21: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CCTGCAGCCC 420 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 480 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 540 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 600 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 660 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 720 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 780 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 840 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 918 900 GAAGAACTGG GATAATAA (2) INFORMATION FOR SEQ ID NO: 22: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 22: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480 CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540 CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 600 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC 660 GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 720 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC 780 CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG 840 GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 900 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA 960 963 TAA (2) INFORMATION FOR SEQ ID NO: 23: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 23: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG GCTTCCTGCT CAAGTCTTTA CGGCTCTGGC 540 GAGCAAGTGA GAAAGATCCA GGCTCTCAGA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT 600 GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA 660 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 720 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA 780 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG 840 AAGAACTGGG AATGGCCCCT 900 GCCCTGCAGC CCTAATAA 918 (2) INFORMATION FOR SEQ ID NO: 24: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 24: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 360 CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC 540 GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 600 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG 660 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 720 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC 780 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 840 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 900 GCCCTGCAGC CCTAATAA 918 (2) INFORMATION FOR SEQ ID NO: 25: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 25: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA 420 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 480 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC 540 TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG 600 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 660 TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG 720 CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG 780 CCGACTTTGC CACCACCATC 840 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 900 CCGGCCTTCG CCTAATAA 918 (2) INFORMATION FOR SEQ ID NO: 26: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 26: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 480 GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG 540 CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 600 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC 660 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC 720 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT 780 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC 840 TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA 900 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA 960 TAA 963 (2) INFORMATION FOR SEQ ID NO: 27: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 27: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CCACCCCGAG 420 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC 480 ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT 540 TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC 600 AGCAGATGGA AGAACTGGGA 660 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 720 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 780 CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG 840 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CTAATAA 927 900 CAGGAGAAGC TGTGTGCCAC (2) INFORMATION FOR SEQ ID NO: 28: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 28: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTTACAAG GTGTGCCACC CCGAGGAGCT GGTGCTGCTC 480 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 540 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 600 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 660 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT 720 TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 780 CGTACCGCGT TCTACGCCAC CTTGCGCAGC 840 GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG CCACACCATT TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG 900 CGCTCCAGGA GAAGCTGTGT 960 972 AA GCCACCTAAT (2) INFORMATION FOR SEQ ID NO: 29: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 29: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG 420 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 480 CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT 540 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 600 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCTG 660 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 720 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 780 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 840 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CTAATAA 927 900 CAGGCCCTGG AAGGGATATC (2) INFORMATION FOR SEQ ID NO: 30: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 30: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 480 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 540 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG 600 AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT 660 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG 720 GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG 780 TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG 840 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC 900 TCCTGCAGGC CCTGGAAGGG 960 ATATCCTAAT AA 972 (2) INFORMATION FOR SEQ ID NO: 31: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 31: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 360 TGGCCCCTGC CCTGCAGCCC 420 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 480 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 540 CAGCCCACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 600 GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 660 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 720 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 780 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 840 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 900 CAGCAGATGG AAGAACTGGG ATAATAA 927 (2) INFORMATION FOR SEQ ID NO: 32: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 32: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG 480 TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC 540 TTGCGCAGCC GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CACACCATTG 600 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 660 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC 720 CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC 780 AACTCCATAG CGGCCTTTTC 840 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 900 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 960 CTGGGATAAT AA 972 (2) INFORMATION FOR SEQ ID NO: 33: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 33: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900 ATGGCCCCTG CCCTGCAGCC CTAATAA 927 (2) INFORMATION FOR SEQ ID NO: 34: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 34: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC 480 AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG 540 GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA 600 TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT 720 GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC 780 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG 840 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 900 TGGGAATGGC CCCTGCCCTG CAGCCCTAAT AA 960 972 (2) INFORMATION FOR SEQ ID NO: 35: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 35: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA 420 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 480 CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG 540 CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG 600 TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG 660 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC 720 TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC 780 TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC 840 CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTAATAA 900 927 (2) INFORMATION FOR SEQ ID NO: 36: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 360 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC 420 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG 480 TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT 540 TCCTGCTCAA GTCTTTAGAG 600 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 660 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 720 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 780 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT 840 TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA 900 CCCAGGGTGC CATGCCGGCC 960 972 AA TTCGCCTAAT (2) INFORMATION FOR SEQ ID NO: 37: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 37: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC 120 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180 GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC 240 ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT 540 CTGGCGGCTC TCAGAGCTTC 600 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 660 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC 720 AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG 780 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC 840 AGCTGGACGT CGCCGACTTT 900 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 960 TAA 963 (2) INFORMATION FOR SEQ ID NO: 38: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 972 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 38: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 60 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA 120 AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC 180 CCCTGGCCAC GGCCGCACCC ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG 240 AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 300 ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540 TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCTAAT AA 972 (2) INFORMATION FOR SEQ ID NO: 39: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 963 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 39: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180 GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240 ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC 480 AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT 540 CTGGCGGCTC TCAGAGCTTC 600 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG 660 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 720 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 780 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 840 GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 900 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 960 963 TAA (2) INFORMATION FOR SEQ ID NO: 40: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 970 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 40: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC 120 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180 GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC 240 GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATGAA TTCCGTCGTA AACTGACCTT 300 CTATCTGAAA ACCTTGGAGA ACGCGCAGGC TCAACAGTAC GTAGAGGGCG GTGGAGGCTC 360 CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC 420 TCATAAATCT CCAAACATGG CTACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA 480 GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 540 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC 600 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 660 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 720 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 780 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 840 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 900 GGAATGGCCC CTGCCCTGCA 960 GCCCTAATAA 970 (2) INFORMATION FOR SEQ ID NO: 41: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 41: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG 480 GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG 540 GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT 600 TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCTG 660 CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 720 AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 780 GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCGGCA ACATGGCGTC TCCCGCTCCG 840 CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CCTTCACAGC 900 AGACTGAGCC AGTGCCCA 918 (2) INFORMATION FOR SEQ ID NO: 42: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 42: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG 480 ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG 540 GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG 600 GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA 660 AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC 720 TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC 780 CCGCTCCGCC TGCTTGTGAC 840 CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG ACTGAGCCAG 900 TGCCCAGAGG TTCACCCT 918 (2) INFORMATION FOR SEQ ID NO: 43: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 43: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480 ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540 GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 600 CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT 660 CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 720 CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC 780 AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CCGAGTCCTC 840 AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT 900 CACCCTTTGC CTACACCT 918 (2) INFORMATION FOR SEQ ID NO: 44: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 44: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 480 TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC 540 TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA 600 CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA 660 GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC 720 TCTGCGTCAG GGAATTCGGC 780 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 840 CGTGACT CCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 900 ACACCTGTCC TGCTGCCT 918 (2) INFORMATION FOR SEQ ID NO: 45: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 45: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC 480 AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG 540 GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC 600 TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC 660 AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG 720 TCAGGGAATT CGGCGGCAAC ATGGCGTCTC 780 TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC CCGCTCCGCC TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG 840 TTCACCCTTT GCCTACACCT 900 GTCCTGCTGC CTGCTGTG 918 (2) FORMATION FOR SEQ ID NO: 46: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 907 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 46: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGT GGAGGCTCCC 360 CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA 420 TAAACTCCAA ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT ACATGGGAGA 480 GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGAGCAGT CTGGGACCCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC 540 CGTCTCCTCC CTTGCTCTCA TTGGGGCCCT TTGGAACCCA GCTTCCTCCA CAGGGCAGGA 600 GCAGGCCTCC CCACAGCTCA CAAGGATCCC 660 AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC ACCCTCTGCG TCAGGGAATT CTGATGCTTG CGGCGGCAAC 720 ATGGCGTCTC TAGGGGGTCC CCGCTCCGCC TCCGAGTCCT CAGTAAACTG CTTCGTGACT 780 TGCTGTGACC CCCATGTCCT TCACAGCAGA 840 CTGACCA GTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT 900 TTAGTTG 907 (2) INFORMATION FOR SEQ ID NO: 47: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 917 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 47: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480 CAGGTCCGTC GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG TCCTCCTTGG 540 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660 GCTTGTGACC TCCGAGTCCT GGCGGCAACA TGGCGTCTCC CGCTCCGCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT 720 GCCCAGAGGT TCACCCTTTG 780 CCTACACCTG TCCTGCTGCC TGCTGTGGAC TTTAGCTTGG GAGAATGGAA AACCCAGATG 840 GAGGAGACCA AGGCACAGGA CATTCTGGGA GCAGTGACCC TTCTGCTGGA GGGAGTGATG 900 GCAGCACGGG GACAACT 917 (2) INFORMATION FOR SEQ ID NO: 48: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 48: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 480 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 540 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GGCGTCTCCC 600 GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CCATGTCCTT 660 CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT 720 GCTGTGGACT TTAGCTTGGG AOAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC 780 ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA 840 CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 900 GCCCTGCAGA GCCTCCTT 918 (2) INFORMATION FOR SEQ ID NO: 49: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 49: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA 480 TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG 540 CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC 600 ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG 660 CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA 720 TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC 780 CCACTTGCCT CTCATCCCTC 840 CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA 900 ACCCAGCTTC CTCCACAG 918 (2) INFORMATION FOR SEQ ID NO: 50: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 60: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 480 CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540 GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 600 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 660 CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 720 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA 780 GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT 840 TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT 900 CCACAGGGCA GGACCACA 918 (2) INFORMATION FOR SEQ ID NO: 51: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 51: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC 480 TCTGCGTCAG GGAATTCGGC 540 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC 600 CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG 660 AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 720 TGCTGGAGGG AGTGATGGCA 780 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 840 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 900 AGGACCACAG CTCACAAG 918 (2) INFORMATION FOR SEQ ID NO: 52: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 52: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG 480 CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACATG 540 GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 600 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 660 CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG 720 GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA 780 CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC 840 CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGG CAGGACCACA 900 GCTCACAAGG ATCCCAAT 918 (2) INFORMATION FOR SEQ ID NO: 53: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 916 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 53: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG 480 TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GACTTTAGCT GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC 540 GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC 600 GTCTCCTCCT TGGGGCCCTG 660 CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 720 AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 780 GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCAACA TGGCGTCTCC CGCTCCGCCT 840 GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCA 900 915 (2) INFORMATION FOR SEQ ID NO: 54: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 64: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG 480 GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC 540 CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC 600 CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 660 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 720 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC 780 ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC 840 CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCT 900 915 (2) INFORMATION FOR SEQ ID NO: 65: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 55: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480 ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540 GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 600 CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT 660 CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 720 CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC 780 AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 840 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCT 900 915 (2) INFORMATION FOR SEQ ID NO: 56: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 56: TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 480 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 540 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 600 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 660 AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 720 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 780 AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 840 GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 90 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 CCTGTCCTGC TGCCT 915 or (2) INFORMATION FOR SEQ ID NO: 57: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 57: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480 CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 540 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA GGCAACATGG CGTCTCCCGC CCCTCTGCGT CAGGGAATTC TCCGCCTGCT TGTGACCTCC 660 GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC 720 CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG 780 AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 840 TGCTGGAGGG AGTGATGGCA GCACGGGGAC 900 915 (2) INFORMATION FOR SEQ ID NO: 58: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 68: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480 CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGC-. TCCTCCACAG 540 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA GGCAACATGG CGTCTCCCGC CCCTCTGCGT CAGGGAATTC TCCGCCTGCT TGTGACCTCC 660 GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC 720 CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG 780 AATsGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 840 TGCTGGAGGG AGTGATGGCA 900 GCACGGGGAC AACTG 915 (2) INFORMATION FOR SEQ ID NO: 69: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 916 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 59: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480 CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 540 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 720 CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 780 ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 840 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 900 GCACGGGGAC AACTG 915 (2) INFORMATION FOR SEQ ID NO: 60: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 60: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC 480 GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG 540 GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC 600 GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA 660 CACCTGTCCT GCTGCCTGCT GTGGACTTTA 720 ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT GCTTGGGAGA CTGGGAGCAG TGACCCTTCT GCTGGAGGGA 780 GTGATGGCAG CACGGGGACA ACTGGGACCC 840 ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC 900 CTGCAGAGCC TCCTT 915 (2) INFORMATION FOR SEQ ID NO: 61: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 61: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG 480 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC 540 CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA 600 GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA 660 GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA 720 TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG 780 CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG 840 GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGGCCC TGCAGAGCCT CCTTGGAACC 900 CAGCTTCCTC CACAG 915 (2) INFORMATION FOR SEQ ID NO: 62: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 62: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCACAAGGAT TCTTCCTGAG CTTCCAACAC 480 CTGCTCCGAG CCCAATGCCA GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540 GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTCAGTAAA 600 CCTGCTTGTG ACCTCCGAGT CTGCTTCGTG ACTCCCATGT CCTTCACAGC GGTTCACCCT 660 TTGCCTACAC AGACTGAGCC AGTGCCCAGA CTGTCCTGCT GCCTGCTGTG TGGGAGAATG GAAAACCCAG 720 ATGGAGGAGA GACTTTAGCT CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG 780 ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT 840 GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GCTTCCTCCA 900 CAGGGCAGGA CCACA 915 (2) INFORMATION FOR SEQ ID NO: 63: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 63: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540 AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 600 GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 660 CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG 720 ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA 780 CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC 840 CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG 900 ACCACAGCTC ACAAG 915 (2) INFORMATION FOR SEQ ID NO: 64: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 64: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA 480 GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA 540 AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC 600 CTTTGCCTAC ACCTGTCCTG 660 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 720 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 780 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 840 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAAT 900 915 (2) INFORMATION FOR SEQ ID NO: 65: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 65:CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 GACTTCCAAA CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA 180 TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG 240 CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT 300 TGGTTACCCT TGAGCAAGCG CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG 360 TAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 420 TCTCCAAACA TGGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT 480 AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA 540 GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC 600 TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC 660 CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC 720 ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA 780 GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGCG 840 CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC 921 900 AGCAGACTGA GCCAGTGCCC (2) INFORMATION FOR SEQ ID NO: 66: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 66: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG 480 GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC 540 CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC 600 CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 660 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 720 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC 780 ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AGCGCCGCCT 840 GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA TCACCCT 927 900 CTGAGCCAGT GCCCAGAGGT (2) INFORMATION FOR SEQ ID NO: 67: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 67: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCsGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480 ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540 GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA 600 GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG 660 CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG_720_GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG 780 CGCCGCCTGC TTGTGACCTC 840 CGAGTCCTCA GCGTCCCCAG GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCT 900 927 (2) INFORMATION FOR SEQ ID NO: 68: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 68: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 480 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 540 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA 600 CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA 660 GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC 720 TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC 780 CCGCCTGCTT GTGACCTCCG AGTCCTCAGT GTCCCCAGCG AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA 840 GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCT 900 927 (2) INFORMATION FOR SEQ ID NO: 69: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 69: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC 480 AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC 540 AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC 600 TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC 660 AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG 720 TCAGGGAATT CGGCGGCAAC GGCGGCAACA 780 GCTTGTGACC TCCGAGTCCT CAGTAAACTG TGGCGTCCCC AGCGCCGCCT CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT 840 GCCCAGAGGT TCACCCTTTG 900 CCTACACCTG TCCTGCTGCC TGCTGTG 927 (2) INFORMATION FOR SEQ ID NO: 70: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 70: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC 480 ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA 540 CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 600 GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 660 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 720 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG 780 GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 840 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 900 CTGCTGCCTG CTGTGGACTT TAGCTTG 927 (2) INFORMATION FOR SEQ ID NO: 71: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 71: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA GGCCCTGCAG AGCCTCCTTG 480 CAGGTCCGTC GAACCCAGCT TCCTCCACAG TCCTCCTTGG 540 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660 GGCGGCAACG CTTGTGACCT CCGAGTCCTC GCGGCAACAT GGCGTCCCCA GCGCCGCCTG 720 AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT 780 CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 840 ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 900 GGAGTGATGG CAGCACGGGG ACAACTG 927 (2) INFORMATION FOR SEQ ID NO: 72: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 72: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 120 ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA GCTGTCAAGA- TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 480 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 540 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG 600 GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 660 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 720 CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG 780 GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA 840 CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC 900 CTCCTTGGGG CCCTGCAGAG CCTCCTT 927 (2) INFORMATION FOR SEQ ID NO: 73: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 73: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA 480 TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG 540 CGTCCCCAGC TGTGACCTCC GAGTCCTCAG TAAACTGCTT GCCGCCTGCT 600 CGTGACTCCC ATGTCCTTCA CAGCAGACTG 660 AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT 720 AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA 780 GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC 840 TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC TCCACAG 927 900 CTCCTTGGAA CCCAGCTTCC (2) INFORMATION FOR SEQ ID NO: 74: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 74: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 480 CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540 GAATTCGGCG GCAACGGCGG CAACATGGCG TCCCCAGCGC CGCCTGCTTG TGACCTCCGA 600 GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA 660 GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA 720 TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG 780 CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG 840 GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC GACCACA 927 900 CAGCTTCCTC CACAGGGCAG (2) INFORMATION FOR SEQ ID NO: 75: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 75: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TsGCAAGAAT TCCGGOAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540 GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTOACCTCCG AGTCCTCAGT 600 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 660 CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 720 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA 780 GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT 840 TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT TCACAAG 927 900 CCACAGGGCA GGACCACAGC (2) INFORMATION FOR SEQ ID NO: 76: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 76: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTOAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG 480 CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGGC 540 GGCAACATGG TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTCCCCAGC GCCGCCTGCT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC 600 CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG 660 AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 720 TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC 780 TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA 840 CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAAT 900 927 (2) INFORMATION FOR SEQ ID NO: 77: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 906 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 77: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC 600 CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG 660 AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC 720 TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC 780 TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA 840 CCCAGGGCAG CACAAG GACCACAGCT 900 906 (2) INFORMATION FOR SEQ ID NO: 78: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 78: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 480 GGACACTCTC TGGGCATCCC 'CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC 540 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG 600 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 660 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT 720 TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 780 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGGCGGCGG CTCTGACATG 840 GCTACACCAT TAGGCCCTGC CAGCTCCCTG 900 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA 960 GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 79: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 79: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTOAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 480 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 540 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 600 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 660 CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTAGG CCCTGCCAGC 720 TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT 780 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG 840 GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 900 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 960 CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 80: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 80: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG 480 TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GGCTACACCA TTAGGCCCTG 540 CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG 600 GCGATGGCGC AGCGCTCCAG 660 GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA 720 GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC 780 AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC 840 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA 900 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA 960 TAA 993 (2) INFORMATION FOR SEQ ID NO: 81: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 81: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480 CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540 CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC 600 CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT TCTGACATGG CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG 660 CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC 720 TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC 780 AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC 840 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG 900 TCGCCGACTT. TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 82: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 82: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 60 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 120 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC 180 CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG 240 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 300 ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 360 CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540 TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA 600 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG 660 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC 720 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 780 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 840 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 900 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 960 CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 83: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1027 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 83: ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 60 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG 480 CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC 540 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC 600 TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG 660 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 720 TGGCAGGCTG CTTGAGCCAA 780 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC 840 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC 900 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TCCTGGTTGC 960 TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTGATAA 1020 1027 (2) INFORMATION FOR SEQ ID NO: 84: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 459 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 84: TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 240 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC 300 CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC 360 TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 459 (2) INFORMATION FOR SEQ ID NO: 85: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 447 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 85: TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 240 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA 300 CCACAGCTCA CAAGGATCCC 360 AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGG 420 447 (2) INFORMATION FOR SEQ ID NO: 86: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 459 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 86: TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT 240 CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC 300 CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC 360 TGCTCCGAGG AAAGGTGCGT 420 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 459 (2) INFORMATION FOR SEQ ID NO: 87: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 464 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 87: CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG 60 CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA 120 ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT 180 CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA 240 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA 300 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA 360 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 420 ATGTAAGGTA CCGCATGCAA GCTT 464 (2) INFORMATION FOR SEQ ID NO: 88: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 419 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 88: CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG 60 CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA 120 ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT 180 CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA 240 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA 300 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGGTGGTTCT 360 GGCGGCGGCT CCAACATGTA AGGTACCGCA TGCAAGCTT 419 (2) INFORMATION FOR SEQ ID NO: 89: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 89: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC 120 GCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG TCTGCGGGGC CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCCENTOAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 405 (2) INFORMATION FOR SEQ ID NO: 90: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 420 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 90: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG (2) INFORMATION FOR SEQ ID NO: 91: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 366 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 91: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC 240 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC CTTTCAGGAG TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC 300 AGTGTCAGCC CGACTCCTCA 360 ACCCTG 366 (2) INFORMATION FOR SEQ ID NO: 92: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 92: CCAACACAGC CCCATCTCCT CCGACTTCGC GGAACTCAGG ATTGTTCTTT TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC 360 AGCCC 405 (2) INFORMATION FOR SEQ ID NO: 93: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 420 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 93: CCAACACAGC CCCATCTCCT CCGACTTCGC GGTACCCAGG ATTGTTCTTT TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC 360 AGCCCGACTC CTCAACCCTG 420 (2) INFORMATION FOR SEQ ID NO: 94: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 94: GCCACTCAGG ACTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC 360 AGCCC 405 (2) INFORMATION FOR SEQ ID NO: 95: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 420 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 95: TCAACACAGC CCCATCTCCT CCGACTTCGC GCCACTCAGG ACTGCTCTTT TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC 360 AGCCCGACTC CTCAACCCTG 420 (2) INFORMATION FOR SEQ ID NO: 96: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 96: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465 (2) INFORMATION FOR SEQ ID NO: 97: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 97: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCAGGCG GTAACGGCAG TGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC 360 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 450 (2) INFORMATION FOR SEQ ID NO: 98: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 435 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 98: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGCG GCAACGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 360 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 420 GCCTCCAACC TGCAG 435 (2) INFORMATION FOR SEQ ID NO: 99: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 99: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA 240 TCCGGTGGCA ATGGGAGCGG CGGAAATGGA ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGG 465 (2) INFORMATION FOR SEQ ID NO: 100: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 100: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA 240 TCCGGAGGTA ATGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 300 sCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 360 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 420 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 450 (2) INFORMATION FOR SEQ ID NO: 101: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 435 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 101: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG CGGCAACGGC 240 ACGCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 300 GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 360 GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC 420 AAGACTGTCG CTGGG 435 (2) INFORMATION FOR SEQ ID NO: 102: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 102: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGCAG TGGTGGCAAT 180 GGGAGCGGTG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC 465 (2) INFORMATION FOR SEQ ID NO: 103: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 103: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCAGGCG GTAACGGCAG TGGAGGTAAT 180 GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 240 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 300 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 360 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 420 CACTTTGTCA CCAAATGTGC CTTTCAGCCC 450 (2) INFORMATION FOR SEQ ID NO: 104: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 435 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 104: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC 180 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 240 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 300 GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 360 GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 420 TGTGCCTTTC AGCCC 435 (2) INFORMATION FOR SEQ ID NO: 105: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 451 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 105: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGAG GTAGTGGATC CGGAGGTTCT GGCAACCCAG GACTGCTCCT TCCAACACAG 360 CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA 420 TTACCCAGTC ACCGTGGCCT CCAACCTGCA G 451 (2) INFORMATION FOR SEQ ID NO: 106: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 106: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGAG GTAGTGGATC CGGTGGCAGT GGGAGCGGCO GATCTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465 (2) INFORMATION FOR SEQ ID NO: 107: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 437 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 107: CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180 AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC • GTGAACACGG 240 AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300 AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360 GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420 CCCTGGGCGG TGGATCC 437 (2) INFORMATION FOR SEQ ID NO: 108: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 436 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 108: GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 60 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 120 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 180 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 240 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 300 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 360 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 420 TCAACCCTGT AAGCTT 436 (2) INFORMATION FOR SEQ ID NO: 109: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 449 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 109: CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180 AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240 AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300 AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360 GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420 CCCTGGGCGG TGGGTCAGGA GGTGGATCC 449 (2) INFORMATION FOR SEQ ID NO: 110: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 439 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 110: GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 60 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 120 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 180 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 240 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 300 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 360 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 420 TCCTCAACCC TGTAAGCTT 439 (2) INFORMATION FOR SEQ ID NO: 111: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 461 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 111: CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180 AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240 AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300 AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360 GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420 CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC C 461 (2) INFORMATION FOR SEQ ID NO: 112: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 457 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 112: GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 60 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 120 TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 180 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 240 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 300 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 360 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 420 CTGCAGTGTC AGCCCGACTC CTCAACCCTG TAAGCTT 457 (2) INFORMATION FOR SEQ ID NO: 113: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 438 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 113: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 360 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 420 GTGGCCTCCA ACCTGCAG 438 (2) INFORMATION FOR SEQ ID NO: 114: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 441 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 114: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GATCCGGAGG TGGCACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 360 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 420 ACCGTGGCCT CCAACCTGCA G 441 (2) INFORMATION FOR SEQ ID NO: 115: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C). NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 115: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 360 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 450 (2) INFORMATION FOR SEQ ID NO: 116: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 469 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 116: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 360 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 420 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG 459 (2) INFORMATION FOR SEQ ID NO: 117: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 117: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG 300 GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 360 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 420 TGCAG 465 (2) INFORMATION FOR SEQ ID NO: 118: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 483 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 118: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGCCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAG 483 (2) INFORMATION FOR SEQ ID NO: 119: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 119: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 480 TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 540 TCTGGCGGCT GGTCCTGGCA 600 CAGCGCTGGA TGCGGGGCGC TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT 660 TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG 720 AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT 780 GCCTGGAGCT GCAGTGTCAG 840 CCC 343 (2) INFORMATION FOR SEQ ID NO: 120: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 858 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 120: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 480 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGCGC TCTGGCGGCT GGTCCTGGCA 600 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720 CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840 CCCGACTCCT CAACCCTG 858 (2) INFORMATION FOR SEQ ID NO: 121: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 121: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT 720 GTCAGGCGGT CACCCAGGAC 780 TGCTCCTTCC AACGGCAGTG GAGGTAATGG AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG (2) INFORMATION FOR SEQ ID NO: 122: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 122: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGATCCG GTGGCAATGG GAGCGGCGGA 780 AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 123: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 873 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 123: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 480 GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT .CCCCCCCCCA CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC 660 TCCTTCCAAC ACAGCCCCAT CTGTCTGGCG GCAACGGCAC GCAGGACTGC CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC 720 AAGATTACCC AGTCACCGTG 780 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCCCT GGCGGCTGGT CCTGGCACAG 840 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG 873 (2) INFORMATION FOR SEQ ID NO: 124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 124: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGTCTGGAG GTAACGGATC CGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC 720 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780 TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG 888 (2) INFORMATION FOR SEQ ID NO: 125: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 125: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 480 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 540 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC 660 GGGAGCGGCG GAAATGGAAC CCAGGACTGC CGGTGGCAAT TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 720 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 780 TGCAGGACGA GGAGCTCTGC 840 GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 900 GGG 903 (2) INFORMATION FOR SEQ ID NO: 126: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 873 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 126: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGCGGC 600 AACGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720 CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840 ATACACTTTG TCACCAAATG TGCCTTTCAG CCC 873 (2) INFORMATION FOR SEQ ID NO: 127: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 127: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA 480 AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT 540 CCTCAACCCT GTCAGGCGGT CACCCAGGAC TGCTCCTTCC 600 AACGGCAGTG AACACAGCCC CATCTCCTCC GAGGTAATGG GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 660 TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC 720 TCTGGCGGCT GGTCCTGGCA 780 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 888 (2) INFORMATION FOR SEQ ID NO: 128: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT 600 AACGGCAGTG GTGGTAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC 660 AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 720 GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG 780 CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900 CCC 903 (2) INFORMATION FOR SEQ ID NO: 129: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 129: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC AACACAGCCC CATCTCCTCC CAAACATGGC GACTCAGGAC TGTTCTTTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 480 TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC 540 TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA 600 AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT 660 TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG 720 AGACCTCCGA GCAGCTGGTG 780 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840 CCC 843 (2) INFORMATION FOR SEQ ID NO: 130: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 858 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 130: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC AACCCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 480 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 600 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720 CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840 CCCGACTCCT CAACCCTG 858 (2) INFORMATION FOR SEQ ID NO: 131: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 131: GCCACTCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCTACGT AGAGGGCGGT 420 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA 480 TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA 540 ACAACCTCAA TTCTGAAGAC 600 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 660 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 720 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 780 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 840 CAG 843 (2) INFORMATION FOR SEQ ID NO: 132: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 132: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC 780 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888 (2) INFORMATION FOR SEQ ID NO: 133: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 133: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG CCAACATGGC GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT 720 GTCAGGCGGT CACCCAGGAC 780 TGCTCCTTCC AACGGCAGTG GAGGTAATGG AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888 (2) INFORMATION FOR SEQ ID NO: 134: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 873 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 134: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGTCTGGCG GCAACGGCAC GCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 720 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 780 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 840 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG 873 (2) INFORMATION FOR SEQ ID NO: 135: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 136: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 480 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 540 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC 660 GGCACCCAGG ACTGCTCCTT CCAACACAGC CGGAGGTAAT CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT 720 CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC 780 TCTGCGGGGG CCTCTGGCGG 840 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG 888 (2) INFORMATION FOR SEQ ID NO: 136: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 136: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC 720 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 780 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 840 GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 900 GGG 903 (2) INFORMATION FOR SEQ ID NO: 137: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 873 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 137: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA 480 AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT 540 CCTCAACCCT AGGACTGCTC CTTCCAACAC GTCTGGCGGC 600 AGCCCCATCT CCTCCGACTT AACGGCACGC CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG 660 TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC 720 TGGCACAGCG CTGGATGGAG 780 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840 ATACACTTTG TCACCAAATG TGCCTTTCAG CCC 873 (2) INFORMATION FOR SEQ ID NO: 138: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 138: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT 600 AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 888 (2) INFORMATION FOR SEQ ID NO: 139: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 139: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA 480 AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT 540 CCTCAACCCT GTCTGGAGGT 600 AACGGCAGTG AGGACTGCTC CTTCCAACAC GTGGCAATGG GAGCGGCGGA AATGGAACCC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC 660 TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG 720 AGCTCTGCGG GGGCCTCTGG 780 CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900 CCC 903 (2) INFORMATION FOR SEQ ID NO: 140: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 140: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GTCTGGAGGT AGTGGATCCG GAGGTTCTGG CACCCAGGAC 780 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888 (2) INFORMATION FOR SEQ ID NO: 141: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 141: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT 720 AGTGGATCCG GTGGCAGTGG GAGCGGCGGA 780 TCTGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 142: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 858 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 142: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTAACTG CTCTATAATG 540 ATCGATGAAA TTATACATCA CTTAAAGAGA CCACCTAACC CTTTGCTGGA CCCGAACAAC 600 CTCAATTCTG AAGACATGGA TATCCTGATG GAACGAAACC TTCGAACTCC AAACCTGCTC 660 GCATTCGTAA GGGCTGTCAA GCACTTAGAA AATGCATCAG GTATTGAGGC AATTCTTCGT 720 AATCTCCAAC CATGTCTGCC CTCTGCCACG GCCGCACCCT CTCGACATCC AATCATCATC 780 AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA AAACTGACGT TCTATCTGGT TACCCTTGAG 840 CAAGCGCAGG AACAACAG 858 (2) INFORMATION FOR SEQ ID NO: 143: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 143: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 720 CCCAGGACTG CTCCTTCCAA 780 TCCGGAGGTA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 840 CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAG 876 (2) INFORMATION FOR SEQ ID NO: 144: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 144: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC 780 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 840 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG 879 (2) INFORMATION FOR SEQ ID NO: 145: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 145: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG 720 GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG 780 TCAAAATCCG TGAGCTGTCT 840 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888 (2) INFORMATION FOR SEQ ID NO: 146: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 146: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT 780 ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCOT 840 GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAG 897 (2) INFORMATION FOR SEQ ID NO: 147: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 147: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT 480 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG 720 GGTCAGGAGG TGGATCCGGA 780 AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT GGTGGCACCC CGCTGTCAAA 840 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 148: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 148: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720 CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 780 GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 900 ACCGTGGCCT CCAACCTGCA G 921 (2) INFORMATION FOR SEQ ID NO: 149: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 149: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 720 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 780 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 840 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGG 876 (2) INFORMATION FOR SEQ ID NO: 150: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 150: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 480 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 540 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GATCCGGAGG TGGCACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 720 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 780 ACCGTGGCCT CCAACCTGCA GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 840 879 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGG (2) INFORMATION FOR SEQ ID NO: 151: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 151: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 720 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780 TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 840 888 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG (2) INFORMATION FOR SEQ ID NO: 152: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 152: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 480 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 540 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 720 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840 CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGG 897 (2) INFORMATION FOR SEQ ID NO: 153: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 163: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC 720 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 780 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 840 GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG 900 903 (2) INFORMATION FOR SEQ ID NO: 164: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 164: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 480 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 540 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 600 GTCAGCCCGA CTCCTCAACC 660 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 720 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 780 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 840 CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG 900 G 921 (2) INFORMATION FOR SEQ ID NO: 165: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 155: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 600 TCCGGAGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 660 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720 CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840 876 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCC (2) INFORMATION FOR SEQ ID NO: 156: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 156: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 600 TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 660 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 720 AACCTGCAGG ATGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 780 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 840 879 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCC (2) INFORMATION FOR SEQ ID NO: 157: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 167: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG 600 TCAGGAGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA 840 888 CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC (2) INFORMATION FOR SEQ ID NO: 158: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 158: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA 480 AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT 540 CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT 600 GCTCCTTCCA ACACAGCCCC 660 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCC 897 (2) INFORMATION FOR SEQ ID NO: 159: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 159: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGO 600 TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCACCC AGGACTGCTC CTTCCAACAC 660 AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 720 GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG 780 CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900 903 CCC (2) INFORMATION FOR SEQ ID NO: 160: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 160: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA 480 AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT 540 CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCTCAG 600 GGGGAGGTAG TGGTACCCAG 660 GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT 720 CCAACCTGCA GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT 780 GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA 840 ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC C 900 921 (2) INFORMATION FOR SEQ ID NO: 161: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 161: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG 840 888 CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA (2) INFORMATION FOR SEQ ID NO: 162: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 162: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 840 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAA 900 903 (2) INFORMATION FOR SEQ ID NO: 163: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 163: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 780 GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC 840 888 TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG (2) INFORMATION FOR SEQ ID NO: 164: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 164: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAAGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA 480 AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT 540 TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA 600 TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 780 GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 840 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA GTG CCCAGTCACC 900 903 (2) INFORMATION FOR SEQ ID NO: 165: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 165: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 720 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC 840 888 TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACT (2) INFORMATION FOR SEQ ID NO: 166: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 166: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC 480 CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT 540 CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG 600 AGCTGCAGTG TCAGCCCGAC 660 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCACC 720 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 780 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 840 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 900 ACT 903 (2) INFORMATION FOR SEQ ID NO: 167: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 167: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 600 GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720 CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG 840 888 TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT (2) INFORMATION FOR SEQ ID NO: 168: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 168: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 480 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 540 GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC 600 AACACAGCCC CATCTCCTCC 660 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTT 900 903 • (2) INFORMATION FOR SEQ ID NO: 169: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 169: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG 600 GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660 TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780 GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840 ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 888 (2) INFORMATION FOR SEQ ID NO: 170: (i) CHARACTERISTICS SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 170: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT 480 CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG 540 GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA 600 TCTCCTCCGA CTTCGCTGTC 660 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720 CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 900 903 CAG (2) INFORMATION FOR SEQ ID NO: 171: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 171: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 840 876 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAA (2) INFORMATION FOR SEQ ID NO: 172: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 172: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TOCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGATCCGGAG GTGGCACCCA GGACTGCTCC TTC.CAACACA GCCCCATCTC CTCCGACTTC 840 879 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAA (2) INFORMATION FOR SEQ ID NO: 173: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 173: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 840 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAA 897 (2) INFORMATION FOR SEQ ID NO: 174: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF STRANDS: one (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 840 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 921 900 CTGTCTGACT ACCTGCTTCA (2) INFORMATION FOR SEQ ID NO: 175: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 869 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 175: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACTGCT 780 CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT 840 ACCTGCTTCA AGATTACCCA GTCACCGTG 869 (2) INFORMATION FOR SEQ ID NO: 176: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 872 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 176: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCACT 780 GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG 840 ACTACCTGCT TCAAGATTAC CCAGTCACCG TG 872 (2) INFORMATION FOR SEQ ID NO: 177: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 890 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 177: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA 780 GGGGGAGGTA GTGGTACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 840 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 890 (2) INFORMATION FOR SEQ ID NO: 178: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 917 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 178: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG CTGCAGOACG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT 540 TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA 600 TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 660 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 720 GTGGGTCAGG AGGTGGGTCA 780 GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA GGACTGCTCC TTCCAACACA 840 GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG 900 ATTACCCAGT CACCGTG 917 (2) INFORMATION FOR SEQ ID NO: 179: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 179: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660 TCCTCAACCC TGGGCGGTGG ATCCGGAGGT ACCCAGGACT GCTCCÍTTCCA ACACAGCCCC 720 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 780 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGGCCT CTGGCGGCTG 840 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACT 876 (2) INFORMATION FOR SEQ ID NO: 180: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 180: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC 480 CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT 540 CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG 600 AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCACCCAGG 660 ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT 720 CTGACTACCT GCTTCAAGAT 780 TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACT 879 (2) INFORMATION FOR SEQ ID NO: 181: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 181: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 AACACGGAGA TACACTTTOT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660 TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCTCAGGGG GAGGTAGTGG TACCCAGGAC 720 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 780 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 840 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACT 897 (2) INFORMATION FOR SEQ ID NO: 182: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 182: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT 540 CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG 600 AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG 660 GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA 720 GCCCCATCTC CTCCGACTTC 780 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 840 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 900 TGGATGGAGC GGCTCAAGAC T 921 (2) INFORMATION FOR SEQ ID NO: 183: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 183: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACCCAG 600 GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660 TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780 GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840 ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTT 876 (2) INFORMATION FOR SEQ ID NO: 184: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE : nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 184: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 480 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 540 GTGGATCCGG CAGGACTGCT CCTTCCAACA CAGCCCCATC AGGTGGCACC 600 TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG 660 CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC 720 GCTGGATGGA GCGGCTCAAG 780 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 840 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTT 879 (2) INFORMATION FOR SEQ ID NO: 185: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 185: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA 600 GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 660 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 720 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 780 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 840 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTT 897 (2) INFORMATION FOR SEQ ID NO: 186: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 186: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 480 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 540 GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA 600 CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG 660 AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG 720 AGGAGCTCTG CGGGGGCCTC 780 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 840 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 900 CAGCCCCCCC CCAGCTGTCT T 921 (2) INFORMATION FOR SEQ ID NO: 187: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 187: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 600 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 660 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 720 CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC 780 AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC 840 TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAG 876 (2) INFORMATION FOR SEQ ID NO: 188: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCACCCA GGACTGCTCC 600 TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC 660 CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG 720 GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 780 TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT 840 GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAG 879 (2) INFORMATION FOR SEQ ID NO: 189: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 897 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 189: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 600 GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 660 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 720 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 780 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 840 CACTTTGTCA CCAAATGTGC CTTTCAGCCCENTOAGCT GTCTTCGCTT CGTCCAG 897 (2) INFORMATION FOR SEQ ID NO: 190: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 190: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAsAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT 480 CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG 540 GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT 600 CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT 660 ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG 720 GGGGCCTCTG GCGGCTGGTC 780 CTGGCACAGC GCTGGATGOA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 840 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 900 AGCTGTCTTC GCTTCGTCCA G 921 (2) INFORMATION FOR SEQ ID NO: 191: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2247 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 191: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600 GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 660 TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 720 GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC 780 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 840 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 900 AGCTGTCTTC GCTTCGTCCA G 921 (2) INFORMATION FOR SEQ ID NO: 192: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 192: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC 600 ACCCAGGACT GCTCCTTCCA ACACAGCCCC 660 AAACATGGCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900 CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020 CAGTGTCAGC CCGACTCCTC AACCCTG 1047 (2) INFORMATION FOR SEQ ID NO: 193: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 942 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 193: GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACCC? GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA 540 TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC 600 AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC 660 GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA 720 TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA 780 CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA 840 TCACTCGCCA GAACTTCTCC 900 CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TG 942 (2) INFORMATION FOR SEQ ID NO: 194: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 194: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG GCCATGGATC 360 CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTAGGCCCT 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTGCTTAG AGCAAGTGAG GAAGATCCAG 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 960 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 1020 CGCGTTTTAC GCCACCTTGC GCAGCCC 1047 (2) INFORMATION FOR SEQ ID NO: 195: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1569 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 195: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC 600 AAACATGGCC ACTCAGGACT GCTCTTTTCA ACACAGCCCC 660 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900 CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020 CAGTGTCAGC CCGACTCCTC AACCCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 1080 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 1140 CCAAACATGG CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT CTACCCAGGA GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT 1200 ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC 1260 TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG 1320 GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC 1380 CCCCCAGCTG TCTTCGCTTC 1440 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 150 0 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 1560 TCAACCCTG 1569 (2) INFORMATION FOR SEQ ID NO: 196: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1380 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 196: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA 120 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT 180 CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACTCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 480 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 600 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720 CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840 CCCGACTCCT CAACCCTGTA CGTAGAGGGC GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT 900 CCAATCTCTA CTATCAACCC GTCTCCTCCG TCTAAAGAAT CTCATAAATC TCCAAACATG 960 GCTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 1020 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1080 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 1140 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 1200 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 1260 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 1320 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 1380 (2) INFORMATION FOR SEQ ID NO: 197: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1569 base pairs ( B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 197: TCAACACAGC CCCATCTCCT CCGACTTCGC GCCACTCAGG ACTGCTCTTT TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTGGGCCCT 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 960 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 1020 CGCGTTCTAC GCCACCTTGC GCAGCCCTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 1080 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 1140 CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 1200 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 1260 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 1320 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 1380 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 1440 GTCCAGACCA ACATCTCCCO CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 1500 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 1560 TCAACCCTG 1569 (2) INFORMATION FOR SEQ ID NO: 198: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1003 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 198: GGCCACTCAG GACTGCTCTT TTCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT 60 CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA 120 GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG 180 GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT 240 ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC 300 CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT 360 CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT 420 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGGC 480 TACACCATTG GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG 540 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 600 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 660 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 720 GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 780 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC 840 CAGGGTGCCA TGCCGGCCTT 900 CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 960 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCG 1003 (2) INFORMATION FOR SEQ ID NO: 199: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 199: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780 GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA 888 (2) INFORMATION FOR SEQ ID NO: 200: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 200: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC 480 GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG 540 TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC 600 GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC 660 TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG 720 ACTCCTCAAC CCTGGGCGGT 780 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 840 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 900 CAA 903 (2) INFORMATION FOR SEQ ID NO: 201: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 201: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 780 GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG 888 (2) INFORMATION FOR SEQ ID NO: 202: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 202: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAAGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA 480 AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT 540 TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA 600 TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 660 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 720 GTGGGTCAGG AGGTGGGTCA 780 GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 840 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 900 GTG 903 (2) INFORMATION FOR SEQ ID NO: 203: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 203: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 720 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840 CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACT 888 (2) INFORMATION FOR SEQ ID NO: 204: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 204: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC 480 CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT 540 CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG 600 AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG 660 GTGGATCCGG CAGGACTGCT CCTTCCAACA CAGCCCCATC AGGTGGCACC 720 TCCTCCGACT TCGCTGTCAA AATCCGTGAG 780 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 840 GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 900 ACT 903 (2) INFORMATION FOR SEQ ID NO: 206: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: acid nucleic (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 20d: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 600 GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720 CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT 888 (2) INFORMATION FOR SEQ ID NO: 206: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 206: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 480 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 540 GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC 600 AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 660 TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC 720 TCTGGCGGCT GGTCCTGGCA 780 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 900 CTT 903 (2) INFORMATION FOR SEQ ID NO: 207: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 207: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG 600 GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660 TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780 GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840 ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 888 (2) INFORMATION FOR SEQ ID NO: 208: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 208: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT 480 CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG 540 GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA 600 TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC 660 CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG 720 TCCTGGCACA GCGCTGGATG 780 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 209: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 209: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600 GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 660 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720 CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 210: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF STRANDS: one (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CAACCTGCAA GATGAAGAGC TGTGTGGGGG CCTCTGGCGG 480 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 540 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 600 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 660 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 720 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 780 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 840 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 900 TACCCAGTCA CCGTGGCCTC C 921 (2) INFORMATION FOR SEQ ID NO: 211: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 211: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCTGCAGGAT GAGGAACTGT GCGGCGGCCT CTGGCGGCTG 480 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 540 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCTTT TCAGCCCCCC 600 CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 660 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC 720 AGGAGGTGGA 780 TCCGGAGGTG GGTGGGTCAG GAGGTGGGTC GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG 840 ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA C 900 921 (2) INFORMATION FOR SEQ ID NO: 212: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 212: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCAAGATGAA GCGGCTGGTC 480 CTGGCACAGC GAGCTGTGTG GTGGTCTCTG GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT 540 GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC 600 TGCAGGAGAC CTCCGAGCAG 660 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 720 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 780 GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 840 TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT 900 G 921 (2) INFORMATION FOR SEQ ID NO: 213: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 213: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGAAGAACTG TGTGGTGGTC TGTGGCGGCT GGTCCTGGCA 480 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 540 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 600 CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 660 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT 720 CAGGAGGTGG ATCCGGAGGT 780 TACCCAGGAC TGCTCCTTCC AACACAGCCC GGCTCAGGGG GAGGTAGTGG CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 840 TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA C 900 921 (2) INFORMATION FOR SEQ ID NO: 214: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 214: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGAGCTGTGT GGTGGCCTGT GGCGTCTGGT CCTGGCACAG 480 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 540 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 600 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 660 CTGAAGCCCT GGATCACTCG CCAAAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 720 GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 780 TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 840 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA 900 G 921 (2) INFORMATION FOR SEQ ID NO: 215: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 216: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC 480 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 540 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 600 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 660 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 720 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 780 GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 840 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA 900 G 921 (2) INFORMATION FOR SEQ ID NO: 216: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 216: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TTCTAATCTG CAAGATGAAG AGCTGTGCGG GGGCCTCTGG 480 CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 540 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 600 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC 660 AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 720 CTGGGCGGTG 5 GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC 780 AGGACTGCTC CTTCCAACAC AGCCCCATCT 840 CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA CCTCCGACTC 900 GATTACCCAG TCACCGTGGC C 0 921 (2) INFORMATION FOR SEQ ID NO: 217: 5 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear or (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 217: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 5 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCAAGATGAA GAACTGTGCG GTGGTCTCTG GCGGCTGGTC 480 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 540 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC 600 TGCGGGAGAC TGAAGCCCTG GATCACTCGC CTCCGAGCAG 660 CAGAACTTCT CCCGGTGCCT CCGGTGGCGC GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG 720 GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT 780 CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT 840 ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT G 900 921 (2) INFORMATION FOR SEQ ID NO: 218: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 218: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC 480 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 540 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 600 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 660 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCGGCCCGAC 720 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 780 GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 840 GCTGTCAAGA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 900 TCCAACCTGC AGGACGAGGA G 921 (2) INFORMATION FOR SEQ ID NO: 219: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 906 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 219: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG GGTGGAGGCT CCCCGGGTGA TCACCGTGTA CGTAGAGGGC 480 ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT 540 CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC 600 CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 660 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 720 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 780 CGACATCCAA TCATCATCAA GGCAGGTGAC 840 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 900 CAACAG 906 (2) INFORMATION FOR SEQ ID NO: 220: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 220: AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG GCGGATGAGG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGGCCCTGG 240 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG 300 ACTGCTCCTT CCAACACAGC 360 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420 TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 480 GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 540 TCTCCAAACA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA 600 CCACCTAACC CTTTGCTGGA CCCGAACAAC CTCAATTCTG AAGACATGGA TATCCTGATG 660 GAACGAAACC TTCGAACTCC AAACCTGCTC GCATTCGTAA GGGCTGTCAA GCACTTAGAA 720 AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CTCTGCCACG 780 GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA 840 AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAG 888 (2) INFORMATION FOR SEQ ID NO: 221: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 221: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC AGAGGGCGGT GGAGGCTCCC CGGGTGAACC TGCAGTACGT GTCTGGTCCA ATCTCTACTA 480 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA 540 TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA 600 ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 222: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 222: AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG GCAGACGAGG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG 300 GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 223: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 223: GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCCTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CCTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 480 GGAGGCTCCC CGGGTGAACC TGCAGTACGT AGAGGGCGGT GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA 540 TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA 600 ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 224: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 224: TGGCCTCTGG CGGCTGGTCC TGGCACAGCG GCGGATGAGG AGCTGTGTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CTGGATGGGG 60 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 225: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 904 pairs of bases (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 225: GGCCGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT 60 CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA 120 GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT 180 TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA 240 GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG 300 CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC 360 AGGAGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC 420 CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAATACG TAGAGGGCGG TGGAGGCTCC 480 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 540 CATAAATCTC CAAACATGGC TAACTGCTCT ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC 600 CTAACCCTTT GCTGGACCCG AACAACCTCA ATTCTGAAGA 660 CATGGATATC CTGATGGAAC GAAACCTTCG AACTCCAAAC CTGCTCGCAT TCGTAAGGGC 720 TGTCAAGCAC TTAGAAAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 780 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG 840 GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA 900 ACAG 904 (2) INFORMATION FOR SEQ ID NO: 226: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 226: ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GCCGCCTCCA GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA 60 AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT 120 TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG 180 AGACCTCCGA GCAGCTGGTG 240 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 300 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 360 GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 903 CAG (2) INFORMATION FOR SEQ ID NO: 227: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 pairs of bases (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 227: GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 60 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 120 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 180 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 240 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTOGCA CCCAGGACTG CTCCTTCCAA 300 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 360 CAGGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 420 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA GGAGGCTCCC CGGGTGAACC AGACTTACGT AGAGGGCGGT 480 GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA 540 TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA 600 ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 903 CAG (2) INFORMATION FOR SEQ ID NO: 228: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 228: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 903 CAG (2) INFORMATION FOR SEQ ID NO: 229: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 229: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 180 GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 903 CAG (2) INFORMATION FOR SEQ ID NO: 230: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 230: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 180 GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA 600 ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC 840 TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 231: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 231: GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 60 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 120 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 180 GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 240 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 300 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 360 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AACGCGTGAA CACGGAGATA 420 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTTTTTTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 232: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 232: GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 60 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 120 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 180 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 240 CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 300 GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 360 TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 420 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 480 GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA 600 ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA 660 ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT 720 CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC 780 CCTCTCOACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 840 CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 233: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 233: GGGGGCCTCT GGCGGCTGGT GCTTCAAATC TGCAGGATGA AGAGCTGTGC CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA 60 TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC 120 AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA 180 CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC 240 TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG 300 GAGGTGGATC CGGAGGTGGC 360 CCAGGACTGC TCCTTCCAAC ACAGCCCCAT TCAGGGGGAG GTAGTGGTAC CTCCTCCGAC 420 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 480 GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 234: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 234: GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTTG 60 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 120 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 180 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 240 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 300 TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG 360 GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 420 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 480 AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT AACTACGTAG CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA 600 ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA 660 ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT 720 CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 235: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 235: TGGCGGCTGG TCCTGGCACA GCGCAAGATG AGGAACTGTG TGGTGGTCTC GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT 60 TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC 120 CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC 180 AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC 240 AGTGTCAGCC CGACTCCTCA 300 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 360 GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CCCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 236: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 236: GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 60 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 120 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 180 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 240 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 300 GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 360 GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 480 AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT GACTACGTAG CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA 600 ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA 900 G 921 (2) INFORMATION FOR SEQ ID NO: 237: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 237: GCTCTGTGCG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 300 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 420 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA 900 G 921 (2) INFORMATION FOR SEQ ID NO: 238: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 238: GCACTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 300 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 420 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA 900 G 921 (2) INFORMATION FOR SEQ ID NO: 239: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 239: GCTCTGTGTG GCGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA GATCCGTGAG 420 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA 600 ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA 660 ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT 720 CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC 780 CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 840 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G 900 921 (2) INFORMATION FOR SEQ ID NO: 240: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 240: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 241: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 945 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 241: TGGCGGCTGG TCCTGGCACA GCTCAAGATG ATGAGCTGTG TGGTGGTCTC GCGCTGGATG GAGCGGCTCA 60 TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG .AGACTGTCGC GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC 120 CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC 180 AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC 240 AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 300 GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC GGGAGGTAGT GGTACCCAGG 360 GGAAGCGGAG ACTGCTCCTT CCAACACAGC GTGGCTCTGG 420 CCCATCTCCT CCGACTTCGC TGTCAAAATC CTGACTACCT GCTTCAAGAT 480 TACCCAGTCA CGTOAGCTGT CCGTGGCCTC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA CAACCTGTAC CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT 540 CTAAAGAATC TCATAAATCT CCAAACATGG CTAACTGCTC 600 TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA 660 CCTAACCCTT TGCTGGACCC GAACAACCTC AATTCTGAAG ACATGGATAT CCTGATGGAA 720 CGAAACCTTC GAACTCCAAA CCTGCTCGCA CTTAGAAAAT 780 GCATCAGGTA TTCGTAAGGG CTGTCAAGCA TTGAGGCAAT TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC 840 GCACCCTCTC GACATCCAAT CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA 900 CTGACGTTCT ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAG 945 (2) INFORMATION FOR SEQ ID NO: 242: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 242: AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCCCAAGATG GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT 60 TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC 120 CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC 180 AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC 240 AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC 360 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 420 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903 (2) INFORMATION FOR SEQ ID NO: 243: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 243: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 360 CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA 600 ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA 660 ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT 720 CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921 (2) INFORMATION FOR SEQ ID NO: 244: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 244: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 60 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 120 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 180 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 240 AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110 (2) INFORMATION FOR SEQ ID NO: 245: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 245: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCA AATCTGCAAG ACGAGGAGCT GTGCGGGGGC 660 CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC 720 AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC 780 TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGATCA ACATCTCCCG CCTCCTGCAG 840 GAGACCTCCG AGCAGCTGGT GGCGCTGAAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG 900 TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTGG GCGGTGGGTC AGGAGGTGGG 960 TCAGGAGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 1020 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 1080 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 1110 (2) INFORMATION FOR SEQ ID NO: 246: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 246: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC 600 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 660 AAACATGGCC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 720 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 780 GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 840 GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 900 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 960 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 1020 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 1080 CACTTTGTCA CCAAATGTGC CTTTCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 247: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 247: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 600 CTGCAGGATG TGGCGGCTGG TCCTGGCACA AGGAACTGTG CGGCGGCCTC GCGCTGGATG GAGCGGCTCA 660 AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT 720 TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA 780 TCTCCCGCCT CCTGCAGGAG 840 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 900 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 960 GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA 1020 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 1080 CAAGATTACC CAGTCACCGT GGCCTCCAAC 1110 (2) INFORMATION FOR SEQ ID NO: 248: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 248: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT CTGCAGGATG AGGAACTGTG CGGCGGCCTC 660 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 720 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 780 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 840 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 900 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 960 GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA 1020 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 1080 CAAGATTACC CAGTCACCGT GGCCTCCAAC 1110 (2) INFORMATION FOR SEQ ID NO: 249: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 249: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 60 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 120 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 180 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 240 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT 300 TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GAAGAACTGT GTGGTGGTCT GTGGCGGCTG 660 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 720 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 780 CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 840 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 900 CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA 960 TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 1020 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 1080 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 1110 (2) INFORMATION FOR SEQ ID NO: 250: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 250: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GAGCTGTGTG GTGGCCTGTG GCGTCTGGTC 660 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 720 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 780 AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 840 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 900 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 960 GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 1020 TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 1080 GTCACCGTGG CCTCCAACCT GCAGGACGAG 1110 (2) INFORMATION FOR SEQ ID NO: 251: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 251: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 600 CTGTGCGGTG GCACAGCGCT GGATGGAGCG GTCTGTGGCG TCTGGTCCTG GCTCAAGACT GTCGCTGGGT 660 CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 720 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 780 AGGAGACCTC CGAGCAGCTG 840 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 900 CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 960 GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 1020 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 1080 ACCGTGGCCT CCAACCTGCA GGACGAGGAG 1110 (2) INFORMATION FOR SEQ ID NO: 252: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 60 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 120 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 180 GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC 960 GCCACCGCAC CGACCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 1020 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1080 TCCAACCTGC AG 1092 (2) INFORMATION FOR SEQ ID NO: 253: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGC GTCAGGCGGT 960 GGTTCTGGCG GAGGATCCGG CGGCGGAAGC GGAGGTGGCT CTGGGGGAGG TAGTGGTACC 1020; CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 1080 i CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCOTGG CCTCCAACCT GCAG 1134 (2) INFORMATION FOR SEQ ID NO: 264: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs s (B) TfPO: nucleic acid (C) NUMBER OF STRANDS: one (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 264: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAßGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG ÁGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC 960 GCCACCGCAC CGACCGCTGG ACAACCGCCT CTGACCCAGG ACTGCTCCTT CCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110 \ 2) INFORMATION FOR SEQ ID NO: 265: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 256: GCCGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCCC 60 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 120 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA 180 TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC 240 GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG 300 GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC 360 AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC 420 TTCAA 465 (2) INFORMATION FOR SEQ ID NO: 256: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 466 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 256: GCCGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 60 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 120 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG 180 AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT 240 GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT 300 CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT 360 CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 420 465 CCGTG (2) INFORMATION FOR SEQ ID NO: 257: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 257: GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 60 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 120 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG 180 ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA 240 CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG 300 AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG 360 AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA 420 465 AGACT (2) INFORMATION FOR SEQ ID NO: 258: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 258: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 180 CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT 240 GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG 300 ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT 360 GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG 420 CTGGG 465 (2) INFORMATION FOR SEQ ID NO: 259: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 259: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC 180 ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC 240 AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT 300 GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA 360 TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC 420 AGCCC 465 (2) INFORMATION FOR SEQ ID NO: 260: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 260: GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 60 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 120 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT 180 CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 240 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 300 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 360 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 420 465 GTCTT (2) INFORMATION FOR SEQ ID NO: 261: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 261: GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 120 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG 180 TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA 240 ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA 300 TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA 360 CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG 420 465 TCCAG (2) INFORMATION FOR SEQ ID NO: 262: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 262: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT 600 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA 660 CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 720 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC 780 TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG 840 AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT 900 GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 263: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 263: CGTCTGGTCC TGGCACAGCG GCAGATGAAG AACTGTGTGG GGGACTGTGG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 264: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1062 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 264: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCGC TGGACAACCG 360 CCTCTGACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 540 ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 600 GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 660 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 720 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 780 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 840 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 900 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 960 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 1020 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1062 (2) INFORMATION FOR SEQ ID NO: 265: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1089 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 265: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360 AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA 480 GTAGAGGGCG GTGGAGGCTC CCTGCAGTAC CCCGGGTGGT 540 GGTTCTGGCG CCATTGGGCC CTGCCAGCTC CCTGCCCCAG GCGGCTCCAA CATGGCTACA AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 600 AGGGCGATGG CGCAGCGCTC 660 CAGGAGAAGC AGGAAGATCC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC 720 CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 780 ACCAGGGGCT CCTGCAGGCC 840 CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC 900 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG 960 CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC 1020 CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCG 1080 1089TION FOR SEQ ID NO: 266: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1044 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 266: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGTACGTAGA GGGCGGTGGA 480 GGCTCCCCGG GTGGTGGTTC TGGCGGCGGC TCCAACATGG CTACACCATT GGGCCCTGCC 540 AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGRAA GATCCAGGGC 600 GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 660 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC 720 CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG 780 GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 840 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG 900 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC 960 CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC 1020 GTTCTACGCC ACCTTGCGCA GCCG 1044 (2) INFORMATION FOR SEQ ID NO: 267: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1077 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 267: AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG GCGGATGAGG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGGCCCTGG 240 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG 300 ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT 360 CTGACTACCT GCTTCAAGAT 420 TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 480 GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 540 TCTCCAAACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC 600 AAGTGCTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG 660 TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 720 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 780 AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA 840 TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC 900 ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT 960 GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 1020 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCC 1077 (2) INFORMATION FOR SEQ ID NO: 268: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 268: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 480 GGAGGCTCCC CGGGTGAACC TGCAGTACGT AGAGGGCGGT GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG_540_GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA 600 TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 (2) INFORMATION FOR SEQ ID NO: 269: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 269: GCAGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 720 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC 780 TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG 840 AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTG TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 270: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 270: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC 60 AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG 120 GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC 180 ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC 240 AAGATTACCC AGTCACCGTG 300 GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCGTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TATACGCCAC CTTGCGCAGC 1080 CC 1092 (2) INFORMATION FOR SEQ ID NO: 271: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 271: GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 60 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 120 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 180 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 240 CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 300 GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 360 TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 420 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 480 GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC ATCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 272: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 272: GCTAATCTGC AAGATGAGGA GCTGTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 60 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 120 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTOTCTTCGC 180 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 240 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 300 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 360 GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 420 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 480 AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT TCCTACGTAG CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 720 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC 780 TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTA TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 273: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 273: CTCTGGCGGC TGGTCCTGGC GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC ATGGAGCGGC TCAAGACTGT CGCTGGGTCC ACAGCGCTTG 60 AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC 120 CCCCCAGCTG TCTTCGCTTC 180 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 240 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 300 TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG 360 GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 420 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 480 AACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 . (2) INFORMATION FOR SEQ ID NO: 274: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 1 10 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY : linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 274:CTGGCACAGC GCTGGATGGA GCACTGTGCG GTGGTCTGTG GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG 60 TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC 120 GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC 180 TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT 240 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGAGCTACAG GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT 300 CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT 360 TCGCTGTCAA AATCCGTGAG 420 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 275: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 275: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 (2) INFORMATION FOR SEQ ID NO: 276: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 276: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 480 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG_540_GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA 600 TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 660 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT 720 GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC 780 TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 1080 CC 1092 (2) INFORMATION FOR SEQ ID NO: 277: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 277: GCGCTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCAACT TCGCTGTCAA GATCCGTGAG 420 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT TTTTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 278: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 278: GTCCTGGCAC AGCGCTGGAT GCTGAACTGT GTGGTGGTCT GTGGCGTCTG GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC 60 GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC 120 TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG 180 CGCTGAÁGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC 240 CCGACTCCTC AACCCTGGGC AGGAGGTGGA TCCGGAGGTG 300 GGTGGGTCAG GCTCAGGGGG AGGTAGTGGT GAGGTGGGTC 360 ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 420 GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 480 GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 279: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 279: GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 60 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 120 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 180 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 240 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 300 GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 360 GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 480 GACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 280: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 280: GCTCAGGACG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 360 GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 720 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC 780 TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 281: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 281: GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 120 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC 180 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTTGCTG TCAAAATCCG TGAGCTGTCT 240 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 300 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 360 GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 420 AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 (2) INFORMATION FOR SEQ ID NO: 282: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1065 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 282: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG 300 GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 660 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1065 (2) INFORMATION FOR SEQ ID NO: 283: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 283: GCTCAAGATG AAGAACTGTG CGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGCGGAT CCGGAGGTGG CTCAGGGGGA 360 GGTAGTGGTA CCCAGGACTO CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTCCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTOAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 284: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1098 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 284: GCGCTGTGTG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 GTCACCAAAT ATGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300 GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC 360 TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAGA TCCGTGAGCT GTCTGACTAC 420 CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 480 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACAC 540 CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA GAGCAAGTGA 600 GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT 660 GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA 720 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 780 TTTTCCTCTA CCAGGGGCTC 840 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 900 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 960 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 1020 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 1080 CGCCACCTTG CGCAGCCC 1098 (2) INFORMATION FOR SEQ ID NO: 285: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 285:GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TTCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 (2) INFORMATION FOR SEQ ID NO: 286: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 286: TGGCGGCTGG TCCTGGCACA GCTCAAGACG AAGAACTGTG TGGTGGTCTC GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT 60 TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC 120 CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC 180 AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC 240 AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 300 GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC 360 GGAAGCGGAG GTGGCTCTGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 420 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 480 TACCCAGTCA CCGTGGCCTC CAACCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600 CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 (2) INFORMATION FOR SEQ ID NO: 287: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1092 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO : 287: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC 360 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 420 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 (2) INFORMATION FOR SEQ ID NO: 288: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 288: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 360 CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 720 GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 289: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 134 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 289: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360 AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480 CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC 600 CCCAGAGCTT CCTGCTCAAG 660 AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA TGCTTAGAGC GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC 720 TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC 780 AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC 840 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG 900 TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 (2) INFORMATION FOR SEQ ID NO: 290: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 290: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCCCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360 AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480 CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600 CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 (2) INFORMATION FOR SEQ ID NO: 291: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 291: GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCGC TGGACAACCG 360 CCTCTGACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCACCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 292: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1041 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 292: GCTGATGAGG AGCTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGT AGAGACGGTG 300 TTTCACCGTG TCAGCCAGGA TGGTCTAGAT CTCCTGACCT CGACCCAGGA CTGCTCCTTC 360 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 420 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC ACGTAGAGGG CGGTGGAGGC 480 TCCCCGGGTG AACCTGCAGT GTGGTTCTGG CGGCGGCTCC AACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG 540 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 600 TGTGCCACCC CGAGGAGCTG 660 GTGCTGCTCG ACTAACAAGC GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG 720 GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC 780 CCACCTTGGA CACACTGCAG 840 CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC 900 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG 960 GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT 1020 CTACGCCACC TTGCGCAGCC G 1041 (2) INFORMATION FOR SEQ ID NO: 293: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1152 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 293: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC 300 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 360 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC 420 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC 480 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 540 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 600 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 660 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 720 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 780 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 840 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 900 TACCGCGTTC TACGCCACCT TGCGCAGCCC TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 960 GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1020 TCTCCAAACA TGGCAACCCA GGACTGCTCT TTTCAACACA GCCCCATCTC CTCCGACTTC 1080 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1140 TCCAACCTGC AG 1152 (2) INFORMATION FOR SEQ ID NO: 294: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 294: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG 120 GAGCCGAAGA GCCCGGACAC CCATACTAGT AGGCCCTGCC 180 AGCTCCCTGC CCGCCATCTC CGACACCATT CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA 240 AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC 300 CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA 360 GCGGCCTTTT CCTCTACCAG 420 GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GCCCCACCTT GGACACACTG 480 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG 540 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC 600 CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC 660 GTTCTACGCC ACCTTGCGCA GCCCTCTGCA GAACCGAAAT CTCCGGATAC TCATACCAGC 720 CCGCCATCCC CGGGTTCTAA TCTGCAAGAT GAAGAGCTGT GCGGGGGCCT CTGGCGGCTG 780 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900 CCCAGCTGCC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020 CAGTGTCAGC CCGACTCCTC AACCCTG 1047 (2) INFORMATION FOR SEQ ID NO: 295: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1043 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 295: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTGGCAGG GGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCCGAAG AGCCCGGACA CCCATACTAG TCCGCCATCT 300 CCGGGTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 360 GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACT 420 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC 480 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT 540 GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA 600 CTTTGCCACC ACCATCTGGC 660 AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 720 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA 780 GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GCAGAACCGA 840 AATCTCCGGA TACTCATACC AGCCCGCCAT CCCCGGGTAA GGCCTTTCAG CCCCCCCCCA 900 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 960 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 1020 GTCAGCCCGA CTCCTCAACC CTG 1043 (2) INFORMATION FOR SEQ ID NO: 296: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1065 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 296: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATC TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTCCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 600 AGAAGCTGTG AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG TGCCACTAAC 660 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 720 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 780 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT 840 TTGCCACCAC CATCTGGCAG 900 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA, CCCAGGGTGC CATGCCGGCC 960 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1065 (2) INFORMATION FOR SEQ ID NO: 297: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 297: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 60 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 120 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 180 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 240 AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATCTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTCCTCCTT CCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGCGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110 (2) INFORMATION FOR SEQ ID NO: 298: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1065 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 298: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTCTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTA GAGCTGCAGT CTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACTAAC 660 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1Q65 (2) INFORMATION FOR SEQ ID NO: 299: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1110 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 299: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC 600 AAACATGGCA GATGAAGAAC CTGGTCCTGG CACAGCGCTG TGTGTGGGGG CCTGTGGCGG GATGGAGCGG CTCAAGACTG 660 TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA 720 CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT CTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTCTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACTCAGG ACTGTTCTTT TCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110 (2) INFORMATION FOR SEQ ID NO: 300: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1002 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 300: GCCACTCAGG ACTCCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATCTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480 ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CTGTGCCACC CCGAGGAGCT GGTGCTGCTC CACTAACAAG 600 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 660 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 720 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG 780 CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC 840 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 900 CTAGCCATCT GCAGAGCTTC 960 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002 (2) INFORMATION FOR SEQ ID NO: 301: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1002 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 301: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT 240 CTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG 300 TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 360 AGCCCGACTC CTCAACCCTG 420 CTGCAGTCTC TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480 ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 600 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002 (2) INFORMATION FOR SEQ ID NO: 302: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 978 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 302: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTACG TAGAGGGCGG TGGAGGCTCC 420 CCGGGTGGTG ATGGCTACAC CATTGGGCCC TGCCAGCTCC GTTCTGGCGG CGGCTCCAAC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA 480 GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT 540 GCCACCCCGA GGAGCTGGTG GTGTGCCACT AACAAGCTGT CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA 600 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 660 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA 720 CCTTGGACAC ACTGCAGCTG 780 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 840 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 900 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 960 CGCCACCTTG CGCAGCCG 978 (2) INFORMATION FOR SEQ ID NO: 303: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1002 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 303: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480 ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 600 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002 (2) INFORMATION FOR SEQ ID NO: 304: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1001 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 304: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GCGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480 ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACTAACAAG 600 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 660 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 720 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG 780 CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC 840 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 900 CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 960 C 1001 (2) INFORMATION FOR SEQ ID NO: 305: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1056 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 305: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT GAGCTTCCTG 600 CTGGTTGCTA GCCATCTGCA GAGGTGTCGT ACCGCGTTCT CTGGCGGCTC TGGCGGCTCT ACGCCACCTT 660 CAGAGCTTCC TGCTCAAGTC GCGCAGCCCT TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA 720 AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC 780 TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 840 GCTTGAGCCA ACTCCATAGC 00 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 960 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 1020 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCC 1056 (2) INFORMATION FOR SEQ ID NO: 306: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1001 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 306: GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT 60 CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT CTGGCGGCTC TGGCGGCTCT ACGCCACCTT 120 CAGAGCTTCC TGCTCAAGTC GCGCAGCCCT TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA 180 AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC 240 TGGGCATCCC CTGGGCTCCC 300 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 360 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 420 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 480 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCTACG TAGAGGGCGG TGGAGGCTCC 540 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 600 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 660 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 720 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 780 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 840 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG 900 GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT 960 TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC 1020 TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA G 1080 1101 (2) INFORMATION FOR SEQ ID NO: 307: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1032 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 307: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCC GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 600 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 660 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 720 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 780 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 840 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 900 GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 960 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1020 TCCAACCTGC AG 1032 (2) INFORMATION FOR SEQ ID NO: 308: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1005 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 308: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 600 AAATCCGTGA GCTGTCTGAC TACCTGCTTC 660 AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC AAAATTACCC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 720 AGCGGCTCAA GACTGTCGCT 780 GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 840 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 900 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 960 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTG 1005 (2) INFORMATION FOR SEQ ID NO: 309: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1660 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: single finger (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 309: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 660 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC. CATCTGGCAG 900 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 1080 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 1140 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 1200 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 1260 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 1320 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 1380 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 1440 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 1500 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1560 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1620 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1650 (2) INFORMATION FOR SEQ ID NO: 310: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1632 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 310: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC 480 AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA 540 TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC 600 TGTGTGGTGG TCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA 720 CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 1140 GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1200 TCTCCAAACA TGGCTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 1260 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1320 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 1380 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 1440 AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 1500 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 1560 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 1620 TCCTCAACCC TG 1632 (2) INFORMATION FOR SEQ ID NO: 311: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1695 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 311: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 60 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 120 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 180 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 240 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT 300 TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA 360 CCCAGGGTGC CATGCCGGCC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 1140 GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1200 TCTCCAAACA TGGCTGATGA AGAACTGTGT GGTGGTCTGT .GGCGGCTGGT CCTGGCACAG 1260 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 1320 GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 1380 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 1440 CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 1500 GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 1560 TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 1620 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 1680 GCCTCCAACC TGCAG 1695 (2) INFORMATION FOR SEQ ID NO: 312: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1606 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 312: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC TGATGAAGAA GCTGGTCCTG 480 GCACAGCGCT CTGTGTGGTG GTCTGTGGCG GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG 540 CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC 600 AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC 660 GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG 720 GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT 780 TCCAACACAG CCCCATCTCC 840 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 900 ACCGTGGCCT CCAACCTGCA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT 960 GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 1020 ATGGCTGATG AAGAACTGTG TGGTGGTCTG TGGCGGCTGG TCCTGGCACA GCGCTGGATG 1080 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 1140 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 1200 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 1260 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 1320 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 1380 GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 1440 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 1500 CTGCAG 1506 (2) INFORMATION FOR SEQ ID NO: 313: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1674 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 313: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 600 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 660 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 720 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 780 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 600 TGGAGCGCGT GAACACGGAG 660 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 720 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 780 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 1080 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 1140 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 1200 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 1260 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC 1320 TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG 1380 AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT 1440 GGCAGCAGAT GGAAGAACTG 150 0 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1560 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1620 TACCGCGTTC TACGCCACCT TGCGCAGCCC TGATAAGGAT CCGAATTCGG CAGC 1674 (2) INFORMATION FOR SEQ ID NO: 314: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1470 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 314: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC 60 TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA 120 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 180 TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 240 GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 960 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCCGA CGAGGAGCTC 1020 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 1080 GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 1140 AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC 1200 CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC 1260 TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA 1320 GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC 1380 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1440 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1470(2) INFORMATION FOR SEQ ID NO: 315: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1194 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 315: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGGAATTCA AGCTTGAGCC CAGAGGGCCC ACAATCAAGC CCTGTCCTCC ATGCAAATGC 540 CCAGCACCTA ACCTCTTGGG TGGACCATCC GTCTTCATCT TCCCTCCAAA GATCAAGGAT 600 GTACTCATGA TCTCCCTGAG CCCCATAGTC ACATGTGTGG TGGTGGATGT GAGCGAGGAT 660 GACCCAGATG TCCAGATCAG CTGGTTTGTG AACAACGTGG AAGTACACAC AGCTCAGACA 720 CAAACCCATA GAGAGGATTA CAACAGTACT CTCCGGGCGG TCAGTGCCCT CCCCATCCAG 780 CACCAGGACT GGATGAGTGG CAAGGAGTTC AAATGCAAGG TCAACAACAA AGACCTCCCA 840 GCGCCCATCG AGAGAACCAT CTCAAAACCC AAAGGGTCAG TAAGAGCTCC ACAGGTATAT 900 GTCTTGCCTC CACCAGAAGA AGAGATGACT AAGAAACAGG TCACTCTGAC CTGCATGGTC 960 ACAGACTTCA TGCCTGAAGA CATTTACGTG GAGTGGACCA ACAACGGGAA AACAGAGCTA 1020 AACTACAAGA ACACTGAACC AGTCCTGGAC TCTGATGGTT CTTACTTCAT GTACAGCAAG 1080 CTGAGAGTGG AAAAGAAGAA CTGGGTGGAA AGAAATAGCT ACTCCTGTTC AGTGGTCCAC 1140 GAGGGTCTGC ACAATCACCA CACGACTAAG AGCTTCTCCC GGACTCCGGG TAAA 1194 (2) INFORMATION FOR SEQ ID NO: 316: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 131 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 316: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA 60 CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG 120 CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG 180 AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 GAATTCAAGC TTGAGCCCAG AGGGCCCACA ATCAAGCCCT GTCCTCCATG CAAATGCCCA 480 GCACCTAACC TCTTGGGTGG ACCATCCGTC TTCATCTTCC CTCCAAAGAT CAAGGATGTA 540 CTCATGATCT CCCTGAGCCC CATAGTCACA TGTGTGGTGG TGGATGTGAG CGAGGATGAC 600 CCAGATGTCC AGATCAGCTG GTTTGTGAAC AACGTGGAAG TACACACAGC TCAGACACAA 660 ACCCATAGAG AGGATTACAA CAGTACTCTC CGGGCGGTCA GTGCCCTCCC CATCCAGCAC 720 CAGGACTGGA TGAGTGGCAA GGAGTTCAAA TGCAAGGTCA ACAACAAAGA CCTCCCAGCG 780 CCCATCGAGA GAACCATCTC AAAACCCAAA GGGTCAGTAA GAGCTCCACA GGTATATGTC 840 TTGCCTCCAC CAGAAGAAGA GATGACTAAG AAACAGGTCA CTCTGACCTG CATGGTCACA 900 GACTTCATGC CTGAAGACAT TTACGTGGAG TGGACCAACA ACGGGAAAAC AGAGCTAAAC 960 TACAAGAACA CTGAACCAGT CCTGGACTCT GATGGTTCTT ACTTCATGTA CAGCAAGCTG 1020 AGAGTGGAAA AGAAGAACTG GGTGGAAAGA AATAGCTACT CCTGTTCAGT GGTCCACGAG 1080 GGTCTGCACA ATCACCACAC GACTAAGAGC TTCTCCCGGA CTCCGGGTAA A 1131 (2) INFORMATION FOR SEQ ID NO: 317: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 317: ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGCACTCC GAGTC 45 (2) INFORMATION FOR SEQ ID NO: 318: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 318: ATGCACGAAT TCCCTGACGC AGAGGGTGGA 30 (2) INFORMATION FOR SEQ ID NO: 319: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 319: TGACAAGCTT ACCTGACGCA GAGGGTGGAC CCT 33 (2) INFORMATION FOR SEQ ID NO: 320: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 320: AATTCGGCAA 10 (2) INFORMATION FOR SEQ ID NO: 321: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 321: CATGTTGCC 10 (2) INFORMATION FOR SEQ ID NO: 322: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 322: AATTCGGGG CAA 13 (2) INFORMATION FOR SEQ ID NO: 323: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 323: CATGTTGCCG CCG 13 (2) INFORMATION FOR SEQ ID NO: 324: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO : 324: AATTCGGCGG CAACGGCGGC AA 22 (2) INFORMATION FOR SEQ ID NO: 325: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 325: CATGTTGCCG CCGTTGCCGC CG 22 (2) INFORMATION FOR SEQ ID NO: 326: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 326: CGATCCATGG AGGTTCACCC TTTGCCT 27 (2) INFORMATION FOR SEQ ID NO: 327: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 327: GATCAAGCTT ATGGGCACTG GCTCAGTCT 29 (2) INFORMATION FOR SEQ ID NO: 328: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 328: CGATACATGT TGCCTACACC TGTCCTG 27 (2) INFORMATION FOR SEQ ID NO: 329: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 329: GATCAAGCTT AAGGGTGAAC CTCTGGGCA 29 (2) INFORMATION FOR SEQ ID NO: 330: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 330: CGATCCATGG TCCTGCTGCC TGCTGTG 27 (2) INFORMATION FOR SEQ ID NO: 331: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 331: GATCAAGCTT AAGGTGTAGG CAAAGGGTG 29 (2) INFORMATION FOR SEQ ID NO: 332: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) ) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 332: CGATCCATGG CTGTGGACTT TAGCTTGGGA 30 (2) INFORMATION FOR SEQ ID NO: 333: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 333: GATCAAGCTT AAGGCAGCAG GACAGGTGT 29 (2) INFORMATION FOR SEQ ID NO: 334: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 334: CGATCCATGG ACTTTAGCTT GGGAGAA 27 (2) INFORMATION FOR SEQ ID NO: 335: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 335: GATCAAGCTT ACACAGCAGG CAGCAGGAC 29 (2) INFORMATION FOR SEQ ID NO: 336: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 336: CGATCCATGG GAGAATGGAA AACCCAG 27 (2) INFORMATION FOR SEQ ID NO: 337: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 337: GATCAAGCTT ACAAGCTAAA GTCCACAGC 29 (2) INFORMATION FOR SEQ ID NO: 338: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 338: CGATCCATGG GACCCACTTG CCTCTCA 27 (2) INFORMATION FOR SEQ ID NO: 339: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 339: GATCAAGCTT ACAGTTGTCC CCGTGCTGC 29 (2) INFORMATION FOR SEQ ID NO: 340: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 340: CAGTCCATGG GAACCCAGCT TCCTCCA 27 (2) INFORMATION FOR SEQ ID NO: 341: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) ) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 341: GATCAAGCTT AAACGAGGCT CTGCAGGGC 29 (2) INFORMATION FOR SEQ ID NO: 342: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 342: CGATCCATGG GCAGGACCAC AGCTCAC 27 (2) INFORMATION FOR SEQ ID NO: 343: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 343: GATCAAGCTT ACTGTGGAGG AAGCTGGGTT 30 (2) INFORMATION FOR SEQ ID NO: 344: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 344: CGATCCATGG CTCACAAGGA TCCCAATGCC 30 (2) INFORMATION FOR SEQ ID NO: 345: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 3. 4. 5: GATCAAGCTT ATGTGGTCCT GCCCTGTGG 29 (2) INFORMATION FOR SEQ ID NO: 346: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 346: CGATCCATGG ATCCCAATGC CATCTTCCTG 30 (2) INFORMATION FOR SEQ ID NO: 347: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 347: GATCAAGCTT ACTTGTGAGC TGTGGTCCT 29 (2) INFORMATION FOR SEQ ID NO: 348: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 348: CGATCCATGG CCATCTTCCT GAGCTTCCAA 30 (2) INFORMATION FOR SEQ ID NO: 349: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 349: GATCAAGCTT AATTGGGATC CTTGTGAGCT GT 32 (2) INFORMATION FOR SEQ ID NO: 350: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 83 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 360: AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60 ACGTAGAGGG CGGTGGAGGC TCC 83 (2) INFORMATION FOR SEQ ID NO: 351: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 83 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 351: CCGGCGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGRRCTCC AAGGTTTTCA 60 GATAGAAGGT CAGTTTACGA CGG 83 (2) INFORMATION FOR SEQ ID NO: 352: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 352: GTTACCCTTG AGCAAGCGCA GGAACAACEG GGTGGTGGCT CTAACTGCTC TATAATGAT 69 (2) INFORMATION FOR SEQ ID NO: 363: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 66 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 353: CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG 56 (2) INFORMATION FOR SEQ ID NO: 354: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 83 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 354: GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC 60 GGTTCTAACT GCTCTATAAT GAT 83 (2) INFORMATION FOR SEQ ID NO: 355: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 355: CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT 60 GTTCCTGCGC TTGCTCAAGG 80 (2) INFORMATION FOR SEQ ID NO: 356: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 356: GATCGACCAT GGCTCTGGAC CCGAACAACC TC 32 (2) INFORMATION FOR SEQ ID NO: 357: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 367: CTGGATTACG TACAAAGGTG CAGGTGGT 28 (2) INFORMATION FOR SEQ ID NO: 368: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 358: GATCGACCAT CGCTAATGCA TCAGGTATTG AG 32 (2) INFORMATION FOR SEQ ID NO: 359: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 359: CTCGATTACG TATICTAAGT TCTTGACA 28 (2) INFORMATION FOR SEQ ID NO: 360: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 360: GATCGACCAT GGCTGCACCC TCTCGACATC CA 32 (2) INFORMATION FOR SEQ ID NO: 361: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 361: CTCGATTACG TAGGCCGTGG CAGAGGGC 28 (2) INFORMATION FOR SEQ ID NO: 362: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 362: GATCGACCAT GGCTGCAGGT GACTGGCAAG AA 32 (2) INFORMATION FOR SEQ ID NO: 363: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 363: CTCGATTACG TACTTGATGA TGATTGGA 28 (2) INFORMATION FOR SEQ ID NO: 364: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 364: GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG 54 (2) INFORMATION FOR SEQ ID NO: 365: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 365: CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG 54 (2) INFORMATION FOR SEQ ID NO: 366: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 366: GGGCTGCGCA AGCTGGCG 18 (2) INFORMATION FOR SEQ ID NO: 367: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 367: ACACCATTGG GCCCTGCCAG C 21 (2) INFORMATION FOR SEQ ID NO: 368: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 368: GATCGACCAT GGCTTACAAG CTGTGCCACC CC 32 (2) INFORMATION FOR SEQ ID NO: 369: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 369: CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT 36 (2) INFORMATION FOR SEQ ID NO: 370: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: only one ( D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 370: GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC 32 (2) INFORMATION FOR SEQ ID NO: 371: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 371: CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT 36 (2) INFORMATION FOR SEQ ID NO: 372: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 372: GATCGACCAT GGCTATGGCC CCTGCCCTGC AG 32 (2) INFORMATION FOR SEQ ID NO: 373: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 373: CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT 36 (2) INFORMATION FOR SEQ ID NO: 374: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 374: GATCGACCAT GGCTACCCAG GGTGCCATGC CG 32 (2) INFORMATION FOR SEQ ID NO: 375: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 375: CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA 36 (2) INFORMATION FOR SEQ ID NO: 376: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO : 376: GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG 32 (2) INFORMATION FOR SEQ ID NO: 377: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 377: CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC 36 (2) INFORMATION FOR SEQ ID NO: 378: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 378: GTAGAGGGCG GTGGAGGCTC C 21 (2) INFORMATION FOR SEQ ID NO: 379: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 379: CCGGGGAGCC TCCACCGCCC TCTAC 25 (2) INFORMATION FOR SEQ ID NO: 380: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 53 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 380: TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TGG 53 (2) INFORMATION FOR SEQ ID NO: 381: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 53 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 381: CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA 53 (2) INFORMATION FOR SEQ ID NO: 382: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH 37 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 382: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37 (2) INFORMATION FOR SEQ ID NO: 383: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: only one ( D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 383: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37 (2) INFORMATION FOR SEQ ID NO: 384: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 384: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38 (2) INFORMATION FOR SEQ ID NO: 385: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 385: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC 38 (2) INFORMATION FOR SEQ ID NO: 386: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 386: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38 (2) INFORMATION FOR SEQ ID NO: 387: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 387: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTAC 39 (2) INFORMATION FOR SEQ ID NO: 388: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 388: TCTGACAAGC TTACACGGTG ACTGGGTAAT CTTGAAGC 38 (2) INFORMATION FOR SEQ ID NO: 389: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 389: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37 (2) INFORMATION FOR SEQ ID NO: 390: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 390: GTCAAGAAGC TTACGGCTGA AAGGCACATT TG 32 (2) INFORMATION FOR SEQ ID NO: 391; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 391: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 34 (2) INFORMATION FOR SEQ ID NO: 392: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 392: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37 (2) INFORMATION FOR SEQ ID NO: 393: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 393: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57 (2) INFORMATION FOR SEQ ID NO: 394: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 394: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 57 (2) INFORMATION FOR SEQ ID NO: 395: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 395: GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG 57 (2) INFORMATION FOR SEQ ID NO: 396: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 396: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA 57 (2) INFORMATION FOR SEQ ID NO: 397: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 397: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 57 (2) INFORMATION FOR SEQ ID NO: 398: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 398: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC 57 (2) INFORMATION FOR SEQ ID NO: 399: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 67 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 399: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 67 (2) INFORMATION FOR SEQ ID NO: 400: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 400: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 (2) INFORMATION FOR SEQ ID NO: 401: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 401: GTTGCCATGG CWGATGAAGA ACTGTGTGGN GGNCTGTGGC GG 42 (2) INFORMATION FOR SEQ ID NO: 402: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 402: TATGCAAGCT TAGGCCACGG TGACTGGGTA 30 (2) INFORMATION FOR SEQ ID NO: 403: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 403: TATGCAAGCT TAGGAGGCCA CGGTGACTGG 30 (2) INFORMATION FOR SEQ ID NO: 404: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 404: TATGCAAGCT TAGTTGGAGG CCACGGTGAC 30 (2) INFORMATION FOR SEQ ID NO: 406: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 406: TATGCAAGCT TACAGGTTGG AGGCCACGGT 30 (2) INFORMATION FOR SEQ ID NO: 406: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 406: TATGCAAGCT TAGTCCAGGT TGGAGGCCAC 30 (2) INFORMATION FOR SEQ ID NO: 407: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 407: TATGCAAGCT TACTCGTCCA GGTTGGAGGC 30 (2) INFORMATION FOR SEQ ID NO: 408: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 408: TATGCAAGCT TACTCCTCGT CCAGGTTGGA 30 (2) INFORMATION FOR SEQ ID NO: 409: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 409: GACTAGCCAT GGCNGAYGAR GARCTGTGYG GTGGCCTCTG GCGG 44 (2) INFORMATION FOR SEQ ID NO: 410: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 410: GACTAGTACG TACTGCAGGT TGGAGGCCAC GG 32 (2) INFORMATION FOR SEQ ID NO: 411: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 411: GCAGGTTACG TATTGAAGCA GGTAGTCAGA CAGCTC 36 (2) INFORMATION FOR SEQ ID NO: 412: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 412: GCAGGTTACG TACACGGTGA CTGGGTAATC TTGAAG 36 (2) INFORMATION FOR SEQ ID NO: 413: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 413: GCAGGTTACG TAAGTCTTGA GCCGCTCCAT CCAGC 3d (2) INFORMATION FOR SEQ ID NO: 414: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 414: GCAGGTTACG TAGCCAGCGA CAGTCTTGAG CCGCTC 36 (2) INFORMATION FOR SEQ ID NO: 415: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 415: GTCAAGCCAT CGCNCCRCCR AGCTGTCTRC GCTTCGTTCA GACCAACTC 49 (2) INFORMATION FOR SEQ ID NO: 416: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 416: GCAGGTTACG TACGGCTGAA AGGCACATTT GGTGACAA 38 (2) INFORMATION FOR SEQ ID NO: 417: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 417: GCAGGTTACG TAAAGACAGC TGGGGGGGGG 30 (2) INFORMATION FOR SEQ ID NO: 418: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 418: GCAGGTTACG TACTGGACGA AGCGAAGACA GCTG 34 (2) INFORMATION FOR SEQ ID NO: 419: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 419: TATGCTACGT AGGCCACGGT GACTGGGTA 29 (2) INFORMATION FOR SEQ ID NO: 420: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 420: TATGCTACGT AGGACGCCAC GGTGACTGG 420 (2) INFORMATION FOR SEQ ID NO: 421: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 421: TATGCTACGT AGTTGGAGGC CACGGTGAC 29 (2) INFORMATION FOR SEQ ID NO: 422: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 422: TATGCTACGT ACAGGTTGGA GGCCACGGT 29 (2) INFORMATION FOR SEQ ID NO: 423: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 423: TATGCTACGT AGTCCAGGTT GGAGGCCAC 29 (2) INFORMATION FOR SEQ ID NO: 424: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 424: TATGCTACGT ACTCGTCCAG GTTGGAGGC 29 (2) INFORMATION FOR SEQ ID NO: 425: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 425: TATGCTACGT ACTCCTCGTC CAGGTTGGA 29 (2) INFORMATION FOR SEQ ID NO: 426: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 426: TCAGTTGGAT CCGGCGGCGG AAGCGGAGGT GGCTCTGGGG GAGGTA 46 (2) INFORMATION FOR SEQ ID NO: 427: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 427: TCAGTTGGAT CCTCCGCCAG AACCACCGCC TGACCCACCT CCTGACCC 48 (2) INFORMATION FOR SEQ ID NO: 428: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 428: GTCTGAGGCG CCACCGCACC GACCGCTGGA CAACCGCCTC TGACCCAGGA CTGCTCCTTC 60 (2) INFORMATION FOR SEQ ID NO: 429: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 429: GTCTGAGGCG CCACCGCACC GACCACCCAG GACTGCTCCT TCCAAC 46 (2) INFORMATION FOR SEQ ID NO: 430: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 430: GTCTGAGGCG CCGAGTGGAC GCCGGCTCCA CGGTGGCGGC AGGGTTGAGG AGTCGGGCTG 60 (2) INFORMATION FOR SEQ ID NO: 431: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 431: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57 (2) INFORMATION FOR SEQ ID NO: 432: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 67 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 432: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 57 (2) INFORMATION FOR SEQ ID NO: 433: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 433: GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG 57 (2) INFORMATION FOR SEQ ID NO: 434: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 67 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 434: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA 57 (2) INFORMATION FOR SEQ ID NO: 435: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 435: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 57 (2) INFORMATION FOR SEQ ID NO: 436: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 436: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC 57 (2) INFORMATION FOR SEQ ID NO: 437: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 437: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57 (2) INFORMATION FOR SEQ ID NO: 438: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 438: 132.

GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 (2) INFORMATION FOR SEQ ID NO: 439: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 439: TATGCAAGCT TAGGCCACGG TGACTGGGTA 30 (2) INFORMATION FOR SEQ ID NO: 440: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 440: TATGCAAGCT TAGGAGGCCA CGGTGACTGG 30 (2) INFORMATION FOR SEQ ID NO: 441: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 441: TATGCAAGCT TAGTTGGAGG CCACGGTGAC 30 (2) INFORMATION FOR SEQ ID NO: 442: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 442: TATGCAAGCT TACAGGTTGG AGGCCACGGT 30 (2) INFORMATION FOR SEQ ID NO: 443: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 443: TATGCAAGCT TACTGCAGGT TGGAGGCCAC 30 (2) INFORMATION FOR SEQ ID NO: 444: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 444: TATGCAAGCT TAGTCCTGCA GGTTGGAGGC 30 (2) INFORMATION FOR SEQ ID NO: 445: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 445: TATGCAAGCT TACTCGTCCT GCAGGTTGGA 30 (2) INFORMATION FOR SEQ ID NO: 446: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 446: TATGCAAGCT TACTCCTCGT CCTGCAGGTT 30 (2) INFORMATION FOR SEQ ID NO: 447: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 47 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 447: GCTACGTCTA GATCTCCTGA CCTCGACCCA GGACTGCTCC TTCCAAC 47 (2) INFORMATION FOR SEQ ID NO: 448: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 448: GCTAGTTCTA GACCATCCTG GCTGACACGG TGAAACACCG TCTCTACGGG CTGACACTGC 60 AGCTCCAG 68 (2) INFORMATION FOR SEQ ID NO: 449: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 56 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 449: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGCTCCTGC AGGTTGGAGG CCACGG 56 (2) INFORMATION FOR SEQ ID NO: 450: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 450: GTCAGTACTA GTCCGCCATC TCCGACACCA TTAGGCCCTG CCAGC 45 (2) INFORMATION FOR SEQ ID NO: 451: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 451: GTCAGTTCCG GAGATTTCGG TTCTGCAGAG GGCTGCGCAA GGTGGCGTA 49 (2) INFORMATION FOR SEQ ID NO: 452: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 64 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 462: GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT TCTAATCTGC AAGATGAAGA 60 GCTG 64 (2) INFORMATION FOR SEQ ID NO: 453: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 61 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 453: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGAAAGGCA CATTTGGTGA CAAAGTGTAT 60 C 61 (2) INFORMATION FOR SEQ ID NO: 454: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: only one ( D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 454: GTCAGTACTA GTCCGCCATC TCCGGGTACA CCATTAGGCC CTGCCAGC 48 (2) INFORMATION FOR SEQ ID NO: 455: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 456: GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT AAGGCCTTTC AGCCCCCCCC 60 CAG 63 (2) INFORMATION FOR SEQ ID NO: 456: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 456: GTCAGACCAT GGCCACTCAG GACTCCTCTT TTC 33 (2) INFORMATION FOR SEQ ID NO: 457: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 467: CACTTTGTCA CCAAATCTGC CTTTCAG 27 (2) INFORMATION FOR SEQ ID NO: 468: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 458: CTGAAAGGCA GATTTGGTGA CAAAGTG 27 (2) INFORMATION FOR SEQ ID NO: 459: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 459: GCCCCCCCCC AGCTCTCTTC G 21 (2) INFORMATION FOR SEQ ID NO: 460: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 460: CGAAGAGAGC TGGGGGGGGG C 21 (2) INFORMATION FOR SEQ ID NO: 461: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 461: GTCAGTTACG TACAGGGTTG AAGGAGTCGG GCTGAGACTG C 41 (2) INFORMATION FOR SEQ ID NO: 462: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 462: GTCAGTCCAT GGCTACTCAA GGTGCTATGC 30 (2) INFORMATION FOR SEQ ID NO: 463: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 463: GTAGCATACG TAGGGCTGCA GGGCAGGGGC C 31 (2) INFORMATION FOR SEQ ID NO: 464: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 166 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 464: Wing Pro Pro Arg Leu lie Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu 1 5 10 15 Leu Glu Wing Lys Glu Wing Glu Asn lie Thr Thr Gly Cys Wing Glu His 25 30 Cys Ser Leu Asn Glu Asn lie Thr Val Pro Asp Thr Lys Val Asn Phe 40 45 Tyr Wing Trp Lys Arg Met Glu Val Gly Gln Gln Wing Val Glu Val Trp 50 55 60 Gln Gly Leu Wing Leu Leu Ser Glu Wing Val Leu Arg Gly Gln Wing Leu 65 70 75 80 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp 85 90 95 Lys Wing Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu 100 105 110 Gly Ala Gln Lys Glu Ala lie Ser Pro Pro Asp Ala Ala Be Ala Ala 115 120 125 Pro Leu Arg Thr He Thr Wing Asp Thr Phe Arg Lys Leu Phe Arg Val 130 135 140 Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Wing 145 150 155 160 Cys Arg Thr Gly Asp Arg 165 (2) INFORMATION FOR SEQ ID NO: 465: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 165 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 465: Glu Gly He Cys Arg Asn Arg Val Thr Asn Asn Val Lys Asp Val Thr 1 5 10 15 Lys Leu Val Wing Asn Leu Pro Lys Asp Tyr Met He Thr Leu Lys Tyr 25 30 Val Pro Gly Met Asp Val Leu Pro Ser His Cys Trp He Ser Glu Met 40 45 Val Val Gln Leu Ser Asp Ser Leu Thr Asp Leu Leu Asp Lys Phe Ser 50 55 60 Asn He Ser Glu Gly Leu Ser Asn Tyr Ser He He Asp Lys Leu Val 65 70 75 80 Asn He Val Asp Asp Leu Val Glu Cys Val Lys Glu Asn Ser Ser Lys 85 90 95 Asp Leu Lys Lys Ser Phe Lys Ser Pro Glu Pro Arg Leu Phe Thr Pro 100 105 '110 Glu Glu Phe Phe Arg He Phe Asn Arg Ser He Asp Wing Phe Lys Asp 115 120 125 Phe Val Val Wing Ser Glu Thr Ser Asp Cys Val Val Ser Ser Thr Leu 130 135 140 Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu 145 150 155 160 Pro Pro Val Ala Ala 165 (2) INFORMATION FOR SEQ ID NO: 466: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 466: Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Wing 1 5 10 15 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 25 30 Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp 40 45 Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing 50 55 60 Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 65 70 75 80 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 85 90 95 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 100 105 110 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 115 120 125 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 130 135 (2) INFORMATION FOR SEQ ID NO: 467: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 467: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Wing Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu 50 55 60 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Ala Wing Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 145 150 155 (2) INFORMATION FOR SEQ ID NO: 468: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 468: Pro Pro Pro Wing Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp 'He Leu 50 55 60 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Ala Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Be Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala 145 150 155 160 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 165 170 175 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 180 185 190 His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu 195 200 205 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 210 215 220 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln 225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Gly 260 265 270 Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu Ser Phe Gln 275 280 285 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 290 295 300 Thr Leu Cys Val Arg 305 (2) INFORMATION FOR SEQ ID NO: 469: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 312 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 469: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 50 55 60 Gly Wing Val Thr Leu Leu Glu Glu Val Met Ala Ala Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Wing Ser 145 150 155 160 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 165 170 175 Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His 180 185 190 Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly 195 200 205 Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu Gly 210 215 220 Wing Val Thr Leu Leu Val Glu Glu Val Met Ala Ala Arg Gly Gln Leu 225 230 235 240 Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val 245 250 255 Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro 260 265 270 Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu 275 280 285 Being Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 290 295 300 Gly Gly Ser Thr Leu Cys Val Arg 305 310 (2) INFORMATION FOR SEQ ID NO: 470: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 313 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 470: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 50 55 60 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Ala Wing Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Wing 145 150 155 160 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 165 170 175 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 180 185 190 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 195 200 205 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu 210 215 220 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln 225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 260 265 270 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 275 280 285 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 290 295 300 Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 (2) INFORMATION FOR SEQ ID NO: 471: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 316 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 471: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 50 55 60 Gly Wing Val Thr Leu Leu slu Gly Val Met Wing Wing Arg Gly Gln 65 70 75 80 Leu sly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Oly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 115 120 125 Leu Ser Phe Oln His Leu Leu Arg sly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Oly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly sly Asn Gly Gly 145 150 155 160 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser 165 170 175 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys 180 185 190 Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp 195 200 205 Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln 210 215 220 Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala 225 230 235 240 Arg sly sln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly sln Leu 245 250 255 Be Gly Gln Leu Le Gly 260 265 270 Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn 275 280 285 Wing He Phe Leu Ser Phe Gln His Leu Leu Arg Oly Lys Val Arg Phe 290 295 300 Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 315 (2) INFORMATION FOR SEQ ID NO: 472: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 472: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Val Phe 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 130 135 140 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 145 150 155 160 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 165 170 175 Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 180 185 190 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 195 200 205 Thr He Trp Oln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln 210 215 220 Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg 225 230 235 240 Wing Gly Gly Val Leu Val Wing Ser His Leu sln Ser Phe Leu Olu Val 245 250 255 Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly 260 265 270 Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Olu sln Val Arg Lys He 275 280 285 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 290 295 300 (2) INFORMATION FOR SEQ ID NO: 473:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 473: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 '70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Olu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160 Being Leu Gly He Pro Trp Wing Pro Leu Being Ser Cys Pro Being Gln Ala 165 170 175 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser sly Leu Phe Leu 180 185 190 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 195 200 205 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 210 215 220 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 225 230 235 240 Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing 245 250 255 Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe Leu Glu Val Ser 260 265 270 Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Gly 275 280 285 Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln 290 295 300 Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 305 310 315 (2) INFORMATION FOR SEQ ID NO: 474: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 474: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Pro Wing Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu sln Wing Oln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser sly Gly Gly Ser 115 120 125 Asn Met Pro Wing Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 130 135 140 Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly 145 150 155 160 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 165 170 175 Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu 180 185 190 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln 195 200 205 Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu 210 215 220 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 225 230 235 240 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 245 250 255 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 260 265 270 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 275 280 285 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 290 295 300 (2) INFORMATION FOR SEQ ID NO: 475: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 475: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu sln Wing Gln Glu Gln sln Tyr 100 105 '110 Val Glu Oly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val 145 150 155 160 Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met 165 170 175 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser 180 185 190 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln 195 200 205 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 210 215 220 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu 225 230 235 240 Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu 245 250 255 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 260 265 270 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 275 280 285 Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 290 295 300 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser 305 310 315 (2) INFORMATION FOR SEQ ID NO: 476: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 476: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Olu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Ala Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro 130 135 140 Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala 145 150 155 160 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 165 170 175 Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu 180 185 190 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 195 200 205 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 210 215 220 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser 225 230 235 240 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 245 250 255 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He 260 265 270 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 275 280 285 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly 290 295 300 (2) INFORMATION FOR SEQ ID NO: 477: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 477: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Val Phe 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Olu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln slu Oln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Met Wing Pro Wing Leu Oln Pro Thr Gln Gly Wing Met Pro Wing 145 150 155 160 Phe Ala Be Ala Phe sln Arg Arg Ala sly Gly Val Leu Val Ala Ser 165 170 175 His Leu Gln Ser Phe Leu slu Val Ser Tyr Arg Val Leu Arg His Leu 180 185 190 Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys 195 200 205 Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln 210 215 220 Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu slu Leu Val 225 230 235 240 Leu Leu sly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Ser Cys 245 250 255 Pro Ser Gln Ala Leu Oln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 260 265 270 Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Olu Gly He Ser 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 290 295 300 Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly 305 310 315 (2) INFORMATION FOR SEQ ID NO: 478: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 478: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Ala Wing Pro Wing Leu Gln Pro Thr Gln Oly Wing Met Pro Wing 145 150 155 160 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 165 170 175 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 180 185 190 Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys 195 200 205 Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln 210 215 220 Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240 Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Ser Cys 245 250 255 Pro Ser Gln Ala Leu aln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 260 265 270 Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 290 295 300 Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly 305 310 315 (2) INFORMATION FOR SEQ ID NO: 479:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 479: sn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg 145 150 155 160 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 165 170 175 Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser 180 185 190 Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys 195 200 205 He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr 210 215 220 Lys Leu Cys His Pro Olu Glu Leu Val Leu Leu Gly His Ser Leu Oly 225 230 235 240 He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu 245 250 255 Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly 260 265 270 Leu Leu Gln Ala Leu Glu sly He Ser Pro Glu Leu Gly Pro Thr Leu 275 280 285 Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln 290 295 300 Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 305 310 315 (2) INFORMATION FOR SEQ ID NO: 480: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 480: sn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala 130 135 140 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160 Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu 165 170 175 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 180 185 190 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 195 200 205 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 210 215 220 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 225 230 235 240 Be Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 245 250 255 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala ' 260 265 270 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu sly Met Wing 275 280 285 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 290 295 300 (2) INFORMATION FOR SEQ ID NO: 481: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 481: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Oly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser 145 150 155 160 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 165 170 175 Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys 180 185 190 Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln 195 200 205 slu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 210 215 220 Leu Leu sly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys 225 230 235 240 Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser 245 250 255 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 260 265 270 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 275 280 285 Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro 290 295 300 Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing 305 310 315 (2) INFORMATION FOR SEQ ID NO: 482: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 482: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Oln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Oly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Oly Gly Ser 115 120 125 Asn Met Wing Tyr Lys Leu Cys His Pro Glu Olu Leu Val Leu Leu Gly 130 135 140 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 145 150 155 160 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 165 170 175 Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 180 185 190 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 195 200 205 Thr He Trp Oln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu Gln 210 215 220 Pro Thr Gln Oly Wing Met Pro Wing Phe Wing Being Wing Phe Oln Arg Arg 225 230 235 240 Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val 245 250 255 Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly Pro 260 265 270 Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val 275 280 285 Arg Lys He Gln Gly Asp Gly Ala Ala Glu Gllu Glu Lys Leu Cys Ala 290 295 300 Thr 305 (2) INFORMATION FOR SEQ ID NO: 483: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 483: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Val Phe 40 45 Arg Wing Val Lys Asn Leu Glu Asn Wing Ser sly He slu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Wing Thr Wing Wing Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160 Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing 165 170 175 Leu Gln Leu Ala Oly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 180 185 190 Tyr aln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu aly 195 200 205 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 210 215 220 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 225 230 235 240 Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala 245 250 255 Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu slu Val Ser 260 265 270 Tyr Arg Val Leu Arg His Leu Wing Oln Pro Thr Pro Leu Gly Pro Wing 275 280 285 Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg 290 295 300 Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 305 310 315 320 (2) INFORMATION FOR SEQ ID NO: 484: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 484: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40"45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln Tyr 100 105 110 Val Olu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Oly Gly Ser 115 120 125 Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 130 135 140 Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu Leu Gly 145 150 155 160 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 165 170 175 Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu 180 185 190 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln 195 200 205 Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 210 215 220 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 225 230 235 240 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 245 250 255 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Ser 260 265 270 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 275 280 285 Ser Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He 290 295 300 Ser 305 (2) INFORMATION FOR SEQ ID NO: 485:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 485: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val alu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 '120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val 145 150 155 160 Wing Asp Phe Wing Thr Thr He Trp Gln sln Met slu Olu Leu Gly Met 165 170 175 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser 180 185 190 Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln 195 200 205 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro 210 215 220 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys 225 230 235 240 Ser Leu Clu Oln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln 245 250 255 Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 260 265 270 Leu Leu Gly His Ser Leu sly Pro Pro Pro Wing Leu Ser Ser Cys 275 280 285 Pro Ser Oln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 290 295 300 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser 305 310 315 320 (2) INFORMATION FOR SEQ ID NO: 486: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 486: sn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly G - and Gly Ser 115 120 125 Asn Met Wing Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Ala Met Pro 130 135 140 Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing 145 150 155 160 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 165 170 175 Leu Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 180 185 190 Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 195 200 205 Ala Ala Glu Gllu Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 210 215 220 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro 225 230 235 240 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 245 250 255 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 260 265 270 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 275 280 285 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 290 295 300 Gly 305 (2) INFORMATION FOR SEQ ID NO: 487: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 487: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu sly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing 145 150 155 160 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 165 170 175 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 180 185 190 Wing Gln Pro Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe 195 200 205 Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing 210 215 220 Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu 225 230 235 240 Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu 245 250 255 Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln 260 265 270 Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu 275 280 285 Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 290 295 300 Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly 305 310 315 320 (2) INFORMATION FOR SEQ ID NO: 488: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 488: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro sly Gly Gly Ser Oly Gly Gly Ser 115 120 125 Asn Met Ala Thr sln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln 130 135 140 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu 145 150 155 160 Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu 165 170 175 Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Ser Leu Glu 180 185 190 Gln Val Arg Lys He Gln Oly Asp Gly Ala Ala Leu Gln Olu Lys Leu 195 200 205 Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 210 215 220 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 225 230 235 240 Ala Leu Gln Leu Ala Oly Cys Leu Ser sln Leu His Ser sly Leu Phe 245 250 255 Leu Tyr Oln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu 260 265 270 Oly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 275 280 285 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln 290 295 300 Pro 305 (2) INFORMATION FOR SEQ ID NO: 489: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 489: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln slu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala aln Glu Gln Gln Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120. 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg 145 150 155 160 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 165 170 175 Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro Leu Gly 180 185 190 Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln 195 200 205 Val Arg Lys He Gln Gly Asp Gly Wing Wing Wing Glu Lys Leu Cys 210 215 220 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240 Being Leu sly He Pro Trp Wing Pro Leu Being Ser Cys Pro Ser Gln Wing 245 250 255 Leu Gln Leu Ala Oly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 260 265 270 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 275 280 285 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 290 295 300 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 305 310 315 320 (2) INFORMATION FOR SEQ ID NO: 490: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 490: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala sln Glu Gln sln Tyr 100 105 110 Val slu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Wing Being Wing Phe Oln Arg Arg Wing sly sly Val Leu Val Wing 130 135 140 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160 Leu Ala Gln Pro Thr Pro Leu Gly Pro Wing Ser Ser Leu Pro Gln Ser 165 170 175 Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Oly Asp Gly 180 185 190 Wing Wing Leu Gln alu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro 195 200 205 Glu Glu Leu Val Leu Leu Gly His Ser Leu sly He Pro Trp Wing Pro 210 215 220 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Oly Cys Leu Ser 225 230 235 240 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 245 250 255 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 260 265 270 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 275 280 285 Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe 290 295 300 Wing 305 (2) INFORMATION FOR SEQ ID NO: 491:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 491: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 40 45 Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr 100 105 110 Val Olu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 115 120 125 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Being 145 150 155 160 His Leu Gln Ser Phe Leu Olu Val Ser Tyr Arg Val Leu Arg His Leu 165 170 175 Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe 180 185 190 Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing 195 2Q0 205 Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu 210 215 220 Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu 225 230 235 240 Ser Ser Cys Pro Ser Gln Ala Leu aln Leu Wing Gly Cys Leu Ser Gln 245 250 255 Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu 260 265 270 Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 275 280 285 Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Olu Glu Leu Gly 290 295 300 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 305 310 315 320 (2) INFORMATION FOR SEQ ID NO: 492: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 321 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 492: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp 1 5 10 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Wing Val Lys 20 25 30 Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Oln 40 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He 50 55 60 He Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80 Leu Val Thr Leu Glu Gln Wing Gln Glu Gln sln sly Gly Gly Ser Asn 85 90 95 Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro 100 105 110 Wing Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu 210 215 220 Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 290 295 300 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Wing Leu Gln 305 310 315 320 Pro (2) INFORMATION FOR SEQ ID NO: 493: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 321 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 493: Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu 1 5 10 15 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala 25 30 Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 35 40 45 Leu Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He 50 55 60 Met He Asp Glu He He His His Leu Lys Arg Pro Pro Wing Pro Leu 65 70 75 80 Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp 85 90 95 Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys 100 105 110 Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu 210 215 220 'Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 260 265"270 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 290 295 300 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln 305 * 310 315 320 Pro (2) INFORMATION FOR SEQ ID NO: 494: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 321 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 494: Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu 1 5 10 15 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 25 30 Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He 40 45 He His His Leu Lys Arg Pro Pro Pro Leu Leu Asp Pro Asn Asn 50 55 60 Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu 65 70 75 80 Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala 85 90 95 Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 100 105 110 Wing Thr Wing Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Wing Thr Gln Oly Wing Met Pro Wing Phe Wing Being 145 150 155 160 Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Oln 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 290 295 300 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln 305 310 315 320 Pro (2) INFORMATION FOR SEQ ID NO: 495: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 321 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 495: Wing Gly Asp Trp Gln alu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val 1 5 10 15 Thr Leu Glu sln Wing sln Glu Gln sln Gly Gly Gly Ser Asn Cys Ser 25 30 He Met He Asp Olu He He His His Leu Lys Arg Pro Pro Wing Pro 35 40 45 Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met 50 55 60 Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val 65 70 75 80 Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu 85 90 95 Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro He 100 105 110 He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu 210 215 220 Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 290 295 300 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln 305 310 315 320 Pro (2) INFORMATION FOR SEQ ID NO: 496: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 496: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp 1 5 10 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg Ala Val Lys 20 25 30 Asn Leu Glu Asn Wing Be Gly He Glu Wing He Leu Arg Asn Leu Gln 40 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He 50 55 60 He Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80 Leu Val Thr Leu Glu Gln Wing Gln alu Gln Oln Gly Gly aly Ser Cly 85 90 95 aly aly Ser aly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He 100 105 110 He His His Leu Lys Arg Pro Pro Wing Pro Leu Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Gly Pro Be Ser Thr He Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Olu Val Ser Tyr Arg 180 185 190 Val Leu Arg His Leu Wing Oln Pro Ser sly Oly Ser Gly Gly Ser Gln 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp 210 215 220 Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Olu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu 260 265 270 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing 275 280 285 Leu Glu Oly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 290 295 300 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: 497: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 497: Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu 1 5 10 15 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala 25 30 Gly Asp Trp Oln alu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 35 40 45 Leu Glu Gln Wing Gln Glu Gln sln Oly Gly Gly Ser Oly Gly Gly Ser 50 55 60 Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His 65 70 75 80 Leu Lys Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp 85 90 95 Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu 100 105 110 Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg 180 185 190 Val Leu Arg His Leu Wing Gln Pro Ser Gly Gly Ser Gly Oly Ser Gln 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Oln Gly Asp 210 215 220 Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 245 250 255 Pro Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu 260 265 270 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing 275 280 285 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 290 295 300 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met slu alu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: 498: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 498: Ala Pro Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu 1 5 10 15 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Olu Gln Ala Gln 25 30 Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn 40 45 Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro 50 55 60 Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He 65 70 75 80 Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val Arg 85 90 95 Wing Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg 100 105 110 Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Clu Val Ser Tyr Arg 180 185 190 Val Leu Arg His Leu Ala aln Pro Ser aly Gly Ser Gly Gly Ser Gln 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp 210 215 220 Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu aly He Pro Trp Wing 245 250 255 Pro Leu Ser Ser Cys Pro Ser Cln Ala Leu Gln Leu Ala Gly Cys Leu 260 265 270 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala 275 280 285 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 290 295 300 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln sln Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: 499: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 499: Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Thr Phe Tyr Val 1 5 10 15 Thr Glu Gln Wing Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly 25 30 Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His 35 40 45 His Lys Arg Pro Pro Ala Pro Asp Pro Asn Asn Asn 50 55 60 Asp Glu Asp Val Ser He Met Asp Arg Asn Arg Pro Asn 65 70 75 80 Glu Ser Phe Val Arg Ala Val Lys Asn Glu Asn Ala Ser aly 85 90 95 He Glu Ala He Arg Asn Gln Pro Cys Pro Ser Ala Thr 100 105 110 Ala Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln 145 150 155 160 Oly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly 165 170 175 Val Val Ala Ser His Gln Ser Phe Glu Val Ser Tyr Arg 180 185 190 Val Arg His Wing Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln 195 200 205 Ser Phe Lys Ser Glu Gln Val Arg Lys He Gln Gly Asp 210 215 220 Gly Ala Ala aln Glu Lys Cys Wing Thr Tyr Lys Cys His 225 230 235 240 Pro Glu Glu Val Gly His Ser Gly He Pro Trp Wing 245 250 255 Pro Ser Ser Cys Pro Ser Gln Ala sln Ala aly Cys Leu 260 265 270 Ser Oln His Ser Gly Phe Tyr Gln Gly Gln Wing 275 280 285 Glu Gly He Ser Pro Olu Gly Pro Thr Asp Thr Gln 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu 305 310 315 320 Gly Met Ala Pro Ala Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: 500:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: lineai (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 500: Met Wing Asn Cys Ser He Met Met He Asp Glu He He His His Lys 1 5 10 15 Arg Pro Pro Wing Pro Asp Pro Asn Asn Asn Asp Glu Asp 25 30 Val Ser He Met Asp Arg Asn Arg Pro Asn Glu Be 40 45 Phe Val Arg Ala Val Lys Asn Glu Asn Wing Ser Gly He Glu Wing 50 55 60 He Arg Asn Cln Pro Cys Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg 85 90 95 Glu Lys Thr Phe Tyr Val Thr Glu Gln Ala Gln Glu Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly alu Pro Ser Gly Pro 115 120 125 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Tyr Lys Cys His Pro Glu Glu Val 145 150 155 160 Gly His Ser Gly He Pro Trp Wing Pro Ser Ser Cys Pro Ser 165 170 175 Gln Ala Gln Wing Gly Cys Ser Gln His Ser Gly 180 185 190 Phe Tyr Gln Gly Gln Wing Glu Gly He Ser Pro Glu 195 200 205 Gly Pro Thr Asp Thr Gln Asp Val Wing Asp Phe Ala 210 215 220 Thr Thr He Trp Gln Gln Met Glu Glu Gly Met Wing Pro Ala 225 230 235 240 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 245 250 255 Arg Ala Gly Gly Val Val Ala Ser His Gln Ser Phe Glu 260 265 270 Val Ser Tyr Arg Val Arg His Wing Gln Pro Gly Gly Gly Ser 275 280 285 Asp Met Wing Thr Pro Gly Pro Wing Being Ser Pro Gln Ser Phe 290 295 300 Lys Ser Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala 305 310 315 320 Ala Gln Glu Lys Cys Ala Thr 325 (2) INFORMATION FOR SEQ ID NO: 501:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 501: Met Wing Asn Cys Ser He Met He Asp Glu He He His His Lys 1 5 10 15 Arg Pro Pro Pro Wing Asp Pro Asn Asn Asn Asp Glu Asp 20 25 30 Val Ser He Met Asp Arg Asn Arg Pro Asn Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Glu Asn Wing aly He Glu Ala 50 55 60 He Arg Asn Gln Pro Cys Pro Be Ala Thr Ala Ala Pro 65 70 75 80 Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln 100 105 110 Gln Tyr Val Olu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Wing Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 145 150 155 160 Asp Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu Leu 165 170 175 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 180 185 190 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Ser 195 195 205 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing 210 215 220 Gln Pro Gly Gly Gly Ser Asp Met Wing Thr Pro Leu Gly Pro Wing Ser 225 230 235 240 Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys 245 250 255 He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr 260 265 270 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 275 280 285 He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu 290 295 300 Wing Gly Cys Leu Ser Gln Leu His Ser Cly Leu Phe Leu Tyr Gln Gly 305 310 315 320 Leu Leu aln Ala Leu Glu Gly He Ser 325 (2) INFORMATION FOR SEQ ID NO: 502:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 502: Met Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys 1 5 10 15 Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 25 30 Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing 50 55 60 He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val 145 150 155 160 Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 165 170 175 His Leu Wing Gln Pro Gly Gly Gly Being Asp Met Wing Thr Pro Leu Cly 180 185 190 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Oln 195 200 205 Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys 210 215 220 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240 Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing 245 250 255 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 260 265 270 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 275 280 285 Pro Thr Leu -Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr 290 295 300 He Trp aln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 305 310 315 320 Thr Gln Gly Ala Met Pro Ala Phe Ala 325 (2) INFORMATION FOR SEQ ID NO: 503: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 503: Met Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys 1 5 10 15 Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 20 25 30 Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing 50 55 60 He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Olu Pro Ser Gly Pro 115 120 125 I Have Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Wing Met Wing Pro Pro Wing Leu Gln Pro Thr Gln Gly Wing Met 145 150 155 160 Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val 165 170 175 Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 180 185 190 His Leu Wing Gln Pro Gly Gly Gly Ser Asp Met Wing Thr Pro Leu Gly 195 200 205 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln 210 215 220 Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys 225 230 235 240 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Being Leu Gly He Pro Trp Wing Pro Leu Being Ser Cys Pro Being Gln Ala 260 265 270 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 He Trp Gln Gln Met Glu Glu Leu Gly 325 (2) INFORMATION FOR SEQ ID NO: 504: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 504: Met Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Leys 1 5 10 15 Arg Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 25 30 Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing 50 55 60 He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Ser Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg. 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe 145 150 155 160 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Gly Gly 180 185 190 Gly Ser Asp Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln 195 200 205 Being Phe Leu Leu Lys Being Leu Glu Gln Val Arg Lys He Gln Gly Asp 210 215 220 Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Oly He Pro Trp Wing 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu 260 265 270 Ser Gln Leu His Ser aly Leu Phe Leu Tyr Gln aly Leu Leu Gln Wing 275 280 285 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 290 295 300 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: dOd: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 319 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: dOd: Met Wing Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys 1 5 10 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 25 30 Gln Asp He Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Wing 40 45 Phe Asn Arg Wing Val Lys Ser Leu Gln Asn Wing Ser Wing He Glu Ser 50 55 60 He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Wing Thr Wing Wing Pro 65 70 75 80 Thr Arg His Pro He His He Lys Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Wing Gln Wing Oln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 I Have Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe 145 150 155 160 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Ser Gly 180 185 190 Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu alu Gln Val 195 200 205 Arg Lys He Gl-n Oly Asp Gly Ala Ala Leu Gln Olu Lys Leu Cys Ala 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240 Leu Oly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu 245 250 255 Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr 260 265 270 Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro 275 280 285 Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He 290 295 300 Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 305 310 315 (2) INFORMATION FOR SEQ ID NO: 606: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 506: Met Wing Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys 1 5 10 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn sly Glu Asp 25 30 Gln Asp He Leu Met Olu Asn Asn Leu Arg Arg Pro Asn Leu Glu Wing 35 40 45 Phe Asn Arg Wing Val Lys Ser Leu Gln Asn Wing Ser Wing He Olu Ser 50 55 60 He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Wing Thr Ala Wing Pro 65 70 75 80 Thr Arg His Pro He He He Arg Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Wing Gln Ala Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe 145 150 155 160 Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Ser Leu Gln Ser Phe 165 170 175 Leu Olu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Ser Leu 195 200 205 Olu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Clu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro alu Clu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 290 295 300 Thr Thr He Trp Gln aln Met Glu Clu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gln Pro (2) INFORMATION FOR SEQ ID NO: 507: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 319 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 507: Met Wing Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys 1 5 10 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gln Asp He Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Wing 35 40 45 Phe Asn Arg Wing Val Lys Ser Leu Gln Asn Wing Ala He Glu Being 50 55 60 He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80 Thr Arg His Pro He He He Arg Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Wing Gln Ala Gln 100 105 110 Cln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 I Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gln aly Ala Met Pro Ala Phe Ala Be Ala Phe 145 150 155 160 aln Arg Arg Ala aly Oly Val Leu Val Ala Ser His Leu Gln Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala aln Pro Ser Gly 180 185 190 Gly Ser aly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val 195 200 205 Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240 Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu 245 250 255 Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr 260 265 270 Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly Pro 275 280 285 Thr Leu Asp Thr Leu Oln Leu Asp Val Wing Asp Phe Wing Thr Thr He 290 295 300 Trp Gln Gln Met Glu Glu Leu Oly Met Ala Pro Ala Leu Gln Pro 305 310 315 (2) INFORMATION FOR SEQ ID NO: 508: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 508: Met Wing Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys 1 5 10 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gln Asp He Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Wing 40 45 Phe Asn Arg Wing Val Lys Ser Leu Gln Asn Wing Ser Wing He Glu Ser 50 55 60 He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Wing Thr Wing Wing Pro 65 70 75 80 Thr Arg His Pro He His He Lys Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Wing Gln Wing Gln 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe 145 150 155 160 Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His Leu Gln Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu 195 200 205 alu aln Val Arg Lys He Cln Gly Asp Gly Ala Ala Leu Gln Glu Lys 210 215 220 Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro (2) INFORMATION FOR SEQ ID NO: 509:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 509: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Olu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu alu Ser Phe 40 45 Val Arg Ala Val Lys Asn Leu alu Asn Ala Ser aly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Cly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala aln Clu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing 165 170 175 Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing 180 185 190 Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Cly Gln 195 200 205 Leu Ser Gly Gln Val Arg Leu Leu Leu sly Ala Leu Oln Ser Leu Leu 210 215 220 Gly Thr Gln Leu Pro Pro Gln Cly Arg Thr Thr Wing His Lys Asp Pro 225 230 235 240 Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg 245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu 275 280 285 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln 290 295 300 Cys Pro 305 (2) INFORMATION FOR SEQ ID NO: 510:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 510: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 165 170 175 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser sly Gln 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 210 215 220 Pro Pro Gln Gly Arg Thr Thr Wing Kis Lys Asp Pro Asn Wing He Phe 225 230 235 240 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 245 250 255 Val aly aly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Wing 260 265 270 Ser Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 275 280 285 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Oln Cys Pro alu Val 290 295 300 His Pro 305 (2) INFORMATION FOR SEQ ID NO: 511: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 511: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160 Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr 165 170 175 Leu Leu Leu Glu Le Val Met Ala Le Ala Arg Le Gly Gln Le Gly Pro Thr 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly 210 215 220 Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gln 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Wing Ser Pro Wing Pro 260 265 270 Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His 275 280 285 Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro 290 295 300 Thr Pro 305 (2) INFORMATION FOR SEQ ID NO: 512: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 512: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Ala 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Cln Glu Gln Cln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu 145 150 155 160 Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu 165 170 175 Gly Val Met Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala 210 215 220 His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 Arg Glu Phe Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp 260 265 270 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 275 280 285 Arg Leu Ser Gln Cys Pro Glu Val Kis Pro Leu Pro Thr Pro Val Leu 290 295 3Q0 Leu Pro 305 (2) INFORMATION FOR SEQ ID NO: 513: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 513: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr 145 15Q 155 160 Lys Ala Gln Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 165 170 175 Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu '180 185 190 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser 195 200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys 210 215 220 Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 245 250 255 Phe Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg 260 265 270 Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu 275 280 285 Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 290 295 300 Wing Val 305 (2) INFORMATION FOR SEQ ID NO: 514: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 514: Wing Asn Cys Ser He Met lie Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Be 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Olu Gln Wing Gln Olu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Oly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp 145 150 155 160 He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser 180 185 190 Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr 195 200 205 Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing 210 215 220 He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn 245 250 255 Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys 260 265 270 Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro 275 280 285 Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe 290 295 300 Ser Leu 305 (2) INFORMATION FOR SEQ ID NO: 516: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 516: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala sly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly ally Cly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly 145 150 155 160 Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln 165 170 175 Leu Pro Pro Oln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He 180 185 190 Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met 210 215 220 Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu 225 230 235 240 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu 245 250 255 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser 260 265 270 Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He 275 280 285 Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly 290 295 300 Gln Leu 305 (2) INFORMATION FOR SEQ ID NO: 516:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 516: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Olu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys 145 150 155 160 Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val aly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Gly Asn Met Ala Pro Ser Ala Pro Pro Ala Cys Asp Leu Arg 195 200 205 Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu 210 215 220 Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 225 230 235 240 Val Wing Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr 245 250 255 Lys Ala Gln Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 260 265 270 Met Ala Ala Arg Gly Gln Leu Cly Pro Thr Cys Leu Ser Ser Leu Leu 275 280 285 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser 290 295 300 Leu Leu 305 (2) INFORMATION FOR SEQ ID NO: 517: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 517: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly ally Gly Gly Pro Pro ally Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu 145 150 155 160 Being Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 165 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Wing Ser 180 185 190 Pro Pro Wing Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 195 200 205 Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His 210 215 220 Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly 225 230 235 240 Glu Trp Lys Thr Gln Met Olu Glu Thr Lys Ala Gln Asp He Leu Gly 245 250 255 Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln Leu 260 265 270 Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val 275 280 285 Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro 290 295 300 Pro Gln 305 (2) INFORMATION FOR SEQ ID NO: 518: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 518: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Oln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gln His 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr 165 170 175 Leu Cys Val Arg Glu Phe Gly Gly Asn Met Wing Pro Pro Wing Pro Pro 180 185 190 Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 195 200 205 Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr 210 215 220 Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr 225 230 235 240 Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu 245 250 255 Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys 260 265 270 Leu Be Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu 275 280 285 Oly Ala Leu Oln Ser Leu Leu aly Thr aln Leu Pro Pro Gln Gly Arg 290 295 300 Thr Thr 305 (2) INFORMATION FOR SEQ ID NO: 519: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 519: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Olu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg 145 150 155 160 aly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu 225 230 235 240 Glu Thr Lys Ala aln Asp He Leu Oly Wing Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser 260 265 270 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala 290 295 300 His Lys 305 (2) INFORMATION FOR SEQ ID NO: 520: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 520: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing He Phe Leu Ser Phe Oln His Leu Leu Arg Gly Lys Val 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 165 170 175 Gly aly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val 180 185 190 Leu Ser Lys Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 195 200 205 Cln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 210 215 220 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys 225 230 235 240 Ala Gln Asp He Leu aly Ala Val Thr Leu Leu Leu alu sly Val Met 245 250 255 Ala Ala Arg sly Cln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly 260 265 270 Gln Leu Ser Gly Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu 275 280 285 Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp 290 295 300 Pro Asn 305 (2) INFORMATION FOR SEQ ID NO: 521: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 521: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing 165 170 175 Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing 180 185 190 Wing Arg Gly Gln Leu aly Pro Thr Cys Leu Ser Ser Leu Leu sly Gln 195 200 205 Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu 210 215 220 ally Thr Oln Leu Pro Pro aln Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240 Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Oly Lys Val Arg 245 250 255 Phe Leu Met Leu Val aly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser 275 280 285 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys 290 295 300 Pro 305 (2) INFORMATION FOR SEQ ID NO: 522: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 622: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 165 170 175 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 210 215 220 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 225 230 235 240 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 245 250 255 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Wing Ser 260 265 270 Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 275 280 285 Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His 290 295 300 Pro 305 (2) INFORMATION FOR SEQ ID NO: 623:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 523: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160 Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr 165 170 175 Leu Leu Leu Glu Le Val Met Ala Le Ala Arg Le Gly Gln Le Gly Pro Thr 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly 210 215 220 Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu Ser Phe Gln 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Asn Met Wing Pro Pro Wing Pro Pro 260 265 270 Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 275 280 285 Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr 290 295 300 Pro 305 (2) INFORMATION FOR SEQ ID NO: 524: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 524: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu 145 150 155 160 Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu 165 170 175 Gly Val Met Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala 210 215 220 His Lys Asp Pro Asn Wing He Phe Leu Be Phe Gln His Leu Leu- Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 Arg Glu Phe Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu 260 265 270 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 275 280 285 Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu 290 295 300 Pro 305 (2) INFORMATION FOR SEQ ID NO: 626: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 525: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr 145 150 155 160 Lys Ala Gln Asp He Leu Oly Wing Val Thr Leu Leu Leu alu Oly Val 165 170 175 Met Wing Wing Arg Oly Gln Leu Gly Pro Thr Cys Leu Being Ser Leu Leu 180 185 190 Gly Cln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Wing Leu Gln Ser 195 200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys 210 215 220 Asp Pro Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Oly Ser Thr Leu Cys Val Arg Glu 245 250 255 Phe Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val 260 265 270 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 275 280 285 Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 290 295 300 Val 305 (2) INFORMATION FOR SEQ ID NO: 526: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 526: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Wing Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Glu Trp Lys Thr Gln Met alu Glu Thr Lys Ala Gln Asp 145 150 155 160 He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser 180 185 190 Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr 195 200 205 Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing 210 215 220 He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met 245 250 255 Wing Ser Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu 260 265 270 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu 275 280 285 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser 290 295 300 Leu 305 (2) INFORMATION FOR SEQ ID NO: 527: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 527: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala Oly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met aly Pro Thr Cys Leu Ser Leu Leu Gly Gln Leu Ser Gly 145 150 155 160 Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln 165 170 175 Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He 180 185 190 Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Wing 210 215 220 Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 225 230 235 240 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 245 250 255 His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu 260 265 270 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 275 280 285 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln 290 295 300 Leu 305 (2) INFORMATION FOR SEQ ID NO: 528: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 528: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 3C Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln aln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys 145 150 155 160 Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val 195 '200 205 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 210 215 220 Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 225 230 235 240 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys 245 250 255 Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met 260 265 270 Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly 275 280 285 Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Wing Leu Gln Ser Leu 290 295 300 Leu 305 (2) INFORMATION FOR SEQ ID NO: 529:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30d amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 529: Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu aln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu 145 150 155 160 Being Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 165 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro 180 185 190 Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp 195 200 205 Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro alu Val His Pro 210 215 220 Leu Pro Thr Pro Val Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu 225 230 235 240 Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing 245 250 255 Val Thr Leu Leu Leu Glu Gly Val Met Ala Wing Arg Gly Gln Leu Gly 260 265 270 Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg 275 280 285 Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro 290 295 300 Gln 305 (2) INFORMATION FOR SEQ ID NO: 530: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 530: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val alu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing His Lys Asp Pro Asn Wing He Phe Leu Ser Phe Gln His 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr 165 170 175 Leu Cys Val Arg Glu Phe Gly Asn Met Wing Pro Pro Wing Pro Pro Wing 180 185 190 Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu 195 200 205 His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro 210 215 220 Val Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln 225 230 235 240 Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu 245 250 255 Leu Glu Gly Val Met Ala Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu 260 265 270 Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly 275 280 285 Wing Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln aly Arg Thr 290 295 300 Thr 305 (2) INFORMATION FOR SEQ ID NO: 531: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 531: Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln sln 100 105 110 Tyr Val Olu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu 180 185 190 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 195 200 205 Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu 210 215 220 Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Aln Met Clu Glu 225 230 235 240 Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Olu Gly 245 250 255 Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu 260 265 270 Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln 275 280 285 Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His 290 295 300 Lys 305 (2) INFORMATION FOR SEQ ID NO: 532: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 532: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp aln alu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 165 170 175 Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu 180 185 190 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln 195 200 205 Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val 210 215 220 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala 225 230 235 240 Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing 245 250 255 Wing Arg Gly Gln Leu Oly Pro Thr Cys Leu Being Ser Leu Leu Gly Gln 260 265 270 Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu 275 280 285 Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro 290 295 300 Asn 305 (2) INFORMATION FOR SEQ ID NO: 533: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 533: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu slu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Olu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Oln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Clu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Olu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing 165 170 1-75 Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing 180 185 190 Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln 195 200 205 Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu 210 215 220 Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro 225 230 235 240 Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg aly Lys Val Arg 245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Gly Asn Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu 275 280 285 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 290 295 300 Leu Ser Gln Cys Pro 305 (2) INFORMATION FOR SEQ ID NO: 534: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 534: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Clu Ser Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Val Asp Phe Ser Leu 145 150 155 160 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 165 170 175 Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 210 215 220 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 225 230 235 240 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 245 250 255 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly 260 265 270 Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser 275 280 285 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys 290 295 300 Pro slu Val His Pro 305 (2) INFORMATION FOR SEQ ID NO: 53d:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 53d: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala aln Glu Gln aln 100 .105 110 Tyr Val alu Oly Gly Gly Gly Ser Pro Gly Olu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160 Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu sly Wing Val Thr 165 170 175 Leu Leu Leu Glu Le Val Met Ala Le Ala Arg Le Gly Gln Le Gly Pro Thr 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly 210 215 220 Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu Ser Phe Gln 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Wing 260 265 270 Pro Pro Wing Pro Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 275 280 285 Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His 290 295 300 Pro Leu Pro Thr Pro 305 (2) INFORMATION FOR SEQ ID NO: 636: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 636: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu 145 150 155 160 Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu 165 170 175 Gly Val Met Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Being 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala 210 215 220 His Lys Asp Pro Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Wing Ser Pro Pro Pro Wing 260 265 270 Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 275 280 285 Leu His Ser Arg Leu Ser Gln Cys Pro alu Val His Pro Leu Pro Thr 290 295 300 Pro Val Leu Leu Pro 305 (2) INFORMATION FOR SEQ ID NO: 537: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 537: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Cln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Phe Ser Leu Oly Glu Trp Lys Thr Gln Met Glu Glu Thr 145 150 155 160 Lys Ala Gln Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 165 170 175 Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu 180 185 190 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Wing Leu Gln Ser 195 200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys 210 215 220 Asp Pro Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg sly Lys 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 245 250 255 Phe Gly Gly Asn Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys 260 265 270 Asp Leu Arg Val Leu Ser Lys Leu Arg Asp Ser His Val Leu His 275 280 285 Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val 290 295 300 Leu Leu Pro Ala Val 305 (2) INFORMATION FOR SEQ ID NO: 638: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 638: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Olu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln sln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly slu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp 145 150 155 160 He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Ala Arg 165 170 175 Gly Gln Leu Gly Pro Thr Cys Leu Be Ser Leu Leu Gly Gln Leu Ser 180 185 190 Gly Gln Val Arg Leu Leu Leu Gly Wing Leu Oln Ser Leu Leu Gly Thr 195 200 205 Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing 210 215 220 He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn 245 250 255 Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val 260 265 270 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 275 280 285 Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Wing 290 295 300 Val Asp Phe Ser Leu 305 (2) INFORMATION FOR SEQ ID NO: 539: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 539: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly 145 150 155 160 Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln 165 170 175 Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He 180 185 190 Phe Leu Ser Phe Gln His Leu Leu Arg Oly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly 210 215 220 Gly Asn Met Wing Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu 225 230 235 240 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln 245 250 255 Cys Pro Olu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 260 265 270 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing 275 280 285 Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing 290 295 300 Wing Arg Gly Gln Leu 305 (2) INFORMATION FOR SEQ ID NO: 640: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 540: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 - Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Wing His Lys 145 150 155 160 Asp Pro Asn Ala He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Gly Asn Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys 195 200 205 Asp Leu Arg Val Leu Ser Lys Leu Arg Asp Ser His Val Leu His 210 215 220 Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val 225 230 235 240 Leu Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met 245 250 255 Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu 260 265 270 Glu Gly Val Met Wing Wing Arg Gly Gln Leu Cly Pro Thr Cys Leu Ser 275 280 285 Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala 290 295 300 Leu Gln Ser Leu Leu 305 (2) INFORMATION FOR SEQ ID NO: 541:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 641: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Clu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe Leu 145 150 155 160 Being Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 165 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn 180 185 190 Met Wing Pro Pro Wing Pro Pro Wing Cys Asp Leu Arg Val Leu Ser Lys 195 200 205 Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro 210 215 220 Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Wing Val Asp Phe 225 230 235 240 Be Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp 245 250 255 He Leu Gly Wing Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg 260 265 270 Gly Gln Leu sly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser 275 280 285 Gly aln Val Arg Leu Leu Leu Cly Wing Leu Gln Ser Leu Leu Gly Thr 290 295 300 Gln Leu Pro Pro Gln 305 (2) INFORMATION FOR SEQ ID NO: 642:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 642: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly alu Pro Ser Oly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gln His 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Cly Gly Ser Thr 165 170 175 Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro 180 185 190 Pro Pro Wing -Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp 195 200 205 Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro 210 215 220 Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu Gly Glu 225 230 235 240 Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing 245 250 255 Val Thr Leu Leu Leu Glu Gly Val Met Wing Wing Arg Gly Gln Leu Gly 260 265 270 Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg 275 280 285 Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro 290 295 300 Gln Gly Arg Thr Thr 305 (2) INFORMATION FOR SEQ ID NO: 643: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 543: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg 145 150 155 160 Oly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Wing Ser Pro Pro Pro Wing 180 185 190 Wing Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 195 200 205 Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr 210 215 220 Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr 225 230 235 240 Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu 245 250 255 Leu Leu Glu Gly Val Met Ala Ala Arg aly aln Leu Cly Pro Thr Cys 260 265 270 Leu Ser Ser Leu Leu Gly Gln Leu Ser aly Gln Val Arg Leu Leu Leu 275 280 285 Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg 290 295 300 Thr Thr Ala His Lys 305 (2) INFORMATION FOR SEQ ID NO: 544: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 644: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Olu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing He Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 165 170 175 Gly Gly Asn Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Wing Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu 225 230 235 240 Glu Thr Lys Wing Gln Asp He Leu Gly Wing Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser 260 265 270 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu aly Ala Leu 275 280 285 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala 290 295 300 His Lys Asp Pro Asn 305 (2) INFORMATION FOR SEQ ID NO: 646: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 645: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly I have sall Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Olu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu slu Gln Ala Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Wing He Phe Leu Ser Phe Gln His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Gly Asn Met Wing Pro Pro Wing Pro Pro Wing Cys Asp 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gln Cys Pro Olu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu aly slu Trp Lys Thr sln Met Glu 225 230 235 240 Glu Thr Lys Ala sln Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Wing Wing Arg Gly Gln Leu Gly Pro Thr Cys Leu Being 260 265 270 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Oln Ser Leu Leu Gly Thr Gln Gly Arg Thr Thr Ala His Lys 290 295 300 (2) INFORMATION FOR SEQ ID NO: 546: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 153 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 546: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Wing Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Olu aly Val Met Ala Ala Arg Gly Gln 65 70 75 80 Leu Cly Pro Thr Cys Leu Ser Ser Leu Leu Oly Oln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu sly Ala Leu sln Ser Leu Leu Cly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Wing His Lys Asp Pro Asn Wing He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMATION FOR SEQ ID NO: 547: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 149 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 547: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Wing Gln Asp He Leu 50 55 60 Gly Wing Val Thr Leu Leu Glu Glu Val Met Ala Ala Arg Gly Oln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Oln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Oly Ala Leu Gln Ser Leu Leu Gly Thr Gln Gly 100 105 110 Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gln 115 120 125 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 130 135 140 Thr Leu Cys Val Arg 145 (2) INFORMATION FOR SEQ ID NO: 548: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 153 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 548: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu 100 105 110 Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMATION FOR SEQ ID NO: 549: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 135 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 549: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Ala Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Clu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro 130 135 (2) INFORMATION FOR SEQ ID NO: 5d0: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 560: Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 551: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 122 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 551: Thr Gln Asp Cys Wing Ser Phe Gln His Ser Pro Pro Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 40 45 Trp Arg Leu Val Leu Ala Gln Arg Trp Met alu Arg Leu Lys Thr Val 50 55 60 Ala aly Ser Lys Met Cln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Wing Phe Gln Glu Thr Ser Glu Gln Leu Val 85 90 95 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 100 105 110 Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 115 120 (2) INFORMATION FOR SEQ ID NO: 552: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 135 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 562: Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro 130 135 (2) INFORMATION FOR SEQ ID NO: 563: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 553: Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 554: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 135 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 554: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro 130 135 (2) INFORMATION FOR SEQ ID NO: 565: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 565: - Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 40 -45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 566: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 566: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln '1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Olu Leu aln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu Ser Oly Oly Asn Cly Ser Oly Gly Asn Gly Ser 100 105 110 Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Oln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 145 150 155 (2) INFORMATION FOR SEQ ID NO: 557: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 557 : Wing Asp Olu slu Leu Cys sly sly Leu Trp Arg Leu Val Leu Wing Oln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln aly 25 30 Leu Leu alu Arg Val Asn Thr Olu He His Phe Val Thr Lys Cys Ala 40 45 Phe sln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He Ser 50 55 60 Arg Leu Leu sln slu Thr Ser slu aln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg sln Asn Phe Ser Arg Cys Leu Olu Leu Gln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr 100 105 110 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val 115 120 125 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 130 135 140 Val Wing Ser Asn Leu Gln 145 150 (2) INFORMATION FOR SEQ ID NO: 558: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 145 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 568: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Being Thr Leu Being Gly Gly Asn aly Thr Gln Asp Cys Ser Phe 100 105 110 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 115 120 125 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 130 135 140 Gln 145 (2) INFORMATION FOR SEQ ID NO: 659: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 165 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 559: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Being Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe 100 105 110 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 115 120 125 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 130 135 140 Gln 145 (2) INFORMATION FOR SEQ ID NO: 560: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 560: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 25 30 Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 35 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Cln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80 Being Gly Gly Asn Gly Thr Gln Asp Cys Being Phe Gln His Being Pro 85 90 95 Being Being Asp Phe Wing Val Lys He Arg Glu Leu Being Asp Tyr Leu Leu 100 105 110 Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Leu 115 120 125 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met alu Arg 130 135 140 Leu Lys Thr Val Wing Gly 145 150 (2) INFORMATION FOR SEQ ID NO: 561: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 145 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 561: Wing Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80 Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp Phe Wing 85 90 95 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 100 105 110 Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp 115 120 125 Arg Leu Val Leu Wing Gln Arg Trp Met Clu Arg Leu Lys Thr Val Wing 130 135 140 Gly 145 (2) INFORMATION FOR SEQ ID NO: 562: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 562: Wing Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 1 5 10 15 Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr 20 25 30 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly 50 55 60 Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 65 70 75 80 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 85 90 95 Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Wing Gly Ser Lys Met Gln aly Leu Leu alu Arg Val Asn Thr Glu 130 135 140 He His Phe Val Thr Lys Cys Ala Phe Gln Pro 145 150 155 (2) INFORMATION FOR SEQ ID NO: 563: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 563: Wing Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 1 5 10 15 Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr 25 30 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp 50 55 60 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He 65 70 75 80 Arg Clu Leu Ser Asp Tyr Leu Leu aln Asp Tyr Pro Val Thr Val Wing 85 90 95 Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 100 105 110 Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 115 120 125 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gln Pro 145 150 (2) INFORMATION FOR SEQ ID NO: 564: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 145 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 564: Ala Pro Pro Ser Cys Leu Arg Phe Val aln Thr Asn He Ser Arg Leu 1 5 10 15 Leu aln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr 25 30 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe aln His 50 55 60 Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Clu Leu Ser Asp 65 70 75 80 Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp 85 90 95 Olu alu Leu Cys Oly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp 100 105 110 Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Oly Leu Leu 115 120 125 Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln 130 135 140 Pro 145 (2) INFORMATION FOR SEQ ID NO: 565: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 565: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Oln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser 100 105 110 Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Oln His Ser Pro He Ser 115 120 125 Being Asp Phe Wing Val Lys He Arg Glu Leu Being Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 145 150 155 (2) INFORMATION FOR SEQ ID NO: 566: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 566: Wing Asp Olu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Be 50 55 60 Arg Leu Leu Gln slu Thr Ser Olu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Olu Leu Gln Cys Gln Pro 85 90 95 Asp Being Being Thr Leu Being Gly Gly Being Gly Being Gly Gly Being Gly Thr 100 105 110 Gln Asp Cys Ser Phe Cln His Ser Pro Be Ser Be Asp Phe Ala Val 115 120 125 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gln 145 150 (2) INFORMATION FOR SEQ ID NO: 567: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 145 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 567: Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 1 5 10 15 Phe Wing Val Lys He Arg Olu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 20 25 30 Pro Val Thr Val Wing Ser Asn Leu Gln Asp Olu Glu Leu Cys Gly Gly 40 45 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 100 105 110 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg sln Asn Phe Ser Arg 115 120 125 Cys Leu Olu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Oly Gly Gly 130 135 140 Ser 145 (2) INFORMATION FOR SEQ ID NO: 568: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 143 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 568: Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 1 5 10 15 Being Asp Phe Wing Val Lys He Arg Glu Leu Being Asp Tyr Leu Leu Gln 20 25 30 Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys 35 40 45 Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 50 55 60 Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn 65 70 75 80 Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser 85 90 95 Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr 100 105 110 Ser Glu Cln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe 115 120 125 Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 569: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 149 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 569: Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 1 5 10 15 Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 20 25 30 Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 40 45 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 100 105 110 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 115 120 125 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly 130 135 140 Ser Gly Gly Gly Ser 145 (2) INFORMATION FOR SEQ ID NO: 570: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 144 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 670: Gly Be Gly Gly Gly Thr Gln Asp Cys Be Phe Gln His Ser Pro He 1 5 10 15 Be Being Asp Phe Wing Val Lys He Arg Glu Leu Being Asp Tyr Leu Leu 20 25 30 Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Leu 35 40 45 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg 50 55 60 Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 65 70 75 80 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 85 90 95 Be Cys Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu 100 105 110 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 115 120 125 Phe Ser Arg Cys Leu Olu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 571: i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 153 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 571 : Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 1 5 10 15 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 25 30 Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 40 45 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 100 105 110 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 115 120 125 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly 130 135 140 Ser Gly Gly Gly Ser Gly Gly Gly Ser 145 150 (2) INFORMATION FOR SEQ ID NO: 572: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 572: Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser sly Thr sln Asp Cys Ser 1 5 10 15 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 25 30 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 35 40 45 Leu Gln Asp Glu Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 50 55 60 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 65 70 75 80 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 85 90 95 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 100 105 110 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro - 115 120 125 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 130 135 140 Pro Asp Ser Ser Thr Leu 145 150 (2) INFORMATION FOR SEQ ID NO: 573: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 146 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 573: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Be Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser 100 105 110 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 115 120 125 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 130 135 140 Leu Gln 145 (2) INFORMATION FOR SEQ ID NO: 574: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 147 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 574: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly Thr Gln Asp Cys 100 105 110 Be Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg 115 120 125 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser 130 135 140 Asn Leu Gln 145 (2) INFORMATION FOR SEQ ID NO: 57d: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 575: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 100 105 110 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val 115 120 125 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gln 145 150 (2) INFORMATION FOR SEQ ID NO: 576: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 153 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 576: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 _ 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Oly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 115 120 125 Phe Wing Val Lys He Arg Clu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 130 135 140 Pro Val Thr Val Wing Ser Asn Leu Gln 145 150 (2) INFORMATION FOR SEQ ID NO: 577:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear i) TYPE OF MOLECULE : any (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 577: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln aly 20 25 30 Leu Leu slu Arg Val Asn Thr Clu He His Phe Val Thr Lys Cys Ala 40 45 Phealn Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu alu Leu aln Cys aln Pro 85 90 95 Asp Ser Ser Thr Leu Cly Oly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu aln 145 150 155 (2) INFORMATION FOR SEQ ID NO: 578: i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 161 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 578: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Be 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln (2) INFORMATION FOR SEQ ID NO: 679: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 281 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 579: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Oly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Ser 145 150 155 160 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Ala Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Wing Gly Ser Lys Met Gln sly Leu Leu alu Arg Val Asn Thr 210 215 220 alu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Oln Glu Thr Ser 245 250 255 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Oln Cys sln Pro 275 280 (2) INFORMATION FOR SEQ ID NO: 580: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) NUMBER FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 580: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Olu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 145 150 155 160 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 165 170 175 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Wing Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser 245 250 255 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 275 280 285 (2) INFORMATION FOR SEQ ID NO: 581: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 581: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing sly Asp Trp Oln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Oly aly Asn Oly Ser Gly Gly Asn 245 250 255 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 260 265 270 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 582: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 582: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser sly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Be Ser Thr Leu Be Gly Gly Asn Gly Be Gly Gly Asn 245 250 255 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp Phe 260 265 270 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 583:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 583: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Cln Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp 225 230 235 240 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 245 250 255 Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 260 265 270 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg L € 'U Lys Thr 275 280 285 Val Wing Gly 290 (2) INFORMATION FOR SEQ ID NO: 584: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 584: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Being Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Cly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Olu Gly Gly Oly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Ser Oly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser 225 230 235 240 Pro He Ser Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Wing Gly 290 295 (2) INFORMATION FOR SEQ ID NO: 58d: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 58d: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Oly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Cln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 260 265 270 He Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 586: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 586: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro. Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe 195 200 205 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 225 230 235 240 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 260 265 270 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gln Pro 290 (2) INFORMATION FOR SEQ ID NO: 587: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 587: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Oln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr 195 200 205 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val 210 215 220 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gln Pro 290 295 (2) INFORMATION FOR SEQ ID NO: 588:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 588: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys slu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Olu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser 195 200 205 Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser 210 215 220 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 225 230 235 240 Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 290 295 300 (2) INFORMATION FOR SEQ ID NO: 589: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 281 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 589: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Olu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 145 150 155 160 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Wing Oly Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser 245 250 255 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gln Cys Gln Pro 275 280 (2) INFORMATION FOR SEQ ID NO: 590: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 590: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gln Asp Cys Ser Phe Cln His Ser Pro He Ser Ser 145 150 155 160 Asp Phe Wing Val Lys He Arg Clu Leu Ser Asp Tyr Leu Leu Cln Asp 165 170 175 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Ala sln Arg Trp Met slu Arg Leu Lys 195 200 205 Thr Val Ala aly Ser Lys Met Cln sly Leu Leu alu Arg Val Asn Thr 210 215 220 alu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Oln Olu Thr Ser 245 250 255 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Oln Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gln Cys Oln Pro Asp Being Ser Thr Leu 275 280 285 (2) INFORMATION FOR SEQ ID NO: 591: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 591: Wing Asn Cys Ser lie Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Thr Oln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 260 265 270 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 275 280 285 Val Thr Val Wing Ser Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 692:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 692: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Oln 100 105 110 Tyr Val alu Oly Oly Oly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 260 265 270 He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 593: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 593: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Ser Asp 225 230 235 240 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 245 250 255 Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 260 265 270 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 275 280. 285 Val Ala Gly 290 (2) INFORMATION FOR SEQ ID NO: 594: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 594: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu aln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Oly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser 225 230 235 240 Pro He Be Ser Asp Phe Wing Val Lys He Arg Olu Leu Ser Asp Tyr 245 250 255 Leu Leu Cln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu aln Asp alu 260 265 270 slu Leu Cys Oly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Wing Gly 290 295 (2) INFORMATION FOR SEQ ID NO: 595: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 595: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu aln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys aln Pro Asp Ser Ser Thr Leu Ser Oly Gly 210 215 220 Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys 225 230 235 240 Being Phe Gln His Being Pro Being Being Asp Phe Wing Val Lys He Arg 245 250 255 Glu Leu Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being 260 265 270 Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 275 280 285 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 290 295 300 (2) INFORMATION FOR SEQ ID NO: 596:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 696: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Be Arg Cys Leu Clu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe 195 200 205 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 225 230 235 240 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 260 265 270 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gln Pro 290 (2) INFORMATION FOR SEQ ID NO : 597: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 597: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr 195 200 205 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 210 215 220 Lys He Arg Glu Leu Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 260 265 270 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gln Pro 290 295 (2) INFORMATION FOR SEQ ID NO: 598: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 598: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala aly Asp Trp Cln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Oln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Olu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Ser Oly Gly Asn Gly Ser Oly Gly Asn Gly Ser 195 200 205 sly Oly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 210 215 220 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 225 230 235 240 Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 290 295 300 (2) INFORMATION FOR SEQ ID NO: 599: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 599: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met alu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 '220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser 245 250 255 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 260 265 270 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu sln Asp Tyr Pro 275 280 285 Val Thr Val Wing Ser Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 600: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 600: Wing Asn Cys Ser He Met He Asp alu He He His His Leu Lys Arg 1 - 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro -Asn Leu Leu Wing Phe 35 40"45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser 245 250 255 Gly Be Gly Gly Be Gly Thr Gln Asp Cys Be Phe Gln His Ser Pro 260 265 270 Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 601: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 281 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 601: Ala Thr Gln Asp Cys Ser Phe aln His Ser Pro Be Ser As Asp Phe 1 5 10 15 Ala Val Lys He Arg alu Leu Ser Asp Tyr Leu Leu Cln Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Cln Asp Clu Glu Leu Cys Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Olu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Cln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro 130 135 140 Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser 145 150 155 160 Lys slu Ser His Lys Ser Pro Asn Met Wing Asn Cys Ser He Met He 165 170 175 Asp slu He He His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp 180 185 190 Pro Asn Asn Leu Asn Ser slu Asp Met Asp He Leu Met Olu Arg Asn 195 200 205 Leu Arg Thr Pro Asn Leu Leu Ala- Phe Val Arg Ala Val Lys His Leu 210 215 220 Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn Leu Gln Pro Cys 225 230 235 240 Leu Pro Wing Thr Wing Wing Pro Pro Arg His Pro He He He Lys 245 250 255 Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val 260 265 270 Thr Leu Glu Gln Ala Gln Gln Gln Gln 275 280 (2) INFORMATION FOR SEQ ID NO: 602: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) NUMBER FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 602: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn 165 170 175 Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro 180 185 190 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Olu Asp Met Asp He 195 200 205 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg 210 215 220 Wing Val Lys His Leu Glu Asn Wing Gly lie Glu Ala He Leu Arg 225 230 235 240 Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His 245 250 255 Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu 260 265 270 Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 275 280 285 (2) INFORMATION FOR SEQ ID NO: 603: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 268 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 603: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Pro His Pro He He He Lys Wing Gly Asp Trp Gln Olu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Ser 145 150 155 160 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 165 170 175 Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Glu Thr Ser Glu Gln 225 230 235 240 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 245 250 255 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 260 265 (2) INFORMATION FOR SEQ ID NO: 604: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 604: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Cln Olu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Olu Clu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met alu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gln Asp 245 250 255 Cys Ser Phe Gln His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He 260 265 270 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 275 280 285 Ser Asn Leu Gln 290 (2) INFORMATION FOR SEQ ID NO: 605: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 605: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Oln Glu Thr Ser Glu Cln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gln 245 250 255 Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys 260 265 270 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 275 280 285 Wing Being Asn Leu Gln 290 (2) INFORMATION FOR SEQ ID NO: 606: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 606: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Oly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 260 265 270 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 275 280 285 Val Thr Val Wing Being Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 607: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 607: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Alu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Clu Gln Ala Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 .-- 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr alu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Be 260 265 270 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 275 280 285 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 608:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 608: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala Oly 'Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly Ser Gly 245 250 255 Gly Gly Be Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 260 265 270 He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 609: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 609: Wing Asn Cys Ser He Met He Asp alu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser alu Asp Met 25 30 Asp He Leu Met Clu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu aln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys 260 265 270 Be Phe Cln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser 290 295 300 Asn Leu Gln 305 (2) INFORMATION FOR SEQ ID NO: 610: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 610: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Olu Thr Ser alu 180 185 190 aln Leu Val Ala Leu Lys Pro Trp He Thr Arg Oln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ser Ser Ser 225 230 235 240 Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 245 250 255 Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 260 265 270 Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Clu Arg Leu Lys 275 280 285 Thr Val Ala Gly 290 (2) INFORMATION FOR SEQ ID NO: 61 1: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (¡) i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 611: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg sln Asn Phe Ser Arg 195 200 205 Cys Leu Clu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ser Ser 225 230 235 240 Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 245 250 255 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys 260 265 270 Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 275 280 285 Lys Thr Val Wing Gly 290 (2) INFORMATION FOR SEQ ID NO: 612: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 612: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Oly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Clu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser 225 230 235 240 Pro He Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Wing Gly 290 295 (2) INFORMATION FOR SEQ ID NO: 613:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 613: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 - 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 225 230 235 240 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 245 250 255 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 260 265 270 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 275 280 285 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 290 295 (2) INFORMATION FOR SEQ ID NO: 614: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 614: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala aly Asp Trp aln Clu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys 225 230 235 240 Be Phe Gln His Ser Pro Be Be Ser Asp Phe Ala Val Lys He Arg 245 250 255 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser 260 265 270 Asn Leu Gln Asp Olu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 275 280 285 Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 300 (2) INFORMATION FOR SEQ ID NO: 615: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 615: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 180 185 190 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gln Cys sln Pro Asp Ser Ser Thr Leu Oly Gly Gly 210 215 220 Ser Gly ally Oly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Be Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 245 250 255 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 260 265 270 Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 275 280 285 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 Val Ala Gly 305 (2) INFORMATION FOR SEQ ID NO: 616: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 616: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Cln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser 195 200 205 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 210 215 220 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240 Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 245 250 255 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 260 265 270 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 275 280 285 Ala Phe Gln Pro 290 (2) INFORMATION FOR SEQ ID NO: 617: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 617: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40"45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Be 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys 195 200 205 Ser Phe Gln His Ser Pro Be Ser Ser Asp Phe Ala Val Lys He Arg 210 215 220 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser 225 230 235 240 Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 245 250 255 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 260 265 270 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 275 280 285 Cys Ala Phe Gln Pro 290 (2) INFORMATION FOR SEQ ID NO: 618: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 618: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Olu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val slu Oly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Oly Gly Gly Ser Oly Gly Gly Ser Gly Gly Thr 195 200 205 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 210 215 - 220 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 225 230 235 240 Val Wing Ser Asn Leu Cln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gln Pro 290 295 (2) INFORMATION FOR SEQ ID NO: 619: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 619: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Clu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Be Arg Cys Leu slu Leu Oln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Gly sly sly Ser sly Oly Gly Ser Gly Gly Gly 195 200 205 Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 210 215 220 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 225 230 235 240 Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 He His Phe Val Thr Lys Cys Ala Phe Gln Pro 290 295 (2) INFORMATION FOR SEQ ID NO: 620: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 620: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Being Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Being Ser Thr Leu Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 195 200 205 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe sln His Be Pro Be 210 215 220 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 225 230 235 240 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Wing Gly Ser Lys Met sln Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 290, 295 300 (2) INFORMATION FOR SEQ ID NO: 621: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 621: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Being Oly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 145 150 155 160 Arg Leu Leu Oln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 165 170 175 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly sly Ser Gly Gly Gly 195 200 205 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 210 215 220 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 225 230 235 240 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 245 250 255 Gln Asp Glu slu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 260 265 270 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 275 280 285 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 290 295 300 Phe sln Pro 305 (2) INFORMATION FOR SEQ ID NO: 622:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 622: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Olu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Gln alu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240 Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Oly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys 260 265 270 Ser Phe Gln His Ser Pro Be Ser Be Asp Phe Wing Val Lys He Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 623: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 623: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Olu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg 225 230 235 240 Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 260 265 270 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp Phe 275 280 285 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 624: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 624: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Olu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gln aly Leu Leu Olu Arg Val Asn Thr slu He 180 185 190 His Phe Val Thr Lys Cys Wing Phe Oln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Clu aln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg aln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys aln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Oln His Ser Pro 260 265 270 I Am Ser Being Asp Phe Ala Val Lys He Arg Glu Leu Being Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val 290 295 (2) INFORMATION FOR SEQ ID NO: 625: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 625: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val L65 170 175 Wing Gly Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Be Gly Gly Gly Gly Gly Gly Gly Thr Gln Asp Cys Ser 260 265 270 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 275 280 285 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 290 295 300 (2) INFORMATION FOR SEQ ID NO: 626: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 626: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Wing Ala Gly Ser Lys Met sln Oly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 '170 175 Being Cys Leu Arg Phe Val Gln Thr Asn He Being Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe 225 230 235 240 Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu 245 250 255 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu 260 265 270 Gln Asp Glu Glu Glu Leu Gly Gly Leu Trp Arg Leu Val Leu Gln Ala 275 280 285 Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMATION FOR SEQ ID NO: 627: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 627: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Clu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Olu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 210 215 '220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Thr 225 230 235 240 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val 245 250 255 Lys He Arg Glu Leu Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 260 265 270 Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 275 280 285 Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 (2) INFORMATION FOR SEQ ID NO: 628: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 628: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Oly Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe 195 200 205 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 225 230 235 240 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Oly 260 265 270 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gln Pro Pro Pro Ser Cys Leu 290 295 (2) INFORMATION FOR SEQ ID NO: 629: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 629: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Olu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser sly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr 195 200 205 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val 210 215 220 Lys He Arg alu Leu Ser Asp Tyr Leu Leu Cln Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 260 265 270 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 290 295 300 (2) INFORMATION FOR SEQ ID NO: 630: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 630: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 195 200 205 Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu 210 215 220 Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro 275 280 285 Pro Ser Cys Leu Arg Phe Val Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 631:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 631: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly 'Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser 195 200 205 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 210 215 220 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 225 230 235 240 Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 245 250 255 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 260 265 270 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 275 280 285 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 632: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 632: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Olu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Oly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Oln Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He. Thr Arg 225 230 235 240 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His 260 265 270 Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp 275 280 285 Tyr Leu Leu Gln 290 (2) INFORMATION FOR SEQ ID NO: 633: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 633: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Olu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Be Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 260 265 270 His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He Arg Clu Leu Ser 275 280 285 Asp Tyr Leu Leu Gln 290 (2) INFORMATION FOR SEQ ID NO: 634: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 634: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser sly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Oly Asp Trp Oln slu Phe Arg Olu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Oln Glu Thr Ser Glu Oln Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240 Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Oln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly 260 265 270 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 275 280 285 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 635:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 635: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Cly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Be Cys Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 225 230. 235 240 Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 245 250 255 Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 260 265 270 Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu 275 280 285 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg 290 295 300 Leu Lys Thr 305 (2) INFORMATION FOR SEQ ID NO: 636:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 636: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Oly Asp Trp Gln Glu Phe Arg Glu 85 -90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp slu Olu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Wing Gly Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 260 265 270 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 275 280 285 Pro Val Thr Val 290 (2) INFORMATION FOR SEQ ID NO: 637: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 637: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 245 250 255 Cly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 260 265 270 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 275 280 285 Tyr Pro Val Thr Val 290 (2) INFORMATION FOR SEQ ID NO: 638: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 638: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys sln Pro Asp Being Ser Thr Leu sly aly Gly Ser 245 250 255 Gly aly Oly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 260 265 270 His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser 275 280 285 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 290 295 (2) INFORMATION FOR SEQ ID NO: 639: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 639: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala Oly Asp Trp sln slu Phe Arg Olu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Oln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Gly Ser 260 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 275 280 285 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 290 295 300 Val Thr Val 305 (2) INFORMATION FOR SEQ ID NO: 640:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 640: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Being Cys Leu Arg Phe Val sln Thr Asn He Being Arg Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Oln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 225 230 235 240 I Be Being Asp Phe Ala Val Lys He Arg alu Leu Ser Asp Tyr Leu 245 250 255 Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu sln Asp Glu Glu 260 265 270 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu 275 280 285 Arg Leu Lys Thr 290 (2) INFORMATION FOR SEQ ID NO: 641: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 641: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Ala aly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Gluc Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg sln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser 225 230 235 240 Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu 260 265 270 Glu Leu Cys Oly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr 290 (2) INFORMATION FOR SEQ ID NO: 642: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 642: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Olu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg alu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Being Cys Leu Arg Phe Val Gln Thr Asn He Being Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp 225 230 235 240 Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He 245 250 255 Arg Glu Leu As Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala 260 265 270 Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 275 280 285 Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMATION FOR SEQ ID NO: 643: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 643: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Be Cys Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Oly Ser Gly Gly Gly Ser Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 245 250 255 Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 260 265 270 Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu 275 280 285 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met slu Arg 290 295 300 Leu Lys Thr 305 (2) INFORMATION FOR SEQ ID NO: 644: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 644: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln slu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 '125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 195 200 205 I've Been Being Asp Phe Ala Val Lys I've Arg Glu Leu Being Asp Tyr Leu 210 215 220 Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Wing Gly Ser Lys Met sln Oly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro 275 280 285 Pro Ser Cys Leu 290 (2) INFORMATION FOR SEQ ID NO: 645:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 645: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Olu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Oln Wing Gln Glu Oln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser 195 200 205 Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr 210 215 220 Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 225 230 235 240 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 245 250 255 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 260 265 270 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 275 280 285 Pro Pro Ser Cys Leu 290 (2) INFORMATION FOR SEQ ID NO: 646: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 646: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Olu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Olu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Oln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 180 185 190 Gly Oly Oly Being Oly Oly Gly Being Gly Gly Gly Being Gly Thr Gln Asp 195 200 205 Cys Being Phe Gln His Being Pro Being Ser Asp Phe Wing Val Lys He 210 215 220 Arg Glu Leu As Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala 225 230 235 240 Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 245 250 255 Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 260 265 270 Met Gln sly Leu Leu slu Arg Val Asn Thr slu He His Phe Val Thr 275 280 285 Lys Cys Wing Phe Oln Pro Pro Pro Ser Cys Leu 290 295 (2) INFORMATION FOR SEQ ID NO: 647: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 647: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Oln Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Oly Gly Gly Ser Gly Gly Gly Ser Gly Oly Gly Ser 195 200 205 Gly Gly Gly Gly Thr Gln Asp Cys Ser Phe Cln His Ser Pro He 210 215 220 Ser Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 225 230 235 240 Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu 245 250 255 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg 260 265 270 Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 275 280 285 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 290 295 300 Ser Cys Leu 305 (2) INFORMATION FOR SEQ ID NO: 648: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 648: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Cln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser 180 185 190 sly sly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 195 200 205 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 210 215 220 Pro Val Thr Val Ala Ser Asn Leu Gln Asp slu Olu Leu Cys Gly Gly 225 230 235 240 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met slu Arg Leu Lys Thr 245 250 255 Val Ala sly Ser Lys Met sln Gly Leu Leu Glu Arg Val Asn Thr Glu 260 265 270 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 275 280 285 Arg Phe Val Gln 290 (2) INFORMATION FOR SEQ ID NO: 649: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 649: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Oln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Olu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 195 200 205 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 210 215 220 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 225 230 235 240 Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys 245 250 255 Thr Val Wing Gly Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 260 265 270 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys 275 280 285 Leu Arg Phe Val sln 290 (2) INFORMATION FOR SEQ ID NO: 650:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 650: Wing Asn Cys Ser He Met He Asp alu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Oly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 195 200 205 His Ser Pro Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser 210 215 220 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 225 230 235 240 Asp Olu slu Leu Cys Cly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 245 250 255 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 260 265 270 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 275 280 285 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 651: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 651: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Oly Gly Gly Ser Gly Gly Gly Ser 195 200 205 Gly Thr Gln Asp Cys Ser Phe Oln His Ser Pro He Ser Ser Asp Phe 210 215 220 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 225 230 235 240 Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 245 250 255 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 260 '265 270 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 275 280 285 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 290 295 300 Phe Val Gln 305 (2) INFORMATION FOR SEQ ID NO: 652: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 749 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 652: Gly Ser Thr Met Being Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu 1 5 10 15 Val Arg Pro Ala Met Ser Thr Asn Gln Asp Leu Pro Val He Lys Cys 20 25 30 Val Leu He Asn His Lys Asn Asn Asp Ser Ser Val Gly Lys Ser Ser 40 45 Ser Tyr Pro Met Val Ser Glu Ser Pro Glu Asp Leu Gly Cys Ala Leu 50 55 60 Arg Pro Gln Ser Ser Gly Thr Val Tyr Glu Ala Wing Wing Val Glu Val 65 70 75 80 Asp Val Ser Wing Be He Thr Leu Gln Val Leu Val Asp Wing Pro Gly 85 90 95 Asn He Ser Cys Leu Trp Val Phe Lys His Ser Ser Leu Asn Cys Gln 100 105 110 Pro His Phe Asp Leu Gln Asn Arg Gly Val Val Ser Met Val He Leu 115 120 125 Lys Met Thr Glu Thr Gln Wing Gly Glu Tyr Leu Leu Phe He Gln Ser 130 135 140 Glu Ala Thr Asn Tyr Thr He Leu Phe Thr Val Ser He Arg Asn Thr 145 150 155 160 Leu Leu Tyr Thr Leu Arg Arg Pro Tyr Phe Arg Lys Met Glu Asn Gln 165 170 175 Asp Ala Leu Val Cys He Ser Glu Ser Val Pro Glu Pro He Val Glu 180 185 190 Trp Val Leu Cys Asp Ser Gln Gly Glu Ser Cys Lys Glu Glu Ser Pro 195 200 205 Wing Val Val Lys Lys Glu Glu Lys Val Leu His Glu Leu Phe Gly Met 210 215 220 Asp He Arg Cys Cys Wing Arg Asn Glu Leu Gly Arg Glu Cys Thr Arg 225 230 235 240 Leu Phe Thr He Asp Leu Asn Gln Thr Pro Gln Thr Thr Leu Pro Gln 245 250 255 Leu Phe Leu Lys Val Gly Glu Pro Leu Trp He Arg Cys Lys Ala Val 260 265 270 His Val Asn His Gly Phe Gly Leu Thr Trp Glu Leu Glu Asn Lys Ala 275 280 285 Leu Glu Glu Gly Asn Tyr Phe Glu Met Ser Thr Tyr Ser Thr Asn Arg 290 295 300 Thr Met He Arg He Leu Phe Wing Phe Val Ser Ser Val Wing Arg Asn 305 310 315 320 Asp Thr Gly Tyr Tyr Thr Cys Ser Ser Ser Lys His Pro Ser Gln Ser 325 330 335 Wing Leu Val Thr He Val Glu Lys Gly Phe He Asn Wing Thr Asn Ser 340 345 350 Ser Glu Asp Tyr Glu He Asp Gln Tyr Glu Glu Phe Cys Phe Ser Val 355 360 365 Arg Phe Lys Wing Tyr Pro Gln He Arg Cys Thr Trp Thr Phe Ser Arg 370 375 380 Lys Ser Phe Pro Cys Glu Gln Lys Gly Leu Asp Asn Gly Tyr Ser He 385 390 395 400 Ser Lys Phe Cys Asn His Lys His Gln Pro Gly Glu Tyr He Phe His 405 410 415 Wing Glu Asn Asp Asp Wing Gln Phe Thr Lys Met Phe Thr Leu Asn He 420 425 430 Arg Arg Lys Pro Gln Val Leu Wing Glu Wing Being Wing Being Gln Wing Being 435 440 445 Cys Phe Ser Asp Gly Tyr Pro Leu Pro Ser Trp Thr Trp Lys Cys 450 455 460 Ser Asp Lys Ser Pro Asn Cys Thr Glu Glu He Thr Glu Gly Val Trp 465 470 475 480 Asn Arg Lys Wing Asn Arg Lys Val Phe Gly Gln Trp Val Being Ser 485 490 495 Thr Leu Asn Met Ser Glu Ala He Lys Gly Phe Leu Val Lys Cys Cys 500 505 510 Wing Tyr Asn Ser Leu Gly Thr Ser Cys Glu Thr He Leu Leu Asn Ser 515 520 525 Pro Gly Pro Phe Pro Phe He Gln Asp Asn Glu Phe He He Leu Gly 530 535 540 Leu Phe Gly Leu Leu Leu Leu Leu Thr Cys Leu Cys Gly Thr Wing Trp 545 550 555 560 Leu Cys Cys Ser Pro Asn Arg Lys Asn Pro Leu Trp Pro Ser Val Pro 565 570 575 Asp Pro Wing His Ser Being Leu Gly Being Trp Val Pro Thr He Met Glu 580 585 590 Glu Asp Wing Phe Gln Leu Pro Gly Leu Gly Thr Pro Pro He Thr Lys 595 600 605 Leu Thr Val Leu Olu slu Asp slu Lys Lys Pro Val Pro Trp slu Ser 610 615 620 His Asn Be Ser Olu Thr Cys Gly Leu Pro Thr Leu Val Gln Thr Tyr 625 630 635 640 Val Leu Oln Gly Asp Pro Arg Ala Val Ser Thr Gln Pro Gln Ser Gln 645 650 655 Ser Gly Thr Ser Asp Oln Val Leu Tyr Gly Gln Leu Leu Gly Ser Pro 660 665 670 Thr Ser Pro Gly Pro Gly His Tyr Leu Arg Cys Asp Ser Thr Gln Pro 675 680 685 Leu Leu Wing Gly Leu Thr Pro Ser Pro Lys Ser Tyr Glu Asn Leu Trp 690 695 700 Phe Gln Wing Pro Pro Leu Gly Thr Leu Val Thr Pro Wing Pro Ser Gln 705 710 715 720 Glu Asp Asp Cys Val Phe Gly Pro Leu Leu Asn Phe Pro Leu Leu Gln 725 730 735 Gly He Arg Val His Gly Met Glu Ala Leu Gly Ser Phe 740 745 (2) INFORMATION FOR SEQ ID NO: 653: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 349 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 653: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1. 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Oly Asp Gly Ala Wing Leu 20 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Oly He Pro Trp Wing Pro Leu Being 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Be Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Clu Glu Leu Gly Met Wing 115 120 125 Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp 210 215 220 Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 225 230 235 240 Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Olu Arg Val Asn Thr Glu 275 280 285 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Oln Thr Asn He Ser Arg Leu Leu Oln Glu Thr Ser Glu 305 310 315 320 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 325 330 335 Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 340 345 (2) INFORMATION FOR SEQ ID NO: 654: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 314 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 654: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu aln Olu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 180 185 190 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 195 200 205 Val Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly sly Leu Trp Arg 210 215 220 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 225 230 235 240 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 245 250 255 Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 260 265 270 Oln Thr Asn He Ser Arg Leu Leu Oln Glu Thr Ser Glu Gln Leu Val 275 280 285 Wing Leu Lys Pro Trp He Thr Arg sln Asn Phe Ser Arg Cys Leu Glu 290 295 300 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 305 310 (2) INFORMATION FOR SEQ ID NO: 655: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 349 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 655: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Glu Leu Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys 180 185 190 Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu 195 200 205 Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 210 215 220 Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro 225 230 235 240 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly 245 250 255 Leu Phe Leu Tyr Gln Oly Leu Leu Oln Wing Leu alu Gly He Ser Pro 260 265 270 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe 275 280 285 Wing Thr Thr He Trp Oln Gln Met Glu alu Leu aly Met Ala Pro Ala 290 295 300 Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Be Wing Phe Gln 305 310 315 320Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu 325 330 335 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 340 345 (2) INFORMATION FOR SEQ ID NO: 656: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 523 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 656: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp aly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Thr Gln Asp Cys Ser Phe Oln His Ser Pro I Have To Be Asp 210 215 220 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 225 230 235 240 Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Cln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu 305 310 315 320 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 325 330 335 Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Tyr Val Glu 340 345 350 Gly Gly Gly Gly Pro Pro Glu Pro Pro Gly Pro Be Thr He 355 360 365 Asn Pro Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing 370 375 380 Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala 385 390 395 400 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 405 410 415 Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp 420 425 430 Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing 435 440 445 Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 450 455 460 Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480 Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 485 490 495 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 500 505 510 slu Leu Oln Cys Gln Pro Asp Ser Ser Thr Leu 515 520 (2) INFORMATION FOR SEQ ID NO: 657:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 460 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 657: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 145 150 155 160 Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser 245 250 255 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Tyr Val 275 280 285 slu Oly Oly sly sly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr 290 295 300 He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 305 310 315 320 Wing Thr sln Asp Cys Ser Phe sln His Ser Pro He Ser Ser Asp Phe 325 330 335 Wing Val Lys He Arg slu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 340 345 350 Val Thr Val Ala Ser Asn Leu Gln Asp slu Glu Leu Cys Gly Oly Leu 355 360 365 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 370 375 380 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 385 390 395 400 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 405 410 415 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 420 425 430 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 435 440 445 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 450 455 460 (2) INFORMATION FOR SEQ ID NO: 658: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 523 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 658: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly sly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 '70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Oly Oly Ser Pro Gly Glu Pro Ser Oly Pro He Ser Thr He Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Pro Leu Gly Pro Wing Being Being Leu Pro Gln Being Phe Leu Leu Lys Being 180 185 190 Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu 195 200 205 Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 210 215 220 Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro 225 230 235 240 Being Cln Ala Leu Oln Leu Ala Oly Cys Leu Being Gln Leu His Ser Gly 245 250 255 Leu Phe Leu Tyr Oln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro 260 265 270 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe 275 280 285 Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing 290 295 300 Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Be Wing Phe Gln 305 310 315 320 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu 325 330 335 Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr Val Glu 340 345 350 Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He 355 360 365 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 370 375 380 Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing 385 390 395 400 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 405 410 415 Thr Val Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp 420 425 430 Arg Leu Val Leu Wing Gln Arg Trp Met Olu Arg Leu Lys Thr Val Wing 435 440 445 Gly Ser Lys Met Gln Gly Leu Le --- Glu Arg Val Asn Thr Glu He His 450 455 460 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 485 490 495 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 500 505 510 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 515 520 (2) INFORMATION FOR SEQ ID NO: 659: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 334 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 659: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln sly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 _ 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Oly Ser Asn Met Ala 145 150 155 160 Thr Pro Leu sly Pro Wing Being Ser Leu Pro sln Being Phe Leu Leu Lys 165 170 175 Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln 180 185 190 Olu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu sly He Pro Trp Wing Pro Leu Ser Ser Cys 210 215 220 Pro Ser sln Wing Leu Oln Leu Wing Gly Cys Leu Ser Gln Leu His Ser 225 230 235 240 sly Leu Phe Leu Tyr sln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 260 265 270 Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gln Pro Thr Gln Oly Ala Wing Pro Pro Wing Phe Wing Wing Phe 290 295 300 Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 660: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 660: Wing Asn Cys Ser He Met He Asp Olu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly sly Gly Gly Ser Pro Gly slu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Being Arg Leu Leu 210 215 220 Oln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr Gln Asp Cys 260 265 270 Being Phe Gln His Ser Pro Being Ser Asp Phe Wing Val Lys He Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 661:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 661: Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Oln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 195 200 205 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 210 215 220 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Oly Ser sly sly 260 265 270 Oly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp Phe 275 280 285 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 662: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 662: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Clu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln slu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Olu Olu Leu Cys sly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Olu Arg Leu Lys Thr Val 165 170 175 Ala Oly Ser Lys Met Oln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 260 265 270 He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gln Asp Tyr Pro Val Thr Val 290 295 (2) INFORMATION FOR SEQ ID NO: 663: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 663: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Oly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Olu Arg Leu Lys Thr Val 165 170 175 Wing Gly Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 210 215 220 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Be Gly Gly Gly Gly Gly Gly Gly Thr Gln Asp Cys Ser 260 265 270 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Olu 275 280 285 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 290 295 300 (2) INFORMATION FOR SEQ ID NO: 664: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 664: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Olu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Wing Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe 225 230 235 240 Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu 245 250 255 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 260 265 270 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 275 280 285 Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMATION FOR SEQ ID NO: 665: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 665: Wing Asn Cys Ser He Met He Asp Olu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Olu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu sln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Oln Glu Gln Oln 100 105 110 Tyr Val Glu Gly sly sly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Wing Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 165 170 175 Being Cys Leu Arg Phe Val Gln Thr Asn He Being Arg Leu Leu Gln Glu 180 185 190 Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 245 250 255 Lys He Arg Glu Leu Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 260 265 270 Val Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 275 280 285 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 (2) INFORMATION FOR SEQ ID NO: 666: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 666: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu sly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe 195 200 205 Oln His Ser Pro To Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu 225 230 235 240 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 260 265 270 Leu Leu Glu Arg Val Asn Thr alu He His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gln Pro Pro Pro Ser Cys Leu 290 295 (2) INFORMATION FOR SEQ ID NO: 667: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 667: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Oln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro sly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Oln Thr Asn He Ser Arg Leu Leu Gln Glu 145 150 155 160 Thr Ser alu Oln Leu Val Ala Leu Lys Pro Trp He Thr Arg Cln Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gln Cys aln Pro Asp Ser Ser Thr Leu 180 185 190 ally Oly Gly Ser Gly Gly Gly Ser Gly Oly Gly Ser Gly Oly Gly Thr 195 200 205 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val 210 215 220 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gln Arg Trp Met Olu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 290 295 300 (2) INFORMATION FOR SEQ ID NO: 668: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 668: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Gln Ala Gln Gln Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln slu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro 195 200 205 Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Being Asp Tyr Leu 210 215 220 Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro 275 280 285 Pro Ser Cys Leu Arg Phe Val Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 669: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 669: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 145 150 155 160 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Thr Gln Asp Cys Ser 195 200 205 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 210 215 220 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240 Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 245 250 255 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 260 265 270 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 275 280 285 Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 670:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 670: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp 145 150 155 160 Arg Leu Val Leu Wing Gln Arg Trp Met Olu Arg Leu Lys Thr Val Wing 165 170 175 Oly Ser Lys Met Oln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 180 185 190 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 195 200 205 Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Olu Gln Leu 210 215 220 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 225 230 235 240 Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser sly Gly Gly Ser sly Gly Gly Ser Gly Gly Gly Ser Gly 260 265 270 Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala 275 280 285 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 290 295 300 Thr Val Wing 305 (2) INFORMATION FOR SEQ ID NO: 671: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 671: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Olu Oly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 145 150 155 160 Leu Val Leu Wing Oln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 165 170 175 Be Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 180 185 190 Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 195 200 205 Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 210 215 220 Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 225 230 235 240 Leu Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser Gly Gly 245 250 255 Gly Ser Gly Gly Gly Gly Gly Gly Ser Gly Gly Ser Gly Thr 260 265 270 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 275 280 285 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 290 295 300 Val Wing Ser 305 (2) INFORMATION FOR SEQ ID NO: 672: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 672: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala sln slu Gln Gln 100 105 110 Tyr Val Olu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 145 150 155 160 Val Leu Ala Gln Arg Trp Met slu Arg Leu Lys Thr Val Ala sly Ser 165 170 175 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Olu He His Phe Val 180 185 190 Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 195 200 205 Thr Asn He Ser Arg Leu Leu sln slu Thr Ser Olu Gln Leu Val Wing 210 215 220 Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Olu Leu 225 230 235 240 Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 245 250 255 Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln 260 265 270 Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys 275 280 285 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 290 295 300 Wing Ser Asn 305 (2) INFORMATION FOR SEQ ID NO: 673: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 673: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 165 170 175 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 180 185 190 Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr 195 200 205 Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu 210 215 220 Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln 225 230 235 240 Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp 260 265 270 Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He 275 280 285 Arg Glu Leu As Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala 290 295 300 Ser Asn Leu 305 (2) INFORMATION FOR SEQ ID NO: 674: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 674: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg 35 40 45 Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg 50 55 60 Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 65 70 75 80 Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu 85 90 95 Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val 100 105 110 Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr 115 120 125 He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 130 135 140 Wing Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg 145 150 155 160 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 165 170 175 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 180 185 190 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val aln Thr Asn He Ser Arg 195 200 205 Leu Leu Cln Clu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 210 215 220 Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Oln Pro Asp 225 230 235 240 Be Ser Thr Leu Gly Gly Gly Ser Gly Gly Sly Ser Gly Gly Ser Gly 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 260 265 270 His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 275 280 285 Asp Tyr Leu Leu sln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Oln 290 295 300 Asp 305 (2) INFORMATION FOR SEQ ID NO: 675: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 675: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5. 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Oln Gln 100 105 110 Tyr Val Glu Gly Oly Gly Gly Ser Pro Oly Olu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 145 150 155 160 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 165 170 175 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 180 185 190 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 195 200 205 Arg Leu Leu sln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 210 215 220 He Thr Arg Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 225 230 235 240 Asp Ser Ser Thr Leu Gly Gly Gly Ser sly Gly Gly Ser Gly Gly Gly 245 250 255 Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys Be Phe 260 265 270 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 275 280 285 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 290 295 300 Gln Asp Glu 305 (2) INFORMATION FOR SEQ ID NO: 676:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 676: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu aln Ala Gln alu aln aln 100 105 110 Tyr Val alu aly sly aly aly Ser Pro aly slu Pro Ser sly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys slu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala aln Arg 145 150 155 160 Trp Met Clu Arg Leu Lys Thr Val Wing Oly Ser Lys Met sln sly Leu 165 170 175 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 180 185 190 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 195 200 205 Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 210 215 220 Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp 225 230 235 240 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 aly ally Cly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 260 265 270 His Ser Pro Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser 275 280 285 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 290 295 300 Asp Glu Glu 305 (2) INFORMATION FOR SEQ ID NO: 677: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 677: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Pro 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Asn Leu Gln Asp Glu Glu Glu Leu Cys Gly Glu Leu Trp 145 150 155 160 Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing 165 170 175 Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 180 185 190 Phe Val Thr Lys Cys Ala Phe Oln Pro Pro Pro Ser Cys Leu Arg Phe 195 200 205 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 210 215 220 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 225 230 235 240 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Ser Gly 245 250 255 Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Gly 260 265 270 Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Ser Asp Ser Wing 275 280 285 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val 290 295 300 Thr Val Ala 305 (2) INFORMATION FOR SEQ ID NO: 678: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 678: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55, 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 165 170 175 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 180 185 190 Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr 195 200 205 Asn He Ser Arg Leu Leu Arg Glu Thr Ser Glu sln Pro Val Wing Leu 210 215 220 Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Oln 225 230 235 240 Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Gly Gly Gly Be Gly Gly Gly Gly Gly Gly Gly Glp Asp 260 265 270 Cys Ser Phe aln His Ser Pro Be Ser Asp Phe Ala Val Lys He 275 280 285 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala 290 295 300 Ser Asn Leu 305 (2) INFORMATION FOR SEQ ID NO: 679: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 679: Wing Asn Cys Ser He Met He Asp Clu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25. 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val alu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala aln Arg 145 150 155 160 Trp Met Olu Arg Leu Lys Thr Val Ala Oly Ser Lys Met aln Gly Leu 165 170 175 Leu Glu Arg Val Asn Thr Olu He His Phe Val Thr Lys Cys Ala Phe 180 185 190 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 195 200 205 Leu Leu Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 210 215 220 Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Arg Pro Asp 225 230 235 240 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Oly Oly Oly Ser Sly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 260 265 270 His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 275 280 285 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 290 295 300 Asp Glu Glu 305 (2) INFORMATION FOR SEQ ID NO: 680: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 680: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 3rd Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Tyr Val Glu Gly 145 150 155 160 Gly Gly Gly Pro Gly Pro Gly Ser Gly Pro Gust Ser Thr He Asn 165 170 175 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn 180 185 190 Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro 195 200 205 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He 210 215 220 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg 225 230 235 240 Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg 245 250 255 Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Ser Arg His 260 265 270 Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu 275 280 285 Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 681: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 296 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 681: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Arg Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 100 105 110 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val 115 120 125 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160 Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys 165 170 175 Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys Ser He Met He Asp 180 185 190 Glu He He His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro 195 200. 205 Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu Arg Asn Leu 210 215 220 Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing Val Lys His Leu Clu 225 230 235 240 Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu 245 250 255 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala 260 265 270 Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 275 280 285 Leu Glu Gln Wing Gln Glu Gln Gln 290 295 (2) INFORMATION FOR SEQ ID NO: 682:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 682: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Oly Gly 100 105 110 Ser Gly Gly Gly Thr Oln Asp Cys Ser Phe aln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Ala Val Lys He Arg slu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Olu Gly Gly 145 150 155 160 Gly Gly Ser Pro Oly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Ser Wing Thr Wing Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 683: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 683: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Olu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Oln Asp Tyr Pro Val Thr Val Wing As Asn Leu 145 150 155 160 Gln Tyr Val Olu ally Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 5 260 265 270 Ala Pro Ser Arg His Pro He He He Lys Ala Oly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 10 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 684: (i) CHARACTERISTICS OF THE SEQUENCE: 15 (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (¡) i) TYPE OF MOLECULE: none 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 684: Wing Asp Olu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Oln 1 5 10 15 Arg Trp Met slu Arg Leu Lys Thr Val Wing ally Ser Lys Met Oln sly 25 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Leu Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe-. Gln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro As Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln slu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 685: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 685: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Gly Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He Be 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu aly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Oln Gln 305 (2) INFORMATION FOR SEQ ID NO: 686: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 686: Met Wing Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu 1 5 10 15 Leu Cys Gly Oly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu 20 25 30 Arg Leu Lys Thr Val Wing Oly Being Lys Met Gln Gly Leu Leu Glu Arg 40 45 Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro 50 55 60 Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln 65 70 75 80 Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln 85 90 95 Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr 100 105 110 Leu Gly Gly Gly Gly Gly Sly Being sly sly ally Ser Cly sly Oly 115 120 125 Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala 130 135 140 Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Tyr Val Glu Gly 145 150 155 160 Gly Gly Gly Pro Pro Glu Pro Pro Gly Pro Be Thr He Asn 165 170 175 Pro Ser Pro Pro Ser Lys slu Ser His Lys Ser Pro Asn Met Wing Asn 180 185 190 Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro 195 200 205 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He 210 215 220 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg 225 230 235 240 Wing Val Lys His Leu Glu Asn Wing Ser sly He slu Wing He Leu Arg 245 250 255 Asn Leu Oln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Ser Arg His 260 265 270 Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu 275 280 285 Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 687:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 687: Wing Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 1 5 10 15 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 20 25 30 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 35 40 45 Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 50 55 60 Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu G-_n Leu Val 65 70 75 80 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 85 90 95 Leu Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Be Gly Gly 100 105 110 Gly Be Gly Gly Gly Be Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 115 120 125 His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 688: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 688: Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 1 5 10 15 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Cys 20 25 30 Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser 35 40 45 Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 50 55 60 Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly 65 70. 75 80 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp 85 90 95 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He 100 105 110 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 115 120 125 Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 130 135 140 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Pro Pro Glu Pro Pro Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro As Asn Leu Asn Ser slu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Ser Wing Thr Wing Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 689: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 689: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 35 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu 115 120 125 Gln Asp Glu Glu Glu Leu Cys Gly Gly Leu Trp Glu Leu Val Leu Glu Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 690: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 690: Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 1 5 10 15 Leu Oln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr 25 30 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys sln Pro Asp Ser 35 40 45 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 50 55. 60 Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp 65 70 75 80 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 85 90 95 Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln alu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 691: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 691: Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 1 5 10 15 Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 25 30 Leu Gln Cys Gln Pro Asp Ser Thr Leu Gly Gly Gly Ser Gly sly 35 40 45 Gly Ser Gly Gly Oly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 50 55 60 His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 65 70 75 80 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 85 90 95 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 100 105 110 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 115 120 125 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 130 135 140 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val sln Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 2 ^ 0 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 692: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 692: Wing Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser 1 5 10 15 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Cln Asn Phe Ser 20 25 30 Arg Cys Leu Glu Leu Gln Cys Cln Pro Asp Ser Being Thr Leu Gly Gly 40 45 Oly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp 50 55 60 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He 65 70 75 80 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 85 90 95 Ser Asn Leu sln Asp Olu Olu Leu Cys Gly Gly Leu Trp Arg Leu Val 100 105 110 Leu Ala sln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 115 120 125 Met Gln Oly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Phe Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu alu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala sln Olu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 693: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 693: Wing Being Asn Leu sln Asp alu Glu Leu Cys Gly Oly Leu Trp Arg Leu 1 5 10 15 Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Oly Being 25 30 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val 40 45 Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 50 55 60 Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing 65 70 75 80 Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu 85 90 95 Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly 100 105 110 Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln 115 120 125 Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys 130 135 140 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 145 150 155 160 Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I've been Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 694: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 694: Wing Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 1 5 10 15 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 25 30 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 35 40 45 Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr 50 55 60 Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu 65 70 75 80 Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln 85 90 95 Cys Oln Pro Asp Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly Ser 100 105 110 Gly Gly Gly Gly Gly Gly Ser Gly Gly Ser Gly Thr Gln Asp 115 120 125 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He 130 135 140 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 145 150 155 160 Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 695: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 695: Ala Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 1 5 10 15 Ala Gln Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 25 30 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 35 40 45 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 50 55 60 He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 65 70 75 80 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 85 90 95 Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 100 105 110 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys 115 120 125 Be Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg 130 135 140 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser 145 150 155 160 Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 696: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 696: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser 115 120 125 Phe Oln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Clu Asp Met Asp He Leu Met Clu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 697:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 697: Wing Olu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 1 5 10 15 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 20 25 30 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 40 45 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 50 55 60 Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 65 70 75 80 Thr Arg Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Oln Pro Asp 85 90 95 Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be 100 105 110 Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys Be Phe Gln 115 120 125 His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Oln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Oln 145 150 155 160 Asp Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 698: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 698: Wing Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 alu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 40 45 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 ~ 75 80 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Oly Oly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser 115 120 125 Pro He Ser Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Oln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 699: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 699: Wing Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu twenty - . 20 - 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 35 40 45 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser 115 120 125 Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Wing Thr Wing 260 265 270 Wing Pro Being Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Cln 290 295 300 Olu Oln Gln 305 (2) INFORMATION FOR SEQ ID NO: 700: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 700: Wing Leu 'Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 35 40 45 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg 65 70 75 80 Gln Asn Phe Ser Arg Cys Leu alu Leu Gln Cys Arg Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser 115 120 125 Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Oly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Olu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Wing Phe Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro He He Xle Lys Ala Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 701: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 701: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu sln Leu 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Oln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 Gln His Ser Pro Be Ser Be Asp Phe Wing Val Lys He Arg Glu Leu 100 105 110 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 115 120 125 Gln Asp Glu Glu Leu Cys Gly Oly Leu Trp Arg Leu Val Leu Ala Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Tyr Val Olu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser lie Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro As Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Wing Thr Wing Wing Pro Being Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 702: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 315 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 702: Wing Gln Asp Asp Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Oly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 130 135 140 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 145 150 155 160 Tyr Pro Val Thr Val Wing Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly 165 170 175 Be Pro Gly Glu Pro Be Gly Pro Be Be Thr He Asn Pro Be Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys Ser He 195 200 205 Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn Pro Leu 210 215 220 Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu 225 230 235 240 Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing Val Lys 245 250 255 His Leu Glu Asn Wing Being Gly He Glu Wing He Leu Arg Asn Leu Gln 260 265 270 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He 275 280 285 He Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr 290 295 300 Leu Val Thr Leu Glu Gln Ala Gln Glu Gln aln 305 310 315 (2) INFORMATION FOR SEQ ID NO: 703:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 703: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Oln Glu Thr Ser Glu Oln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Be Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly 100 105 110 Wing Thr Wing Pro Thr Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 115 120 125 Ser Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 130 135 140 Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe Val Arg Wing 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gln Gln 290 295 300 (2) INFORMATION FOR SEQ ID NO: 704: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 704: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 40 45 Wing Phe Gln Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Ser Be Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly 100 105 110 Wing Thr Wing Pro Thr Wing Gly Gln Pro Pro Leu Thr Gln Asp Cys Ser 115 120 125 Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Sly Oly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I've been Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Asn Cys Ser He Met He Asp Glu He He His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He 245 250 255 Glu Ala He Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Pro Wing Pro Arg His Pro He He Lys Wing Gly Asp Trp Gln Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln 290 295 300 Glu Gln Gln 305 (2) INFORMATION FOR SEQ ID NO: 705: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 705: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Be Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser sly Oly Gly Ser Gly Thr Gln Asp Cys Ser 325 330 335 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 Leu Gln 370 (2) INFORMATION FOR SEQ ID NO: 706: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 706: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Being 50 55 60 Cys Pro Ser GÍn Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 210 215 220 Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser 225 230 235 240 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val 245 250 255 Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 260 265 270 He Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala 275 280 285 Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu 290 295 300 Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 305 310 315 320 Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln 325 330 335 Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val Lys 340 345 350 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 355 360 365 Ala Ser 370 (2) INFORMATION FOR SEQ ID NO: 707:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 707: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Wing Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 210 215 220 Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 225 230 235 240 Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp 245 250 255 Be Ser Thr Leu Gly Gly Gly Be Gly Gly Gly Be Gly Gly Cly Ser 260 265 270 Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys Ser Phe Gln 275 280 285 His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg slu Leu Ser 290 295 300 Asp Tyr Leu Leu sln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Oln 305 310 315 320 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala sln Arg 325 330 335 Trp Met slu Arg Leu Lys Thr Val Wing sly Ser Lys Met Gln Gly Leu 340 345 350 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 708:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 708: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln Olu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu sly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Cln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 210 215 220 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 225 230 235 240 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 245 250 255 Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr 260 265 270 Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu 275 280 285 Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln 290 295 300 Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320 Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp 325 330 335 Cys Ser Phe Gln His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He 340 345 350 Arg Olu Leu Ser Asp Tyr Leu Leu aln Asp Tyr Pro Val Thr Val Wing 355 360 365 Ser Asn 370 (2) INFORMATION FOR SEQ ID NO: 709: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 709: Wing Thr Pro Leu Oly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Oly Asp Gly Ala Ala Leu 25 30 Gln Olu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 '45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Oly Leu Leu Gln Ala Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Wing Leu Cln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 210 215 220 Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 225 230 235 240 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 245 250 255 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 260 265 270 He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 275 280 285 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 290 295 300 Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320 Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys 325 330 335 Being Phe Gln His Being Pro Pro Being Ser Asp Phe Ala Val Lys He Arg 340 345 350 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser 355 360 365 Asn Leu 370 (2) INFORMATION FOR SEQ ID NO: 710: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 710: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Olu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala ? oo 105 no Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 210 215 220 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 225 230 235 240 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 245 250 255 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 260 265 270 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 275 280 285 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 290 295 300 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 305 310 315 320 Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys Be Phe 325 330 335 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 340 345 350 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 355 360 365 Gln Asp 370 (2) INFORMATION FOR SEQ ID NO: 711: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 711: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Oln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 210 215 220 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 225 230 235 240 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 245 250 255 Gln Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 260 265 270 Leu Leu Gln Glu Thr Ser Glu Oln Leu Val Ala Leu Lys Pro Trp He 275 280 285 Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys sln Pro Asp 290 295 300 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 325 330 335 His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 340 345 350 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 355 360 365 Asp Glu 370 (2) INFORMATION FOR SEQ ID NO: 712: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 712: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln slu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Clu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Being 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp 210 215 220 Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu 225 230 235 240 Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln 245 250 255 Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 260 265 270 Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr 275 280 285 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 290 295 300 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320 Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His 325 330 335 Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp 340 345 350 Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp 355 360 365 Glu Glu 370 (2) INFORMATION FOR SEQ ID NO: 713: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 713: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Oly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Wing Leu Gl Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Olu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Oly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly 305 310 315 320 Ala Thr Ala Pro Thr Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 325 330 335 Be Being Asp Phe Wing Val Lys He Arg Glu Leu Being Asp Tyr Leu Leu 340 345 350 Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 355 360 (2) INFORMATION FOR SEQ ID NO: 714: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 378 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 714: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Olu Gly He 85 90 95 Ser Pro Glu Leu sly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 325 330 335 Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Pro Be Ser 340 345 350 Asp Phe Wing Val Lys He Arg slu Leu Ser Asp Tyr Leu sln Asp 355 360 365 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 370 375 (2) INFORMATION FOR SEQ ID NO: 715:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 715: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Clu sln Val Arg Lys He aln Cly Asp aly Ala Ala Leu 25 30 Gln slu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Olu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr 165 170 175 Val Glu Oly Gly Gly Oly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Be Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320 Wing Thr Wing Pro Thr Wing Gly Gln Pro Pro Leu Thr Gln Asp Cys Ser 325 330 335 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 Leu Gln 370 (2) INFORMATION FOR SEQ ID NO: 716:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 716: Wing Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu 1 5 10 15 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg 25 30 Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 40 45 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro 50 55 60 Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu 65 70 75 80 Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 85 90 95 Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 115 120 125 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val 130 135 140 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 145 150 155 (2) INFORMATION FOR SEQ ID NO: 717: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 717: Wing Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 1 5 10 15 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 25 30 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 35 40 45 Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 50 55 60 Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 65 70 75 80 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 85 90 95 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 115 120 125 His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 145 150 155 (2) INFORMATION FOR SEQ ID NO: 718: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 718: Wing Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr 1 5 10 15 Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys 25 30 Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser 35 40 45 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 50 55 60 Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly 65 70 75 80 Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Thr Oln Asp 85 90 95 Cys Ser Phe Gln His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He 100 105 110 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala 115 120 125 Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 130 135 140 Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 145 150 155 (2) INFORMATION FOR SEQ ID NO: 719: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 719: Wing Being Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 25 30 Val Oln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Oln Leu 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 Gln His Ser Pro Be Ser Be Asp Phe Wing Val Lys He Arg Glu Leu 100 105 110 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 115 120 125 Gln Asp Glu Clu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 145 150 155 (2) INFORMATION FOR SEQ ID NO: 720: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 720: Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 1 5 10 15 Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr 20 25 30 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 40 45 Being Thr Leu Gly Gly Gly Being Gly Gly Gly Being Gly Gly Gly Being Gly 50 55 60 Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 65 70 75 80 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 85 90 95 Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 He His Phe Val Thr Lys Cys Ala Phe Gln Pro 145 150 155 (2) INFORMATION FOR SEQ ID NO: 721: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 721: Wing Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser 1 5 10 15 Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser 25 30 Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly 35 40 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Cly Gly Thr Gln Asp 50 55 60 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He 65 70 75 80 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 85 90 95 Being Asn Leu Gln Asp Glu Glu Leu Cys Gly sly Leu Trp Arg Leu Val 100 105 110 Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Oly Ser Lys 115 120 125 Met Oln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 145 150 155 (2) INFORMATION FOR SEQ ID NO: 722: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 722: Wing Thr Asn He Being Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 1 5 10 15 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 20 25 30 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly 40 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 50 55 60 His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 65 70 75 80 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln 85 90 95 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 100 105 110 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 115 120 125 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 130 135 140 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 145 150 155 (2) INFORMATION FOR SEQ ID NO: 723: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 723: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He Be 50 55 60 Arg Leu Leu sln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Wing Glu Lys Wing Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Oln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 724: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 724: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Am Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser sln Ala Leu aln Leu Ala aly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Oln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 725: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 354 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 725: Wing Asp slu slu Leu Cys sly Oly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met sln sly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Oln Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly Wing 100 105 110 Thr Wing Pro Thr Wing Gly Gln Pro Pro Leu Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly 165 170 175 Being Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being 180 185 190 Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 195 200 205 Wing Wing Wing Glu Lys Wing Lys Wing Thyr Tyr Lys Leu Cys His Pro 210 215 220 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro 225 230 235 240 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 245 250 255 Oln Leu His Ser Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 260 265 270 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 275 280 285 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 290 295 300 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 305 310 315 320 Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 325 330 335 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 340 345 350 Gln Pro (2) INFORMATION FOR SEQ ID NO: 726: 5 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 363 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear 10 ( I) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 726: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 ^ Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 20 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys sln Pro 85 90 95 25 Asp Ser Ser Thr Leu Oly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly 115 120 125 Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Ser Asp 130 135 140 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 145 150 155 160 Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly ally Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu 180 185 190 Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ser Glu Leu 195 200 205 aln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Cln Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 290 295 300 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln 305 310 315 320 Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg 325 330 335 Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val 340 345 350 Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 727: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 348 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 727: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly Ala 100 105 110 Thr Wing Pro Thr Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Tyr Val Glu Gly Gly Gly 145 150 155 160 Gly Ser Pro Oly ally Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro 165 170 175 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Ser Leu 180 185 190 Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys 195 200 205 Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Olu Leu Val Leu Leu 210 215 220 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 225 230 235 240 Gln Ala Leu Oln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 245 250 255 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu 260 265 270 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 275 280 285 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu 290 295 300 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Ala Be Wing Phe Gln Arg 305 310 315 320 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 325 330 335 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 340 345 (2) INFORMATION FOR SEQ ID NO: 728: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 359 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 728: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Arg Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 100 105 110 Oln Asp Cys Ser Phe Oln His Ser Pro Be Ser Asp Phe Wing Val 115 120 125 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 130 135 140 Val Wing Being Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160 Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys 165 170 175 Glu Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Ser 180 185 190 Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys 195 200 205 He Gln Gly Asp Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr 210 215 220 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 225 230 235 240 He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu 245 250 255 Wing Gly Cys Leu Ser Gln Leu His Ser sly Leu Phe Leu Tyr Gln Gly 260 265 270 Leu Leu Gln Ala Leu Olu Gly He Ser Pro Glu Leu Gly Pro Thr Leu 275 280 285 Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln 290 295 300 Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu Gln Pro Thr Gln Gly 305 310 315 320 Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val 325 330 335 Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val 340 345 350 Leu Arg His Leu Ala Gln Pro 355 (2) INFORMATION FOR SEQ ID NO: 729: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 729: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Olu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gln Asp Cys Being Phe Gln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Pro Pro Asn Met Wing Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser sln Leu His Ser Gly Leu 260 265 * 270 Phe Leu Tyr Gln sly Leu Leu sln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe Gln Arg 325 330 335 Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 730: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 730: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Oly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Being Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Gly Gly Gly Gly Gly Gly 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Asp Cys Ser Phe 115 120 - 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala sly sly Val Leu Val Ala Ser His 340 345 350 Leu sln Ser Phe Leu Glu Val Ser Tyr Arg Val Val Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 731: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 731: Wing Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 1 5 10 15 Leu Oln Glu Thr Ser Glu Oln Leu Val Ala Leu Lys Pro Trp He Thr 25 30 Arg Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 40 • 45 Be Thr Leu Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly 50 55 60 Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As As 65 70 75 80 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 85 90 95 Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Tyr Val Olu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Pro 180 185 190 Leu Gly Pro Wing Ser Ser Val Pro Oln Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Oly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val He Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 732: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 732: Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 1 5 10 15 Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser 25 30 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val 35 40 45 Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 50 55 60 Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing 65 70 75 80 Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu 85 90 95 Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln 115 120 125 Asp Cys Ser Phe aln His Ser Pro Be Ser Asp Phe Wing Val Lys 130 135 140 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 145 150 155 160 Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 He Ser Thr He Asn Pro Ser His Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Wing Glu Lys Wing Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 733: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 733: Wing Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 1 5 10 15 Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys 20 25 30 Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr 40 45 Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Xrg Phe Val Gln Thr 50 55 60 Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu 65 70 '75 80 Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln 85 90 95 Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Oly Gly Gly Ser sly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp 115 120 125 Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He 130 135 140 Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 145 150 155 160 Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val He Arg His Leu Wing 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 734:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 734: Ala Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 1 5 10 15 Wing Gln Arg Leu Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met 20 25 30 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 35 40 45 Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 50 55 60 He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 65 70 75 80 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 85 90 95 Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 100 105 110 Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Glp Asp Cys 115 120 125 Being Phe Gln His Ser Pro Being Ser Asp Phe Ala Val Lys He Arg 130 135 140 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser 145 150 155 160 Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Wing Glu Lys Wing Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu Leu 305 310 315 320 Oly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala aly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 735: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 735: Wing Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 35 40 45 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys aln Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser 115 120 125 Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Oln Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Am Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser Gln Ala Leu sln Leu Wing Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 736: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 736: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 sln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Olu Leu 100 105 110 Ser Asp Tyr Leu Leu sln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Pro Pro Asn Met Wing Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Ala 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 737: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 737: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 35 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 115 120 125 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Pro aly Pro Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu aly Pro Ala Ser Ser Leu Pro Oln Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He aln Gly Asp Gly Ala Ala Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Oln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Oln Ser Phe Leu Clu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 738: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 738: Wing Leu Cys Gly Oly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 35 40 45 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Being Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg 65 70 75 80 Oln Asn Phe Ser Arg Cys Leu alu Leu Oln Cys Arg Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser 115 120 125 Pro He Ser Ser Asn Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 He Phe Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Oly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 739: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 739: Wing Olu Leu Cys Cly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp 1 5 10 15 Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu 25 30 Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln 35 40 45 Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 50 55 60 Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Ihr 65 70 75 80 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 85 90 95 Be Thr Leu Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly 100 105 110 Oly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His 115 120 125 Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp 130 135 140 Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Wing Glu Lys Wing Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 740: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 740: Wing Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 1 5 10 15 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 25 30 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 40 45 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg 50 55 60 Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He 65 70 75 80 Thr Arg Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp 85 90 95 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln 115 120 125 His Ser Pro Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 145 150 155 160 Asp Tyr Val alu Gly Gly ally Gly Ser Pro Gly Glu Pro Gly Pro 165 170 175 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 741: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 741: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met alu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 20 25 30 Cly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg aln Asn Phe Ser Arg Cys Leu alu Leu aln Cys Gln 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly aly Ser aly aly aly Ser aly aly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser 115 120 125 Phe Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 742:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 742: Ala Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 1 5 10 15 Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 25 30 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly 35 40 45 Gly Ser Gly Gly Gly Gly Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln 50 55 60 His Ser Pro Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 65 70 75 80 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 85 90 95 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 100 105 110 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 115 120 125 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 130 135 140 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu 195 -. 195 - 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Ala 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 743:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 743: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln 180 185 190 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp 195 200 205 Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His 210 215 220 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 225 230 235 240 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu 245 250 255 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala 260 265 270 Leu Olu aly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 275 280 285 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Cln Gln Met Glu Glu 290 295 300 Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing 305 310 315 320 Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser 325 330 335 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Wing Gln Pro 355 (2) INFORMATION FOR SEQ ID NO: 744:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 744: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 40 45 Wing Phe Gln Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Oly Gly Gly Ser Gly Thr Gln Asp Cys Ser 115 120 125 Phe Gln His Ser Pro Be Ser Ser Asp Ser Ala Val Lys He Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro 245 250 255 Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe 325 330 335 Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 745: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 366 amino acids (B) TYPE: amino acid • (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 745: Wing Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 25 30 Arg Val Asn Thr Glu He His Phe Val Thr Lys Tyr Ala Phe Gln Pro 35 40 45 Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu 50 55 60 Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp He Thr Arg 65 70 75 80 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Arg Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 115 120 125 Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 130 135 140 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Asp Glu Glu Tyr Val Glu 145 150 155 160 Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro He Be Thr He 165 170 175 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 180 185 190 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys 195 200 205 Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln 210 215 220 Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240 Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing Leu Ser Ser Cys 245 250 255 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 260 265 270 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 290 295 300 Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro 305 310 315 320 Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe 325 330 335 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 340 345 350 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 365 (2) INFORMATION FOR SEQ ID NO: 746: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 746: Wing Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His 1 5 10 15 Phe Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 40 45 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Phe Arg Cys Leu 50 55 60 Glu Leu Gln Cys Gln Pro Asp Be Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe 85 90 95 Gln His Ser Pro Be Ser Be Asp Phe Wing Val Lys He Arg Glu Leu 100 105 110 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 115 120 125 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly aly Ser Pro Cly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Pro Pro Asn Met Wing Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Oly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Oly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Oln Wing Leu Glu Gly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Ala 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330"335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360" (2) INFORMATION FOR SEQ ID NO: 747: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 378 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 747: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ser Ser 130 135 140 Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 145 150 155 160 Tyr Pro Val Thr Val Wing Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly 195 200 205 Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu Glu Gln 210 215 220 Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys 225 230 235 240 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala 260 265 270 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 305 310 315 320 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu Gln Pro 325 330 335 Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gln Pro 370 375 (2) INFORMATION FOR SEQ ID NO: 748: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 748: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Be Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly 100 105 110 Wing Thr Wing Pro Thr Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 115 120 125 Ser Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 130 135 140 Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Pro Pro Asn Met Wing Thr Pro 180 185 190 Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu alu Oly He Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing 290 295 300 Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu 305 310 315 320 Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Giu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 355 360 (2) INFORMATION FOR SEQ ID NO: 749: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 749: Wing Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 1 5 10 15 Cln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 50 55 60 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 65 70 75 80 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 85 90 95 Pro Asp Being Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly 100 105 110 Wing Thr Wing Pro Thr Wing Gly Gln Pro Pro Leu Thr Oln Asp Cys Ser 115 120 125 Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Wing Wing Wing Glu Lys Wing Cys Wing Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser - Ser Cys Pro Ser Gln Ala Leu Oln Leu Ala Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 750: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 378 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 750: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Be Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser As Asp 130 135 140 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 145 150 155 160 Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly 165 170 175 Pro Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly 195 200 205 Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Cys Leu Glu Gln 210 215 220 Val Arg Lys He Gln Gly Asp Gly Ala Wing Gln Glu Lys Leu Cys 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Being Leu Gly He Pro Trp Wing Pro Leu Being Ser Cys Pro Being Gln Ala 260 265 270 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 305 310 315 320 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 325 330 335 Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gln Pro 370 375 (2) INFORMATION FOR SEQ ID NO: 761: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 378 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 751: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Pro Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Be 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Cln Asn Phe Ser Arg Cys Leu Olu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Ser Gly Thr Gln Asp Cys Ser Phe sln His Ser Pro I Have To Be Asp 130 135 140 Phe Ala Val Lys He Arg Olu Leu Ser Asp Tyr Leu Leu Cln Asp Tyr 145 150 155 160 Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Glu Pro Be Gly Pro Be Ser Thr He Asn Pro Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly 195 200 205 Pro Wing Ser Ser Leu Pro sln Ser Phe Leu Leu Lys Cys Leu Glu Gln 210 215 220 Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys 225 230 235 240 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Ala 260 265 270 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 305 310 315 320 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro 325 330 335 Thr Gln Gly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg Wing 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gln Pro 370 375 (2) INFORMATION FOR SEQ ID NO: 752: CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 752: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly Ala 100 105 110 Thr Wing Pro Thr Wing Gly Gln Pro Pro Leu Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Oln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Thr Pro ally Olu Pro Ser Gly Pro 165 170 175 I Have Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly 210 215 220 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Pro Wing 245 250 255 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Wing Gly Cys Leu Ser 260 265 270 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu 275 280 285 Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 290 295 300 Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 325 330 335 Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing Ser His 340 345 350 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing 355 360 365 Gln Pro 370 (2) INFORMATION FOR SEQ ID NO: 753:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 347 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 753: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Val Glu Thr Val Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu 100 105 110 Thr Ser Thr Gln Asp Cys Ser Phe Gln His Ser Pro Pro Ser Ser Asp 115 120 125 Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr 130 135 140 Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly 145 150 155 160 Being Pro Gly Gly Gly Being Gly Gly Being Asn Met Wing Thr Pro Leu 165 170 175 Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys Ser Leu Glu 180 185 190 Gln Val Arg Lys He Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu 195 200 205 Cys Wing Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 210 215 220 His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln 225 230 235 240 Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 245 250 255 Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser Pro Glu Leu 260 265 270 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr 275 280 285 Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln 290 295 300 Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg 305 310 315 320 Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val 325 330 335 Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 340 345 (2) INFORMATION FOR SEQ ID NO: 754:) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 754: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Ser Ser Thr Leu Tyr Val Glu Gly Gly Gly Pro Gly Glu 100 105 110 Pro Ser Gly Pro Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu 115 120 125 Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser 130 135 140 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He 145 150 155 160 Gln Gly Asp Gly Wing Wing Leu Gln Glu Lys Leu Cys Wing Thr Tyr Lys 165 170 175 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He 180 185 190 Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing 195 200 205 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 210 215 220 Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 225 230 235 240 Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln 245 250 255 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala 260 265 270 Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu 275 280 285 Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 290 295 300 Arg His Leu Wing Gln Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 305 310 315 320 Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys 325 330 335 Glu Ser His Lys Ser Pro Asn Met Wing Thr Gln Asp Cys Ser Phe Gln 340 345 350 His Ser Pro Pro Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser 355 360 365 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 370 375 380 (2) INFORMATION FOR SEQ ID NO: 755: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 349 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 75d: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing Ser Asn Leu Gln Glu Pro Lys Ser Pro Asp Thr His "35 40 45 Thr Ser Pro Pro Pro Pro Thr Pro Leu Gly Pro Wing Ser Ser Leu Pro 50 55 60 Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly 65 70 75 80 Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys 85 90 95 His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp 100 105 110 Pro Wing Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys 115 120 125 Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Oly Leu Leu Gln 130 135 140 Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu 145 150 155 160 Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met C-lu 165 170 175 Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro 180 185 190 Wing Phe Wing Being Wing Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing 195 200 205 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 210 215 220 Leu Wing Gln Pro Ser Wing Glu Pro Lys Ser Pro Asp Thr His Thr Ser 225 230 235 240 Pro Pro Ser Pro Gly Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu 305 310 315 320 Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg 325 330 335 Cys Leu Glu Leu Gln Cys Oln Pro Asp Ser Ser Thr Leu 340 345 (2) INFORMATION FOR SEQ ID NO: 766: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 347 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 756: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Trp Gln Gly Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Pro Lys Ser Pro Asp Thr His Thr 85 90 95 Ser Pro Pro Pro Pro Gly Pro Pro Leu Gly Pro Pro Ser Be Leu Pro 100 105 110 sln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He sln Gly 115 120 125 Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Tyr Lys Leu Cys His 130 135 140 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 145 150 155 160 Pro Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys leu 165 170 175 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala 180 185 190 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu 31n 195 200 205 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu 210 215 220 Leu Gly Met Wing Pro Wing Leu Gln Pro Thr sln Gly Ala Met Pro Ala 225 230 235 240 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 245 250 255 His Leu Oln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 260 265 270 Wing Gln Pro Ser Wing Olu Pro Lys Ser Pro Asp Thr His Thr Ser Pro 275 280 285 Pro Ser Pro sly Lys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe 290 295 300 Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu 305 310 315 320 Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu 325 330 335 Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu 340 345 (2) INFORMATION FOR SEQ ID NO: 757: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 356 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 757: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Ser Wing 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Oly Gly Ser Gly Oly Gly Ser Gly Thr Gln Asp Being Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln 180 185 190 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp 195 200 205 Gly Wing Ala Leu Gln Glu Lys Leu Cys Wing Thr Asn Lys Leu Cys His 210 215 220 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 225 230 235 240 Pro Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu 245 250 255 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Oly Leu Leu Gln Ala 260 265 270 Leu Glu Oly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 275 280 285 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu 290 295 300 Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 305 310 315 320 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 325 330 335 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Ala Gln Pro 355 (2) INFORMATION FOR SEQ ID NO: 758: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 758: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 150 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Ser 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Ser Ser 325 330 335 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 Leu Gln 370 (2) INFORMATION FOR SEQ ID NO: 759: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 356 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 759: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Ser Leu Arg Phe Val Gln Thr Asn He Be 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg sln Asn Phe Ser Arg Cys Leu Glu Leu Gln Ser Oln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 aln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln 180 185 190 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp 195 200 205 Gly Wing Wing Wing Gln Glu Lys Leu Cys Wing Thr Asn Lys Leu Cys His 210 215 220 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 225 230 235 240 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu 245 250 255 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala 260 265 270 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 275 280 285 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Oln Gln Met Glu Glu 290 295 300 Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 305 310 315 320 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 325 330 335 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His leu 340 345 350 Wing Gln Pro 355 (2) INFORMATION FOR SEQ ID NO: 760: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 760: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp aln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala aly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Be Ser Leu Arg Phe Val Gln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Ser sln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser 325 330 335 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg C-lu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 Leu Gln 370 (2) INFORMATION FOR SEQ ID NO: 761: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 334 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 761: Ala Thr Gln Asp Being Ser Phe Gln His Ser Pro Be Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Glu Leu Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Cln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Ser Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys 165 170 175 Be Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln 180 185 190 Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Olu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 260 265 270 Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe 290 295 300 Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 762: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 334 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 762: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 30 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Ser Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Ser Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly sly Gly Ser Asn Met Wing 145 150 155 160 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu Lys 165 170 175 Ser Leu Olu Gln Val Arg Lys He Gln sly Asp Gly Ala Ala Leu Gln 180 185 190 Olu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gln Ala Leu Oln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 225 230 235 240 Oly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Olu Gly He Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 260 265 270 Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala Phe 290 295 300 3in Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 763: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 326 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 763: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu C-In 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly 130 135 140 Ser Oly ally Cly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 145 150 155 160 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He 165 170 175 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Asn lys 180 185 190 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He 195 200 205 Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing 210 215 220 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 225 230 235 240 Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 245 250 255 Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln 260 265 270 Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Thr Gln Gly Wing 275 280 285 Met Pro Ala Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu 290 295 300 Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 305 310 315 220 Arg His Leu Ala Gln Pro 325 (2) INFORMATION FOR SEQ ID NO: 764: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 334 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 764: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Olu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr Ser Glu C-ln 100 105 110 leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Ser Gln Pro Asp Ser Ser Thr Leu Tyr Val Glu C-ly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Wing 145 150 155 160 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu lys 165 170 175 Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln 180 185 190 Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Cys 210 215 220 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp 260 265 270 Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro 275 280 285 Wing Leu Gln Pro Thr sln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe 290 295 300 Gln Arg Arg Ala Oly sly Val Leu Val Ala Ser His Leu Oln Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 765: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 334 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 765: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 25 30 Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Arg 115 120 125 Leu Glu Leu Gln Ser Gln Pro Asp Being Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 150 Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu lys 165 170 175 Being Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Wing Ala Leu Gln 180 185 190 Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly lie Pro Trp Pro Wing Leu Ser Ser Cys 210 215 220 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Oln Leu Asp Val Wing Asp 260 265 270 Phe Ala Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing Phe 290 295 300 Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Leu Gln Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 766: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 352 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 766: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Olu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu sln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Oly Gly Ser Gly Gly Gly Ser Oly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly C-ly 165 170 175 Gly Ser Asn Met Wing Thr Gln Gly Wing Met Pro Wing Phe Wing Wing Wing 180 185 190 Phe Gln Arg Arg Wing Gly Gly Val Leu Val Wing His Ser Leu Gln Ser 195 200 205 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser 210 215 220 Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln 225 230 235 240 Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu Gln slu Lys Leu Cys 245 250 255 Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 260 265 270 Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing 275 280 285 Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu Hxs Ser Gly Leu Phe Leu 290 295 300 Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly 305 310 315 320 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr 325 330 335 He Trp Gln Gln Met Glu Glu Leu Gly Met Wing Pro Ala Leu Gln Pro 340 345 350 (2) INFORMATION FOR SEQ ID NO: 767: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 367 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ií) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 767: Wing Thr Gln Oly Wing Met Pro Wing Phe Wing Being Wing Phe Gln Arg Arg 1 5 10 15 Ala Gly aly Val Leu Val Ala Ser His Leu aln Ser Phe Leu Glu Val 20 25 30 Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly 40 45 Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys He 50 55 60 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys 65 70 75 80 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He 85 90 95 Pro Trp Wing Pro Leu Be Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing 100 105 110 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 115 120 125 Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 130 135 140 Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln 145 150 155 150 Met Glu Glu Leu Gly Met Wing Pro Wing Leu Gln Pro Tyr Val Glu Gly 165 170 175 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 180 185 190 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asp 195 200 205 Glu Glu Glu Leu Cys Gly Glu Leu Trp Glu Leu Val Leu Ala Gln Arg Trp 210 215 220 Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu 225 230 235 240 Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln 245 250 255 Pro Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu 260 265 270 Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr 275 280 285 Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser 290 295 300 Ser Thr Leu Gly Gly Gly Ser sly Oly Gly Ser Gly Oly Gly Ser Gly 305 310 315 320 Gly Gly Ser sly sly sly Ser sly Thr Oln Asp Cys Ser Phe Gln His 325 330 335 Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp 340 345 350 Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 355 360 365 (2) INFORMATION FOR SEQ ID NO: 768: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 344 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 768: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Oln His Ser Pro He Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val Glu Gly C-ly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asp Glu 180 185 190 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met 195 200 * 205 Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu 210 215 220 Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro 225 230 235 240 Pro Pro Cys Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu 245 250 255 Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg 260 265 270 Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser 275 280 285 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 290 295 300 Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe 305 310 315 320 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 325 330 335 Val Thr Val Ala Ser Asn Leu Gln 340 (2) INFORMATION FOR SEQ ID NO: 769: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 335 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 769: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Cln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu leu 130 135 140 Being Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Being Asn Leu 145 150 155 160 Gln Tyr Val Clu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Be 195 200 205 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 210 215 220 Asn Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu Leu Cys 225 230 235 240 Gly Oly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu 245 250 255 Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Olu Arg Val Asn 260 265 270 Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser 275 280 285 Cys Leu Arg Phe Val Gln Thr Asn He Ser Arg Leu Leu Gln Glu Thr 290 295 300 Ser Glu Gln Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe 305 310 315 320 Be Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Be Ser Thr Leu 325 330 335 (2) INFORMATION FOR SEQ ID NO: 770: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 550 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) "TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 770: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu aln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val alu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln 180 185 190 Being Phe Leu Leu Being Leu Glu Gln Val Arg Lys He Gln Gly Asp 195 200 205 Gly Wing Wing Wing Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His 210 215 220 Pro alu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing 225 230 235 240 Pro Leu Be Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu 245 250 255 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing 260 265 270 Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln 275 280 285 Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu 290 295 300 Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 305 310 315 320 Phe Ala Be Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 325 330 335 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Wing Gln Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 355 360 365 Gly Pro Be Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser H s 370 375 380 Lys Ser Pro Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 385 390 395 400 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing C-ly 405 410 415 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 420 425 430 Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 435 440 445 Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 450 455 460 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu 465 470 475 480 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly 485 490 495 Gly Ser Gly Gly Gly Gly Gly Gly Ser Gly Gly Ser Gly Thr 500 505 510 Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val 515 520 525 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 530 535 540 Val Ala Ser Asn Leu Cln 545 550 (2) INFORMATION FOR SEQ ID NO: 771: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 544 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 771: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Ala Leu 25 30 Gln Olu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Olu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Cln Leu Asp Val Ala 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Wing Leu Gln Pro Thr Gln Gly Wing Met Pro Wing Phe Wing Wing 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Wing Gln Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met slu Arg Leu Lys Thr Val Ala sly Ser Lys Met Gln 225 230 235 240 Oly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Oly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser 325 330 335 Phe Gln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser C-ly 370 375 380 Pro 'He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His lys 385 390 395 400 Ser Pro Asn Met Wing Thr Gln Asp Cys Ser Phe Gln His Ser Pro He 405 410 415 Be Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu leu 420 425 430 Oln Asp Tyr Pro Val Thr Val Wing As Asn Leu Gln Asp Glu Glu leu 435 440 445 Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg 450 455 460 Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val 465 470 475 480 Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro 485 490 495 Be Cys Leu Arg Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu 500 505 510 Thr Ser Glu Oln Leu Val Wing Leu Lys Pro Trp He Thr Arg Gln Asn 515 520 525 Phe Ser Arg Cys Leu Glu Leu Cln Cys Oln Pro Asp Ser Ser Thr Leu 530 535 540 (2) INFORMATION FOR SEQ ID NO: 772:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 565 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 772: Wing Thr Pro Leu Gly Pro Wing Being Ser Leu Pro Gln Being Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gln Val Arg Lys He Gln Gly Asp Gly Ala Wing Leu 20 25 30 Gln Glu Lys Leu Cys Wing Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Val Leu Leu Gly His Ser Leu Gly He Pro Trp Wing Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Wing Leu Gln Leu Wing Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He 85 90 95 Be Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Wing 100 105 110 Asp Phe Wing Thr Thr He Trp Gln Gln Met Glu Glu Leu Gly Met Wing 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Be Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Tyr 165 170 175 Val Glu Gly Gly Cly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser 180 185 190 Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing 210 215 220 Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu lie His Phe Val Thr Lys Cys 245 250 255 Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He 260 265 270 Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro 275 280 285 Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln 290 295 300 Pro Asp Being Ser Thr Leu Gly Gly ally Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser 325 330 335 Phe Cln His Ser Pro He Be Ser Asp Phe Ala Val Lys He Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn 355 360 365 Leu sln Tyr Val slu Oly Gly Gly Gly Ser Pro sly Glu Pro Ser Gly 370 375 380 Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys 385 390 395 400 Ser Pro Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 405 410 415 Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser 420 425 430 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val 435 440 445 Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 450 455 460 Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala 465 470 475 480 Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu 485 490 495 Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Gly Gly Gly 500 505 510 Ser Gly Gly Gly Ser Gly Gly Gly Sery Gly Gly Ser Gly Thr Gln 515 520 525 Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys 530 535 540 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 545 550 555 560 Ala Ser Asn Leu Gln 565 (2) INFORMATION FOR SEQ ID NO: 773:) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 502 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 773: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Pro Wing Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Be He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Wing Cln Arg Trp Met Olu Arg Leu Lys Thr Val Wing Oly Ser Lys Met 165 170 175 Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 180 185 190 Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn 195 200 205 He Be Arg Leu Leu aln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys 210 215 220 Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys 225 230 235 240 Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Be Gly Gly Gly Be Gly Gly Gly Be Gly Thr Gln Asp Cys 260 265 270 Ser Phe Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing 290 295 300 Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 305 310 315 320 Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 325 330 335 Lys Ser Pro Asn Met Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 340 345 350 Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly 355 360 365 Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 370 375 380 Val Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val 385 390 395 400 Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val 405 410 415 Wing Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Clu 420 425 430 Leu Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly 435 440 445 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr 450 455 460 Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser Asp Phe Ala Val 465 470 475 480 Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr 485 490 495 Val Ala Ser Asn Leu Gln 500 (2) INFORMATION FOR SEQ ID NO: 774: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 562 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 774: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Oln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser sly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser sly Thr Oln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Ala Val Lys He Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Wing Ser Asn Leu 145 150 155 160 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Wing Asp Glu Glu Leu Cys Oly Gly Leu Trp Arg Leu 180 185 190 Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser 195 200 205 Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val 210 215 220 Thr Lys Cys Wing Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln 225 230 235 240 Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing 245 250 255 leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu leu 260 265 270 Gln Cys Gln Pro Asp Being Ser Thr Leu Gly Gly Gly Be Gly Gly Gly 275 280 285 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln 290 295 300 Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe Ala Val lys 305 310 315 320 He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val 325 330 335 Wing Being Asn Leu Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu 340 345 350 Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu 355 360 365 Ser His Lys Ser Pro Asn Met Wing Thr Pro Leu Gly Pro Wing Being Ser 370 375 380 Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys He 385 390 395 400 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys 405 410 415 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He 420 425 430 Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gln Wing Leu Gln Leu Wing 435 440 445 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 450 455 460 Leu Gln Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 465 470 475 480 Thr Leu Gln Leu Asp Val Wing Asp Phe Wing Thr Thr He Trp Gln Gln 485 490 495 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala 500 505 510 Met Pro Wing Phe Wing Wing Wing Phe Gln Arg Arg Wing Gly Gly Val leu 515 520 525 Val Wing His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val leu 530 535 540 Arg His Leu Wing Gln Pro Ser Thr Pro Ser Thr Pro Oly Ser Glu Phe 545 550 555 560 Gly Ser (2) INFORMATION FOR SEQ ID NO: 775: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 775: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly 25 30 Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Be Ser 115 120 125 Ser Asp Phe Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln 130 135 140 Asp Tyr Pro Val Thr Val Wing Ser Asn Leu Gln Tyr Val alu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Be Ser Thr- He Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Wing Asn Cys 180 185 190 Ser He Met He Asp Olu He He His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He Leu Arg Asn 245 250 255 leu Gln Pro Cys Leu Pro Ser Wing Thr Wing Wing Pro Ser Arg His Pro 260 265 270 He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln Tyr Val Glu 290 295 300 Gly Gly Gly Gly Pro Pro Gly Glu Pro Gly Pro Be Ser Thr He 305 310 315 320 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 325 330 335 Asp Glu Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln Arg 340 345 350 Trp Met Glu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln Gly Leu 355 360 365 Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe 370 375 380 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Oln Thr Asn He Ser Arg 385 390 395 400 Leu Leu Gln Glu Thr Ser Olu Gln Leu Val Wing Leu Lys Pro Trp He 405 410 415 Thr Arg Gln Asn Phe Be Arg Cys Leu slu Leu Gln Cys Gln Pro Asp 420 425 430 Be Ser Thr Leu sly Oly Gly Be Gly Gly sly Ser Gly Gly Oly Ser 435 440 445 Gly Gly Oly Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Ser 450 455 460 Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp 465 470 475 480 Tyr Pro Val Thr Val Wing Ser Asn Leu Gln 485 490 (2) INFORMATION FOR SEQ ID NO: 776: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 398 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 776: Wing Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Wing Gln 1 5 10 15 Arg Trp Met alu Arg Leu Lys Thr Val Wing Gly Ser Lys Met Gln sly 25 30 Leu Leu slu Arg Val Asn Thr Olu He His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn He Ser 50 55 60 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Wing Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 85 90 95 Asp Being Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe 115 120 125 Gln His Ser Pro Be Ser Asp Phe Wing Val Lys He Arg Glu leu 130 135 140 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn leu 145 150 155 160 Gln Glu Phe Lys Leu Glu Pro Arg Gly Pro Thr He Lys Pro Cys Pro 165 170 175 Pro Cys Lys Cys Pro Pro Wing Asn Leu Leu Gly Gly Pro Ser Val Phe 180 185 190 He Phe Pro Pro Lys He Lys Asp Val Leu Met He Ser Leu Ser Pro 195 200 205 He Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val 210 215 220 Gln He Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr 225 230 235 240 Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Wing 245 250 255 Leu Pro He Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys 260 265 270 Lys Val Asn Asn Lys Asp Leu Pro Wing Pro He Glu Arg Thr He Ser 275 280 285 Lys Pro Lys Gly Ser Val Arg Wing Pro Oln Val Tyr Val Leu Pro Pro 290 295 300 Pro Glu Glu Olu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val 305 310 315 320 Thr Asp Phe Met Pro slu Asp He Tyr Val slu Trp Thr Asn Asn C-ly 325 330 335 Lys Thr Olu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp 340 345 350 Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp 355 360 365 Val Clu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His 370 375 380 Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 385 390 395 (2) INFORMATION FOR SEQ ID NO: 777: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 377 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 777: Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Wing Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro 20 25 30 Val Thr Val Wing Being Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Wing Gln Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Wing Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gln Thr Asn He Be Arg Leu Leu Gln Glu Thr Ser Glu Gln 100 105 110 Leu Val Ala Leu Lys Pro Trp He Thr Arg Gln Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Glu Phe Lys Leu 130 135 140 Glu Pro Arg Gly Pro Thr He Lys Pro Cys Pro Pro Cys Lys Cys Pro 145 150 155 160 Wing Pro Asn Leu Leu Gly Gly Pro Ser Val Phe He Phe Pro Pro Lys 165 170 175 He Lys Asp Val Leu Met He Ser Leu Ser Pro He Val Thr Cys Val 180 185 190 Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln He Ser Trp Phe 195 200 205 Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu 210 215 220 Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Ala Leu Pro He Gln His 225 230 235 240 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys 245 250 255 Asp Leu Pro Pro Wing He Glu Arg Thr He Ser Lys Pro Lys Gly Ser 260 265 270 Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met 275 280 285 Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro 290 295 300 Glu Asp He Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 305 310 315 320 Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 325 330 335 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 340 345 350 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr 355 360 365 Lys Ser Phe Ser Arg Thr Pro Gly Lys 370 375 (2) INFORMATION FOR SEQ ID NO: 778: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 778: Gly Gly Gly Ser 1 (2) INFORMATION FOR SEQ ID NO: 779: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 779: Gly Gly Gly Ser Gly Gly Gly Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 780: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 780: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO: 781: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 781: Being Gly Gly Being Gly Gly Being 1 5 (2) INFORMATION FOR SEQ ID NO: 782: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 782: Gly Phe Gly Asn Met 1 d (2) INFORMATION FOR SEQ ID NO: 783: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 783: Gly Phe Gly Gly Asn Met 1 5 (2) INFORMATION FOR SEQ ID NO: 784: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 784: Glu Phe Gly Gly Asn Gly Gly Asn Met 1 d (2) INFORMATION FOR SEQ ID NO: 785: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 785: Gly Gly Ser Asp Met Wing Gly 1 d (2) INFORMATION FOR SEQ ID NO: 786: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 786: Ser Gly Gly Asn Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 787: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 787: Being Gly Gly Asn Gly Being Gly Gly Asn Gly 1 d 10 (2) INFORMATION FOR SEQ ID NO: 788: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 788: Be Gly Gly Asn Gly Be Gly Gly Asn Gly Be Gly Gly Asn Gly 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 789: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 789: Being Gly Gly Being Gly Being Gly Gly Being Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 790: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 790: Being Gly Gly Being Gly Being Gly Gly Being Gly Being Gly Gly Being Gly 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 791: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 791: Gly Gly Gly Ser Gly Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 792: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 792: Gly Gly Gly Ser Gly Gly Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 793: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 793: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 794: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 794: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 1 d 10 (2) INFORMATION FOR SEQ ID NO: 79d: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 79d: Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 796: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 796: Gly Gly Gly Be Gly Gly Gly Be Gly Gly Gly Gly Gly Gly Ser 1 5 10 15 Gly Gly Gly Ser Gly 20 (2) INFORMATION FOR SEQ ID NO: 797: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 797: Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly Wing Thr Wing Pro Thr Wing 1 5 10 15 Gly Gln Pro Pro Leu 20 (2) INFORMATION FOR SEQ ID NO: 798: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 798: Pro Pro Pro Trp Pro Pro Arg Pro Leu Gly Ala Thr Pro Pro Wing 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 799: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (I) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 799: Val Glu Thr Val Phe His Arg Val Ser Gln Asp Gly Leu Leu Thr Ser 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 800: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 800: Gly Gly Gly Be Gly Gly Gly Gly Gly Gly Ser Glu Gly Gly Gly 1 5 10 15 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser 20 25 30 Gly Gly Gly Ser 35 (2) INFORMATION FOR SEQ ID NO: 801: 5 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear •? O (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 801: He Ser Glu Pro Ser Gly Pro He Ser Thr Lie Asn Pro Pro Pro 1 5 10 '15 Ser His Lys Ser Pro (2) INFORMATION FOR SEQ ID NO: 802: 20 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear 25 ( ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 802: lie Glu Gly Arg He Ser Glu Pro Ser Gly Pro lie Ser Thr He Asn 1 5 10 15 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 25 (2) INFORMATION FOR SEQ ID NO: 803: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 112 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 803: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Pro Asn Asn Leu Asn Wing Glu Asp Val 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gllu Gln Gln 100 105 110 (2) INFORMATION FOR SEQ ID NO: 804: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 112 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 804: Wing Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Wing Phe 35 40 - 45 Val Arg Wing Val Lys His Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gllu Gln Gln 100 105 110 (2) INFORMATION FOR SEQ ID NO: 805: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 112 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) ) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 805: Wing Asn Cys Ser He Met He Asp Glu He He His His Le Lys Val 1 5 10 15 Pro Pro Wing Pro Leu Leu Asp Being Asn Asn Leu Asn Ser Glu Asp Met 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Wing Ser Gly He Glu Wing He 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Glu Gln Gln 100 105 110 (2) INFORMATION FOR SEQ ID NO: 806: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 111 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: none (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 806: Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro As Asn Leu Asn Asp Glu Asp Val Ser 25 30 He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Be Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Be Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro He He He Lys Wing Gly Asp Trp Gln Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Wing Gln Gllu Gln Gln 100 105 110 (2) INFORMATION FOR SEQ ID NO: 807: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 807: CTGACCATGG CNACCCAGGA CTGCTCCTTC CAA 33 (2) INFORMATION FOR SEQ ID NO: 808: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO : 808: ACTGAAGCTT AGGGCTGACA CTGCAGCTCC AG 32 (2) INFORMATION FOR SEQ ID NO: 809: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 809: ACTGAAGCTT ACAGGGTTGA GGAGTCGGGC TG 32 (2) INFORMATION FOR SEQ ID NO: 810: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 810: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46 (2) INFORMATION FOR SEQ ID NO: 811: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 811: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46 (2) INFORMATION FOR SEQ ID NO: 812: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 812: TGTCCAAACT CATCAATGTA TC 22 (2) INFORMATION FOR SEQ ID NO: 813: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 813: CATGGCCATG GCCGACGAGG AGCTCTGCGG GGGCCTCT 38 (2) INFORMATION FOR SEQ ID NO: 814: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 814: GCTAGAAGCT TACTGCAGGT TGGAGGCCAC GGTGAC 36 (2) INFORMATION FOR SEQ ID NO: 815: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 81 d: CATGGCCATG GCCTCCAAGA TGCAAGGCTT GCTGGAGC 38 (2) INFORMATION FOR SEQ ID NO: 816: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 816: GCTAGAAGCT TACCCAGCGA CAGTCTTGAG CCGCTC 36 (2) INFORMATION FOR SEQ ID NO: 817: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 817: CATGGCCATG GCCCCCCCCA GCTGTCTTCG CTTCGT 36 (2) INFORMATION FOR SEQ ID NO: 818: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 818: GCTAGAAGCT TAGGGCTGAA AGGCACATTT GGTGACA 37 (2) INFORMATION FOR SEQ ID NO: 819: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO : 819: CCCTGTCTGG CGGCAACGGC ACCCAGGACT GCTCCTTCCA AC 42 (2) INFORMATION FOR SEQ ID NO: 820: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 820: GCGGTAACGG CAGTGGAGGT AATGGCACCC AGGACTGCTC CTTCCAAC 48 (2) INFORMATION FOR SEQ ID NO: 821: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 67 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 821: ACGGCAGTGG TGGCAATGGG AGCGGCGGAA ATGGAACCCA GGACTGCTCC TTCCAAC 57 (2) INFORMATION FOR SEQ ID NO: 822: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 822: GTGCCGTTGC CGCCAGACAG CGTTGAGGAG TCGGGCTG 38 (2) INFORMATION FOR SEQ ID NO: 823: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 823: ATTACCTCCA CTGCCGTTAC CGCCTGACAG GGTTGAGGAG TCGGGCTG 48 (2) INFORMATION FOR SEQ ID NO: 824: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 824: GCTCCCATTG CCACCACTGC CGTTACCTCC AGACAGGGTT GAGGAGTCGG GCTG 54 (2) INFORMATION FOR SEQ ID NO: 82d: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 825: GATGAGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCACC 60 (2) INFORMATION FOR SEQ ID NO: 826: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 826: GATGACGGAT CCGTTACCTC CAGACAGGGT TGAGGAGTCG GGCTG 45 (2) INFORMATION FOR SEQ ID NO: 827: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 827: GATGACGGAT CCGGAGGTAA TGGCACCCAG GACTGCTCCT TCCAAC 46 (2) INFORMATION FOR SEQ ID NO: 828: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 828: GACTGCCATG GCCGACGAGG AGCTCTGCG 29 (2) INFORMATION FOR SEQ ID NO: 829: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 829: GACTCAAGCT TACTGCAGGT TGGAGGCC 28 (2) INFORMATION FOR SEQ ID NO: 830: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 830: GACTGGGGAT CCGGAGGTTC TGGCACCCAG GACTGCTCC 39 (2) INFORMATION FOR SEQ ID NO: 831: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 831: GACTGGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC C 41 (2) INFORMATION FOR SEQ ID NO: 831: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRiPTION OF THE SEQUENCE: SEQ ID NO: 831: GACTGGGATC CGGTGGCAGT GGGAGCCGCG GATCTGGAAC C 41 (2) INFORMATION FOR SEQ ID NO: 832: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 832: GACTTGGGAT CCACTACCTC CAGACAGGGT TGAGGAGTC 39 (2) INFORMATION FOR SEQ ID NO: 833: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 833: ACTGACGGAT CCACCGCCCA GGGTTGAGGA GTCGGGCTG 39 (2) INFORMATION FOR SEQ ID NO: 834: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 834: ACTGACGGAT CCACCTCCTG ACCCACCGCC CAGGGTTGAG GAGTCGGGCT G 51 (2) INFORMATION FOR SEQ ID NO: 835: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 835: ACTGACGGAT CCACCTCCTG ACCCACCTCC TGACCCACCG CCCAGGGTTG AGGAGTCGGG 60 CTG 63 (2) INFORMATION FOR SEQ ID NO: 836: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 836: ACGTAAAGCT TACAGGGTTG AGGAGTCG 28 (2) INFORMATION FOR SEQ ID NO: 837: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 837: GTCAGTGGAT CCGGAGGTAC CCAGGACTGC TCCTTCCAAC 40 (2) INFORMATION FOR SEQ ID NO: 838: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 838: GTCAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AAC 43 (2) INFORMATION FOR SEQ ID NO: 839: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 839: TCAGTGGATC CGGAGGTGGC TCAGGGGGAG GTGTGGTAC CCAGGACTGC TCCTTCCAAC 60 (2) INFORMATION FOR SEQ ID NO: 840: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 840: TAGTCCATGG CCACCCAGGA CTGCTCC 27 (2) INFORMATION FOR SEQ ID NO: 841: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 841: GCATTACGTA GGGCTGACAC TGCAGCTCCA G 31 (2) INFORMATION FOR SEQ ID NO: 842: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 842: GCATTACGTA CAGGGTTGAG GAGTCGGGCT G 31 (2) INFORMATION FOR SEQ ID NO: 843: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 843: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37 (2) INFORMATION FOR SEQ ID NO: 844: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 844: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC 39 (2) INFORMATION FOR SEQ ID NO: 845: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 845: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37 (2) INFORMATION FOR SEQ ID NO: 846: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 846: TCTGACAAGC TTACACGGTG ACTGGGTAAC TTGAAGC 37 (2) INFORMATION FOR SEQ ID NO: 847: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 847: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38 (2) INFORMATION FOR SEQ ID NO: 848: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 848: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37 (2) INFORMATION FOR SEQ ID NO: 849: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 849: GTCAGACCAT CGCCCGCTTC GTCCAGACCA ACATCTCC 38 (2) INFORMATION FOR SEQ ID NO: 850: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 850: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 36 (2) INFORMATION FOR SEQ ID NO: 851: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 851: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38 (2) INFORMATION FOR SEQ ID NO: 852: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 852: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37 (2) INFORMATION FOR SEQ ID NO: 853: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 853: GATCACATGT CTACAAATCA AGATCTGCCT GTG 33 (2) INFORMATION FOR SEQ ID NO: 854: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 854: GATCGAATTC GTTGTCTTGG ATGAAAGGGA 30 (2) INFORMATION FOR SEQ ID NO: 855: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 855: ACTTGAATTC ATCATCCTGG GCCTGTTGGG OC 32 (2) INFORMATION FOR SEQ ID NO: 856: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO : 856: ACTCAAGCTT AGAAGCTCCC CAGCGCCTCC 30 (2) INFORMATION FOR SEQ ID NO: 857: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 64 base pairs (B) TYPE: nucleic acid (C) FILAMENT NUMBER: one only (D) TOPOLOGY: linear (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 857: GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC 60 ATGG 64 (2) INFORMATION FOR SEQ ID NO: 858: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 174 amino acids (B) TYPE: amino acid (C) NUMBER OF FLAMING: unknown (D) TOPOLOGY: unknown (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 1 (D) OTHER INFORMATION: / NOTE = "Xaa in position 1 is Thr, Ser, Arg, Tyr or Gly; "(ix) ASPECT: (A) NAME / KEY: Of modified site (B) SITUATION: 2 (D) OTHER INFORMATION: / NOTE =" Xaa in position 2 is Leu; "(ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 3 (D) OTHER INFORMATION: / NOTE =" Xaa in position 3 is Leu, Arg, Tyr or Ser; "(ix) ASPECT: (A) NAME / KEY: Of modified site (B) SITUATION: 13 (D) OTHER INFORMATION: / NOTE =" Xaa in position 13 is Phe, Ser, His, Thr or Pro; "(ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 16 (D) OTHER INFORMATION: / NOTE = "Xaa at position 16 is Lys, Pro, Ser, Thr or His;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 17 (D) OTHER INFORMATION: / NOTE = "Xaa at position 17 is Cys, Ser, Gly Ala, He, Tyr or Arg; " (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 18 (D) OTHER INFORMATION: / NOTE = "Xaa in position 18 is Leu, Thr, Pro, His, He or Cys;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 22 (D) OTHER INFORMATION: / NOTE = "Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 24 (D) OTHER INFORMATION: / NOTE = "Xaa at position 24 is He, Pro, Tyr or Leu;" (ix) ASPECT: (A) NAME / KEY: Of modified site (B) SITUATION: 27 (D) OTHER INFORMATION: / NOTE = "Xaa in position 27 is Asp or Giy;" (X) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 30 (D) OTHER INFORMATION: / NOTE = "Xaa at position 30 is Ala, He, Leu or Gly;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 34 (D) OTHER INFORMATION: / NOTE = "Xaa at position 34 is Lys or Ser;" (ix) ASPECT: (A) NAME / KEY: Of modified site (B) SITUATION: 36 (D) OTHER INFORMATION: / NOTE = "Xaa in position 36 is Cys or Ser;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 42 (D) OTHER INFORMATION: / NOTE = "Xaa at position 42 is Cys or Ser;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 43 (D) OTHER INFORMATION: / NOTE = "Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala , Arg, Cys or Leu; " (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 44 (D) OTHER INFORMATION: / NOTE = "Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His , Trp, GIn or Thr; " (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 46 (D) OTHER INFORMATION: / NOTE = "Xaa at position 46 is Glu, Arg, Phe, Arg, He or Ala;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 47 (D) OTHER INFORMATION: / NOTE = "Xaa at position 47 is Leu or Thr;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 49 (D) OTHER INFORMATION: / NOTE = "Xaa at position 49 is Leu Phe, Arg or Ser;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 50 (D) OTHER INFORMATION: / NOTE = "Xaa at position 50 is Leu, He, His, Pro or Tyr;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 54 (D) OTHER INFORMATION: / NOTE = "Xaa at position 54 is Leu or His;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 64 (D) OTHER INFORMATION: / NOTE = "Xaa at position 64 is Cys or Ser;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 67 (D) OTHER INFORMATION: / NOTE = "Xaa at position 67 is Gln, Lys, Leu or Cys; "(ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 70 (D) OTHER INFORMATION: / NOTE =" Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; "(ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 74 (D) OTHER INFORMATION: / NOTE =" Xaa at position 74 is Cys or Ser; "(ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 104 (D) OTHER INFORMATION: / NOTE =" Xaa at position 104 is Asp, Gly or Val; "(ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 108 (D) OTHER INFORMATION: / NOTE =" Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; "(x) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 115 (D) OTHER INFORMATION: / NOTE = "Xaa at position 115 is Thr, His, Leu or Ala;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 120 (D) OTHER INFORMATION: / NOTE = "Xaa at position 120 is Gln, Gly, Arg, Lys or His;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 123 (D) OTHER INFORMATION: / NOTE = "Xaa at position 123 is Glu, Arg, Phe or Thr;" (X) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 144 (D) OTHER INFORMATION: / NOTE = "Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu; " (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 146 (D) OTHER INFORMATION: / NOTE = "Xaa at position 146 is Arg or Gln;" (ix) ASPECT: (A) NAME / KEY: From modified site (B) SITUATION: 147 (D) OTHER INFORMATION: / NOTE = "Xaa at position 147 is Arg or Gln;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 156 (D) OTHER INFORMATION: / NOTE = "Xaa at position 156 is His, Gly or Ser;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 159 (D) OTHER INFORMATION: / NOTE = "Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Glu;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 162 (D) OTHER INFORMATION: / NOTE = "Xaa at position 162 is Glu, Leu, Gly or Trp;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 163 (D) OTHER INFORMATION: / NOTE = "Xaa at position 163 is Val Gly, Arg or Ala;" (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 169 (D) OTHER INFORMATION: / NOTE = "Xaa at position 169 is Arg, Ser, Le, Arg or Cys; (ix) ASPECT: (A) NAME / KEY: Modified site (B) SITUATION: 170 (D) OTHER INFORMATION: / NOTE = "Xaa in position 1 is His, Arg or Ser;" (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 858: Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gln Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly Ala Xaa Leu Gln 20 25 30 Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu Xaa Xaa Val 40 45 Xaa Xaa Gly His Ser Xaa Gly He Pro Trp Ala Pro Leu Ser Ser Xaa 50 55 60 Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gln Leu His Ser 65 70 75 80 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Wing Leu Glu Gly He Ser 85 90 95 Pro Glu Leu Gly Pro .Thr Leu Xaa Thr Leu Gln Xaa Asp Val Ala Asp 100 105 110 Phe Ala Xaa Thr He Trp Gln Gln Met Glu Xaa Xaa Gly Met Ala Pro 115 120 125 Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa 130 135 140 Gln Xaa Xaa Ala Gly Gly Val Leu Val Ala Ser Xaa Leu Gln Xaa Phe 145 150 155 160 Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 133 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one (D) TOPOLOGY: linear (i) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 17 (D) OTHER INFORMATION: / note = "Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln or Arg;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 18 (D) OTHER INFORMATION: / nota = "Xaa at position 18 is Asn, His, Leu, lie, Phe, Arg, or Gln;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 19 (D) OTHER INFORMATION: / note = "Xaa at position 19 is Met, Phe, He, Arg, Gly, Sla or Cys;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 20 (D) OTHER INFORMATION: / note = "Xaa at position 20 is He, Cys, Gln, Glu, Arg, Pro or Ala;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 21 (D) OTHER INFORMATION: / note = "Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 22 (D) OTHER INFORMATION: / note = "Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, or Gly;" (ix) ASPECT: (A) NAME / KEY : modified site. (B) SITUATION: 23 (D) OTHER INFORMATION: / note = "Xaa in position 23 is He, Val, Ala, Gly, Rp, Lys, Phe, Leu, Ser or Arg;" x) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 24 (D) OTHER INFORMATION: / note = "Xaa in position 24 is lie, Gly, Val, Arg, Ser, Phe, Leu; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 25 (D) OTHER INFORMATION: / note =" Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; " (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 26 (D) OTHER INFORMATION: / note = "Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, Trp;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 27 (D) OTHER INFORMATION: / note = "Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 28 (D) OTHER INFORMATION: / note = "Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 29 (D) OTHER INFORMATION: / note = "Xaa at position 29 is Gln, Asn, Leu, Pro, Arg or Val;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 30 (D) OTHER INFORMATION: / note = "Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or L ..." (ix) ASPECT: (A) NAME / KEY: modified site (B) SITUATION: 31 (D) OTHER INFORMATION: / note = "Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu or Gln;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 32 (D) OTHER INFORMATION: / note = "Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 33 (D) OTHER INFORMATION: / note = "Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 34 (D) OTHER INFORMATION: / note = "Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, He or Met;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 35 (D) OTHER INFORMATION: / note = "Xaa at position 35 is Leu, Ala, Gly Asn, Pro, Gln, or Val;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 36 (D) OTHER INFORMATION: / note = "Xaa at position 36 is Asp, Leu or Val;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 37 (D) OTHER INFORMATION: / note = "Xaa at position 37 is Phe, Ser, Pro, Trp or He;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 38 (D) OTHER INFORMATION: / note = "Xaa at position 38 is Asn or Ala;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 40 (D) OTHER INFORMATION: / note = "Xaa at position 40 is Leu, Trp or Arg;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 41 (D) OTHER INFORMATION: / note = "Xaa at position 17 is Asn, Cys, Arg, Leu, His, Met or Pro;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 42 (D) OTHER INFORMATION: / note = "Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Le, Met or To;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 43 (D) OTHER INFORMATION: / note = "Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 44 (D) OTHER INFORMATION: / note = "Xaa at position 17 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 45 ( D) OTHER INFORMATION: / note = "Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 46 (D) OTHER INFORMATION: / note =" Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, GIn, Lys, His, Wing, Tyr, Lie, Val or Gly; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 47 (D) OTHER INFORMATION: / note = "Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro or Hís;" (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 48 (D) OTHER INFORMATION: / note = "Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 49 (D) OTHER INFORMATION: / note = "Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, Hís or Asp;" (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 50 (D) OTHER INFORMATION: / note = "Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 51 (D) OTHER INFORMATION: / note =" Xaa at position 51 is Asn, Arg, Met, Pro, Ser , Thr, or His; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 52 (D) OTHER INFORMATION: / note =" Xaa at position 52 is Asn, His, Arg , Leu, Gly, Ser or Thr; (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 53 (D) OTHER INFORMATION: / note = "Xaa in position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or M ..." (ix) ASPECT: (A ) NAME / KEY: from modified site. (B) SITUATION: 54 (D) OTHER INFORMATION: / note = "Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, GIn, Asn, Lys, His, Ala or Leu;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 5d (D) OTHER INFORMATION: / note = "Xaa at position 65 is Arg, Thr, Val, Ser, Leu or Gly; "(x) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 56 (D) OTHER INFORMATION: / note =" Xaa in position 56 en Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; "(x) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 57 (D) OTHER INFORMATION: / note = "Xaa at position 57 is Asn or Gly;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 58 (D) OTHER INFORMATION: / note = "Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 59 (D) OTHER INFORMATION: / note = "Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 60 (D) OTHER INFORMATION: / note = "Xaa at position 60 is Wing, Ser, Pro, Tyr, Asn or Thr;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 61 (D) OTHER INFORMATION: / note = "Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; "(ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 62 (D) OTHER INFORMATION: / note =" Xaa in the position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or He; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 63 (D) OTHER INFORMATION: / note =" Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 64 (D) OTHER INFORMATION: / note = "Xaa at position 64 is Ala, Asn, Pro, Ser or Lys; (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 65 (D) OTHER INFORMATION: / note = "Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe or Ser; "(ix) ASPECT: (A) NAME / KEY: modified site.

(B) SITUATION: 66 (D) OTHER INFORMATION: / note = "Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu or Ser;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 67 (D) OTHER INFORMATION: / note = "Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or Hís;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 68 (D) OTHER INFORMATION: / note = "Xaa at position 68 is Leu, Vai, Trp, Ser, He, Phe, Thr, or His;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 69 (D) OTHER INFORMATION: / note = "Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or L ..." (ix) ASPECT: (A ) NAME / KEY: from modified site. (B) SITUATION: 70 (D) OTHER INFORMATION: / note = "Xaa at position 70 is Asn, Leu, Val, Trp, Pro or Ala;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 71 (D) OTHER INFORMATION: / nota = "Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 72 (D) OTHER INFORMATION: / note = "Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 73 (D) OTHER INFORMATION: / note = "Xaa at position 73 is Wing, Glu, Asp, Leu, Ser, Gly, Thr or Arg;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 74 (D) OTHER INFORMATION: / note = "Xaa at position 74 is lie, Met, Thr, Pro, Arg, Gly, Ala;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 75 (D) OTHER INFORMATION: / note = "Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 76 (D) OTHER INFORMATION: / note = "Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or A ..." (ix) ASPECT: (A ) NAME / KEY: from modified site. (B) SITUATION: 77 (D) OTHER INFORMATION: / note = "Xaa at position 77 is lie, Ser, Arg, Thr or Leu;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 78 (D) OTHER INFORMATION: / note = "Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 79 (D) OTHER INFORMATION: / note = "Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly or Asp;" (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 80 (D) OTHER INFORMATION: / note = "Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 81 (D) OTHER INFORMATION: / note = "Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 82 (D) OTHER INFORMATION: / note = "Xaa in position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, Hís, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; " (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 83 (D) OTHER INFORMATION: / note = "Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 84 (D) OTHER INFORMATION: / note = "Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 85 (D) OTHER INFORMATION: / note = "Xaa at position 85 is Leu, Asn, Val or Gln;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 86 (D) OTHER INFORMATION: / note = "Xaa at position 86 is Pro, Cys, Arg, Ala or Lys;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 87 (D) OTHER INFORMATION: / note = "Xaa at position 87 is Leu, Ser, Trp or Glu;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 88 (D) OTHER INFORMATION: / nota = "Xaa at position 88 is Ala, Lys, Arg, Val or Trp;" (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 89 (D) OTHER INFORMATION: / note = "Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or S ..." (ix) ASPECT: (A ) NAME / KEY: from modified site. (B) SITUATION: 90 (D) OTHER INFORMATION: / note = "Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He or Met;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 91 (D) OTHER INFORMATION: / note = "Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 92 (D) OTHER INFORMATION: / note = "Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Wing, Gly, He, or Leu; (ix) ASPECT: (A) NAME / KEY: from modified site. (B) SITUATION: 93 (D) OTHER INFORMATION: / note = "Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; "(ix) ASPECT: (A) NAME / KEY: from modified site. (B) SITUATION: 94 (D) OTHER INFORMATION: / note =" Xaa in position 94 is Arg, He, Ser, Glu, Leu, Val, Gln, Lys, Hís, Ala, or Pro; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 95 (D) OTHER INFO: / note = "Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Le or Tyr; (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 96 (D) OTHER INFORMATION: / note = "Xaa at position 96 is Pro, Lys, Tyr, Gly, He or Thr;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 97 (D) OTHER INFORMATION: / note = "Xaa in position 97 is He, Val, Lys, Ala or Asn;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 98 (D) OTHER INFORMATION: / note = "Xaa at position 98 is His, Lie, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met. Val, Lys, Arg, Tyr or Pro; " (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 99 (D) OTHER INFORMATION: / note = "Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or Hís; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 100 (D) OTHER INFORMATION : / note = "Xaa in position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, GIn or ..." (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 101 (D) OTHER INFORMATION: / note = "Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Le, Leu, or Gln.; " (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 102 (D) OTHER INFORMATION: / note = "Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 103 (D) OTHER INFORMATION: / note = "Xaa at position 103 is Asp or Ser;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 104 (D) OTHER INFORMATION: / note = "Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Wing, Phe, or Gly;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 105 (D) OTHER INFORMATION: / note = "Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ie, Asp or His; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 106 (D) OTHER INFORMATION: / note = "Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Lie, Gly or Pro;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 108 (D) OTHER INFORMATION: / note = "Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gln, His, Ser, Ala or Pro;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 109 (D) OTHER INFORMATION: / note = "Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly;" (X) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 110 (D) OTHER INFORMATION: / note = "Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, GIn, His, Glu, Ser or Trp;" (ix) ASPECT: (A) NAME / KEY: of modified site.

(B) SITUATION: 111 (D) OTHER INFORMATION: / nota = "Xaa in position 111 is Leu, lie, Arg, Asp or Met;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 112 (D) OTHER INFORMATION: / note = "Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 113 (D) OTHER INFORMATION: / note = "Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 114 (D) OTHER INFORMATION: / nota = "Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu;" (ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 115 (D) OTHER INFORMATION: / note = "Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 1 16 (D) OTHER INFORMATION: / note = "Xaa in position 1 16 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, Hís, Ala, Tyr, Phe, Gln or He; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 1 17 (D) OTHER INFORMATION: / note = "Xaa at position 1 17 is Thr, Ser, Asn, He, Trp, Lys, or Pro;" (ix) ASPECT: (A ) NAME / KEY: modified site. (B) SITUATION: 1 18 (D) OTHER INFORMATION: / note = "Xaa in position 1 18 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr;" (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 1 19 (D) OTHER INFORMATION: / note = "Xaa in position 1 19 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 120 (D) OTHER INFORMATION: / note = "Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; "(ix) ASPECT: (A) NAME / KEY: from modified site. (B) SITUATION: 121 (D) OTHER INFORMATION: / note =" Xaa at position 121 is Ala, Ser, lie, Asn, Pro, Lys, Asp or Gly; "(ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 122 (D) OTHER INFORMATION: / note =" Xaa at position 122 is Gln, Ser, Met , Trp, Arg, Phe, Pro, Hís, Lie, Tyr or Cys; "(ix) ASPECT: (A) NAME / KEY: of modified site. (B) SITUATION: 123 (D) OTHER INFORMATION: / note =" Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leu; "(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 859: Pro Wing Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xahe Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu 115 120 125 Ser Leu Ala He Phe 130 (2) INFORMATION FOR SEQ ID NO: 860: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 153 amino acids (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: unknown (D) TOPOLOGY: unknown (ii) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: modified site. (B) SITUATION: 112 (D) OTHER INFORMATION: / note = "Position 112 is omitted or is Leu, Wing, Val, He, Pro, Phe, Trp or Met" (ix) ASPECT: (A) NAME / KEY : modified site. (B) SITUATION: 113 (D) OTHER INFORMATION: / note = "Position 113 is omitted or is Pro, Phe, Wing, Val, Leu, He, Trp or Met" (ix) ASPECT: (A) NAME / KEY : modified site. (B) SITUATION: 114 (D) OTHER INFORMATION: / note = "Position 114 is omitted or is Pro, Phe, Wing, Val, Leu, He, Trp or Met" (ix) ASPECT: (A) NAME / KEY : modified site. (B) SITUATION: 115 (D) OTHER INFORMATION: / note = "Position 115 is omitted or is Gln, Gly, Ser, Thr, Tyr or Asn". (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 860: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Val Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp He Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Xaa 100 105 110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMATION FOR SEQ ID NO: 861: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 amino acid (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: protein. (B) SITUATION: 1 (D) OTHER INFORMATION: / note = "where x = (glyglyglyser) n and where n is an integer", (xí) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 861 Xaa 1 (2) INFORMATION FOR SEQ ID NO: 862: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 amino acid (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: peptide (B) SITUATION: 1 (D) OTHER INFORMATION: / note = "where x = (glyglyglygly be) n, and where n is an integer" (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 862 Xaa 1 (2) INFORMATION FOR SEQ ID NO: 863: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 amino acid (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one single (D) TOPOLOGY: linear (I) TYPE OF MOLECULE: protein (¡X) ASPECT: (A) NAME / KEY: protein (B) SITUATION: 1 (D) OTHER INFORMATION: / note = "where x = (glyglyglygly be) n and where n is an integer" (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 863 Xaa 1 (2) INFORMATION FOR SEQ ID NO: 864: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 amino acid (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear ( ii) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: protein (B) SITUATION: 1 (D) OTHER INFORMATION: / note = "where x = (gly n be) ny where n is an integer "(xi) DESCRIPTION OF THE SEQUENCE SEQ ID NO: 864 Xaa 1 (2) INFORMATION FOR SEQ ID NO: 865: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 amino acid (B) TYPE: amino acid (C) NUMBER OF FILAMENTS: one only (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (ix) ASPECT: (A) NAME / KEY: protein (B) SITUATION: 1 (D) OTHER INFORMATION: / note = "where x = (alaglyser) ny where n is an integer" (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 865: Xaa

Claims (2)

1. NOVELTY OF THE INVENTION CLAIMS 1. - A hematopoietic protein characterized in that it comprises: an amino acid sequence of the formula: R-1-L1-R2, R2-L- | -R? , R1-R2 or R2-R. wherein R1 and R2 are independently selected from the group consisting of: (I) a human EPO receptor agonist polypeptide, which * comprises a modified EPO amino acid sequence, corresponding to SEQ ID NO: 464; wherein from 1 to 6 amino acids of the N-terminus and / or 1 to 5 of the C-terminus are optionally omitted from said EPO receptor agonist polypeptide; where the N-terminus is attached to the C-terminus directly or by means of a linker (L2) capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 23-24, 24-25, 25 -26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38 , 38-39, 39-40, 40-41, 41-42, 42-43, 43-44, 44-45, 45.46, 46-47, 47-48, 48-49, 49-50, 50 -51, 51-52, 52-63, 53-54, 54-5d, 65-56, 56-57, 57-68, 77-78, 78-79, 79-80, 80-81, 81-82 , 82-83, 84-85, 85-86, 86-87, 87-88 ,. 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119- 120, 120-121, 121-122, 122-123, 123-124, 124-125, 125- 126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, respectively; (II) a human trunk cell factor receptor agonist polypeptide comprising a modified amino acid sequence of the stem cell factor, corresponding to SEQ ID NO: 465; wherein from 1 to 23 amino acids are optionally omitted from the C-terminus of said trunk cell factor receptor agonist polypeptide; and where the N-terminus is attached to the C-terminus, directly or by means of a linker (L2) capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 23-24, 24-25 , 25-26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37 -38, 38-39, 39-40, 40-41, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 89-90, 90-91 , 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, 103 -104, 104-105, 105-106, 106-107, 107-108, 108-109, 109-110, 110-111, respectively; (lll) a human flt-3 receptor agonist polypeptide, comprising: a modified amino acid sequence of the ligand flt-3, corresponding to SEQ ID NO: 466; wherein from 1 to 7 amino acids are optionally omitted from the C terminus of the flt3 receptor agonist polypeptide; and where the N-terminus is attached to the C-terminus directly or by means of a linker (L2), capable of binding the N-terminus to the C-terminus, and having new C and N termini at amino acids: 28-29, 29-30 , 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 64-65, 65 -66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97 , 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, respectively; (IV) a polypeptide comprising a modified amino acid sequence of human G-FEC, corresponding to SEQ ID NO: 858; where Xaa in position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa in position 2 is Pro or Leu; Xaa in position 3 is Leu, Arg, Tyr or Ser; Xaa in position 13 is Phe, Ser, His, Thr or Pro; Xaa in position 16 is Lys, Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, He, Tyr or Arg; Xaa in position 18 is Leu, Thr, Pro, His, He or Cys; Xaa in position 22 is Arg, Tyr, Ser, Thr or Ala; Xaa in position 24 is He, Pro, Tyr or Leu; Xaa in position 27 is Asp or Gly; Xaa in position 30 is Ala, He, Leu or Gly; Xaa in position 34 is Lys or Ser; Xaa in position 36 is Cys or Ser; Xaa in position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys or Leu; Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln or Thr; Xaa at position 46 is Glu, Arg, Phe, Arg, He or Ala; Xaa in position 47 is Leu or Thr; Xaa in position 49 is Leu, Phe, Arg or Ser; Xaa in position 50 is Leu, He, His, Pro or Tyr; Xaa at position 54 is Leu or His; Xaa in position 64 is Cys or Ser; Xaa at position 67 is GIn, Lys, Leu or Cys; Xaa in position 70 is Gln, Pro, Leu, Arg or Ser; Xaa in position 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position 115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lys or His; Xaa at position 123 is Glu, Arg, Phe or Thr; Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Gly or Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa in position 170 is His, Arg or Ser; wherein from 1 to 11 amino acids of the N-terminus and / or 1 to 5 amino acids of the C-terminus are optionally omitted from the modified amino acid sequence of human G-FEC; and wherein the N-terminus is attached to the C-terminus directly or by means of a linker (L2) capable of binding the N-terminus to the C-terminus, and having new C and N termini at amino acids: 38-39, 39-40, 40-41, 41-42, 42-43, 43-44, 45.46, 48-49, 49-50, 52-53, 53-54, 54-dd, 5d-56, 66-57, 57- 68, 58-59, 59-60, 60-61, 61-62, 62-63, 63-64, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 71-72, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 123-124, 124- 125, 125-126, 126-127, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137-137-138, 138-139, 139-140, 140-141, 141-142 or 142-143, respectively; (V) a polypeptide comprising a modified sequence of human IL-3 amino acid, corresponding to SEQ ID NO: 859; where Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala or Cys; Xaa in position 20 is He, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa in position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; Xaa at position 25 is Thr, His, Gly, GIn Arg, Pro or Ala; Xaa in the position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa in position 36 is Asp, Leu or Val; Xaa at position 37 is Phe, Ser, Pro, Trp or He; Xaa at position 38 is Asn or Ala; Xaa at position 40 is Leu, Trp or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, GIn, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Giu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Le, Val or Gly; Xaa at position 47 is free, Gly, Val, Ser, Arg, Pro or His; Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa in position 51 is Asn, Arg, Met, Pro, Ser, Thr or Hís; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in the position 83 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 55 is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or He; Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; Xaa in position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa in position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or His; Xaa in position 68 is Leu, Val, Trp, Ser, He, Phe, Thr or His; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa at position 74 is read, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is He, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Le, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Val or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser; Xaa "in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He or Met, Xaa in position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His, Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa in position 94 is Arg , He, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro; Xaa at position 95 is His, GIn, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Wing , Trp, Phe, He or Tyr, Xaa at position 96 is Pro, Lys, Tyr, Gly, Le or Thr, Xaa at position 97 is He, Val, Lys, Ala or Asn, Xaa at position 98 is His , He, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro , Gln, Gly, Ser, Phe or His, Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gln or Pro, Xaa at position 101 is Asp, Pro, Met, Lys, His , Thr, Val, Tyr, Gly, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, He, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gln, His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is GIn, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr or Cys; Xaa at position 123 is Ala, Met. Glu, His, Ser, Pro, Tyr or Leu; wherein from 1 to 14 amino acids are optionally omitted from the N-terminus and / or from 1 to 15 amino acids are optionally omitted from the C-terminus of said modified amino acid sequence of human IL-3; where from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin-3 (1-133); and where the N-terminus is attached to the C-terminus directly or by means of a linker (L2), capable of binding the N-terminus to the C-terminus, and having new C and N termini in amino acids: 26-27, 27-28 , 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 49-50, 50-61, 51- 52, 52-63, 53-64, 54-dd, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 71-72, 72-73, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 97-98, 98- 99, 99-100, 100-101, 101-102, 102-103 or 103-104, respectively; (VI) a polypeptide comprising a modified amino acid sequence of human c-mpl ligand corresponding to SEQ ID NO: 860; wherein Xaa at position 112 is omitted or is Leu, Ala, Val, Lie, Pro, Phe, Trp or Met; Xaa at position 113 is omitted or is Pro, Phe, Ala, Val, Leu, He, Trp or Met; Xaa at position 114 is omitted or is Pro, Phe, Ala, Val, Leu, He, Trp or Met; Xaa at position 115 is omitted or is Gln, Gly, Ser, Thr, Tyr or Asn; and where the N-terminus is attached to the C-terminus directly or by means of a linker (L2), capable of binding the N-terminus to the C-terminus, and having new C and N termini at amino acids: 26-27, 27-28 , 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43 -44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58 , 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88 -89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-188, 118-119, 119-120. , 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128, respectively; (VII) a polypeptide comprising a modified amino acid sequence of human IL-3, corresponding to SEQ ID NO: 859; where Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa in the position 19 is Met, Phe, He, Arg, Gly, Ala or Cys; Xaa in position 20 is He, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is ile Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa in position 36 is Asp, Leu or Val; Xaa at position 37 is Phe, Ser, Pro, Trp or He; Xaa at position 38 is Asn or Ala; Xaa at position 40 is Leu, Trp or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, He, Val or Gly; Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro or His; Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in position 63 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa in position 64 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 5d is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 66 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Lie; Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; Xaa in position 64 is Ala, Asn, Pro, Ser or Lys; Xaa in position 65 is Val, Thr, Pro, His, Leu, Phe or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or Hís; Xaa in position 68 is Leu, Val, Trp, Ser, Lie, Phe, Thr or His; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa at position 71 is Ala, Met. Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly or Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is He, Ser, Arg, Thr or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, ile, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Val or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser; Xaa in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His; Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Lie or Tyr; Xaa in position 96 is Pro, Lys, Tyr, Gly, He or Thr; Xaa in position 97 is He, Val, Lys, Ala or Asn; Xaa at position 98 is His, Ie, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or His; Xaa in position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gln or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Lie, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Lie, Gln, His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leu; wherein, from 1 to 14 amino acids are optionally omitted from the N-terminus and / or from 1 to 15 amino acids are optionally omitted from the C-terminus of the modified amino acid sequence of human IL-3; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin-3 (1-133); and (VIII) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, a hematopoietic growth factor; and wherein Li is a linker capable of linking Ri to R2; said hematopoietic protein, optionally, can be immediately preceded by (methionine "1), (aianine" 1) or (methionine "2, alanine" 1); provided that at least Ri or R2 is selected from the polypeptide of formula (I), (li), or (III).
2. 2. A hematopoietic protein, characterized in that it comprises an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1 wherein R1 and R2 are independently selected from the group consisting of: (I) a human EPO receptor agonist polypeptide, comprising: a modified amino acid sequence of EPO, corresponding to SEQ ID NO: 464; wherein from 1 to 6 amino acids of the N-terminus and / or from 1 to 5 of the C-terminus are optionally omitted from the EPO receptor agonist polypeptide; and where the N-terminus is attached to the C-terminus directly or by means of a linker (L2) capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 23-24, 24- 26, 25-26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 43-44, 44-45, 45-46, 46-47, 47-48, 48-49, 49- 50, 50-51, 51-52, 52-53, 53-64, 54-55, 55-66, 56-57, 57-58, 77-78, 78-79, 79-80, 80-81, 81-82, 82-83, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113- 114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, respectively; (II) a human trunk cell factor receptor agonist polypeptide comprising a modified amino acid sequence of the stem cell factor, corresponding to SEQ ID NO: 465; wherein from 1 to 23 amino acids are optionally omitted from the C terminus of the trunk cell factor receptor agonist polypeptide; and wherein the N-terminus is attached to the C-terminus directly or by means of a linker (L2) capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 23-24, 24- 25, 26-26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-36, 35-36, 36-37, 37-38, 38-39, 39-40, 40-41, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 89-90, 90- 91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, 103-104, 104-105, 105-106, 106-107, 107-108, 108-109, 109-110, 110-111, respectively; (lll) a human flt-3 receptor agonist polypeptide, comprising a modified amino acid sequence of ligand flt-3, corresponding to SEQ ID NO: 466, wherein from 1 to 7 amino acids are optionally omitted from the C terminus of the polypeptide agonist flt3 receiver; where the N-terminus is attached to the C-terminus directly or by means of a linker (L2), capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 64-65, 65- 66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, respectively; (IV) a polypeptide comprising an amino acid sequence of human IL-3, corresponding to SEQ ID NO: 859; in which Xaa at position 17 is Ser, Lys, Gly, Asp, Met. Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala or Cys; Xaa at position 20 is free, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, As, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa in position 23 is Ie, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa in position 36 is Asp, Leu or Val; Xaa at position 37 is Phe, Ser, Pro, Trp or He; Xaa at position 38 is Asn or Ala; Xaa at position 40 is Leu, Trp or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is GIn, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, He, Val or Gly; Xaa in position 47 is lie, Gly, Val, Ser, Arg, Pro or His; Xaa in position 48 is Leu, Ser, Cys, Arg, He, Hís, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa in position 49 is Met, Arg, Ala, Gly, Pro, Asn, Hís or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 55 is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa in position 59 is Glu, Tyr, Hís, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa in position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or lie; Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; Xaa in position 64 is Ala, Asn, Pro, Ser or Lys; Xaa in position 65 is Val, Thr, Pro, His, Leu, Phe or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or His; Xaa in position 68 is Leu, Val, Trp, Ser, He, Phe, Thr or His; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa in position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is He, Ser, Arg, Thr or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Lie, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Val or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser; Xaa in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, lie or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His; Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa in position 96 is Pro, Lys Tyr, Gly, He or Thr; Xaa in position 97 is He, Val, Lys, Ala or Asn; Xaa in position 98 is His, He, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or His; Xaa in position 100 is Lys, Tyr, Leu, His, Arg, lie, Ser, GIn or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, He, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gln, His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa in position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, Lie, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leu; where from 1 to 14 amino acids are optionally omitted from the N-terminus and / or from 1 to 15 amino acids are optionally omitted from the C-terminus of the modified amino acid sequence of human IL-3; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin (1-133); (V) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an etherleucine and a hematopoietic growth factor; where Li is a linker capable of linking Ri with R2; and wherein said hematopoietic protein optionally can be immediately preceded by (methionine "1), (alanine" 1) or (methionine2, alanine "1) provided that at least R1 or R2 is selected from the polypeptide of formula (I) , (ll) or (III) 3. The hematopoietic protein according to claim 2, further characterized in that the polypeptide of (IV) is selected from the group consisting of SEQ ID NO: 803, SEQ ID NO: 804; SEQ ID NO: 80d and SEQ ID NO: 806. 4. - A hematopoietic protein, characterized in that it comprises: an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1 wherein R1 is a polypeptide comprising a modified amino acid sequence of the ligand flt-3, corresponding to SEQ ID NO: 466, wherein the N-terminus is attached to the C-terminus directly or via a linker (L2) capable of joining the N-terminus to the C-terminus, and having new C and N ends in the amino acids: 28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 87-88, 88-89, 89- 90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, respectively; wherein R2 is a polypeptide comprising a modified amino acid sequence of human IL-3, corresponding to SEQ ID NO: 859; in which Xaa at position 17 is Ser, Lys, Gly, Asp, Met. Gln or Arg; Xaa in position 18 is Asn, His, Leu, He, Phe, Arg or Gln; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala or Cys; Xaa at position 20 is free, Cys, Gln, Glu, Arg, Pro or Ala; Xaa in position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa in position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa in position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser or Arg; Xaa in position 24 is He, Gly, Val, Arg, Ser, Phe or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp; Xaa in position 27 is Leu, Gly, Arg, Thr, Ser or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa in position 29 is Gln, Asn, Leu, Pro, Arg or Val; Xaa in position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu or Lys; Xaa in position 31 is Pro, Asp, Gly, Aia, Arg, Leu or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr or Glu; Xaa in position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Lie or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln or Val; Xaa in position 36 is Asp, Leu or Val; Xaa at position 37 is Phe, Ser, Pro, Trp or He; Xaa at position 38 is Asn or Ala; Xaa at position 40 is Leu, Trp or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, Hís, Ala, Tyr, He, Val or Gly; Xaa in position 47 is He, Gly, Val, Ser, Arg, Pro or Hís; Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa in position 49 is Met, Arg, Ala, Gly, Pro, Asn, Hís or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser or Thr; Xaa in position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa in position 55 is Arg, Thr, Val, Ser, Leu or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa in position 58 is Leu, Ser, Asp, Arg, Gln, Val or Cys; Xaa at position 59 is Glu, Tyr, His, Leu, Pro or Arg; Xaa in position 60 is Ala, Ser, Pro, Tyr, Asn or Thr; Xaa in position 61 is Phe, Asn, Glu, Pro, Lys, Arg or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or He; Xaa in position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val; Xaa in position 64 is Ala, Asn, Pro, Ser or Lys; Xaa in position 65 is Val, Thr, Pro, Hís, Leu, Phe or Ser; Xaa in position 66 is Lys, He, Arg, Val, Asn, Glu or Ser; Xaa in position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro or His; Xaa in position 68 is Leu, Val, Trp, Ser, He, Phe, Thr or Hís; Xaa in position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leu; Xaa in position 70 is Asn, Leu, Val, Trp, Pro or Ala; Xaa in the position is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp or Asn; Xaa in position 72 is Ser, Glu, Met, Ala, Hís, Asn, Arg or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr or Arg; Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln or Leu; Xaa in position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp; Xaa in position 77 is mess, Ser, Arg, Thr or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met; Xaa at position 84 is Cys, Giu, Gly, Arg, Met or Val; Xaa in position 85 is Leu, Asn, Vai or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala or Lys; Xaa in position 87 is Leu, Ser, Trp or Gly; Xaa at position 88 is Ala, Lys, Arg, Val or Trp; Xaa in position 89 is Thr, Asp, Cys, Leu, Val, Gln, His, Asn or Ser; Xaa in position 90 is Ala, Pro, Ser, Thr, Gly, Asp, lie or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp or His; Xaa in position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa in position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu or Arg; Xaa in position 94 is Arg, He, Ser, Glu, Leu, Val, Gln, Lys, Hís, Ala or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa in position 96 is Pro, Lys, Tyr, Gly, He or Thr; Xaa in position 97 is lie, Val, Lys, Ala or Asn; Xaa at position 98 is His, Ie, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa in position 99 is He, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe or His; Xaa in position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gln or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu or Gln; Xaa in position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro; Xaa at position 103 is Asp or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ie, Asp or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Le, Gly or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, líe, Gln, His, Ser, Ala or Pro; Xaa in position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser or Trp; Xaa in position 111 is Leu, He, Arg, Asp or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln or He; Xaa in position 117 is Thr, Ser, Asn, He, Trp, Lys or Pro; Xaa in position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val or Gln; Xaa in position 121 is Ala, Ser, Lie, Asn, Pro, Lys, Asp or Gly; Xaa at position 122 is GIn, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr or Cys; Xaa at position 123 is Ala, Met, Glu, Hís, Ser, Pro, Tyr or Leu; where from 1 to 14 amino acids are optionally omitted from the N-terminus and / or from 1 to 15 amino acids are optionally omitted from the C-terminus of the modified amino acid sequence of human interleukin-3; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of natural human interleukin-3 (1-133); and where Li is a linker capable of linking Ri to R2; and said hematopoietic protein can be immediately preceded by (methionine '), (alanine "1) or (methionine" 2, alanine "1). 5. - The hematopoietic protein according to claim 4, further characterized in that R2 is selected from the group consisting of: SEQ ID NO: 803, SEQ ID NO: 804, SEQ ID NO: 806 and SEQ ID NO: 806. 6.- A hematopoietic protein, characterized in that it comprises: an amino acid sequence of the formula: RÍ-LÍ-R2, R2-L1-L1, Ri-R2 or R2-R1 wherein R1 is a polypeptide comprising: a modified amino acid sequence of the ligand flt-3, corresponding to SEQ ID NO: 466; wherein the N-terminus is attached to the C-terminus directly or via a linker (L2) capable of binding the N-terminus to the C-terminus and having new C and N termini at amino acids: 28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 64-65, 65- 66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93 93-94, 94-95, 95-96, 96-97, 97 -98, 98-99, 99-100, 100-101, 101-102, 102-103, respectively; where R2 is a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin and a hematopoietic growth factor; where L1 is a linker capable of linking R1 with R2; and said hematopoietic protein, optionally, may be immediately preceded by (methionine "1), (alanine" 1) or (methionine "2, alanine" 1). 7. - A hematopoietic protein, characterized in that it comprises: an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1 wherein R1 is a polypeptide comprising: a modified amino acid sequence of ligand flt-3, corresponding to SEQ ID NO: 466, wherein the N-terminus is attached to the C-terminus directly or via a linker (L2) ), capable of joining the N-terminus to the C-terminus, and having new C and N ends in the amino acids: 28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36- 37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 64.65, 65-66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101- 102, 102-103, respectively; wherein R2 is a polypeptide comprising: a modified amino acid sequence of human G-FEC, corresponding to SEQ ID NO: 858; where Xaa in position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa in position 2 is Pro or Leu; Xaa in position 3 is Leu, Arg, Tyr or Ser; Xaa in position 13 is Phe, Ser, His, Thr or Pro; Xaa in position 16 is Lys, Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, He, Tyr or Arg; Xaa in position 18 is Leu, Thr, Pro, His, He or Cys; Xaa in position 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is He Pro, Tyr or Leu; Xaa in position 27 is Asp or Gly; Xaa in position 30 is Ala, He, Leu or Gly; Xaa in position 34 is Lys or Ser; Xaa in position 36 is Cys or Ser; Xaa in position 42 is Cys or Ser; Xaa in position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys or Leu; Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln or Thr; Xaa at position 46 is Glu, Ar, Phe, Arg, He or Ala; Xaa in position 47 is Leu or Thr; Xaa in position 49 is Leu, Phe, Arg or Ser; Xaa in position 50 is Leu, He, His, Pro or Tyr; Xaa at position 54 is Leu or His; Xaa in position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys, Leu or Cys; Xaa in position 70 is Gln, Pro, Leu, Arg or Ser; Xaa in position 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position 115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lys or His; Xaa at position 123 is Glu, Arg, Phe or Thr; Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu, Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg or Gln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Gly or Ser, Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa in position 170 is His, Arg or Ser; wherein from 1 to 11 amino acids of the N-terminus and / or from 1 to 5 amino acids of the C-terminus are optionally omitted from said modified amino acid sequence of human G-FEC; and where the N-terminus is attached to the C-terminus directly or by means of a linker (L2), capable of binding the N-terminus to the C-terminus, and having new C and N ends at the amino acids: 38-39, 39-40 , 40-41, 41-42, 42-43, 43-44, 45-45, 48-49, 49-50, 52-52, 53-54, 54-55, 55-56, 56-57, 57 -58, 58-59, 59-60, 60-61, 61-62, 62-63, 63-64, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 71-72, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99- 100, 123-124, 124-125, 125-126, 126-127, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141, 141-142 or 142-143, respectively; where Li is a linker capable of linking Ri to R2 and said hematopoietic protein may optionally be immediately preceded by (methionine "1), (alanine" 1) or (methionine "2, alanine" 1). 8. The hematopoietic protein according to claim 1, 2, 3, 4, 5, 6 or 7, further characterized in that the linker (L2) is selected from the group consisting of SEQ ID NO: 778; SEQ ID NO: 779; SEQ ID NO: 780; SEQ ID NO: 781, SEQ ID NO: 782; SEQ ID NO: 783; SEQ ID NO: 784; SEQ ID NO: 785; SEQ ID NO: 786; SEQ ID NO: 787; SEQ ID NO: 788; SEQ ID NO: 789; SEQ ID NO: 790; SEQ ID NO: 791, SEQ ID NO: 792; SEQ ID NO: 793; SEQ ID NO: 794; SEQ ID NO: 795; SEQ ID NO: 796; SEQ ID NO: 797; SEQ ID NO: 798 and SEQ ID NO: 799. 9. The hematopoietic protein according to claim 1, further characterized in that the protein is selected from the group consisting of: SEQ ID NO: 581; SEQ ID NO: 582; SEQ ID NO: 583; SEQ ID NO: 584; SEQ ID NO: 585; SEQ ID NO: 586; SEQ ID NO: 587, SEQ ID NO: 588; SEQ ID No. 743; SEQ ID NO: 659; SEQ ID NO: 705; and SEQ ID NO: 743. 10. The hematopoietic protein according to claim 1, 2 or 6, further characterized in that the stimulator factor of colony (FEC) is selected from the group consisting of FEC-GM, FEC-G, FEC-G Ser17, ligand c-mpl (TPO), M-FEC, erythropoietin, IL-1, I L-4, IL-2 , I L-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, ligand flt3 / flk2, human growth hormone, B cell growth factor, B cell differentiation factor, eosinophil differentiation factor and trunk cell factor (FCT). 11. The hematopoietic protein according to claim 10, further characterized in that said colony stimulating factor is selected from the group consisting of G-FEC, G-FEC Ser17, G-FEC Ala17 and the ligand c-mpl (TPO) . 12. A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 1. 13.- A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 2. 14.- A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 3. 1d.- A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of the claim 4. 16. A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 5. 17. A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 6. 18. - A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 7. 19.- A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 8. 20.- A nucleic acid molecule, characterized in that it encodes The hematopoietic protein of claim 9. 21. A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 10. 22. A nucleic acid molecule, characterized in that it encodes the hematopoietic protein of claim 11. 23. - The nucleic acid molecule according to claim 12, further characterized in that it is selected from the group consisting of SEQ ID NO: 121; SEQ ID NO: 122, SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 12d; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 282, SEQ ID NO: 198; SEQ ID NO: 244; And SEQ ID NO: 282. 24.- A method for producing a hematopoietic protein, characterized in that it comprises: developing, under suitable nutrient conditions, an amphitrogen cell transformed or transfected with a reproducible vector comprising a nucleic acid molecule of claim 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23, in a manner that allows the expression of the hematopoietic protein and recovering said hematopoietic protein. 25. - A pharmaceutical composition, characterized in that it comprises: the hematopoietic protein according to claim 1, 2, 3, 4, 5, 6, 7, 9 or 10; and a pharmaceutically acceptable carrier. 26. The use of the hematopoietic protein according to claim 1, 2, 3, 4, 5, 6, 7, 9 or 10 for the manufacture of a medicament for stimulating the production of hematopoietic cells in a patient. 27. A method for the selective expansion of ex vivo hematopoietic cells, characterized in that it comprises the steps of: (a) culturing the hematopoietic cells in a culture medium comprising the hematopoietic protein of claim 1; and (b) harvesting said cultured cells. 28. A method for the selective expansion of hematopoietic cells ex vivo, characterized in that it comprises the steps of: (a) separating the hematopoietic cells from other cells; (b) culturing the hematopoietic cells in a culture medium comprising the hematopoietic protein of claim 1; and (c) harvesting the cultured cells. 29. The use of a culture of harvested cells according to claim 27, for the manufacture of a medicament for treating a patient having hematopoietic disorders. 30. The use of a culture of harvested, separated cells according to claim 28, for the manufacture of a medicament for treating a patient having a hematopoietic disorder. 31. - The use of a culture of harvested cells, separated, introduced into DNA, comprising the hematopoietic protein of claim 1, for the manufacture of a medicament for therapy with human genes. 32. The use according to claim 29, 30 or 31, further characterized in that the hematopoietic cells are CD34 + cells. 33. The use according to claim 29, 30 or 31, further characterized in that the hematopoietic cells are peripheral blood cells. 34.- A method for the production of dendritic cells, characterized in that it comprises the steps of: a) separating hematopoietic progenitor cells or CD34 + cells from other cells; and b) cultivating said progenitor cells or CD34 + cells in a developing medium comprising the hematopoietic protein of claim 1, 2, 3 or 4. The method according to claim 34, further characterized in that it further comprises the step of : c) pressing said hematopoietic progenitor cells of the culture, or CD34 + cells of the culture, with an antigen. 36. The method according to claim 34, further characterized in that the development means further comprises: one or more factors selected from the group consisting of FEC-GM, IL-4, TNF-alpha, trunk cell factor ( FCT), ligand flt-3, IL-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist. 37. The method according to claim 35, further characterized in that the development means further comprises: one or more factors selected from the group consisting of GM-FEC, IL-4, TNF-alpha, trunk cell factor ( FCT), ligand flt-3, I L-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist. 38.- The use of the hematopoietic protein of claim 1, 2, 3 or 4, for the manufacture of a medicament for treating a human having a tumor, an infection or a self-immunological disease. 39. The use according to claim 38, further characterized by additionally comprising one or more factors selected from the group consisting of-FEC-GM, IL-4, FNT-alpha, trunk cell factor (FCT), ligand flt -3, IL-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist. 40. The use according to claim 38 or 39, further characterized in that it comprises an antigen. 41.- The use of dendritic cell progenitors or mature dendritic cells, mobilized with the hematopoietic protein of claim 1, for the manufacture of a medicament for treating a human having a tumor, an infection or an autoimmune disease; where said dendritic cell precursors or said mature dendritic cells are pulsed with an antigen. 42. The use according to claim 41, further characterized in that the mobilizing factors are selected from the group consisting of FEC-GM, I L-4, FNT-alpha, trunk cell factor (FCT), ligand flt-3, IL-3, a variant of IL-3, a fusion protein, IL-3 variant and a multi-functional receptor agonist. 43. The use according to claim 41, further characterized in that said dendritic cell precursors or said mature dendritic cells are cultured in a developing medium comprising the hematopoietic protein of claim 1, 2, 3 or 4. 44. The use according to claim 43, further characterized in that the development medium further comprises one or more factors selected from the group consisting of GM-FEC, IL-4, TNF-alpha, trunk cell factor (FCT), ligand flt-3, I L-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist. 45.- The use of hematopoietic progenitor cells or CD34 + cells, cultured in a development medium comprising the hematopoietic protein of the claim, to produce dendritic cell precursors or mature dendritic cells, for the manufacture of a medicament for treating a human that have a tumor, an infection or an autoimmune disease. 46. The use according to claim 45, further characterized in that the dendritic cell precursors or the mature dendritic cells are pulsed with an antigen. 47. The use according to claim 45, further characterized in that the hematopoietic progenitor cells or CD34 + cells are separated from the other cells, before cultivation. 48. The use according to claim 45, further characterized in that the culture medium further comprises: one or more factors selected from the group consisting of FEC-GM, IL-4, TNF-alpha, trunk cell factor ( FCT), ligand flt-3, IL-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist. 49. The use according to claim 45, or 46, further characterized in that the culture medium further comprises one or more factors selected from the group consisting of FEC-GM, IL-4, FNT-alpha, cell factor of trunk (FCT), ligand flt-3, IL-3, a variant of IL-3, a fusion protein, variant of IL-3; and a multifunctional receptor agonist. 50.- The use according to claim 47, further characterized in that the culture medium further comprises one or more factors selected from the group consisting of FEC-GM, IL-4, FNT-alpha, trunk cell factor (FCT), ligand flt-3, IL-3, a variant of IL-3, a fusion protein, variant of IL-3, and a multifunctional receptor agonist.